(57) Abrégé/Abstract:
A bicyclic cinnamidine compound represented by the formula (I) [wherein (II) indicates a single bond or double bond; Ar₁ represents phenyl or pyridinyl optionally substituted by one to three substituents; R₁ and R² each represents C₁₋₅ alkyl, hydroxy, etc.; Z₁ represents optionally substituted methylene or vinylene, oxygen, or imino optionally substituted by C₁₋₅ alkyl or C₁₋₅ acyl; and p, q, and r each is an integer of 0-2]. It functions to reduce the production of Aβ40 and Aβ42. It is hence useful especially as a preventive or remedy for neurodegenerative diseases of which Aβ is causative, such as Alzheimer's disease and Down's syndrome.
Inventors (continued): ITO, KOICHI, JP; KANEKO, TOSHIHIKO, JP; SASAKI, TAKEO, JP;
MIYAGAWA, TAKEHIKO, JP; HAGIWARA, HIROAKI, JP; YOSHIDA, YU, JP
A bicyclic cinnamide compound represented by the general formula (I):

wherein \( \ldots \) represents a single bond or a double bond; \( \text{Ar}_1 \) represents a phenyl group or pyridinyl group optionally substituted by one to three substituents; \( \text{R}^1 \) and \( \text{R}^2 \) each represents a C1-6 alkyl group, a hydroxyl group, etc.; \( \text{Z}_1 \) represents an optionally substituted methylene group or vinylene group, an oxygen atom, or an imino group optionally substituted by a C1-6 alkyl group or a C1-6 acyl group; and \( p \), \( q \), and \( r \) each is an integer of 0 to 2. It functions to reduce A\( \beta \)40 and A\( \beta \)42. It is hence useful especially as a prevention or remedy for neurodegenerative diseases of which A\( \beta \) is causative, such as Alzheimer's disease and Down's syndrome.
DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D’UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 442

NOTE : Pour les tomes additionnels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 442

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHIER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:
DESCRIPTION

BICYCLIC CINNAMIDE COMPOUND

TECHNICAL FIELD

[0001]

The present invention relates to a bicyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. More specifically, the present invention relates to a nonpeptidic bicyclic cinnamide compound and an amyloid-\(\beta\) (hereinafter referred to as A\(\beta\)) production inhibitor which comprises the compound as an active ingredient and is particularly effective for treatment of a neurodegenerative disease caused by A\(\beta\) such as Alzheimer's disease or Down's syndrome.

BACKGROUND ARTS

[0002]

Alzheimer's disease is a disease characterized by degeneration and loss of neurons as well as formation of senile plaques and neurofibrillary degeneration. Currently, Alzheimer's disease is treated only with symptomatic treatment using a symptom improving agent typified by an acetylcholinesterase inhibitor, and a fundamental remedy to inhibit progression of the disease has not yet been developed. It is necessary to develop a method for controlling the
cause of the onset of pathology in order to create a fundamental remedy for Alzheimer's disease.

It is assumed that Aβ-proteins as metabolites of amyloid precursor proteins (hereinafter referred to as APP) are highly involved in degeneration and loss of neurons and onset of symptoms of dementia (see Non-Patent Document 1 and Non-Patent Document 2, for example). An Aβ-protein has, as main components, Aβ40 consisting of 40 amino acids and Aβ42 in which the number of amino acids is increased by two at the C-terminal. The Aβ40 and Aβ42 are known to have high aggregability (see Non-Patent Document 3, for example) and to be main components of senile plaques (see Non-Patent Document 3, Non-Patent Document 4 and Non-Patent Document 5, for example). Further, it is known that the Aβ40 and Aβ42 are increased by mutation in APP and presenilin genes which is observed in familial Alzheimer's disease (see Non-Patent Document 6, Non-Patent Document 7 and Non-Patent Document 8, for example). Accordingly, a compound that reduces production of Aβ40 and Aβ42 has been expected as a progression inhibitor or prophylactic agent for Alzheimer's disease.

Aβ is produced by cleaving APP by β-secretase and subsequently by γ-secretase. For this reason, attempts have been made to create γ-secretase and β-secretase inhibitors in order to reduce Aβ production. Many of these secretase inhibitors already known are,
for example, peptides and peptide mimetics such as L-685,458 (see Non-Patent Document 9, for example) and LY-411575 (see Non-Patent Document 10, Non-Patent Document 11 and Non-Patent Document 12, for example).


Non-Patent Document 5: Masters CL, and five others, Amyloid plaque core protein in Alzheimer
disease and Down syndrome, Proceeding National Academy of Science USA, 1985, Jun, 82(12), p.4245-4249;
Non-Patent Document 7: Scheuner D, and twenty others, Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine, 1996, Aug, 2(8), p.864-870;


DISCLOSURES OF INVENTION

PROBLEMS TO BE SOLVED BY THE INVENTION

[0003]

As described above, a compound that inhibits production of Aβ40 and Aβ42 from APP has been expected as a therapeutic or prophylactic agent for a disease caused by Aβ which is typified by Alzheimer's disease. However, a nonpeptidic compound having high efficacy which inhibits production of Aβ40 and Aβ42 has not yet been known. Accordingly, there is a need for a novel low-molecular-weight compound that inhibits production of Aβ40 and Aβ42.
MEANS FOR SOLVING THE PROBLEMS

[0004]

As a result of extensive studies, the present inventors have found a nonpeptidic bicyclic cinnamide compound that inhibits production of Aβ40 and Aβ42 from APP for the first time, and thus found a prophylactic or therapeutic agent for a disease caused by Aβ which is typified by Alzheimer's disease. This finding has led to the accomplishment of the present invention.

[0005]

Specifically, the present invention relates to

1) A compound represented by the formula (I):

[Formula 1]

\[
\begin{align*}
\text{MeO} & \quad \text{O} \\
\text{N} & \quad \text{N} \\
\text{Me} & \quad \text{Ar}_1 \\
\text{R}_1 & \quad \text{R}_2 \\
\text{Z}_1 & \quad \text{p}
\end{align*}
\]

or a pharmacologically acceptable salt thereof,

wherein \(---\) represents a single bond or a double bond; \(\text{Ar}_1\) represents a phenyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A1 or a pyridinyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A1; \(R_1\) and \(R_2\) are the same or different and each represent a group selected from the following Substituent Group A1; \(Z_1\) represents a methylene group or
vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r are the same or different and represent an integer of 0 to 2;

Substituent Group A1: (1) a halogen atom, (2) a hydroxyl group, (3) a cyano group, (4) a C3-8 cycloalkyl group, (5) a C3-8 cycloalkoxy group, (6) a C1-6 alkyl group, wherein the C1-6 alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group, and C3-8 cycloalkoxy group, (7) a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, and C3-8 cycloalkoxy group, (8) an amino group that may be substituted with one or two C1-6 alkyl groups, wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (9) a carbamoyl group that may be substituted with one or two C1-6 alkyl groups, wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (10) a carboxyl group, (11) a C1-6 alkoxy carbonyl group, wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8
cycloalkyl group, and C3-8 cycloalkoxy group), (12) a C1-6 acyl group and (13) C1-6 alkylsulfonyl group;
2) The compound or pharmacologically acceptable salt thereof according to 1) above, wherein the
5 compound is represented by the formula (II):

![Formula 2]

wherein Ar represents a phenyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A1 or a pyridinyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A1; R¹ and R² are the same or different and each represent a group selected from the following Substituent Group A1; Z₁ represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r are the same or different and represent an integer of 0 to 2;

Substituent Group A1: (1) a halogen atom, (2) a hydroxyl group, (3) a cyano group, (4) a C3-8 cycloalkyl group, (5) a C3-8 cycloalkoxy group, (6) a C1-6 alkyl group, wherein the C1-6 alkyl group may be
substituted with 1 to 3 substituents selected from the
group consisting of a halogen atom, hydroxyl group,
cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group,
and C3-8 cycloalkoxy group, (7) a C1-6 alkoxy group,
wherein the C1-6 alkoxy group may be substituted with 1
to 3 substituents selected from the group consisting of
a halogen atom, hydroxyl group, cyano group, C3-8
cycloalkyl group, and C3-8 cycloalkoxy group, (8) an
amino group that may be substituted with one or two C1-
6 alkyl groups, wherein the C1-6 alkyl groups may be
substituted with 1 to 3 halogen atoms, (9) a carbamoyl
group that may be substituted with one or two C1-6
alkyl groups, wherein the C1-6 alkyl groups may be
substituted with 1 to 3 halogen atoms, (10) a carboxyl
group, (11) a C1-6 alkoxy carbonyl group, wherein the
C1-6 alkoxy group may be substituted with 1 to 3
substituents selected from the group consisting of a
halogen atom, hydroxyl group, cyano group, C3-8
cycloalkyl group and C3-8 cycloalkoxy group, (12) a C1-
6 acyl group and (13) C1-6 alkylsulfonyl group);

3) The compound or pharmacologically acceptable
salt thereof according to 1) or 2) above, wherein Z₁
represents a methylene group, wherein the methylene
group may be substituted with 1 or 2 substituents
selected from the group consisting of a C1-6 alkyl
group, hydroxyl group, and halogen atom;

4) The compound or pharmacologically acceptable
salt thereof according to 3) above, wherein Z₁
represents a methylene group that may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group and hydroxyl group;
5) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, hydroxyl group, and halogen atom; and $p$, $q$, and $r$ each represent 1;
6) The compound or pharmacologically acceptable salt thereof according to 5) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group and hydroxyl group; and $p$, $q$, and $r$ each represent 1;
7) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, hydroxyl group, and halogen atom; $p$ and $q$ each represent 1; and $r$ represents 0;
8) The compound or pharmacologically acceptable salt thereof according to 7) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents
selected from the group consisting of a C1-6 alkyl group and hydroxyl group; p and q each represent 1; and r represents 0;

9) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents an oxygen atom; and p, q, and r each represent 1;

10) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, halogen atom, and hydroxyl group; p represents 1; and q and r each represent 0;

11) The compound or pharmacologically acceptable salt thereof according to 10) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group and hydroxyl group; p represents 1; and q and r each represent 0;

12) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, halogen atom, and hydroxyl group; p and r each represent 1; and q represents 0;
13) The compound or pharmacologically acceptable salt thereof according to 12) above, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents
5 selected from the group consisting of a C₁-6 alkyl group and hydroxyl group; p and r each represent 1; and q represents 0;
14) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group, halogen atom, and hydroxyl group; p represents 1; q represents 2; and r represents 0;
15) The compound or pharmacologically acceptable salt thereof according to 14) above, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group and hydroxyl group; p represents 1; q represents 2; and r represents 0;
16) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group, halogen atom, and hydroxyl group; p and r each represent 1; and q represents 2;
17) The compound or pharmacologically acceptable salt thereof according to 16) above, wherein $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group and hydroxyl group; $p$ and $r$ each represent 1; and $q$ represents 2;

18) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups or halogen atoms; $p$ represents 0; and $q$ and $r$ each represent 1;

19) The compound or pharmacologically acceptable salt thereof according to 18), wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups; $p$ represents 0; and $q$ and $r$ each represent 1;

20) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups or halogen atoms; $p$ and $q$ each represent 1; and $r$ represents 0;

21) The compound or pharmacologically acceptable salt thereof according to 20) above, wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups; $p$
and q each represent 1; and r represents 0;

22) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein \( \text{Ar}_1 \) represents a phenyl group substituted with 1 to 3 halogen atoms;

23) The compound or pharmacologically acceptable salt thereof according to 22) above, wherein \( \text{Ar}_1 \) represents a phenyl group substituted with 1 to 3 fluorine atoms or chlorine atoms;

24) The compound or pharmacologically acceptable salt thereof according to 7) or 8) above, wherein \( \text{Ar}_1 \) represents a phenyl group substituted with 2 or 3 halogen atoms;

25) The compound or pharmacologically acceptable salt thereof according to any of 2), 22), 23), and 24) above, wherein \( \text{Ar}_1 \) represents a phenyl group substituted with a fluorine atom;

26) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein \( R^1 \) and \( R^2 \) are the same or different and each represent a substituent selected from the group consisting of a Cl-6 alkyl group, halogen atom, and hydroxyl group;

27) The compound or pharmacologically acceptable salt thereof according to 1) or 2) above, wherein the compound is selected from the following group:

1) (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one,
2) (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one,
3) (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one,
4) (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one,
5) (E)-(3R)-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one,
6) (E)-(3S)-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one,
7) (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
8) (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
9) (E)-(6S,8S,9aR)-6-phenyl-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octhydroquinolizin-4-one,
10) (E)-(6R,8R,9aS)-6-phenyl-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octhydroquinolizin-4-one,
11) (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] octahydroquinolizin-4-one,
12) (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
5 octahydroquinolizin-4-one,
13) (E)-(6S,9aS)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
14) (E)-(6R,9aR)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
10 octahydroquinolizin-4-one,
15) (E)-(6S,8S,9aR)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)
benzylidene] octahydroquinolizin-4-one,
16) (E)-(6R,8R,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)
benzylidene] octahydroquinolizin-4-one,
17) (E)-(6S,8R,9aR)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)
benzylidene] octahydroquinolizin-4-one,
20 benzylidene] octahydroquinolizin-4-one,
18) (E)-(6R,8S,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)
benzylidene] octahydroquinolizin-4-one,
19) (E)-(6S,9aS)-6-(4-fluoro phenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
25 octahydroquinolizin-4-one,
20) (E)-(6R,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolinizin-4-one,

21) (E)-(5S)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(8aS)-hexahydroindolizin-3-one,

22) (E)-(5R)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(8aR)-hexahydroindolizin-3-one,

23) (E)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(8aS)-hexahydroindolizin-3-one,

24) (E)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(8aR)-hexahydroindolizin-3-one,

25) (Z)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(8aS)-hexahydroindolizin-3-one,

26) (Z)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(8aR)-hexahydroindolizin-3-one,

27) (E)-(5R, 8aS)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]hexahydroindolizin-3-one,

28) (E)-(5S, 8aR)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]hexahydroindolizin-3-one,

29) (E)-(6R, 9aS)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-(4-methoxyphenyl)octahydroquinolinizin-4-one,
30) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(4-methoxyphenyl)octahydroquinolizin-4-one,
31) (E)-(4S,10aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrrolo[1,2-a]azepin-6-one,
32) (E)-(4R,10aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrrolo[1,2-a]azepin-6-one,
33) (E)-(5R,7aS)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrrolidin-3-one,
34) (E)-(3R,9aR)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrrolo[1,2-a]azepin-5-one,
35) methyl (E)-4-((4S*,9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxooctahydroquinolizin-4-yl)benzoate,
36) (E)-(6S*,9aR*)-6-(4-hydroxymethylphenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
37) (E)-(6S*,9aR*)-6-(4-cyanophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
38) (E)-4-((4S*,9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxooctahydroquinolizin-4-yl)benzoic acid,
39) (E)-(6S*,9aR*)-6-(4-aminophenyl)-3-[3-methoxy-4-(4-
19 methyl-1H-imidazol-1-yl)benzylidene) octahydroquinolinizin-4-one,
40) \( (E)-4-\{(4S^*, 9aR^*)-7-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene]-6\text{-oxooctahydroquinoliniz} \)
4-yl\} - N,N-dimethylbenzamide,
41) \( (E)-(6S, 9aR)-6-(3\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene] \)
octahydroquinolinizin-4-one,
42) \( (E)-(6R, 9aS)-6-(3\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene] \)
octahydroquinolinizin-4-one,
43) \( (E)-(6S, 9aR)-6-(2\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene] \)
octahydroquinolinizin-4-one,
44) \( (E)-(6R, 9aS)-6-(2\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene] \)
octahydroquinolinizin-4-one,
45) \( (E)-(6S, 8R, 9aR)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene]-8-
20 \text{methyl-octahydroquinolinizin-4-one}, \)
46) \( (E)-(6R, 8S, 9aS)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene]-8-
methyl-octahydroquinolinizin-4-one, \)
47) \( (E)-(6S, 8R, 9aR)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene]-8-
methyloctahydroquinolinizin-4-one, \)
48) \( (E)-(6R, 8S, 9aS)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-yl})benzylidene]-8-
methyloctahydroquinolizin-4-one,
49) (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
50) (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
51) (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one,
52) (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one,
53) (E)-(4R,9aS)-7-[3-methoxy-4-(4-methylimidazol-1-yl)benzylidene]-4-phenylhexahydropyrido[2,1-c][1,4]oxazin-6-one,
54) (E)-(5S,7aR)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrrolidin-3-one,
55) (E)-(3S,9aS)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrrolo[1,2-a]azepin-5-one,
56) (E)-(3S,8aS)-3-(4-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one,
57) (E)-(3S,8aS)-3-(2,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one,
21

58) (E)-(3S,8aS)-3-(2,3,4-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
59) (E)-(3S,8aS)-3-(2,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
60) (E)-(3S,8aS)-3-(3-fluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
61) (E)-(3S,8aS)-3-(2,6-difluoropyridin-3-yl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
62) (E)-(3S,8aS)-3-(2,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
63) (E)-(3S,8aS)-3-(3-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
64) (E)-(3S,8aS)-3-(3,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] hexahydroindolizin-5-one,
65) (E)-(6S,9aS)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] octahydroquinolinolizin-4-one,
66) (E)-(6R,9aR)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene] octahydroquinolinolizin-4-one,
67) (E)-(6S,9aS)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene) octahydroquinolinizin-4-one,

68) (E)-(6R,9aR)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
5 octahydroquinolinizin-4-one,

69) (E)-(S)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(
4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-
hexahydroquinolinizin-4-one,

70) (E)-(R)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-
10 (4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-
hexahydroquinolinizin-4-one,

71) (E)-(6S,8S,9aR)-8-fluoro-3-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl) octahydroquinolinizin-4-one,

72) (E)-(6S,8R,9aR)-8-methoxy-3-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl) octahydroquinolinizin-4-one,

73) (E)-(R)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-3,4,8,9-
tetrahydro-7H-pyrido[2,1-c][1,4]oxazin-6-one,

74) (E)-(S)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-3,4,8,9-
tetrahydro-7H-pyrido[2,1-c][1,4]oxazin-6-one,

75) (E)-(4R,9aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]

hexahydropyrido[2,1-c][1,4]oxazin-6-one,

76) (E)-(4S,9aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
hexahydropyrido[2,1-c][1,4]oxazin-6-one,
77) (E)-(6S,8R,9aR)-8-fluoro-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolinizin-4-one,
78) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)-
1,2,3,6,9,9a-hexahydroquinolinizin-4-one,
79) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)-
1,2,3,6,7,9a-hexahydroquinolinizin-4-one,
80) (E)-(4R,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-4-(3,4,5-
trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-
one,
81) (E)-(4S,9aS)-7-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-4-(3,4,5-
trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-
one,
82) (E)-(4S,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-4-(3,4,5-
trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-
one,
83) (E)-(4R,9aS)-7-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-4-(3,4,5-
trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-
one,
84) (E)-(6R,7S,9aR)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-

trifluorophenyl)octahydroquinolinizin-4-one,
85) \((E)-(6S,7R,9aS)-7\text{hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-}
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolinizin-4-one,
86) \((E)-(6R,7R,9aR)-7\text{hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-}
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolinizin-4-one,
87) \((E)-(6S,7S,9aS)-7\text{hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl-}
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolinizin-4-one,
88) \((E)-(6S,9aR)-6-(4\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,6,9,9a-
hexahydroquinolinizin-4-one,
89) \((3S,8aS)-6\{1\text{-[3\text{-methoxy}-4-(4\text{-methyl-1H-imidazol-1-}
yl)phenyl]}-(E)-methylidene\}-3-(2,4,6-
trifluorophenyl)hexahydropindolizin-5-one,
90) \((6S,9aR)-6-(3,4\text{-difluorophenyl})-3\{1\text{-[3\text{-methoxy}-4-(}
4\text{-methyl-1H-imidazol-1-yl)phenyl]}-(E)-
methylidene\}\text{octahydroquinolinizin-4-one,}
91) \((6S,9aR)-6-(3,4,5\text{-trifluorophenyl})-3\{1\text{-[3\text{-methoxy}-}
4\text{-}[4\text{-methyl-1H-imidazol-1-yl)phenyl]}-(E)-
methylidene\}\text{octahydroquinolinizin-4-one,}
92) \((6S,9aR)-6-(4\text{-chlorophenyl})-3\{1\text{-[3\text{-methoxy}-4-(4-
methyl-1H-imidazol-1-yl)phenyl]}-(E)-
methylidene\}\text{octahydroquinolinizin-4-one,}
93) \((E)-(3S,8aS)-3-(2,3\text{-difluorophenyl})-6-[3\text{-methoxy}-4-
(4\text{-methyl-1H-imidazol-1-yl)benzylidene]}
hexahydropindolizin-5-one,
94) (4R,9aS)-4-(4-fluorophenyl)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}hexahydropyrido[2,1-c][1,4]oxazin-6-one,
95) (4R,9aS)-4-(3,4-difluorophenyl)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}hexahydropyrido[2,1-c][1,4]oxazin-6-one,
96) (4R,9aS)-4-(4-chlorophenyl)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}hexahydropyrido[2,1-c][1,4]oxazin-6-one,
97) methyl (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,
98) methyl (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,
99) methyl (4R,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,
100) methyl (4S,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,
101) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
102) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
103) (4S,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
104) (4R,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
105) (4S,9aR)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
106) (4R,9aS)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
107) (4R,9aR)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
108) (4S,9aS)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
109) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-methyl-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
110) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-methyl-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
111) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-methyl-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
(E)-methylidene)-2-propyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
112) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-propyl-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
113) (4R*,9aS*)-2-acetyl-7-{1-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
114) (4R*,9aS*)-2-methanesulfonyle-7-{1-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-
(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-
one, and
115) (4R*,9aS*)-7-{1-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)phenyl]-(E)-methylidene}6-oxo-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-
carboxylic acid dimethylamide;
28) A pharmaceutical agent comprising the
compound or pharmacologically acceptable salt thereof
according to any of 1) to 27) above as an active
ingredient;
29) The pharmaceutical agent according to 28
above), which is a prophylactic or therapeutic agent
for a disease caused by amyloid-β; and
30) The pharmaceutical agent according to 29)
above, wherein the disease caused by amyloid-β is
Alzheimer's disease, senile dementia, Down's syndrome,
or amyloidosis.
[0006]

Meanings of symbols, terms, and the like used in the present specification will be explained, and the present invention will be described in detail below.

[0007]

In the present specification, a structural formula of a compound may represent a certain isomer for convenience. However, the present invention includes all isomers and isomer mixtures such as geometric isomers which can be generated from the structure of a compound, optical isomers based on asymmetric carbon, stereoisomers, and tautomers. The present invention is not limited to the description of a chemical formula for convenience, and may include any one of the isomers or mixtures thereof. Accordingly, the compound of the present invention may have an asymmetric carbon atom in the molecule, and exist as an optically active compound or racemate, and the present invention includes each of the optically active compound and the racemate without limitations.

Although crystal polymorphs of the compound may be present, the compound is not limited thereto as well and may be present as a single crystal form or a mixture of single crystal forms. The compound may be an anhydride or hydrate.

[0008]

The "disease caused by Aβ" refers to a wide variety of diseases such as Alzheimer's disease (see
effects of the swedish mutant amyloid precursor protein on β-amyloid accumulation and secretion in neurons and nonneuronal cells, The journal of biological chemistry, 1997, Dec 19, 272(51), p.32247-32253, for example),

senile dementia (see Blass JP, Brain metabolism and brain disease: Is metabolic deficiency the proximate cause of Alzheimer dementia? Journal of Neuroscience Research, 2001, Dec 1, 66(5), p.851-856, for example),

damage in transgenic mice overexpressing the amyloid precursor protein, The journal of neuroscience, 1997, Oct 15, 17(20), p.7655-7661, for example), vascular dementia (see Sadowski M, and six others, Links between the pathology of Alzheimer's disease and vascular dementia, Neurochemical Research, 2004, Jun, 29(6), p.1257-1266, for example), ophthalmoplegia (see O'Riordan S, and seven others, Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities, Neurology, 2002, Oct 8, 59(7), p.1108-1110, for example), multiple sclerosis (see Gehrmann J, and four others, Amyloid precursor protein (APP) expression in multiple sclerosis lesions, Glia, 1995, Oct, 15(2), p.141-51; and Reynolds WF, and six others, Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease, Experimental Neurology, 1999, Jan, 155(1), p.31-41, for example), head injury, cranial trauma (see Smith DH, and four others, Protein accumulation in traumatic brain injury, NeuroMolecular Medicine, 2003, 4(1-2), p.59-72, for example), apraxia (see Matsubara-Tsutsui M, and seven others, Molecular evidence of presenilin 1 mutation in familial early onset dementia, American journal of Medical Genetics, 2002, Apr 8, 114(3), p.292-298, for example), prion disease, familial amyloid neuropathy, triplet repeat disease (see Kirkitadze MD, and two others, Paradigm shifts in Alzheimer's disease and other neurodegenerative...
accumulation of amyloid-β in Non-Alzheimer Neurodegeneration, Journal of Alzheimer's Disease, 1999, Oct, 1(3), p.183-193, for example), parkinsonism-dementia complex (see Schmidt ML, and six others,

Amyloid plaques in Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex contain species of Aβ similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging, Acta Neuropathologica (Berl), 1998, Feb, 95(2), p.117-122;

and Ito H, and three others, Demonstration of β amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam, Neuropathology and applied neurobiology, 1991, Oct, 17(5), p. 365-373, for example), frontotemporal dementia and parkinsonism linked to chromosome 17 (see Rosso SM, and three others, Coexistent tau and amyloid pathology in hereditary frontotemporal dementia with tau mutations, Annals of the New York academy of sciences, 2000, 920, p.115-119, for example), dementia with argyrophilic grains (see Tolnay M, and four others, Low amyloid (Aβ) plaque load and relative predominance of diffuse plaques distinguish argyrophilic grain disease from Alzheimer's disease, Neuropathology and applied neurobiology, 1999, Aug, 25(4), p.295-305, for example), Niemann-Pick disease (see Jin LW, and three others, Intracellular accumulation of amyloidogenic fragments of amyloid-β precursor protein in neurons with Niemann-Pick type C defects is associated with
260; and Primavera J, and four others, Brain accumulation of amyloid-β in Non-Alzheimer Neurodegeneration, Journal of Alzheimer's Disease, 1999, Oct, 1(3), p.183-193, for example), intracerebral hemorrhage (see Atwood CS, and three others, Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply, Brain Research Reviews, 2003, Sep, 43(1), p.164-78; and Lowenson JD, and two others, Protein aging: Extracellular amyloid formation and intracellular repair, Trends in cardiovascular medicine, 1994, 4(1), p.3-8, for example), convulsion (see Singleton AB, and thirteen others, Pathology of early-onset Alzheimer's disease cases bearing the Thr113-114ins presenilin-1 mutation, Brain, 2000, Dec, 123(Pt12), p.2467-2474, for example), mild cognitive impairment (see Gattaz WF, and four others, Platelet phospholipase A2 activity in Alzheimer's disease and mild cognitive impairment, Journal of Neural Transmission, 2004, May, 111(5), p.591-601; and Assini A, and fourteen others, Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment, Neurology, 2004, Sep 14, 63(5), p.828-831, for example), and arteriosclerosis (see De Meyer GR, and eight others, Platelet phagocytosis and processing of β-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis, Circulation Reserach,
The "Cl-6 alkyl group" used herein refers to a linear or branched alkyl group having 1 to 6 carbon atoms. Preferable examples of the group include linear or branched alkyl groups such as a methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, tert-butyl group, n-pentyl group, i-pentyl group, neopentyl group, n-hexyl group, 1-methylpropyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 2-ethylbutyl group, 1,3-dimethylbutyl group, 2-methylpentyl group, and 3-methylpentyl group.

The "Cl-6 acyl group" refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is substituted with a carbonyl group. Preferable examples of the group include an acetyl group, propionyl group, and butyryl group.

The "halogen atom" refers to a fluorine atom, chlorine atom, bromine atom, iodine atom, or the like, and is preferably a fluorine atom, chlorine atom, or bromine atom.
The "C3-8 cycloalkyl group" refers to a cyclic alkyl group having 3 to 8 carbon atoms. Preferable examples of the group include a cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, and cyclooctyl group.

The "C3-8 cycloalkoxy group" refers to a cyclic alkyl group having 3 to 8 carbon atoms in which one hydrogen atom is substituted with an oxygen atom. Preferable examples of the group include a cyclopropoxy group, cyclobutoxy group, cyclopentoxy group, cyclohexoxy group, cycloheptyloxy group, and cyclooctyloxy group.

The "C1-6 alkoxy group" refers to an alkyl group having 1 to 6 carbon atoms in which a hydrogen atom is substituted with an oxygen atom. Preferable examples of the group include a methoxy group, ethoxy group, n-propoxy group, i-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, tert-butoxy group, n-pentoxy group, i-pentoxy group, sec-pentoxy group, tert-pentoxy group, n-hexoxy group, i-hexoxy group, 1,2-dimethylprooxy group, 2-ethylprooxy group, 1-methyl-2-ethylprooxy group, 1-ethyl-2-methylprooxy group, 1,1,2-trimethylprooxy group, 1,1-dimethylbutoxy group, 2,2-dimethylbutoxy group, 2-ethylbutoxy group, 1,3-dimethylbutoxy group, 2-methylpentoxy group, 3-methylpentoxy group, and hexyloxy group.
The "C1-6 alkoxycarbonyl group" refers to a so-called ester group in which a carbonyl group is bonded to a C1-6 alkoxy group. Preferable examples of the group include a methoxycarbonyl group, ethoxycarbonyl group, n-propoxycarbonyl group, i-propoxycarbonyl group, n-butoxycarbonyl group, i-butoxycarbonyl group, n-pentoxy carbonyl group, and n-hexoxy carbonyl group.

The "C1-6 alklylsulfonyl group" refers to an alkyl group having 1 to 6 carbon atoms in which one hydrogen atom is substituted with a sulfur atom. Preferable examples of the group include methylsulfonyl group, ethylsulfonyl group, n-propylsulfonyl group, i-propylsulfonyl group, n-butylsulfonyl group, i-butylsulfonyl group, tertiaylly butylsulfonyl group, n-pentylsulfonyl group, i-pentylsulfonyl group, neopentylsulfonyl group, n-hexylsulfonyl group, and 1-methylpropylsulfonyl group.

The "methylene group that may be substituted with 1 or 2 substituents selected from Substituent Group A1" may be, for example, a group of any of the formulas:
In addition to the above, the group may be another methylene group that may be substituted with 1 or 2 substituents selected from Substituent Group Al.

The "vinylene group that may be substituted with 1 or 2 substituents selected from Substituent Group Al" may be, for example, a group of the formula:

In addition to the above, the group may be another vinylene group that may be substituted with 1 or 2 substituents selected from Substituent Group Al.

The "imino group that may be substituten with a substituent selected from Substituent Group Al" may be, for example, a group of the formula:
[0020]

Preferable examples of the "C1-6 alkyl group wherein the C1-6 alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group, and C3-8 cycloalkoxy group" in Substituent Group A1 include a methyl group, trifluoromethyl group, hydroxymethyl group, cyanomethyl group, ethyl group, 2-hydroxyethyl group, n-propyl group, i-propyl group, 3-hydroxy-n-propyl group, tert-butyl group, n-pentyl group, i-pentyl group, neopentyl group, n-hexyl group, 1-methylpropyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, 1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group, 1,1,2-trimethylpropyl group, 1-methylbutyl group, 2,2-dimethylbutyl group, 2-ethylbutyl group, 2-methylpentyl group, and 3-methylpentyl group.

[0021]

Examples of the "C1-6 alkoxy group wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8..."
cycloalkyl group, and C3-8 cycloalkoxy group" include a methoxy group, trifluoromethoxy group, hydroxymethoxy group, cyanomethoxy group, ethoxy group, 2-hydroxyethoxy group, n-propoxy group, i-propoxy group, 3-hydroxy-n-propoxy group, tert-butoxy group, n-pentoxy group, i-pentoxy group, neopentoxy group, n-hexoxy group, 1-methylprooxy group, 1,2-dimethylprooxy group, 1-ethylprooxy group, 1-methyl-2-ethylprooxy group, 1-ethyl-2-methylprooxy group, 1,1,2-trimethylprooxy group, 1-methylbutoxy group, 2,2-dimethylbutoxy group, 2-ethylbutoxy group, 2-methylpentoxy group, and 3-methylpentoxy group.

[0022]

The "amino group that may be substituted with one or two C1-6 alkyl groups wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms" refers to an amino group in which one or two hydrogen atoms are substituted with one or two C1-6 alkyl groups that may be substituted with 1 to 3 halogen atoms.

Preferable examples of the group include a methylamino group, trifluoromethylamino group, dimethylamino group, ethylamino group, diethylamino group, n-propylamino group, i-propylamino group, 3-hydroxy-n-propylamino group, tert-butylamino group, n-pentylamino group, i-pentylamino group, neopentylamino group, n-hexylamino group, 1-methylpropylamino group, 1,2-dimethylpropylamino group, 1-ethylpropylamino group, 1-methyl-2-ethylpropylamino group, 1-ethyl-2-
methylpropylamino group, 1,1,2-trimethylpropylamino group, 1-methylbutylamino group, 2,2-dimethylbutylamino group, 2-ethylbutylamino group, 2-methylpentylamino group, difluoromethylamino group, fluoromethylamino group, 2,2,2-trifluoroethylamino group, 2,2-difluoroethylamino group and 3-methylpentylamino group.

[0023]

The "carbamoyl group that may be substituted with one or two C1-6 alkyl groups wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms" refers to a carbamoyl group in which one or two hydrogen atoms are substituted with one or two alkyl groups having 1 to 6 carbon atoms. Preferable examples of the group include a methylcarbamoyl group, dimethylcarbamoyl group, ethylcarbamoyl group, diethylcarbamoyl group, n-propylcarbamoyl group, trifluoromethylcarbamoyl group, and di-n-propylcarbamoyl group.

[0024]

Preferable examples of the "C1-6 alkoxy carbonyl group wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, and C3-8 cycloalkoxy group" include a methoxycarbonyl group, trifluoromethoxycarbonyl group, hydroxymethoxycarbonyl group, cyanomethoxycarbonyl group, ethoxycarbonyl group, 2-hydroxyethoxycarbonyl group, n-propoxycarbonyl
group, i-propoxycarbonyl group, 3-hydroxy-n-propoxycarbonyl group, tert-butoxycarbonyl group, n-pentoxy carbonyl group, i-pentoxy carbonyl group, neopentoxy carbonyl group, n-hexoxycarbonyl group, 1-methylpropoxycarbonyl group, 1,2-dimethylpropoxycarbonyl group, 1-ethylpropoxycarbonyl group, 1-methyl-2-ethylpropoxycarbonyl group, 1-ethyl-2-methylpropoxycarbonyl group, 1,1,2-trimethylpropoxycarbonyl group, 1-methylbutoxycarbonyl group, 2,2-dimethylbutoxycarbonyl group, 2-ethylbutoxycarbonyl group, 2-methylpentoxycarbonyl group, and 3-methylpentoxycarbonyl group.

The "Cl-6 alkylsulfonyl group" refers to sulfonyl group with linear or branched alkyl group having 1 to 6 carbon atoms. Preferable examples of the group include linear or branched alkylsulfonyl group such as a methansulfonyl group, ethylmethylsulfonyl group, n-propylsulfonyl group, i-propylsulfonyl group, n-butylsulfonyl group, i-butylsulfonyl group, tert-butylsulfonyl group, n-pentyl sulfonyl group, i-pentyl sulfonyl group, neopentyl sulfonyl group, n-hexylsulfonyl group, 1-methylpropylsulfonyl group, and so on.

[0025]

In the present specification, there are no specific limitations to the "pharmacologically acceptable salt" insofar as it is a pharmacologically acceptable salt formed with a compound of the general
formula (I) or (II) that is a prophylactic or therapeutic agent for a disease caused by Aβ. Preferable specific examples of the salt include hydrogen halides (such as hydrofluorides, hydrochlorides, hydrobromides, and hydroiodides), inorganic acid salts (such as sulfates, nitrates, perchlorates, phosphates, carbonates, and bicarbonates), organic carboxylates (such as acetates, oxalates, maleates, tartrates, fumarates, and citrates), organic sulfonates (such as methanesulfonates, trifluoromethanesulfonates, ethanesulfonates, benzenesulfonates, toluenesulfonates, and camphorsulfonates), amino acid salts (such as aspartates and glutamates), quaternary amine salts, alkali metal salts (such as sodium salts and potassium salts), and alkali earth metal salts (such as magnesium salts and calcium salts).

Next, the compound of the formula (I) or (II) of the present invention will be described.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof, Ar₁ is preferably a phenyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A₁ or a pyridinyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A₁,
Ar₁ is more preferably a phenyl group substituted with 1 to 3 halogen atoms, and

Ar₁ is most preferably a phenyl group substituted with 1 to 3 fluorine atoms or chlorine atoms.

[0028]

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof, R¹ and R² are preferably a hydrogen atom; a halogen atom; a hydroxyl group; a cyano group; a C₃-8 cycloalkyl group; a C₃-8 cycloalkoxy group; a C₁-6 alkyl group, wherein the C₁-6 alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C₃-8 cycloalkyl group, C₁-6 alkoxy group, and C₃-8 cycloalkoxy group; a C₁-6 alkoxy group, wherein the C₁-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C₃-8 cycloalkyl group, and C₃-8 cycloalkoxy group; an amino group, wherein the amino group may be substituted with one or two C₁-6 alkyl groups that are appropriately substituted with 1 to 3 halogen atoms; a carbamoyl group, wherein the carbamoyl group may be substituted with one or two C₁-6 alkyl groups that are appropriately substituted with 1 to 3 halogen atoms; a carboxyl group; or a C₁-6 alkoxy carbonyl group, wherein the C₁-6 alkoxy group may be substituted with 1 to 3 substituents selected from
the group consisting of a halogen atom, hydroxyl group,
cyano group, C3-8 cycloalkyl group, and C3-8
cycloalkoxy group.

In the compound of the formula (I) or (II) or
pharmacologically acceptable salt thereof, more
preferably, R¹ and R² are the same or different and each
represent hydrogen atom, a C1-6 alkyl group, halogen
atom, or hydroxyl group.

[0029]

In the compound of the formula (I) or (II) or
pharmacologically acceptable salt thereof,

Z₁ is preferably a methylene group that may be
substituted with 1 or 2 substituents selected from
Substituent Group A, and

Z₁ is more preferably a methylene group,
wherein the methylene group may be substituted with 1
or 2 substituents selected from the group consisting of
a C1-6 alkyl group, hydroxyl group, and halogen atom.

[0030]

In the compound of the formula (I) or (II) or
pharmacologically acceptable salt thereof,

preferably, Z₁ represents a methylene group,
wherein the methylene group may be substituted with 1
or 2 substituents selected from the group consisting of
a C1-6 alkyl group, hydroxyl group, and halogen atom;
and p, q, and r each represent 1.

In the compound of the formula (I) or
pharmacologically acceptable salt thereof,
preferably, \( Z_1 \) represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a \( C1-6 \) alkyl group, hydroxyl group, and halogen atom; \( p \) and \( q \) each represent 1; and \( r \) represents 0.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof,

preferably, \( Z_1 \) represents an oxygen atom; and \( p \), \( q \), and \( r \) each represent 1.

In the compound of the formula (I) or pharmacologically acceptable salt thereof,

preferably, \( Z_1 \) represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a \( C1-6 \) alkyl group, halogen atom, and hydroxyl group; \( p \) represents 1; and \( q \) and \( r \) each represent 0.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof,

preferably, \( Z_1 \) represents a methylene group,

wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a \( C1-6 \) alkyl group, halogen atom, and hydroxyl group; \( p \) and \( r \) each represent 1; and \( q \) represents 0.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof,

preferably, \( Z_1 \) represents a methylene group,

wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of
a C1-6 alkyl group, halogen atom, and hydroxyl group; p represents 1; q represents 2; and r represents 0.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof,

preferably, $Z_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, halogen atom, and hydroxyl group; p and r each represent 1; and q represents 2.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof,

preferably, $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups or halogen atoms; p represents 0; and q and r each represent 1.

In the compound of the formula (I) or (II) or pharmacologically acceptable salt thereof,

preferably, $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups or halogen atoms; p and q each represent 1; and r represents 0.

In particular, a compound selected from the following group or a pharmacologically acceptable salt thereof is particularly suitable, for example, and is useful as a therapeutic or prophylactic agent for a disease such as Alzheimer's disease, senile dementia, Down's syndrome, or amyloidosis.
1) (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(9R)-hexahydroindoliniz-5-one,
2) (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(9R)-hexahydroindoliniz-5-one,
3) (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(9S)-hexahydroindoliniz-5-one,
4) (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(9S)-hexahydroindoliniz-5-one,
5) (E)-(3R)-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(9R)-hexahydroindoliniz-5-one,
6) (E)-(3S)-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-(9S)-hexahydroindoliniz-5-one,
7) (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinoliniz-4-one,
8) (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinoliniz-4-one,
9) (E)-(6S,8S,9aR)-6-phenyl-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinoliniz-4-one,
10) (E)-(6R,8R,9aS)-6-phenyl-8-hydroxy-3-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
11) (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
12) (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
13) (E)-(6S,9aS)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
14) (E)-(6R,9aR)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
15) (E)-(6S,8S,9aR)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
16) (E)-(6R,8R,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
17) (E)-(6S,8R,9aR)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
18) (E)-(6R,8S,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
19) (E)-(6S,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene] octahydroquinolizin-4-one,
20) (E)-(6R,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
5 octahydroquinolizin-4-one,
21) (E)-(5S)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydroindolizin-
3-one,
22) (E)-(5R)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-(8aR)-hexahydroindolizin-
3-one,
23) (E)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-
hexahydroindolizin-3-one,
24) (E)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-
hexahydroindolizin-3-one,
25) (Z)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-
hexahydroindolizin-3-one,
26) (Z)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-
hexahydroindolizin-3-one,
27) (E)-(5R,8aS)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-
3-one,
28) (E)-(5S,8aR)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-
3-one,
29) (E)-(6R,9aS)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-(4-methoxyphenyl)octahydroquinolizin-4-one,
30) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-(4-methoxyphenyl)octahydroquinolizin-4-one,
31) (E)-(4S,10aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]
octahydropyrrolo[1,2-a]azepin-6-one,
32) (E)-(4R,10aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]
octahydropyrrolo[1,2-a]azepin-6-one,
33) (E)-(5R,7aS)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]
hexahydropyrrolidin-3-one,
34) (E)-(3R,9aR)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]
octahydropyrrololo[1,2-a]azepin-5-one,
35) methyl (E)-4-{(4S*,9aR*)}-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-oxooctahydroquinolizin-4-yl)benzoate,
36) (E)-(6S*,9aR*)-6-(4-hydroxymethylphenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]
octahydroquinolizin-4-one,
37) (E)-(6S*,9aR*)-6-(4-cyanophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]
octahydroquinolizin-4-one,
38) \((E)-4-\{((4S^*, 9aR^*)-7-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]-6\text{-oxooctahydroquinolinizin-4-yl}\}\text{benzoic acid},

39) \((E)-(6S^*, 9aR^*)-6-(4\text{-aminophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]\text{octahydroquinolinizin-4-one},

40) \((E)-4-\{((4S^*, 9aR^*)-7-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]-6\text{-oxooctahydroquinolinizin-4-yl}\}\text{N,N-dimethylbenzamide},

41) \((E)-(6S, 9aR)-6-(3\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]\text{octahydroquinolinizin-4-one},

42) \((E)-(6R, 9aS)-6-(3\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]\text{octahydroquinolinizin-4-one},

43) \((E)-(6S, 9aR)-6-(2\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]\text{octahydroquinolinizin-4-one},

44) \((E)-(6R, 9aS)-6-(2\text{-fluorophenyl})-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]\text{octahydroquinolinizin-4-one},

45) \((E)-(6S, 8R, 9aR)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]-8\text{-methyl-octahydroquinolinizin-4-one},

46) \((E)-(6R, 8S, 9aS)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3\text{-methoxy}-4-(4\text{-methyl}-1H-\text{imidazol}-1-\text{yl})\text{benzylidene}]-8\text{-methyl-octahydroquinolinizin-4-one},

47) \((E)-(6S, 8R, 9aR)-6-(4\text{-fluorophenyl})-8\text{-hydroxy}-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one,
48) (E)-(6R,8S,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one,
49) (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
50) (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
51) (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one,
52) (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one,
53) (E)-(4R,9aS)-7-[3-methoxy-4-(4-methylimidazol-1-yl)benzylidene]-4-phenylhexahydropyrido[2,1-c][1,4]oxazin-6-one,
54) (E)-(5S,7aR)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrroloidin-3-one,
55) (E)-(3S,9aS)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrrolo[1,2-a]azepin-5-one,
56) (E)-(3S,8aS)-3-(4-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-
58
57) (E)-(3S,8aS)-3-(2,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydroindolizin-5-one,

58) (E)-(3S,8aS)-3-(2,3,4-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydroindolizin-5-one,

59) (E)-(3S,8aS)-3-(2,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]

10 hexahydroindolizin-5-one,

60) (E)-(3S,8aS)-3-(3-fluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydroindolizin-5-one,

61) (E)-(3S,8aS)-3-(2,6-difluoropyridin-3-yl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]

15 hexahydroindolizin-5-one,

62) (E)-(3S,8aS)-3-(2,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]

hexahydroindolizin-5-one,

63) (E)-(3S,8aS)-3-(3-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydroindolizin-5-one,

64) (E)-(3S,8aS)-3-(3,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]

25 hexahydroindolizin-5-one,

65) (E)-(6S,9aS)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]

octahydroquinolinizin-4-one,
66) (E)-(6R,9aR)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
67) (E)-(6S,9aS)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
68) (E)-(6R,9aR)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
octahydroquinolizin-4-one,
69) (E)-(S)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-
hexahydroquinolizin-4-one,
70) (E)-(R)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-
hexahydroquinolizin-4-one,
71) (E)-(6S,8S,9aR)-8-fluoro-3-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one,
72) (E)-(6S,8R,9aR)-8-methoxy-3-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one,
73) (E)-(R)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-3,4,8,9-
tetrahydro-7H-pyrido[2,1-c][1,4]oxazin-6-one,
74) (E)-(S)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-3,4,8,9-
tetrahydro-7H-pyrido[2,1-c][1,4]oxazin-6-one,
75) (E)-(4R,9aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene] hexahydropyrido[2,1-c][1,4]oxazin-6-one,
76) (E)-(4S,9aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydropyrido[2,1-c][1,4]oxazin-6-one,
77) (E)-(6S,8R,9aR)-8-fluoro-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
78) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
79) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)-1,2,3,6,7,9a-hexahydroquinolizin-4-one,
80) (E)-(4R,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
81) (E)-(4S,9aS)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
82) (E)-(4S,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
83) (E)-(4R,9aS)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-
trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,

84) (E)-(6R,7S,9aR)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one,

85) (E)-(6S,7R,9aS)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one,

86) (E)-(6R,7R,9aR)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one,

87) (E)-(6S,7S,9aS)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one,

88) (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-1,2,3,6,9,9a-
hexahydroquinolizin-4-one,

89) (3S,8aS)-6-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-3-(2,4,6-
trifluorophenyl)hexahydroindolizin-5-one,

90) (6S,9aR)-6-(3,4-difluorophenyl)-3-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-
methylidene}octahydroquinolizin-4-one,

91) (6S,9aR)-6-(3,4,5-trifluorophenyl)-3-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-
methylidene}octahydroquinolizin-4-one,

92) (6S,9aR)-6-(4-chlorophenyl)-3-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-
methylidene)octahydroquinolinizin-4-one,
93) (E)-(3S,8aS)-3-(2,3-difluorophenyl)-6-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydropyridolizin-5-one,
94) (4R,9aS)-4-(4-fluorophenyl)-7-{1-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)phenyl]-(E)-
methylidene)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
95) (4R,9aS)-4-(3,4-difluorophenyl)-7-{1-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-
methylidene)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
96) (4R,9aS)-4-(4-chlorophenyl)-7-{1-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)phenyl]-(E)-
methylidene)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
97) methyl (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-
carboxylate,
98) methyl (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-
carboxylate,
99) methyl (4R,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-
carboxylate,
100) methyl (4S,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-
carboxylate,

101) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

102) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

103) (4S,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

104) (4R,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

105) (4S,9aR)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

106) (4R,9aS)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

107) (4R,9aR)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

108) (4S,9aS)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
110) (4R,9aS)-7-1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene]-2-methyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one, 
111) (4S,9aR)-7-1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene]-2-propyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one, 
112) (4R,9aS)-7-1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene]-2-propyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one, 
113) (4R*,9aS*)-2-acetyl-7-1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene]-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one, 
114) (4R*,9aS*)-2-methanesulfonyl-7-1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene]-4-
15 (3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one, and
115) (4R*,9aS*)-7-1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene]-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylic acid dimethylamide.

[0032]

Preferable embodiments of the compound of the general formula (I) are as described above. The pharmaceutically active ingredient of the present invention is not limited to compounds specifically described in the present specification, and any embodiment may be arbitrarily selected within the definition of the compound of the general formula (I).
Methods for preparing the compound of the general formula (I) of the present invention will be described below.

The compound represented by the general formula (I):

\[
\text{[Formula 6]}
\]

wherein \( \text{---} \) represents a single bond or a double bond; and \( \text{Ar}_1, \text{Z}_1, \text{R}_1, \text{R}_2, \text{p}, \text{q}, \text{and r} \) are as defined above, is synthesized according to a method such as the following General Preparation Method 1 to General Preparation Method 4, for example. It is obvious that, in order to prepare the compound of the present invention conveniently, the method comprises a protection reaction step and a deprotection reaction step appropriately, using a protecting group known to a person skilled in the art which is suitably selected for each step (see T. Greene et al., "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1981).

[0034]

General Preparation Method 1
66

Typically used General Preparation Method 1 for the compound of the general formula (I) of the present invention will be described below.

[Formula 7]

In the formula, ---- represents a single bond or a double bond; and Ar₁, Z₁, R₁, R₂, p, q, and r are as defined above.

[0035]

The above General Production Method 1 is an example of a method for preparing the compound of the general formula (I) comprising converting an aldehyde compound (1) and a lactam compound (2) into an aldol adduct (3) by aldol reaction in Step 1-1 and then dehydrating the adduct.

[0036]

Preparation of compound of general formula (I)

The compound of the general formula (I) can be prepared from an aldol adduct (3) according to Step
1-2. Specifically, the dehydration reaction in Step 1-2 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A known method described in many documents may be used for the reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.194-226, for example). Preferable examples of the method include i) a method of treating an aldol adduct (3) with preferably 0.1 to 100.0 equivalents of an acid, for example (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.194-196, for example); and ii) a method of converting an alcohol group of an aldol adduct (3) into a leaving group such as an acetyl group, carboxylate group, sulfonate group, or halogen atom, and then treating the adduct with preferably 1.0 to 10.0 equivalents of a base, for example (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.198-205, for example).

[0037]

In the method i), the acid, solvent, and
temperature conditions used vary according to the starting material and are not specifically limited. Preferable examples of the acid used include hydrochloric acid, sulfuric acid, phosphoric acid, potassium hydrogen sulfide, oxalic acid, p-toluenesulfonic acid, a boron trifluoride-ether complex, thionyl chloride, and alumina oxide. The method may be performed without a solvent, or with a solvent or a mixture thereof that does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent used include nonpolar solvents such as toluene and benzene; polar solvents such as acetone, dimethyl sulfoxide, and hexamethylphosphoramide; halogenated solvents such as chloroform and methylene chloride; and water. In addition, a combination of an acid with an organic base such as pyridine may preferably improve the reaction rate and reaction yield in some cases, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 200°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled
in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0038] Preferable examples of the leaving group in the method ii) include an acetyl group, methanesulfonate group, p-toluenesulfonate group, chlorine atom, bromine atom, and iodine atom. The method of conversion into such a leaving group varies according to the starting material and is not specifically limited. A method known to a person skilled in the art may be used as such a conversion method. Preferably 1.0 to 10.0 equivalents of an acetylat ing agent such as acetyl chloride or acetic anhydride; a sulfonating agent such as methanesulfonyl chloride or p-toluenesulfonyl chloride; or a halogenating agent such as thionyl chloride, for example, may be used preferably in a halogenated solvent such as methylene chloride or chloroform; a nonpolar solvent such as toluene or benzene; an ether solvent such as tetrahydrofuran or ethylene glycol dimethyl ether; or a mixed solvent thereof, for example. The target product may be efficiently obtained when using a base such as preferably pyridine or triethylamine in an amount of preferably 1.0 to 10.0 equivalents, for example, or as a reaction solvent in this step. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and
is preferably -78 to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization. In the leaving reaction as the second step, preferably 1.0 to 10.0 equivalents of an organic base such as diazabicycloundecene, pyridine, 4-dimethyaminopyridine or triethylamine; a quaternary ammonium salt such as tetrabutylammonium hydroxide; an alkali metal salt such as sodium methoxide or potassium tert-butoxide; an alkali metal hydroxide such as sodium hydroxide; an alkali metal carbonate such as lithium carbonate or potassium carbonate; or an organic metal reagent such as lithium diisopropylamide, for example, is preferably used as a base preferably in a halogenated solvent such as methylene chloride or chloroform; a nonpolar solvent such as toluene or benzene; a polar solvent such as acetonitrile, dimethylformamide, or dimethyl sulfoxide; an ether solvent such as tetrahydrofuran or ethylene glycol dimethyl ether; or a mixed solvent thereof, for example. An organic base such as pyridine may also be used as a solvent. The reaction temperature must be a temperature that can complete the reaction without
promoting formation of an undesirable by-product, and is preferably -78 to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0039]

Preparation of aldol adduct (3)

The aldol adduct (3) can be prepared from an aldehyde compound (1) and 1.0 to 5.0 equivalents of a lactam compound (2) with respect to the aldehyde compound (1) according to Step 1-1, for example. Specifically, the aldol reaction in Step 1-1 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A method known to a person skilled in the art may be used for the reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.20, Yuki Gosei (Organic Synthesis) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., July 1992, p.94-100, for example).

Preferable examples of the method include i) a method of converting a lactam compound (2) into an alkali metal enolate by preferably 1.0 to 5.0 equivalents of a
base, for example (preferably lithium diisopropylamide, butyl lithium, sodium amide, sodium hydride, sodium methoxide, or potassium tert-butoxide, for example) and then reacting the enolate with an aldehyde compound (1) (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.20, Yuki Gosei (Organic Synthesis) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., July 1992, p.97-98, for example); and ii) a method of converting a lactam compound (2) into an alkali metal enolate by preferably 1.0 to 5.0 equivalents of a base, for example (preferably lithium diisopropylamide, butyl lithium, sodium amide, sodium hydride, sodium methoxide, or potassium tert-butoxide, for example), reacting the enolate with a silicon halide reagent (preferably trimethylchlorosilane or tert-butyldimethylchlorosilane, for example) to once prepare silyl enol ether, and then reacting the ether with an aldehyde compound (1) in the presence of preferably 0.05 to 5.0 equivalents of a Lewis acid, for example (preferably titanium tetrachloride or boron trifluoride, for example) (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.20, Yuki Gosei (Organic Synthesis) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., July 1992, p.96-97, for example). The solvent and reaction temperature used vary according to the starting material and are not specifically limited. As a solvent that does not inhibit the reaction and allows the starting material
to be dissolved therein to a certain extent, an ether solvent such as tetrahydrofuran, 1,4-dioxane, or diethyl ether; a halogenated solvent such as methylene chloride, 1,2-dichloroethane, or chloroform; a nonpolar solvent such as toluene or benzene; or a mixed solvent thereof may be preferably used, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to room temperature, for example. Under preferable reaction conditions, the reaction is preferably completed in 0.5 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.
Preparation of aldehyde compound (1)

(4a) \[\rightarrow \] (4c) \[\rightarrow \] (4b) \[\rightarrow \] (4d)

In the formula, $L_1$ represents a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a sulfonate group such as a triflate group, a trialkyltin group, a boronic acid group, a boronate group, or the like; and $L_2$ represents an alkyl ester group such as a methyl ester group, an aldehyde group, a cyano group, or the like.

Preparation of aldehyde compound (1)

The aldehyde compound (1) can be prepared from a compound (1a) as a starting material according to Step 2-5. Specifically, Step 2-5 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A method known to a person skilled
in the art may be used for the reaction. For example, 

i) when \( L_2 \) is an alkyl ester group, a reduction reaction 
described in many known documents may be used (see 
Jikken Kagaku Koza (Courses in Experimental Chemistry), 
vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited 
by The Chemical Society of Japan, Maruzen Co., Ltd., 
April 1992, p.159-266, for example). Preferably, the 
desired aldehyde compound \( \text{(1)} \) can be obtained by a 
reduction method using 1.0 to 10.0 equivalents of a 
metal hydride such as diisobutylaluminum hydride, for 
example. More preferably, the desired aldehyde 
compound \( \text{(1)} \) can be efficiently obtained by a reduction 
method using 1.0 to 10.0 equivalents of an aluminum 
hydride complex such as lithium aluminum hydride or 
sodium bis(2-methoxyethoxy)aluminum hydride with 
respect to a compound \( \text{(1a)} \) in the presence of 1.0 to 
10.0 equivalents of an amine with respect to a reducing 
agent, for example (see T. Abe et al., "Tetrahedron", 
2001, vol.57, p.2701-2710, for example). For example, 

ii) when \( L_2 \) is a cyano group, a reduction reaction 
described in many known documents may be used (see 
Jikken Kagaku Koza (Courses in Experimental Chemistry), 
vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited 
by The Chemical Society of Japan, Maruzen Co., Ltd., 
April 1992, p.159-266, for example). Preferably, the 
desired aldehyde compound \( \text{(1)} \) can be obtained by a 
reduction method using 1.0 to 10.0 equivalents of a 
metal hydride such as sodium bis(2-
methoxyethoxy)aluminum hydride or diisobutylaluminum hydride, for example (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol. 26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p. 231, for example). Alternatively, for example, iii) the desired aldehyde compound (1) can be efficiently obtained by reducing a compound (1a) to an alcohol compound using a technique known to a person skilled in the art (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol. 26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p. 159-266, for example), and then oxidizing the alcohol compound to an aldehyde compound (1) (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol. 23, Yuki Gosei (Organic Synthesis) [V], edited by The Chemical Society of Japan, Maruzen Co., Ltd., October 1991, p. 1-550, for example).

[0042]

The base used in the reduction reaction varies according to the starting material and is not specifically limited. A secondary amine may be used as a base. Preferably, the desired aldehyde compound (1) can be efficiently obtained when using 1.0 to 10.0 equivalents of a linear or cyclic secondary alkylamine such as diethylamine or pyrrolidine with respect to a reducing agent, for example. The solvent used varies according to the starting material and is not
specifically limited. As a solvent that does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent, an ether solvent such as tetrahydrofuran, 1,4-dioxane, or diethyl ether; a nonpolar solvent such as toluene or benzene; or a mixed solvent thereof may be preferably used, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to room temperature, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0043] The oxidizing agent, solvent, and reaction temperature used in the oxidation reaction vary according to the starting material and are not specifically limited. Preferable examples of the oxidizing agent include chromic acid oxidizing agents such as chromium oxide and dichromic acid; active manganese dioxide; dimethyl sulfoxide; periodic acid oxidizing agents such as Dess-Martin periodinane; and a mixture of an organic amine N-oxide such as 4-
methylmorpholine N-oxide with tetrapropylammonium perruthenate (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.21, Yuki Gosei (Organic Synthesis) [III], edited by The Chemical Society of Japan, Maruzen Co., Ltd., February 1991, p.2-23, for example). 1.0 to 50.0 equivalents of the oxidizing agent is preferably used with respect to the compound, for example. As a solvent that does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent, an ether solvent such as tetrahydrofuran, 1,4-dioxane, or diethyl ether; a halogenated solvent such as methylene chloride, 1,2-dichloroethane, or chloroform; a nonpolar solvent such as toluene or benzene; or a mixed solvent thereof may be preferably used, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0044]
Preparation of compound (1a)
The compound (1a) can be prepared from i) a compound (4a) as a starting material according to Step 2-1, for example. Alternatively, the compound (1a) can be prepared from ii) a compound (4d) as a starting material according to Step 2-4.

In the method i), Step 2-1 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A method known to a person skilled in the art may be used for the reaction. For example, a compound (4a) and 4-methylimidazole are preferably subjected to coupling reaction under neutral or basic conditions (see D.D. Davey et al., "J. Med. Chem.", 1991, vol.39, p.2671-2677). Specifically, 1.0 to 5.0 equivalents of the compound (4a) is preferably used with respect to 4-methylimidazole, for example. Preferably, the reaction may efficiently proceed in some cases when 1.0 to 5.0 equivalents of a base is used, for example. Preferable examples of the base include sodium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, barium carbonate, and organic bases such as pyridine. The solvent used in this reaction varies according to the starting material, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent.
Preferable examples of the solvent include tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidine, and acetonitrile. An organic base may also be used as a solvent. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably 50°C to 200°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0046]

In the method ii), Step 2-4 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A method known to a person skilled in the art may be used for the reaction (see Chemical & Pharmaceutical Bulletin, 1986, vol.34, p.3111, for example). Preferably, the desired compound (1a) can be obtained by heating a compound (4d) and 1.0 to 100.0 equivalents of ammonia or an ammonium salt with respect to the compound (4d), for example. The solvent and reaction temperature used vary according to the starting material and are not specifically limited. As
a solvent that does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent, an ether solvent such as tetrahydrofuran, 1,4-dioxane, or diethyl ether; a halogenated solvent such as methylene chloride, 1,2-dichloroethane, or chloroform; an alcohol solvent such as ethanol or methanol; a polar solvent such as dimethylformamide or N-methylpyrrolidone; a nonpolar solvent such as toluene; an organic acid such as acetic acid; or a mixed solvent thereof may be preferably used, for example. More preferably, the compound (1a) can be efficiently obtained by using 5.0 to 20.0 equivalents of ammonium acetate in an acetic acid solvent, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 200°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0047]

*Preparation of compound (4a)*

The compound (4a) is commercially available
or can be obtained by a technique known to a person skilled in the art. If not commercially available, the preferable compound (4a), wherein L represents a fluorine atom, chlorine atom, or bromine atom, can be obtained by oxidizing a corresponding methyl compound or alcohol compound by an oxidation reaction known to a person skilled in the art; by reducing a corresponding ester compound by a known reduction reaction, or by methylating a corresponding phenol compound.

Preparation of compound (4d)

The compound (4d) can be prepared from a compound (4c) as a starting material according to Step 2-3, for example. Specifically, Step 2-3 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A method known to a person skilled in the art may be used for the reaction (see Helvetica Chimica Acta, 1998, vol. 81, p. 1038).

Preferably, the compound (4d) can be obtained by stirring a compound (4c) and 1.0 to 10.0 equivalents of 2-halogenated acetone (preferably 2-chloroacetone, 2-bromoacetone, or 2-iodoacetone, for example) with respect to the compound (4c) in the presence of 1.0 to 10.0 equivalents of a base with respect to the compound (4c), for example. Preferable examples of the base used include alkali metal hydrides (preferably sodium hydride and lithium hydride, for example), alkali metal
salts (preferably potassium carbonate, sodium carbonate, and cesium carbonate, for example), and metal alkoxides (preferably sodium methoxide and tert-butyl potassium, for example). The solvent and reaction temperature used vary according to the starting material and are not specifically limited. As a solvent that does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent, an ether solvent such as tetrahydrofuran, 1,4-dioxane, or diethyl ether; a halogenated solvent such as methylene chloride, 1,2-dichloroethane, or chloroform; a polar solvent such as dimethylformamide or N-methylpyrrolidone; a nonpolar solvent such as toluene or benzene; or a mixture thereof may be preferably used, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 200°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Preparation of compound (4c)
The compound (4c) can be prepared from a compound (4b) as a starting material according to Step 2-2, for example. Specifically, the desired formylamide compound (4c) can be preferably obtained by a method of heating under reflux a compound (4b) in 10.0 to 100.0 equivalents of formic acid with respect to the compound (4b), or by a method of using formic acid and a dehydration condensation agent (an acid anhydride or dicyclohexylcarbodiimide, for example) for a compound (4b), for example. Preferably, the compound (4c) can be efficiently obtained by using 1 to 20 equivalents of formic acid with respect to the compound (4b) and 1 to 3 equivalents of a dehydration condensation agent with respect to the compound (4b), for example. The solvent used varies according to the starting material and is not specifically limited. As a solvent that does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent, an ether solvent such as tetrahydrofuran, 1,4-dioxane, or diethyl ether; a halogenated solvent such as methylene chloride, 1,2-dichloroethane, or chloroform; a polar solvent such as dimethylformamide or N-methylpyrrolidone; a nonpolar solvent such as toluene or benzene; or a mixture thereof may be preferably used, for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room
temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0050]

10 **Preparation of compound (4b)**

The compound (4b) is commercially available or can be prepared by a method known to a person skilled in the art. If not commercially available, the compound (4b) can be prepared by methylating a corresponding nitrophenol compound by a method known to a person skilled in the art, and then reducing the nitroanisole compound.
Preparation of lactam compound (2)

In the formula, \(-\) represents a single bond or a double bond; \(A_{r_1}, Z_1, R_{1}, R_{2}, p, q,\) and \(r\) are as defined above; \(L_3\) represents an alkyl ester group such as a methyl ester group or ethyl ester group, or an alkyl ketone group, aryl ketone group, or aralkyl ketone group such as an acetyl group, benzoyl group, or aryl methyl ketone group; \(L_4\) represents an alkoxy group such as a methoxy group or ethoxy group; \(L_5\) represents a carbamate protecting group such as a methyl carbamate group, benzyl carbamate group, or tert-butyl carbamate group, or an amide protecting group such as an acetyl group; \(L_6\) represents a halogen atom such as a bromine...
atom or iodine atom; $L_7$ represents a nitrile group, an alkyl ester group such as a methyl ester group, or an alkyl ketone group such as an acetyl group; $L_{14}$ represents a hydrogen atom, an alkyl group such as a methyl group or ethyl group, a phenyl group that may be substituted with 1 to 3 substituents selected from the above Substituent Group A1, an ester group such as a methyl ester group or ethyl ester group, a phosphate group such as dimethyl phosphate or diethyl phosphate, an alkylsulfonyl group such as a methylsulfonyl group, an arylsulfonyl group such as a phenylsulfonyl group, or the like; and $L_{15}$ represents an alkyl ketone group such as an acetyl group, an aryl ketone group such as a benzoyl group, a formyl group, an alkyl ester group such as a methyl ester group or ethyl ester group, or an aryl ester group such as a phenyl ester group.

[0052]

The above reaction formula shows an example of a method for preparing the lactam compound (2).

Specifically, the formula shows (i) a method for preparing the lactam compound (2) comprising converting an imide compound (5a) as a starting material that is commercially available or prepared using a method known to a person skilled in the art (see Tetrahedron: Asymmetry, 1998, vol.9, p.4361, for example) into an alkoxy lactam compound (5b) according to Step 3-1, and then continuously performing carbon Prolongation reaction and cyclization reaction in Step 3-2; (ii) a
method for preparing the lactam compound (2) comprising converting a 4-pyridone compound (5c) as a starting material that is commercially available or prepared using a method known to a person skilled in the art (see Tetrahedron Letters, 1986, vol.27, p.4549, for example) into an acylated compound (5d) according to Step 3-3, and then performing cyclization reaction in Step 3-4; (iii) a method for preparing the lactam compound (2) comprising converting an oxazolidine compound (5e) as a starting material that is commercially available or prepared using a method known to a person skilled in the art (see European Journal of Organic Chemistry, 2004, vol.23, p.4823, for example) into an amide alcohol compound (5f) according to Step 3-5, and then performing cyclization reaction in Step 3-6; (iv) a method for preparing the lactam compound (2) comprising converting a vinyl group substituted cyclic amine compound (5g) as a starting material that is commercially available or prepared using a method known to a person skilled in the art (see Tetrahedron Letters, 1998, vol.39, p.5421, and Tetrahedron Letters, 2004, vol.45, p.4895, for example) into an acylated compound (5h) according to Step 3-7, and then performing cyclization reaction in Step 3-8; (v) a method for preparing the lactam compound (2) comprising converting a cycloalkyl ketone compound (5i) as a starting material that is commercially available or prepared using a method known to a person skilled in
the art (see The Journal of Organic Chemistry, 2001, vol.66, p.886, for example) into an azide compound (5j) according to Step 3-9, and then performing cyclization reaction in Step 3-10; or (vi) a method for preparing the lactam compound (2) comprising converting a vinyl group substituted cyclic amine compound (5g) as a starting material into a compound (5k) according to Step 3-11, and then performing cyclization reaction in Step 3-12.

Conversion of imide compound (5a) into alkoxy lactam compound (5b)

Partial reduction of an imide group in Step 3-1 varies according to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction. Preferably, the desired alkoxy lactam compound (5b) can be obtained by reacting an imide compound (5a) with 1.0 to 5.0 equivalents of sodium borohydride with respect to the imide compound (5a) in an alcohol solvent such as methanol (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.207-237, for example) or reacting an imide compound (5a) with 1.0 to 5.0 equivalents of borane with respect to the imide compound (5a) in an ether solvent such as tetrahydrofuran (see Jikken Kagaku Koza...
(Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.237-248, for example); and then performing reaction in an alcohol solvent such as methanol in the presence of 0.1 to 10.0 equivalents of an inorganic acid such as sulfuric acid with respect to the imide compound (5a), for example. Alternatively, the desired alkoxy lactam compound (5b) can be preferably obtained in one step by stirring an imide compound (5a) and 1.0 to 5.0 equivalents of sodium borohydride with respect to the imide compound (5a) in an alcohol solvent such as methanol in the presence of 0.1 to 5.0 equivalents of an inorganic acid such as sulfuric acid with respect to the imide compound (5a), for example (see Tetrahedron: Asymmetry, 1998, vol.9, p.4361, for example). The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0054]
Conversion of alkoxy lactam compound (5b) into lactam compound (2)

In Step 3-2, the desired lactam compound (2) can be obtained by reacting L₁ of the alkoxy lactam compound (5b) with a Wittig reagent (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.254-262, for example), a Grignard reagent (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.59-72, for example), or an alkyl lithium reagent (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.9-51, for example) to derive an olefin derivative therefrom, and then reacting the derivative with an acid such as hydrochloric acid. Preferably, the desired lactam compound (2) can be obtained in a high yield by stirring the alkoxy lactam compound (5b) and 1.0 to 10.0 equivalents of a Grignard reagent such as trimethylsilylmethylmagnesium chloride with respect to the alkoxy lactam compound (5b) in an ether solvent such as tetrahydrofuran in the presence of 1.0 to 10.0 equivalents of cerium chloride with respect to the alkoxy lactam compound (5b); and then reacting the
solution with an inorganic acid such as hydrochloric acid, for example (see Tetrahedron: Asymmetry, 1998, vol.9, p.4361, for example). The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Conversion of 4-pyridone compound (5c) into acylated compound (5d)

Step 3-3 consists of deprotection reaction of an amine moiety and subsequent amidation reaction. As deprotection reaction of a compound (5c), a deprotection reaction described in many known documents may be used (see T.W. Green, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981, for example). In this reaction, the amine compound may be obtained from a corresponding carbamate compound (preferably a tert-butyl carbamate compound, benzyl carbamate compound, or 9-fluorenylmethyl carbamate compound, for example) or from a corresponding amide
compound (preferably a formamide compound, acetamide compound, trifluoroacetamide compound, for example). This deprotection reaction varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A known method may be used for the reaction. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization. The amidation reaction varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A known method described in many documents may be used for the reaction (see Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol.14, Yuki Kagobutsu No Gosei To Hannou (Synthesis and Reaction of Organic Compounds) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., February 1978, p.1136-1162, for example). Preferable examples of the method include i) a method of reacting the amine compound with 1.0 to 5.0 equivalents of an acid halide compound with respect to the amine compound (see Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol.14, Yuki Kagobutsu No Gosei To Hannou (Synthesis and
Reaction of Organic Compounds) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., February 1978, p.1142-1145, for example); and ii) a method of reacting the amine compound with 1.0 to 5.0 equivalents of a carboxylic acid compound with respect to the amine compound using 1.0 to 5.0 equivalents of a condensing agent with respect to the amine compound (see "Yukikagaku Jikken No Tebiki (Introduction to Organic Chemistry Experiments) [4]", Kagaku-Dojin Publishing Company, Inc., September 1990, p.27-52, for example).

[0056]

In the method i), the base used varies according to the starting material and is not specifically limited. The base is preferably 1.0 to 100.0 equivalents of pyridine, triethylamine, N,N-diisopropylethylamine, lutidine, quinoline, or isoquinoline with respect to the amine compound, for example. The solvent used is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include tetrahydrofuran and 1,4-dioxane. A base may be used as a solvent. Alternatively, it is possible to use a two-layer partition system consisting of a base that is an alkali solution, preferably a sodium hydroxide or potassium hydroxide solution, for example, and a halogenated solvent such as methylene chloride or 1,2-dichloroethane. The reaction
temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0057]

In the method ii), the condensing agent used varies according to the starting material and is not specifically limited. For example, 1.0 to 2.0 equivalents of 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, diethyl cyanophosphonate, or bis(2-oxo-3-oxazolidinyl)phosphinic chloride may be appropriately used with respect to the carboxylic acid used. Preferably, 1.0 to 2.0 equivalents of N-hydroxysuccinimide or N-hydroxybenzotriazole may be added with respect to the carboxylic acid compound used in order to make the reaction efficiently proceed, for example. This reaction is preferably performed in the presence of a solvent from the viewpoint of operativity and stirring efficiency. The solvent used varies
according to the starting material and the condensing agent used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent that can be used include halogenated solvents such as methylene chloride and 1,2-dichloroethane, and polar solvents such as tetrahydrofuran and N,N-dimethylformamide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

Conversion of acylated compound (5d) into lactam compound (2)

Step 3-4 is cyclization reaction through radical formation. Specifically, for example, the desired lactam compound (2) can be preferably obtained in a high yield by reacting the compound (5d) with preferably 1.0 to 2.0 equivalents of an alkyltin
reagent such as tributyltin with respect to the compound (5d), for example, in a nonpolar solvent such as toluene in the presence of preferably 0.1 to 1.0 equivalent of a radical initiator such as 2,2-
5 azobis(isobutyronitrile) with respect to the compound (5d), for example. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably 50°C to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization. After cyclization, Z₁ may be converted in various manners using a ketone group as a scaffold by a method known to a person skilled in the art such as reduction reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.159-266, for example), addition reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.9-72, for example), or addition dehydration reaction (see Jikken
Kagaku Koza (Courses in Experimental Chemistry),
vol.19, Yuki Gosei (Organic Synthesis) [I], edited by
The Chemical Society of Japan, Maruzen Co., Ltd., June
1992, p.57-85, for example).

Conversion of oxazolidine compound (5e) into amide
alcohol compound (5f)

Step 3-5 is oxidative cleavage reaction of an
oxazolidine ring which derives an amide alcohol
compound (5f) from a compound (5e). Specifically, the
desired amide alcohol compound (5f) can be preferably
obtained in a high yield by reacting a compound (5e)
with 2.0 to 10.0 equivalents of potassium permanganate
with respect to the compound (5e) in an aqueous solvent
such as a mixture of water with acetone, for example
(see European Journal of Organic Chemistry, 2004,
vol.23, p.4823, for example), or the compound (5f) can
be preferably obtained by reacting a compound (5e) with
1.0 to 10.0 equivalents of bromine with respect to the
compound (5e) in a halogenated solvent such as
methylene chloride, for example (see Synlett, 1994,
vol.2, p.143, for example). The solvent used in this
step varies according to the starting material and the
oxidizing agent used, and is not specifically limited
insofar as the solvent does not inhibit the reaction
and allows the starting material to be dissolved
therein to a certain extent. The reaction temperature
must be a temperature that can complete the reaction
without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0060]

Conversion of amide alcohol compound (5f) into lactam compound (2)

Step 3-6 consists of conversion of L7 of the amide alcohol compound (5f) into an alcohol or amine and subsequent cyclization reaction. Specifically, the conversion of L7 of the amide alcohol compound (5f) into an alcohol varies according to the starting material, and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.20, Yuki Gosei (Organic Synthesis) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., July 1992, p.1-30, for example). The conversion of L7 of the amide alcohol compound (5f) into an amine varies according to the starting material, and can be performed by a method known to a person skilled in the art insofar as the
conditions are similar to those in this reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.20, Yuki Gosei (Organic Synthesis) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., July 1992, p.279-318, for example). The cyclization reaction of the alcohol compound or the amine compound varies according to the starting material, and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Journal of Fluorine Chemistry, 1997, vol.2, p.119, or Scientia Pharmaceutica, 1996, vol.64, p.3, for example). Preferably, the lactam compound (2) can be obtained in a high yield by heating the alcohol compound in a solvent or without a solvent in the presence of 0.1 to 10 equivalents of an organic acid such as p-toluenesulfonic acid or camphorsulfonic acid or an inorganic acid such as sulfuric acid or hydrochloric acid with respect to the alcohol compound, for example. The cyclization reaction of the amine compound varies according to the starting material, and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Petrochemia, 1990, vol.30, p.56; WO 2003/076386; or Tetrahedron Letters, 1982, vol.23, p.229, for example). Preferably, the lactam compound (2) can be obtained in a high yield by stirring the amine compound in a solvent such as tetrahydrofuran, toluene, methylene chloride, or
dimethylformamide in the presence of 0.1 to 1.0 equivalents of an organic metal such as tetrakistriphenylphosphine palladium or tristriphenylphosphine ruthenium with respect to the amine compound, for example. Obviously, the solvent used in this step varies according to the starting material and the reagent used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0061]

Conversion of vinyl group substituted cyclic amine compound (5g) into acylated compound (5h)

The acylated compound (5h) can be prepared from a vinyl group substituted cyclic amine compound (5g) as a starting material in Step 3-7. Specifically, Step 3-7 is performed by the same method as in Step 3-
Conversion of acylated compound (5h) into lactam compound (2)

Step 3-8 consists of ring closing metathesis reaction and subsequent double bond modification reaction. The ring closing metathesis reaction varies according to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Comprehensive Organometallic Chemistry, 1982, vol.8, p.499, or Angewandte Chemie International Edition, 2000, vol.39, p.3012, for example). Preferably, the double bond modification reaction may be performed by, for example, i) catalytic hydrogenation (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.251-266, for example); ii) hydroboration (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.83-134, for example); or iii) oxidation of a carbon-carbon double bond (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.23, Yuki Gosei (Organic Synthesis) [V], edited by The Chemical Society of Japan, Maruzen Co., Ltd., October 1991, p.237-267, for
example).

[0063]

The ring closing metathesis reaction is preferably a method of stirring the acylated compound (5h) in a solvent in the presence of 0.01 to 0.2 equivalent of a metal catalyst with respect to the acylated compound (5h), for example. Preferable examples of the solvent used include halogenated solvents such as methylene chloride and chloroform; ether solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; and mixed solvents thereof. The metal catalyst used varies according to the starting material and the solvent. Preferable examples of the metal catalyst used include ruthenium catalysts such as bis(tricyclohexylphosphine)benzylidene ruthenium (IV) dichloride, benzylidene[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(tricyclohexylphosphine) ruthenium (IV), and [1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(o-isopropoxyphenylmethylidene)ruthenium (IV); and molybdenum catalysts such as 2,6-diisopropylphenylimidoneophy lilidene biphen molybdenum (VI) and 2,6-diisopropylphenylimidoneophy lilidene molybdenum (VI) bis(hexafluoro-tert-butoxide). The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room
temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Conversion of cycloalkyl ketone compound (5i) into azide compound (5j)

Step 3-9 consists of i) halogenation reaction at the α-position of an aromatic ring (-CH₂-Ar₁) and ii) subsequent azide introduction reaction.

The halogenation reaction i) varies according to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.422-458, for example). Preferable examples of the method include a method of stirring a cycloalkyl ketone compound (5i) and 1.0 to 2.0 equivalents of a halogenating agent with respect to the cycloalkyl ketone compound (5i) in a solvent. Preferable examples of the halogenating agent used
include N-bromosuccinimide and bromine. In addition, the reaction may be remarkably promoted by adding preferably 0.01 to 0.5 equivalent of a radical initiator such as benzoyl peroxide or 2,2-azobisisobutyronitrile with respect to the cycloalkyl ketone compound (5i), for example, or by adding preferably 0.01 to 0.5 equivalent of an acid catalyst such as hydrobromic acid with respect to the cycloalkyl ketone compound (5i), for example. The solvent used varies according to the starting material, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include carbon tetrachloride and benzene. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0066]

The azidation reaction ii) varies according
to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.20, Yuki Gosei (Organic Synthesis) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., July 1992, p.415-420, for example). Preferably, the halogenated compound and 1.0 to 5.0 equivalents of an azidating agent with respect to the halogenated compound are stirred in a solvent, for example. Preferable examples of the azidating agent used include sodium azide and trimethylsilyl azide. Preferably, the reaction may be remarkably promoted by using 0.1 to 5.0 equivalents of a quaternary amine salt such as tetrabutylammonium fluoride with respect to the azidating agent used, for example. The solvent used varies according to the starting material, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent used include ether solvents such as tetrahydrofuran and dioxane; halogenated solvents such as chloroform and methylene chloride; nonpolar solvents such as benzene and toluene; and polar solvents such as acetone, acetonitrile, dimethylformamide, and N-methylpyrrolidine. The reaction temperature must be a temperature that can complete the reaction without
promoting formation of an undesirable by-product, and is preferably room temperature to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Conversion of azide compound (5j) into lactam compound (2)

Step 3-10 is a method for preparing the lactam compound (2) comprising stirring an azide compound (5j) in a solvent in the presence of 1.0 to 10.0 equivalents of an acid with respect to the azide compound (5j) to cause rearrangement reaction. Specifically, this step varies according to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see The Journal of Organic Chemistry, 2001, vol.66, p.886, for example). Preferable examples of the acid used include trifluoromethanesulfonic acid, trifluoroacetic acid, sulfuric acid, and hydrochloric acid. Although the acid may be used as a solvent, this reaction is preferably performed in the presence of a separate
solvent from the viewpoint of operativity and stirring efficiency. The solvent used varies according to the starting material, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include halogenated solvents such as chloroform and methylene chloride; and nonpolar solvents such as benzene and toluene. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to 50°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Conversion of vinyl group substituted cyclic amine compound (5g) into compound (5k)

The compound (5k) can be prepared from the vinyl group substituted cyclic amine compound (5g) as a starting material in Step 3-11. Step 3-11 consists of double bond reduction reaction and subsequent carbon prolongation reaction.
A method described in many known documents may be used for the double bond reduction reaction. Preferable examples of the method include i) catalytic hydrogenation reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.251-266, for example); and ii) reduction using a metal and metal salt (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.165-1856, for example).

Examples of the method i) include a method of stirring the compound (5g) together with a hydrogen source in a solvent in the presence of 0.01 to 0.5 equivalent of a metal catalyst with respect to the compound (5g). The metal catalyst used varies according to the starting material and is not specifically limited. Preferable examples of the catalyst include palladium-carbon, rhodium-carbon, ruthenium-carbon, palladium hydroxide, platinum oxide, Raney nickel, and a Wilkinson catalyst. The hydrogen source varies according to the starting material and the metal catalyst used, and is not specifically limited. Preferable examples of the hydrogen source include hydrogen gas, formic acid, ammonium formate,
and cyclohexadiene. The solvent used varies according to the starting material and the metal catalyst, and is not specifically limited. Preferable examples of the solvent include methanol, ethanol, ethyl acetate, toluene, THF, 1,4-dioxane, chloroform, methylene chloride, water, and a mixture thereof. An organic acid, inorganic acid, or organic base may be appropriately added in order to make the reaction efficiently proceed. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Examples of the method ii) include a method of stirring the compound (5g) in a solvent in the presence of 1.0 to 10.0 equivalents of a metal or metal salt with respect to the compound (5g). The metal or metal salt used varies according to the starting material and is not specifically limited. Preferable examples of the metal or metal salt include alkali
metals such as lithium and sodium; alkali earth metals such as magnesium and calcium; and salts thereof. The solvent used varies according to the starting material and the metal used, and is not specifically limited. Preferable examples of the solvent include ammonia, methanol, ethanol, tert-butanol, tetrahydrofuran, 1,4-dioxane, diethyl ether, water, and a mixture thereof. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78°C to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

A method described in many known documents may be used for the carbon prolongation reaction subsequent to the double bond reduction. Preferable examples of the method include i) Wittig reaction, ii) Horner-Emmons reaction, and iii) Peterson reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.57-85, for example).
Preferable examples of the Wittig reaction include a method of stirring in a solvent an aldehyde compound derived from the compound (5 g) and 1.0 to 3.0 equivalents of a known Wittig reagent with respect to the aldehyde compound in the presence of 1.0 to 5.0 equivalents of a base with respect to the aldehyde compound. The solvent used varies according to the starting material and the base used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include polar solvents such as nitromethane, acetonitrile, 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; halogenated solvents such as chloroform and methylene chloride; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene;
organic metals such as butyl lithium and lithium diisobutylamide; and alkali metal hydrides such as sodium hydride. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Preferable examples of the Horner-Emmons reaction include a method of stirring in a solvent an aldehyde compound derived from the compound (5g) and 1.0 to 3.0 equivalents of a known Horner-Emmons reagent with respect to the aldehyde compound in the presence of 1.0 to 5.0 equivalents of a base with respect to the aldehyde compound. The solvent used varies according to the starting material and the base used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include polar solvents such as 1-methyl-2-pyrrolidone, N,N-
dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.
Preferable examples of the Peterson reaction include a method of stirring in a solvent an aldehyde compound derived from the compound (5g) and 1.0 to 3.0 equivalents of a known Peterson reagent with respect to the aldehyde compound in the presence of 1.0 to 5.0 equivalents of a base with respect to the aldehyde compound. The solvent used varies according to the starting material and the base used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include polar solvents such as 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal
ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0075]

**Conversion of compound (5k) into lactam compound (2)**

The lactam compound (2) can be prepared from the compound (5k) as a starting material by intramolecular amidation reaction according to Step 3-12. Specifically, Step 3-12 is performed by the same method as in Step 3-3.

[0076]

**General Preparation Method 2**

Typically used General Preparation Method 2 for the compound of the general formula (I) of the present invention will be described below.
In the formula, ---- represents a single bond or a double bond; Ar₁, Z₁, R¹, R², p, q, and r are as defined above; and L₈ represents a phosphite group such as a diethylphosphonyl group, a phosphonium salt such as triphenylphosphonium bromide, a silyl group such as a trimethylsilyl group, an ester group such as a methyl ester group or ethyl ester group, or a carboxyl group.

The above General Preparation Method 2 is an example of a method for preparing the compound of the general formula (I) comprising introducing a leaving group L₈ into a lactam compound (2) according to Step 4-1 and then condensing the compound with an aldehyde compound (1) according to Step 4-2.

Preparation of compound of general formula (I)

The condensation reaction of Step 4-2 varies
according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A known method described in many documents may be used for the reaction. Preferable examples of the method include Wittig reaction, Horner-Emmons reaction, Peterson reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.57-85, for example), and Knoevenagel reaction.

[0079]

Preferable examples of the Wittig reaction include a method of stirring in a solvent a compound (6), wherein L₈ is a phosphonium salt, preferably 0.5 to 2.0 equivalents of an aldehyde compound (1) with respect to the compound (6), for example, and preferably 1.0 to 5.0 equivalents of a base with respect to the compound (6), for example. This reaction may be a method of first treating a compound (6) and a base to form a phosphonium ylide and then adding an aldehyde compound (1) to the ylide; or a method of adding a base in the presence of a compound (6) and an aldehyde compound (1). The solvent used varies according to the starting material and the base used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain
extent. Preferable examples of the solvent include polar solvents such as nitromethane, acetonitrile, 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; halogenated solvents such as chloroform and methylene chloride; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; and alkali metal hydrides such as sodium hydride. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional
chromatography technique, extraction, or/and crystallization.

[0080]

Preferable examples of the Horner-Emmons reaction include a method of stirring in a solvent a compound (6), wherein L₈ is a phosphite group, preferably 0.5 to 2.0 equivalents of an aldehyde compound (1) with respect to the compound (6), for example, and preferably 1.0 to 5.0 equivalents of a base with respect to the compound (6), for example. This reaction may be a method of first treating a compound (6) and a base to form a carbanion and then adding an aldehyde compound (1) to the carbanion; or a method of adding a base in the presence of a compound (6) and an aldehyde compound (1). The solvent used varies according to the starting material and the base used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include polar solvents such as 1-methyl-2-pyrroldione, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include
alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0081]

Preferable examples of the Peterson reaction include a method of stirring in a solvent a compound (6), wherein L₈ is a silyl group, preferably 0.5 to 2.0 equivalents of an aldehyde compound (1) with respect to the compound (6), for example, and preferably 1.0 to 5.0 equivalents of a base with respect to the compound (6), for example. This reaction may be a method of
first treating a compound (6) and a base to form a
carbanion and then adding an aldehyde compound (1) to
the carbanion; or a method of adding a base in the
presence of a compound (6) and an aldehyde compound
(1). The solvent used varies according to the starting
material and the base used, and is not specifically
limited insofar as the solvent does not inhibit the
reaction and allows the starting material to be
dissolved therein to a certain extent. Preferable
examples of the solvent include polar solvents such as
1-methyl-2-pyrrolidone, N,N-dimethylformamide, and
dimethyl sulfoxide; ether solvents such as
tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane;
nonpolar solvents such as benzene, toluene, and xylene;
alcohol solvents such as ethanol and methanol; water;
and mixed solvents thereof. The base used varies
according to the starting material and the solvent.
Preferable examples of the base include alkali metal
hydroxides such as sodium hydroxide and lithium
hydroxide; alkali metal carbonates such as sodium
carbonate; alkali metal salts of alcohols such as
sodium methoxide and potassium tert-butoxide; organic
bases such as triethylamine, pyridine, and
diazabicyclononene; organic metals such as butyl
lithium and lithium diisobutyramide; alkali metal
hydrides such as sodium hydride; and alkali metal
ammonium salts such as sodium amide. The reaction
temperature must be a temperature that can complete the
reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Preferable examples of the Knoevenagel reaction include a method of stirring in a solvent a compound (6), wherein L₆ is an ester group or carboxyl group, preferably 0.5 to 2.0 equivalents of an aldehyde compound (1) with respect to the compound (6), for example, and preferably 1.0 to 5.0 equivalents of a base with respect to the compound (6), for example. This reaction may be a method of first treating a compound (6) and a base to form a carbanion and then adding an aldehyde compound (1) to the carbanion; or a method of adding a base in the presence of a compound (6) and an aldehyde compound (1). The solvent used varies according to the starting material and the base used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include
polar solvents such as 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.
[0083]

Preparation of compound (6)

The compound (6) can be prepared from a lactam compound (2) as a starting material according to Step 4-1. Preferably, for example, i) the Wittig reagent (6), wherein L₈ is a phosphonium salt, can be prepared by halogenating a lactam compound (2) by a method known to a person skilled in the art (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.430-438, for example), and then reacting the compound with an organic phosphine compound such as triphenylphosphine (see Organic Reaction, 1965, vol.14, p.270, for example). ii) The Horner-Emmons reagent (6), wherein L₈ is a phosphite, can be prepared by halogenating a lactam compound (2) by a method known to a person skilled in the art (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.430-438, for example), and then reacting the compound with an alkyl phosphinite by Arbuzov reaction (see Chemical Review, 1981, vol.81, p.415, for example) or with a metal phosphonite by Becker reaction (see Journal of the American Chemical Society, 1945, vol.67, p.1180, for example). Alternatively, the Horner-Emmons reagent can be prepared from a lactam compound (2) and a
chlorophosphate in the presence of a base (see The Journal of Organic Chemistry, 1989, vol.54, p.4750, for example). iii) The Peterson reagent (6), wherein L₈ is a silyl group, can be prepared from a lactam compound (2) and a trialkylsilyl chloride in the presence of a base (see Journal of Organometallic Chemistry, 1983, vol.248, p.51, for example). iv) The ester compound or carboxylic acid compound, wherein L₈ is an ester group or carboxyl group, can be prepared from a lactam compound (2) and a carbonic diester, a halogenated carbonate, or carbon dioxide in the presence of a base (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.22, Yuki Gosei (Organic Synthesis) [IV], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.14-30 and p.54-71, for example).

Typically used General Preparation Method 3

for the compound of the general formula (I) of the present invention will be described below.
In the formula, \( \equiv \) represents a single bond or a double bond; \( \text{Ar}_1, Z_1, R^2_1, R^2, p, q, \) and \( r \) are as defined above; \( x \) and \( y \) each represent an integer of 0 to 2; \( L_9 \) represents a halogen atom such as chlorine, bromine, or iodine, or a sulfonate group such as a triflate group; and \( L_{10} \) represents an ester group such as a methyl ester group or ethyl ester group, or carboxylic acid.

The above General Preparation Method 3 is an example of i) a method for preparing the compound of the general formula (I) comprising deriving a compound (7) from an aldehyde compound (1) according to Step 5-1 or according to Step 5-5 through Step 5-4, converting the compound (7) into an amide compound (8) by condensation reaction with an amine compound (16) in
Step 5-2, and then subjecting the amide compound (8) to ring closing metathesis reaction and subsequent double bond modification reaction in Step 5-3; or ii) a method for preparing the compound of the general formula (I) comprising deriving a compound (9) from an aldehyde compound (1) according to Step 5-4, converting the compound (9) into an amide compound (10) in Step 5-6, and then subjecting the amide compound (10) to Heck reaction and subsequent double bond modification reaction in Step 5-7.

[0086]

Preparation of compound of general formula (I)

In the method i), the compound of the general formula (I) can be prepared from an amide compound (8) according to Step 5-3. Step 5-3 consists of ring closing metathesis reaction and subsequent double bond modification reaction. Specifically, the first-stage ring closing metathesis reaction varies according to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Comprehensive Organometallic Chemistry, 1982, vol.8, p.499, or Angewandte Chemie International Edition, 2000, vol.39, p.3012, for example). The second-stage double bond modification reaction may be performed by, for example, i) catalytic hydrogenation (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited
by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.251-266, for example); ii) hydroboration (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.83-134, for example); or iii) oxidation of a carbon-carbon double bond (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.23, Yuki Gosei (Organic Synthesis) [V], edited by The Chemical Society of Japan, Maruzen Co., Ltd., October 1991, p.237-267, for example).

[0087] Preferably, the ring closing metathesis reaction is a method of performing intramolecular cyclization reaction by stirring an amide compound (8) in a solvent in the presence of 0.01 to 0.2 equivalent of a metal catalyst with respect to the amide compound (8). Preferable examples of the solvent used include halogenated solvents such as methylene chloride and chloroform; ether solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; and mixed solvents thereof. The metal catalyst used varies according to the starting material and the solvent. Preferable examples of the metal catalyst used include ruthenium catalysts such as bis(tricyclohexylphosphine)benzylidene ruthenium (IV) dichloride, benzylidene[1,3-bis(2,4,6-trimethylphenyl)-
2-imidazolidinylidene)dichloro(tricyclohexylphosphine) ruthenium (IV), and [1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylidene)ruthenium (IV); and molybdenum catalysts such as 2,6-diisopropylphenylimidoneophyldene biphien molybdenum (VI) and 2,6-diisopropylphenylimidoneophyldene molybdenum (VI) bis(hexafluoro-tert-butoxide). The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0088]

The double bond modification reaction is preferably catalytic hydrogenation, for example, in which the cyclized compound obtained by the ring closing metathesis reaction is reduced in a hydrogen stream preferably at 1 to 10 atm, for example, in the presence of preferably 0.01 to 0.2 equivalent of a metal catalyst with respect to the cyclized compound, for example. This reaction is preferably performed in
the presence of a solvent from the viewpoint of operativity and stirring efficiency. Preferable examples of the solvent used include alcohol solvents such as ethanol and methanol; halogenated solvents such as methylene chloride and chloroform; ether solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; polar solvents such as ethyl acetate and acetonitrile; and mixed solvents thereof.

The metal catalyst used varies according to the starting material and the solvent. Preferable examples of the catalyst include platinum, platinum oxide, platinum black, Raney nickel, and palladium-carbon. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably room temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

[0089]

In the method ii), the compound of the general formula (I) can be prepared from an amide compound (10) according to Step 5-7. Specifically,
Step 5-7 consists of Heck reaction and subsequent double bond modification reaction. Specifically, the first-stage Heck reaction varies according to the starting material and can be performed by a method known to a person skilled in the art insofar as the conditions are similar to those in this reaction (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p.123-132, for example). The second-stage double bond modification reaction may be performed by, for example, i) catalytic hydrogenation (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.26, Yuki Gosei (Organic Synthesis) [VIII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., April 1992, p.251-266, for example); ii) hydroboration (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.25, Yuki Gosei (Organic Synthesis) [VII], edited by The Chemical Society of Japan, Maruzen Co., Ltd., September 1991, p.83-134, for example); or iii) oxidation of a carbon-carbon double bond (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol.23, Yuki Gosei (Organic Synthesis) [V], edited by The Chemical Society of Japan, Maruzen Co., Ltd., October 1991, p.237-267, for example).

[0090]

Preferable examples of the Heck reaction include a method of stirring a compound (10) in a
solvent in the presence of 0.01 to 0.2 equivalent of a transition metal catalyst with respect to the compound (10). The solvent used varies according to the starting material and the transition metal catalyst used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene, 1-methyl-2-pyrrolidone, and N,N-dimethylformamide. The reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 150°C, for example. This reaction is performed preferably in an inert gas atmosphere, and more preferably in a nitrogen or argon atmosphere. The transition metal catalyst is preferably a palladium complex, for example, and more preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0), or tris(dibenzylideneacetone)dipalladium (0). In addition, it is preferable to appropriately add preferably 1.0 to 5.0 equivalents of a phosphorus ligand (preferably triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, or 2-(di-tert-butylphosphino)biphenyl, for example) with respect to the transition metal catalyst used, for example, in
order to make the reaction efficiently proceed. A preferable result may be obtained in the presence of a base, and the base used is not specifically limited insofar as the base is used in a coupling reaction similar to this reaction. The base is preferably 0.1 to 5.0 equivalents of triethylamine, N,N-diisopropylethylamine, N,N-dicyclohexylmethylamine, or tetrabutylammonium chloride with respect to the compound (10), for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique.

[0091]

15 **Preparation of amide compound (8)**

The amidation reaction in Step 5-2 varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A known method described in many documents may be used for the reaction (see Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol.14, Yuki Kagobutsu No Gosei To Hannou (Synthesis and Reaction of Organic Compounds) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., February 1978, p.1136-1162, for example). Preferable examples of the method include i) a method of converting a compound (7) into an acid halide and reacting the acid halide with an
amine compound (16) under basic conditions (see Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol.14, Yuki Kagobutsu No Gosei To Hannou (Synthesis and Reaction of Organic Compounds) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., February 1978, p.1142-1145, for example); and ii) a method of reacting a compound (7) with an amine compound (16) using a condensing agent (see "Yukikagaku Jikken No Tebiki (Introduction to Organic Chemistry Experiments) [4]", Kagaku-Dojin Publishing Company, Inc., September 1990, p.27-52, for example).

[0092]

Preferable examples of the reaction of converting a compound (7) into an acid halide in the method i) include a method of stirring a compound (7) in a solvent in the presence of 1.0 to 10.0 equivalents of a halogenating agent with respect to the compound (7). The halogenating agent used varies according to the starting material and is not specifically limited. Preferable examples of the halogenating agent include thionyl chloride, phosphorus pentachloride, and oxalyl chloride. The solvent used is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include methylene chloride, chloroform, and toluene. The reaction may efficiently proceed when 0.1 to 1.0 equivalent of an organic base such as pyridine,
dimethylformamide, or the like is appropriately added with respect to the compound (7). The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0093]

Preferable examples of the subsequent coupling reaction include a method of stirring the acid halide and 1.0 to 5.0 equivalents of an amine compound (16) with respect to the acid halide in a solvent in the presence of 1.0 to 100.0 equivalents of a base with respect to the acid halide. The base used varies according to the starting material and is not specifically limited. Preferable examples of the base include pyridine, triethylamine, N,N-diisopropylethylamine, lutidine, quinoline, and isoquinoline. The solvent used is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable
examples of the solvent include methylene chloride, chloroform, toluene, tetrahydrofuran, and 1,4-dioxane. A base may be used as a solvent. Alternatively, it is possible to use a two-layer partition system consisting of a base that is an alkali solution, preferably a sodium hydroxide or potassium hydroxide solution, for example, and a halogenated solvent such as methylene chloride or 1,2-dichloroethane. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

Preferable examples of the method ii) include a method of stirring in a solvent a compound (7) and 1.0 to 5.0 equivalents of an amine compound (16) with respect to the compound (7) in the presence of 1.0 to 5.0 equivalents of a condensing agent with respect to the compound (7). The condensing agent used varies according to the starting material and is not specifically limited. Preferable examples of the
condensing agent include 1,3-dicyclohexylcarbodiimide, 
1-ethyl-3-[(3'-dimethylaminopropyl)carbodiimide, 
benzotriazol-1-ylxytris(dimethylamino)phosphonium 
hexafluorophosphate, diethyl cyanophosphonate, and 
bis(2-oxo-3-oxazolidinyl)phosphinic chloride. 
Preferably, 1.0 to 2.0 equivalents of N-
hydroxysuccinimide or N-hydroxybenzotriazole may be 
added with respect to the compound (7) in order to make 
the reaction efficiently proceed, for example. This 
reaction is preferably performed in the presence of a 
solvent from the viewpoint of operativity and stirring 
efficiency. The solvent used varies according to the 
starting material and the condensing agent used, and is 
not specifically limited insofar as the solvent does 
not inhibit the reaction and allows the starting 
material to be dissolved therein to a certain extent. 
Preferable examples of the solvent used include 
halogenated solvents such as methylene chloride and 
1,2-dichlooroethane, and polar solvents such as 
tetrahydrofuran and N,N-dimethylformamide. The 
reaction temperature must be a temperature that can 
complete the reaction without promoting formation of an 
undesirable by-product, and is preferably ice-cold 
temperature to 100°C, for example. Under preferable 
reaction conditions, the reaction is preferably 
completed in 1 to 24 hours, for example, and the 
progress of the reaction can be monitored by a known 
chromatography technique. An undesirable by-product
can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0095]

5 Preparation of amine compound (16)

The amine compound (16) is commercially available or can be prepared by a method known to a person skilled in the art (see Tetrahedron Letters, 1998, vol.39, p.5421, for example).

[0096]

Preparation of compound (7)

The compound (7) can be prepared i) from an aldehyde compound (1) according to Step 5-1, or ii) by deriving a compound (9), wherein L₁₀ represents an ester group, from an aldehyde compound (1) according to Step 5-4 and then subjecting the compound (9) to Step 5-5.

[0097]

[Conversion of aldehyde compound (1) into compound (7)]

Step 5-1 consists of a first stage of deriving a cinnamate compound from an aldehyde compound (1) and a subsequent second stage of hydrolyzing the ester group into a carboxylic acid group. The cinnamate compound can be prepared from an aldehyde compound (1) and any of various Horner-Emmons reagents by a method known to a person skilled in the art (see W.S. Wadsworth, Jr., Organic Reactions, 1997, vol.25, p.73, for example). Preferably, for example, the compound (7) can be obtained in a high yield by using
an aldehyde compound (1), preferably 1.0 to 2.0 equivalents of the Horner-Emmons reagent, for example, and preferably 1.0 to 5.0 equivalents of a base, for example. The Horner-Emmons reagent can be prepared by a method known to a person skilled in the art. For example, the Horner-Emmons reagent can be prepared by alkylation of commercially available trialkylphosphonoacetic acid (see Synthetic Communication, 1991, vol.22, p.2391, for example), Arbuzov reaction using an alkylphosphinite of α-halogenoacetic acid derivative (see Chemical Review, 1981, vol.81, p.415, for example), or Becker reaction using a metal phosphonite (see Journal of the American Chemical Society, 1945, vol.67, p.1180, for example).

Preferable examples of the solvent used include polar solvents such as 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and
diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization. A known deprotection method known to a person skilled in the art may be used for hydrolysis reaction to obtain a compound (7) from the cinnamate compound as a starting material (see T.W. Green, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981, p.154-186).

Conversion of compound (9) into compound (7)

The compound (7) can be prepared by coupling a compound (9) as a starting material with a corresponding alkene compound according to Step 5-5. Specifically, a method known to a person skilled in the art may be used for the coupling reaction in Step 5-5. Preferable examples of the method include Heck reaction

In the Heck reaction, a halide or a triflate compound (9), for example, is preferably coupled with preferably 1.0 to 5.0 equivalents of an alkene compound with respect to the compound (9), for example, in the presence of preferably 0.01 to 0.2 equivalent of a transition metal catalyst with respect to the compound (9), for example. This reaction is preferably performed in the presence of a solvent from the viewpoint of operativity and stirring efficiency. The solvent used varies according to the starting material and the transition metal catalyst used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylenes, 1-methyl-2-pyrrolidone, and N,N-dimethylformamide. The reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 150°C, for example. This reaction is performed preferably in an inert gas atmosphere, and more
preferably in a nitrogen or argon atmosphere. The transition metal catalyst is preferably a palladium complex, for example, and more preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0), or tris(dibenzylideneacetone)dipalladium (0). In addition, a phosphorus ligand (preferably triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, or 2-(di-tert-butylphosphino)biphenyl, for example) may be appropriately added in order to make the reaction efficiently proceed. A preferable result may be obtained in the presence of a base, and the base used is not specifically limited insofar as the base is used in a coupling reaction similar to this reaction. Preferable examples of the base include triethylamine, N,N-diisopropylethylamine, N,N-dicyclohexylmethylamine, and tetrabutylammonium chloride. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique.

In the Suzuki reaction, a halide or a triflate compound (9), for example, is preferably coupled with preferably 1.0 to 5.0 equivalents of a boronic acid compound or a boronate compound with respect to the compound (9), for example, in the
presence of preferably 0.01 to 0.5 equivalent of a transition metal catalyst with respect to the compound (9), for example. This reaction is preferably performed in the presence of a solvent from the viewpoint of operativity and stirring efficiency. The solvent used varies according to the starting material and the transition metal catalyst used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, benzene, toluene, xylene, 1-methyl-2-pyrrolidone, N,N-dimethylformamide, water, and a mixed solvent thereof. The reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 200°C, for example. This reaction is performed preferably in an inert gas atmosphere, and more preferably in a nitrogen or argon atmosphere. The transition metal catalyst is preferably a known palladium complex, and more preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0), or tris(dibenzylideneacetone)dipalladium (0). In addition, a phosphorus ligand (preferably triphenylphosphine, tri-o-tolylphosphine, tricyclohexylphosphine, or tri-tert-butylphosphine, for
example) may be appropriately added in order to make the reaction efficiently proceed. A quaternary ammonium salt, preferably tetrabutylammonium chloride or tetrabutylammonium bromide, for example, may also be appropriately added in order to make the reaction efficiently proceed. In this reaction, a preferable result may be obtained in the presence of a base. The base used at this time varies according to the starting material and the solvent used, and is not specifically limited. Preferable examples of the base include sodium hydroxide, barium hydroxide, potassium fluoride, cesium fluoride, sodium carbonate, potassium carbonate, cesium carbonate, and potassium phosphate. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique.

[0101]

In the Stille coupling reaction, a halide or a triflate compound (9) is coupled with preferably 1.0 to 10.0 equivalents of a trialkyltin compound with respect to the compound (9), for example, in the presence of preferably 0.01 to 0.2 equivalent of a transition metal catalyst with respect to the compound (9), for example. In addition, preferably 0.1 to 5.0 equivalents of copper (I) halide or and lithium chloride may be appropriately added with respect to the compound (9), for example, in order to make the
reaction efficiently proceed. Preferable examples of the solvent used in this reaction include toluene, xylene, N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, and dimethyl sulfoxide. The reaction temperature must be a temperature that can complete the coupling reaction, and is preferably room temperature to 100°C, for example. The transition metal catalyst used is a palladium complex, preferably a known palladium complex such as palladium (II) acetate, dichlorobis(triphenylphosphine)palladium (II), tetrakis(triphenylphosphine)palladium (0), or tris(dibenzylideneacetone)dipalladium (0), for example, and more preferably tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium (0), for example. This reaction is performed preferably in an inert gas atmosphere, and more preferably in a nitrogen or argon atmosphere. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique.

[0102]
Conversion of compound (1) into compound (9)

The compound (9) can be prepared by reacting the compound (1) as a starting material with halogenated phosphonoacetic acid in Horner-Emmons reaction according to Step 5-4 (see Organic Letter, 2000, vol.2, p.1975, for example).
Conversion of compound (9) into compound (10)

The compound (10) can be prepared from the compound (9) as a starting material according to Step 5-6. Step 5-6 and preparation of the amine compound used are the same as in the above Step 5-2.

General Preparation Method 4

Typically used General Preparation Method 4 for the compound of the general formula (I) of the present invention will be described below.

[Formula 12]

In the formula, ----- represents a single bond or a double bond; Ar₁, Z₁, R¹, R², p, q, and r are as defined above; L₁₀ represents a halogen atom such as a chlorine atom or bromine atom, or a sulfonate group such as a mesyl group or tosyl group; L₁₁ represents a
phosphite group such as a diethylphosphonyl group; \( L_{12} \) and \( L_{13} \) each represent a hydroxyl group, a hydroxyl group having a protecting group, an amino group, or an amino group having a protecting group; and \( V_1 \) represents an ester group such as a methyl ester group or ethyl ester group, or a carboxylic acid group.

[0105]

The above General Preparation Method 4 is an example of a method for preparing the compound of the general formula (I) comprising deriving a compound (12) from an aldehyde compound (1) and a Horner-Emmons reagent (11) according to Step 6-1, subjecting the compound (12) to amidation reaction according to Step 6-2, forming a lactam ring according to Step 6-3, and finally subjecting the lactam compound (15) to second cyclization reaction in Step 6-4.

[0106]

**Preparation of compound of general formula (I)**

The compound of the general formula (I) can be prepared from a lactam compound (15) according to Step 6-4. Step 6-4 consists of deprotection reaction of alcohol groups or amine groups in \( L_{12} \) and \( L_{13} \) of a compound (15) and subsequent cyclization reaction. A deprotection reaction described in many known documents may be used (see T.W. Green, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981). The cyclization reaction varies according to the starting material and is not specifically limited
insofar as the conditions are similar to those in this reaction. A method known to a person skilled in the art may be used for the reaction. Preferable examples of the method include i) a method of forming a cyclic ether from a diol (see Journal of Fluorine Chemistry, 1997, vol.2, p.119, or Scientia Pharmaceutica, 1996, vol.64, p.3, for example); and ii) a method of forming a cyclic amine from an aminoalcohol (see Petrochemia, 1990, vol.30, p.56; WO 2003/076386; or Tetrahedron Letters, 1982, vol.23, p.229, for example). More preferably, for example, the compound of the general formula (I) can be obtained in a high yield by heating the deprotected compound in a solvent or without a solvent in the presence of 0.1 to 10 equivalents of an organic acid such as p-toluenesulfonic acid or camphorsulfonic acid or an inorganic acid such as sulfuric acid or hydrochloric acid with respect to the deprotected compound, or by heating the deprotected compound in the presence of 0.1 to 1.0 equivalent of an organic metal such as tetrakistriphenylphosphine palladium or tristriphenylphosphine ruthenium with respect to the deprotected compound. The solvent used in this step varies according to the starting material and the reagent used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include methylene chloride, chloroform,
1,4-dioxane, 1,2-dimethoxyethane, dimethyl sulfoxide, toluene, tetrahydrofuran, dimethylformamide, ethanol, methanol, water, and a mixed solvent thereof. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

Preparation of lactam compound (15)

The lactam compound (15) can be prepared from a cinnamide compound (14) as a starting material by cyclization reaction that involves leaving of L10 of the cinnamide compound (14) according to Step 6-3. Specifically, for example, the desired lactam compound (15) can be obtained in a high yield by treating a compound (14) with 1.0 to 5.0 equivalents of a base with respect to the compound (14), for example. This reaction is preferably performed in the presence of a solvent from the viewpoint of operativity and stirring efficiency. The solvent used varies according to the starting material and the base used, and is not
specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include polar solvents such as 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-
product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique, extraction, or/and crystallization.

Preparation of cinnamide compound (14)

The cinnamide compound (14) can be prepared from a compound (12) and preferably 1.0 to 5.0 equivalents of an amine compound (13) with respect to the compound (12), for example, according to amidation reaction in Step 6-2. The amidation reaction varies according to the starting material and is not specifically limited insofar as the conditions are similar to those in this reaction. A known method described in many documents may be used for the reaction (see Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol.14, Yuki Kagobutsu No Gosei To Hannou (Synthesis and Reaction of Organic Compounds) [II], edited by The Chemical Society of Japan, Maruzen Co., Ltd., February 1978, p.1136-1162, for example). Preferable examples of the method include i) a method of converting a compound (12) into an acid halide and reacting the acid halide with an amine compound (13) under basic conditions (see Shin Jikken Kagaku Koza (New Courses in Experimental Chemistry), vol.14, Yuki Kagobutsu No Gosei To Hannou (Synthesis and Reaction of Organic Compounds) [II], edited by The Chemical Society of Japan, Maruzen Co.,
Ltd., February 1978, p.1142-1145, for example); and ii) a method of reacting a compound (12) with an amine compound (13) using a condensing (see "Yukikagaku Jikken No Tebiki (Introduction to Organic Chemistry Experiments) [4]", Kagaku-Dojin Publishing Company, Inc., September 1990, p.27-52, for example).

Preferable examples of the reaction of converting a compound (12) into an acid halide in the method i) include a method of stirring a compound (12) in a solvent in the presence of 1.0 to 10.0 equivalents of a halogenating agent with respect to the compound (12). The halogenating agent used varies according to the starting material and is not specifically limited. Preferable examples of the halogenating agent include thionyl chloride, phosphorus pentachloride, and oxalyl chloride. The solvent used is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include methylene chloride, chloroform, and toluene. The reaction may efficiently proceed when 0.1 to 1.0 equivalent of an organic base such as pyridine, dimethylformamide, or the like is appropriately added with respect to the compound (12). The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to
150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

Preferable examples of the subsequent coupling reaction include a method of stirring in a solvent the acid halide and 1.0 to 5.0 equivalents of an amine compound (13) with respect to the acid halide in the presence of 1.0 to 100.0 equivalents of a base with respect to the acid halide. The base used varies according to the starting material and is not specifically limited. Preferable examples of the base include pyridine, triethylamine, N,N-diisopropylethylamine, lutidine, quinoline, and isoquinoline. The solvent used is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent include methylene chloride, chloroform, toluene, tetrahydrofuran, and 1,4-dioxane. A base may be used as a solvent. Alternatively, it is possible to use a two-layer partition system consisting of a base that is an alkali solution, preferably a
sodium hydroxide or potassium hydroxide solution, for example, and a halogenated solvent such as methylene chloride or 1,2-dichloroethane. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

[0111]

Preferable examples of the method ii) include a method of stirring in a solvent a compound (12) and 1.0 to 5.0 equivalents of an amine compound (13) with respect to the compound (12) in the presence of 1.0 to 5.0 equivalents of a condensing agent with respect to the compound (12). The condensing agent used varies according to the starting material and is not specifically limited. Preferable examples of the condensing agent include 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide, benzotriazol-1-yloyxtris(dimethylamino)phosphonium hexafluorophosphate, diethyl cyanophosphonate, and bis(2-oxo-3-oxazolidinyl)phosphinic chloride.
Preferably, 1.0 to 2.0 equivalents of N-hydroxysuccinimide or N-hydroxybenzotriazole may be added with respect to the compound (12) in order to make the reaction efficiently proceed, for example. This reaction is preferably performed in the presence of a solvent from the viewpoint of operativity and stirring efficiency. The solvent used varies according to the starting material and the condensing agent used, and is not specifically limited insofar as the solvent does not inhibit the reaction and allows the starting material to be dissolved therein to a certain extent. Preferable examples of the solvent that can be used include halogenated solvents such as methylene chloride and 1,2-dichloroethane, and polar solvents such as tetrahydrofuran and N,N-dimethylformamide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably ice-cold temperature to 100°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person skilled in the art such as a conventional chromatography technique or/and crystallization.

Preparation of amine compound (13)
The amine compound (13) is commercially available or can be prepared by a method known to a person skilled in the art. If not commercially available, the amine compound (13) can be prepared by converting a corresponding aldehyde group into a vinyl group and then aminohydroxylating the compound (see Journal of the American Chemical Society, 2001, vol. 123, p. 1862, for example).

Preparation of compound (12)

Step 6-1 consists of a step of synthesizing a cinnamate compound by condensation reaction of an aldehyde compound (1) with a Horner-Emmons reagent (11) and a subsequent step of deprotecting an ester group into carboxylic acid. Specifically, in the Horner-Emmons reaction, the cinnamate compound can be prepared from an aldehyde compound (1) as a starting material by a method known to a person skilled in the art (see Jikken Kagaku Koza (Courses in Experimental Chemistry), vol. 19, Yuki Gosei (Organic Synthesis) [I], edited by The Chemical Society of Japan, Maruzen Co., Ltd., June 1992, p. 57-85, for example). Preferably, the desired cinnamate compound can be obtained by reacting an aldehyde compound (1) with preferably 1.0 to 5.0 equivalents of a Horner-Emmons reagent (11) with respect to the aldehyde compound (1), for example, in the presence of preferably 1.0 to 5.0 equivalents of a base with respect to the aldehyde compound (1), for
example. The solvent used varies according to the starting material and the reagent used and is not specifically limited. Preferable examples of the solvent include polar solvents such as 1-methyl-2-pyrrolidone, N,N-dimethylformamide, and dimethyl sulfoxide; ether solvents such as tetrahydrofuran, 1,4-dioxane, and 1,2-dimethoxyethane; nonpolar solvents such as benzene, toluene, and xylene; alcohol solvents such as ethanol and methanol; water; and mixed solvents thereof. The base used varies according to the starting material and the solvent. Preferable examples of the base include alkali metal hydroxides such as sodium hydroxide and lithium hydroxide; alkali metal carbonates such as sodium carbonate; alkali metal salts of alcohols such as sodium methoxide and potassium tert-butoxide; organic bases such as triethylamine, pyridine, and diazabicyclononene; organic metals such as butyl lithium and lithium diisobutylamide; alkali metal hydrides such as sodium hydride; and alkali metal ammonium salts such as sodium amide. The reaction temperature must be a temperature that can complete the reaction without promoting formation of an undesirable by-product, and is preferably -78 to 150°C, for example. Under preferable reaction conditions, the reaction is preferably completed in 1 to 24 hours, for example, and the progress of the reaction can be monitored by a known chromatography technique. An undesirable by-product can be removed by a technique known to a person
skilled in the art such as a conventional chromatography technique, extraction, or and crystallization. A known deprotection method known to a person skilled in the art may be used for hydrolysis reaction to obtain a compound (12) from the cinnamate compound as a starting material (see T.W. Green, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981, p.154-186). Preferably, for example, the compound (12) can be obtained in a high yield by reacting the cinnamate compound preferably in an alcohol solvent such as methanol or ethanol, for example, in the presence of preferably 1.0 to 50.0 equivalents of an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide with respect to the cinnamate compound, for example.

Preparation of compound (11)

The compound (11) is commercially available or can be prepared by a method known to a person skilled in the art if not commercially available. For example, the compound (11) can be prepared by alkylation of commercially available trialkylphosphonoacetic acid (see Synthetic Communication, 1991, vol.22, p.2391, for example), Arbuzov reaction using an alkylphosphinite of \( \alpha \)-halogenoacetic acid derivative (see Chemical Review, 1981, vol.81, p.415, for example), or Becker reaction using a metal phosphonite (see Journal of the American
The compound of the general formula (I) or (II) or pharmacologically acceptable salt thereof according to the present invention has an effect of reducing Aβ42 production. Accordingly, the present invention can particularly provide a therapeutic or prophylactic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

Compounds included in the present invention exhibit excellent pharmaceutical utility, for example, in vitro activity, in vivo activity, solubility, stability, pharmacokinetics, and reduction in toxicity.

The therapeutic or prophylactic agent of the present invention can be prepared by a conventional method. Preferable examples of the dosage form include tablets, powders, fine granules, granules, coated tablets, capsules, syrups, troches, inhalants, suppositories, injections, ointments, ophthalmic solutions, ophthalmic ointments, nasal drops, ear drops, cataplasms, and lotions. The therapeutic or prophylactic agent can be prepared by using ingredients typically used such as an excipient, a binder, a lubricant, a colorant, and a corrective, and ingredients used where necessary such as a stabilizer, an emulsifier, an absorbefacient, a surfactant, a pH
adjuster, a preservative, and an antioxidant, and can be prepared by blending ingredients generally used as materials for a pharmaceutical preparation. Examples of such ingredients include animal and vegetable oils such as soybean oil, beef tallow, and synthetic glyceride; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldecyl myristate and isopropyl myristate; higher alcohols such as ceteostearl alcohol and behenyl alcohol; a silicone resin; silicone oil; surfactants such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, and a polyoxyethylene-polyoxypropylene block copolymer; water-soluble polymers such as hydroxyethylcellulose, polyacrylic acid, a carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, and methylcellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as glycerin, propylene glycol, dipropylene glycol, and sorbitol; sugars such as glucose and sucrose; inorganic powders such as silicic anhydride, magnesium aluminum silicate, and aluminum silicate; and purified water. Examples of the excipient used include lactose, corn starch, saccharose, glucose, mannitol, sorbitol, crystalline cellulose, and silicon dioxide. Examples of the binder used include polyvinyl alcohol, polyvinyl ether,
methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, a polypropylene glycol-polyoxyethylene block copolymer, and meglumine. Examples of the disintegrator used include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, and carboxymethylcellulose calcium. Examples of the lubricant used include magnesium stearate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil. Examples of the colorant used include those that are permitted to be added to pharmaceuticals. Examples of the corrective used include cocoa powder, menthol, empasm, mentha oil, borneol, and cinnamon powder.

[0117]

For example, an oral preparation is prepared by adding an active ingredient compound or a salt thereof or a hydrate of the compound or salt, an excipient, and, where necessary, a binder, a disintegrator, a lubricant, a colorant, and a corrective, for example, and then forming the mixture into powder, fine granules, granules, tablets, coated tablets, or capsules, for example, by a conventional method. It is obvious that tablets or granules may be appropriately coated, for example, sugar coated, where necessary. A syrup or an injection preparation is
prepared by adding a pH adjuster, a solubilizer, and an isotonizing agent, for example, and a solubilizing aid, a stabilizer, and the like where necessary by a conventional method. An external preparation may be prepared by any conventional method without specific limitations. As a base material, any of various materials usually used for a pharmaceutical, a quasi drug, a cosmetic, or the like may be used. Examples of the base material include materials such as animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, and purified water. A pH adjuster, an antioxidant, a chelator, a preservative and fungicide, a colorant, a flavor, or the like may be added where necessary. Further, an ingredient having a differentiation inducing effect such as a blood flow enhancer, a bactericide, an antiphlogistic, a cell activator, vitamin, amino acid, a humectant, or a keratolytic agent may be blended where necessary. The dose of the therapeutic or prophylactic agent of the present invention varies according to the degree of symptoms, age, sex, body weight, mode of administration, type of salt, and specific type of disease, for example. Typically, the compound of the formula (I) or pharmacologically acceptable salt thereof is orally administered to an adult at 30 μg to 10 g, preferably 100 μg to 5 g, and more preferably 100
µg to 1 g per day, or is administered to an adult by injection at about 30 µg to 1 g, preferably 100 µg to 500 mg, and more preferably 100 µg to 30 mg per day, in a single dose or multiple doses, respectively.

5 BEST EMBODIMENT FOR CARRYING OUT THE INVENTION

[0118]

The present invention will now be described in detail with reference to examples and test examples. However, the examples and test examples are provided only for illustration purposes. The prophylactic or therapeutic agent for a disease caused by Aβ according to the present invention is not limited to the following specific examples in any case. A person skilled in the art can fully implement the present invention by making various modifications to not only the following examples and test examples but also the claims of the present specification, and such modifications are within the scope of the claims of the present specification.

[0119]

The following abbreviations are used in the following examples.

DMF: N,N-dimethylformamide
THF: Tetrahydrofuran
LAH: Lithium aluminum hydride
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
HOBT: 1-Hydroxybenzotriazole
IPEA: Diisopropylethylamine
TEA: Triethylamine
DPPA: Diphenylphosphorylazide

CDI: N,N'-carbonyldiimidazole
TBAF: Tetrabutylammonium fluoride
PYBOP: Benzotriazol-1-yl oxytris(pyrrolidino)phosphonium hexafluorophosphate
DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene

DAST: Diethylaminosulfur trifluoride
DMSO: Dimethylsulfoxide
DIBAL-H: Diisobutylaluminum hydride
Dess-Martin reagent: Dess-Martin periodinane
DME: 1,2-Dimethoxyethane

TBSCl: tert-Butyldimethylsilyl chloride
DMAP: 4-Dimethylaminopyridine
AIBN: 2,2'-Azobis(isobutyronitrile)
NMP: 1-Methyl-2-pyrrolidinone
LDA: Lithium diisopropylamide

TBSOTf: tert-Butyldimethylsilyl trifluoromethanesulfonate
BOPCl: Bis(2-oxo-3-oxazolidinyl)phosphinic chloride
Grubbs catalyst 2nd generation:
Tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-
4,5-dihydroimidazol-2-ylidene][benzylidene]ruthenium
(IV) dichloride
TMED: N,N,N',N'-tetramethylethylenediamine
TMSI: Iodotrimethylsilane
mCPBA: m-Chloroperbenzoic acid

Chromatography was performed using BW-300 manufactured by Fuji Silysia Chemical Ltd. as a carrier unless otherwise specified.

5 LC-MS: High performance liquid chromatography for preparative isolation of a target compound using mass spectroscopy. As an elution solvent, a 10% to 99% linear gradient system of water containing 0.1% trifluoroacetic acid and acetonitrile containing 0.1% trifluoroacetic acid was used.

[0120]
Examples 1, 2, 3, and 4

Synthesis of (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]- (9R)-hexahydroindolizin-5-one, (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one, (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one, and (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one

[Formula 13]
Synthesis of methyl 3-methoxy-4-nitrobenzoate

Methyl iodide (463 g) was added dropwise to a mixture of 3-hydroxy-4-nitrobenzoic acid (199 g) with potassium carbonate (450 g) in DMF (1 L) at room temperature. The reaction solution was stirred at room temperature overnight, and then methyl iodide (230 g) was added to the reaction solution. The reaction solution was further stirred at room temperature for six hours. The reaction solution was added to ice water, and the precipitated solid was collected by filtration. The resulting solid was dried at 50°C overnight to obtain 178 g of the title compound. The property values corresponded to the reported values (CAS #5081-37-8).

Synthesis of methyl 4-amino-3-methoxybenzoate

10% palladium-carbon (containing 50% water, 15 g) was added to a solution of methyl 3-methoxy-4-nitrobenzoate (150 g) in methanol (600 mL) and THF (300 mL), and the reaction solution was stirred at a hydrogen pressure of 0.9 MPa at 50°C to 64°C for 6.5 hours. The reaction solution was left to cool to room temperature and then filtered through celite. The resulting filtrate was concentrated under reduced pressure to obtain 134 g of the title compound. The property values corresponded to the reported values (CAS #41608-64-4).
Synthesis of methyl 4-formylamino-3-methoxybenzoate

Acetic anhydride (268 mL) was added dropwise to formic acid (401 mL) at room temperature, and the reaction solution was stirred at room temperature for 40 minutes. A solution of methyl 4-amino-3-methoxybenzoate (134 g) in THF (600 mL) was added dropwise to the reaction solution at room temperature, and the reaction solution was stirred for one hour.

3.8 L of ice water was added to the reaction solution, and the precipitated solid was filtered and further washed with water (2L). The resulting solid was dried at 50°C overnight to obtain 111 g of the title compound. The property values corresponded to the reported values (CAS #700834-18-0).

Synthesis of methyl 4-[formyl-(2-oxopropyl)amino]-3-methoxybenzoate

Chloroacetone (84.5 mL) was added dropwise to a mixture of methyl 4-formylamino-3-methoxybenzoate (111 g), cesium carbonate (346 g), and potassium iodide (8.78 g) in DMF (497 mL) at room temperature, and the reaction solution was stirred for three hours. Cesium carbonate (173 g) and chloroacetone (42.0 mL) were added to the reaction solution, which was then stirred at room temperature for two hours. Ice water and ethyl acetate were added to the reaction solution, and the organic layer was separated. Ethyl acetate was added
to the aqueous layer, and the organic layer was separated. The organic layers were combined and washed with water and brine in this order. The resulting organic layers were dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was diluted with toluene, and the solution was concentrated under reduced pressure. tert-Butyl methyl ether and heptane were added to the resulting residue, and the precipitated solid was collected by filtration and washed with a solution of 50% tert-butyl methyl ether in heptane. The resulting solid was air-dried overnight to obtain 118 g of the title compound.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
2.19 (s, 3H), 3.91 (s, 3H), 3.94 (s, 3H), 4.49 (s, 2H),
7.31 (d, J=8.0 Hz, 1H), 7.63 (d, J=2.0 Hz, 1H), 7.69 (dd, J=8.0, 2.0 Hz, 1H), 8.33 (s, 1H).

[0125]

Synthesis of methyl 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzoate

A solution of methyl 4-[[formyl-(2-oxopropyl)amino]-3-methoxybenzoate (118 g) and ammonium acetate (172 g) in acetic acid (255 mL) was heated and stirred at 140°C for one hour. After the reaction was completed, the reaction solution was neutralized with aqueous ammonia under ice-cooling. Ethyl acetate was added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over anhydrous magnesium sulfate and then filtered on a
silica gel pad, and the filtrate was concentrated under reduced pressure. tert-Butyl methyl ether and heptane were added to the residue, and the precipitated solid was collected by filtration and washed with a solution of 50% tert-butyl methyl ether in heptane. The resulting solid was air-dried overnight to obtain 68.4 g of the title compound. Further, the crystallization mother liquor was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 22.3 g of the title compound.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
2.30 (s, 3H), 3.94 (s, 3H), 3.96 (s, 3H), 6.98 (brs, 1H),
7.32 (d, J=8.4 Hz, 1H), 7.71-7.73 (m, 2H), 7.79 (brs, 1H).

Synthesis of 3-methoxy-4-((4-methyl-1H-imidazol-1-yl)benzaldehyde

A solution of pyrrolidine (18 mL) in THF (45 mL) was added dropwise to a solution of sodium bis(2-methoxyethoxy)aluminum hydride (65% solution in toluene, 56 mL) in THF (60 mL) at -5°C or less over 15 minutes. The reaction solution was stirred at room temperature for one hour. Then, a suspension of tert-butoxide (2.10 g) in THF (15 mL) was added dropwise to the reaction solution at room temperature, and the reaction solution was stirred for 15 minutes. The above reaction solution was added dropwise to a solution of methyl 3-methoxy-4-((4-methyl-1H-imidazol-1-
yl)benzoate (20 g) in THF (50 mL) under ice-cooling over 30 minutes. The reaction solution was stirred at room temperature for two hours, and then a 5 N sodium hydroxide solution (150 mL) was added dropwise to the reaction solution. Ethyl acetate was added to the reaction solution, and the organic layer was separated. The organic layer was washed with a saturated ammonium chloride solution and brine in this order. The organic layer was dried over anhydrous magnesium sulfate and filtered on a silica gel pad, and then the filtrate was concentrated under reduced pressure. The residue was diluted with ethyl acetate, and the precipitated solid was collected by filtration. The resulting solid was air-dried overnight to obtain 7.10 g of the title compound. Further, the crystallization mother liquor was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate-2-propanol system) to obtain 2.65 g of the title compound.

\[ ^1H-\text{NMR (CDCl}_3\text{)} \delta (\text{ppm}): \]
\[ 2.31 (s, 3H), 3.97 (s, 3H), 7.02 (brs, 1H), 7.44 (d, J=8.0Hz, 1H), 7.55 (dd, J=1.6Hz, 8.0Hz, 1H), 7.58 (d, J=1.6Hz, 1H), 7.84 (brs, 1H), 10.00 (s, 1H). \]

[0127]

Synthesis of (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one, (E)-(3R)-(3,4,5-
trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one, (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one, and (E)-(3R)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one

LDA (1.5 M solution in cyclohexane, 0.14 mL) was added to a solution of 3-(3,4,5-trifluorophenyl)-9-hexahydroindolizin-5-one (36 mg) synthesized according to the method described in The Journal of Organic Chemistry, 2001, vol. 66, p. 886 in THF (2 mL) at -78°C, and the reaction solution was stirred at -78°C for one hour. A solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (36 mg) in THF (1 mL) was added to the reaction solution at -78°C. The reaction solution was stirred at -78°C for one hour, and then 2 N aqueous hydrochloric acid and a toluene-THF (2:1) mixed solution were added to the reaction solution. The reaction solution was heated to room temperature, and the organic layer was separated. The resulting organic layer was washed with brine and then dried over magnesium sulfate and concentrated under reduced pressure to obtain 67 mg of a crude aldon adduct.

Thionyl chloride (0.02 mL) was added to a solution of the resulting crude aldon adduct (67 mg) in DME (3 mL), and the reaction solution was stirred at room temperature for one hour. A 2 N sodium hydroxide
solution and a toluene-THF mixed solution (2:1) were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, and then dried over magnesium sulfate and concentrated under reduced pressure. Sodium methoxide (5.2 M solution in methanol, 0.04 mL) was added to a solution of the resulting residue in THF (3 mL), and the reaction solution was stirred at room temperature for one hour. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate) to obtain an isomer mixture of the title compound. The isomer mixture was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 6 minutes (3.8 mg; >99% ee), the title optically active compound with a retention time of 7 minutes (2.0 mg; >99% ee), the title optically active compound with a retention time of 9 minutes (2.1 mg; >99% ee), and the title optically active compound with a retention time of 11 minutes (3.8 mg; >99% ee).

The property values of the title optically active compound with a retention time of 6 minutes (Example 1) are as follows.
174

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.42-1.85 (m, 3H), 2.21-2.36 (m, 5H), 2.45-2.53 (m, 1H),
2.70 (tt, $J=14.4, 3.2$ Hz, 1H), 3.11 (dt, $J=16.0, 2.8$ Hz, 1H),
3.85 (s, 3H), 3.88-3.99 (m, 1H), 5.10 (t, $J=8.0$ Hz, 1H),
5.68 (dd, $J=8.0, 6.0$ Hz, 2H), 6.93 (s, 1H), 7.01 (brs, 1H),
7.04 (brd, $J=8.0$ Hz, 1H), 7.25 (d, $J=8.0$ Hz, 1H), 7.72 (d, $J=2.4$ Hz,
1H), 7.81 (s, 1H).

The property values of the title optically active compound with a retention time of 7 minutes

10 (Example 2) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.65-1.87 (m, 3H), 2.06-2.14 (m, 1H), 2.30-2.39 (m, 5H), 2.69-
2.80 (m, 1H), 3.15 (brt, $J=16.8$ Hz, 1H), 3.76-3.85 (m, 1H),
3.86 (s, 3H), 5.10 (d, $J=8.8$ Hz, 1H), 6.79 (dd, $J=8.4, 6.4$ Hz, 2H),
5.69 (s, 1H), 7.05 (brs, 1H), 7.08 (brd, $J=8.0$ Hz, 1H),
7.26 (d, $J=8.0$ Hz, 1H), 7.74 (brs, 1H), 7.85 (s, 1H).

The property values of the title optically active compound with a retention time of 9 minutes
(Example 3) are as follows.

20 $^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.65-1.87 (m, 3H), 2.06-2.14 (m, 1H), 2.30-2.39 (m, 5H),
2.69-2.80 (m, 1H), 3.15 (brt, $J=16.8$ Hz, 1H), 3.76-3.85 (m, 1H),
3.86 (s, 3H), 5.10 (d, $J=8.8$ Hz, 1H), 6.79 (dd, $J=8.4, 6.4$ Hz, 2H),
6.95 (s, 1H), 7.05 (brs, 1H), 7.08 (brd, $J=8.0$ Hz, 1H),
7.26 (d, $J=8.0$ Hz, 1H), 7.74 (brs, 1H), 7.85 (s, 1H).

The property values of the title optically active compound with a retention time of 11 minutes
(Example 4) are as follows.
\[
{^1}H-NMR (CDCl_3) \delta (ppm): 1.42-1.85 (m, 3H), 2.21-2.36 (m, 5H), 2.45-2.53 (m, 1H), 2.70 (tt, J=14.4, 3.2Hz, 1H), 3.11 (dt, J=16.0, 2.8Hz, 1H), 3.85 (s, 3H), 3.88-3.99 (m, 1H), 5.10 (t, J=8.0Hz, 1H), 6.88 (dd, J=8.0, 6.0Hz, 2H), 6.93 (s, 1H), 7.01 (brs, 1H), 7.04 (brd, J=8.0Hz, 1H), 7.25 (d, J=8.0Hz, 1H), 7.72 (d, J=2.4Hz, 1H), 7.81 (s, 1H).
\]

(E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one was also separately synthesized by the following method.

[0129]

**Synthesis of ethyl (2R,5S)-5-(3,4,5-trifluorophenyl)pyrrolidine-2-carboxylate**

To a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (CAS No. 128811-48-3; 4.1 g) in THF (100 mL), 3,4,5-trifluorophenylmagnesium bromide (0.35 M solution in diethyl ether; 55 mL) was added dropwise at -40°C over 20 minutes, and the reaction solution was stirred at -40°C for five hours. Saturated aqueous ammonium chloride and ethyl acetate were added to the solution. The reaction solution was heated to room temperature, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane ->
heptane:ethyl acetate = 1:1) to obtain 4.8 g of ethyl (R)-2-tert-butoxycarbonylamino-5-oxo-5-(3,4,5-trifluorophenyl)pentanoate. A solution of 4 N hydrochloric acid in ethyl acetate (30 mL) was added to a solution of the resulting ethyl (R)-2-tert-butoxycarbonylamino-5-oxo-5-(3,4,5-trifluorophenyl)pentanoate in ethyl acetate (30 mL), and the solution was stirred for 16 hours. The reaction solution was concentrated under reduced pressure. Ethyl acetate and saturated sodium bicarbonate water were added to the residue, and the organic layer was separated. The resulting organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. 10%

palladium-carbon (100 mg) was added to a solution of the residue in ethyl acetate (50 mL), and the reaction solution was stirred in a hydrogen atmosphere at 1 atm for six hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 2.91 g of the title compound. The property value of the compound is as follows.

ESI-MS;m/z274[M^+H].

$^1$H-NMR(CDCl$_3$) δ (ppm):

1.31(t, J=6.8Hz, 3H), 1.57-1.70(m, 1H), 2.04-2.22(m, 3H), 3.93(dd, J=8.0, 5.2Hz, 1H), 4.17-4.27(m, 3H)

7.13(dd, J=8.8, 6.4Hz, 2H).
Synthesis of [(2R,5S)-5-(3,4,5-trifluorophenyl)pyrrolidin-2-yl]methanol

LAH (483 mg) was added to a solution of ethyl (2R,5S)-5-(3,4,5-trifluorophenyl)pyrrolidine-2-carboxylate (2.91 g) in THF (50 mL) at -15°C over one hour. The reaction solution was stirred at -15°C for 19 hours. Water (0.5 mL), a 5 N sodium hydroxide solution (0.5 mL), and water (1.5 mL) were sequentially added to the reaction solution, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 2.4 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 232 [M+H].

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.51-1.63 (m, 1H), 1.66-1.77 (m, 1H),
1.89-2.00 (m, 1H), 2.10-
2.20 (m, 1H), 3.43 (dd, J=10.0, 5.6 Hz, 1H),
3.47-3.55 (m, 1H), 3.64 (dd, J=10.0, 3.6 Hz, 1H),
4.23 (t, J=8.0 Hz, 1H), 7.02 (t, J=8.0 Hz, 2H).

[0131]

Synthesis of ethyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(3,4,5-trifluorophenyl)pyrrolidin-2-yl]acrylate

Triethylamine (1.95 mL) and BOPCl (2.85 g) were added to a solution of [(2R,5S)-5-(3,4,5-trifluorophenyl)pyrrolidin-2-yl]methanol (2.17 g) and vinylacetic acid (0.67 mL) in THF (50 mL), and the
reaction solution was stirred at room temperature for 12 hours. A toluene-THF (1:1) mixed solution and 1 N aqueous hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with a 1 N sodium hydroxide solution, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure.

A solution of DMSO (1.17 g) in methylene chloride (5 mL) was added dropwise to a solution of oxalyl chloride (1.77 g) in methylene chloride (15 mL) at -78°C, and the reaction solution was stirred at the same temperature for 20 minutes. A solution of the above residue in dichloromethane (10 mL) was added dropwise to the reaction solution at -78°C, and the reaction solution was stirred at the same temperature for 70 minutes. Triethylamine (6.5 mL) was added dropwise to the solution, and the reaction solution was stirred at -78°C for one hour. A toluene-THF (1:1) mixed solution and a saturated ammonium chloride solution were added to the reaction solution. The mixture was returned to room temperature, and the organic layer was separated. The resulting organic layer was washed with 1 N aqueous hydrochloric acid, saturated sodium bicarbonate water, and brine in this order, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure.

Triethylphosphonoacetic acid (3.7 mL) was added to a suspension of sodium hydride (containing 60%
mineral oil, 746 mg) in THF (70 mL) at 0°C, and the reaction solution was stirred at the same temperature for one hour. A solution of the above residue in THF (30 mL) was added to the reaction solution, which was then stirred at room temperature for one hour. Ethyl acetate and a saturated ammonium chloride solution were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane -> heptane:ethyl acetate = 1:1) to obtain 1.33 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 368[M+H].

[0132]

Synthesis of (3S,8aR)-3-(3,4,5-trifluorophenyl)-
2,3,6,8a-tetrahydro-1H-indolizin-5-one

A solution of ethyl (E)-3-[(2R,5S)-1-(3-
butenoyl)-5-(3,4,5-trifluorophenyl)pyrrolidin-2-
yl]acrylate (1.33 g) and Grubbs catalyst 2nd generation (153 mg) in methylene chloride (60 mL) was heated under reflux for two hours. The reaction solution was left to cool to room temperature. Then, triethylamine (0.5 mL) was added to the reaction solution, and the mixture was stirred for one hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography
(heptane:ethyl acetate = 1:1 -> ethyl acetate) to obtain 680 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 268 [M⁺+H].

1H-NMR (CDCl₃) δ (ppm):

1.74-1.86 (m, 2H), 2.10-2.18 (m, 1H), 2.29-2.42 (m, 1H),
2.95-3.00 (m, 2H) 4.22-4.32 (m, 1H), 5.01 (d, J=9.2 Hz, 1H),
5.98-6.05 (m, 1H), 6.07-6.32 (m, 1H), 6.67-6.76 (m, 2H).

[0133]

10 Synthesis of (3S,8aR)-3-(3,4,5-trifluorophenyl)hexahydroindolizin-5-one

Platinum oxide (100 mg) was added to a solution of (3S,8aR)-3-(3,4,5-trifluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-5-one (680 mg) in methanol (20 mL), and the reaction solution was stirred in a hydrogen atmosphere at 1 atm at room temperature for 2.5 hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 684 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 270 [M⁺+H].

1H-NMR (CDCl₃) δ (ppm):

1.52-1.88 (m, 4H), 2.00-2.10 (m, 2H), 2.18-2.48 (m, 4H),
3.54-3.64 (m, 1H), 4.99 (d, J=9.2 Hz, 1H), 6.74 (dd, J=8.4,
6.4 Hz, 2H).

[0134]

Synthesis of (E)-(3S)-(3,4,5-trifluorophenyl)-6-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-(9S)-hexahydroindolizin-5-one

Iodotrimethylsilane (0.54 mL) was added dropwise to a solution of (3S,8aR)-3-(3,4,5-
trifluorophenyl)hexahydroindolizin-5-one (684 mg) and N,N,N',N'-tetramethylethlenediamine (1.34 mL) in methylene chloride (15 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (967 mg) was added to the reaction solution at 0°C, and the reaction solution was stirred at 0°C for one hour. A saturated sodium thiosulfate solution and ethyl acetate were added to the reaction solution. The mixture was returned to room temperature, and then the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. A solution of the residue in triethyl phosphite (5 mL) was stirred at 120°C for one hour. The reaction solution was left to cool to room temperature and concentrated under reduced pressure. To a solution of the residue in THF (15 mL) and ethanol (3 mL), 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (549 mg) and lithium hydroxide monohydrate (319 mg) were added, and the reaction solution was stirred at room temperature for 15 hours. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over anhydrous magnesium sulfate and then concentrated
under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate = 1:1 -> ethyl acetate -> ethyl acetate:methanol = 9:1) to obtain 762 mg of the title compound.

Examples 5 and 6

Synthesis of (E)-(3R)-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9R)-hexahydroindolizin-5-one and (E)-(3S)-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(9S)-hexahydroindolizin-5-one

[Formula 14]

LDA (1.5 M solution in cyclohexane, 3.6 mL) was added to a solution of 3-(3,4-difluorophenyl)-9-hexahydroindolizin-5-one (900 mg) synthesized according to the method described in The Journal of Organic Chemistry, 2001, vol.66, p.886 in THF (20 mL) at -78°C, and the reaction solution was stirred at -78°C for one hour. A solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (774 mg) in THF (5 mL) was added to the reaction solution at -78°C. The reaction solution was stirred at -78°C for one hour, and then 2 N aqueous
hydrochloric acid and a toluene-THF (2:1) mixed solution were added to the reaction solution. The reaction solution was heated to room temperature, and the organic layer was separated. The resulting organic layer was washed with brine and then dried over magnesium sulfate and concentrated under reduced pressure to obtain 1.67 g of a crude aldol adduct. Thionyl chloride (0.52 mL) was added to a solution of the resulting crude aldol adduct (1.67 g) in DME (30 mL) at 0°C, and the reaction solution was stirred at room temperature for one hour. A 2 N sodium hydroxide solution and a toluene-THF mixed solution (2:1) were added to the reaction solution at 0°C, and the organic layer was separated. The resulting organic layer was washed with brine, and then dried over magnesium sulfate and concentrated under reduced pressure. Sodium methoxide (5.2 M solution in methanol, 1.1 mL) was added to a solution of the resulting residue in THF (30 mL), and the reaction solution was stirred at room temperature for one hour. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate) to obtain 430 mg of a racematate of the title compound.

The racemate (43 mg) was separated by
CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a short retention time (9.6 mg; >99% ee) and the title optically active compound with a long retention time (7.3 mg; >99% ee).

The property values of the title optically active compound with a short retention time (Example 5) are as follows.

$^1$H-NMR (CDCl$_3$)$\delta$(ppm):

1.70–1.86 (m, 3H), 2.05–2.12 (m, 1H), 2.29–2.38 (m, 5H),
2.69–2.80 (m, 1H), 3.16 (dt, $J$=16.8, 2.0Hz, 1H),
3.76–3.84 (m, 1H), 3.85 (s, 3H), 5.16 (d, $J$=9.2Hz, 1H),
6.89–6.99 (m, 3H), 7.04 (d, $J$=1.2Hz, 1H),

7.07 (dd, $J$=8.0, 1.2Hz, 1H), 7.10 (dd, $J$=10.0, 8.0Hz, 1H),
7.25 (d, $J$=8.0Hz, 1H), 7.75 (brs, 2H).

The property values of the title optically active compound with a long retention time (Example 6) are as follows.

$^1$H-NMR (CDCl$_3$)$\delta$(ppm):

1.70–1.86 (m, 3H), 2.05–2.12 (m, 1H), 2.29–2.38 (m, 5H),
2.69–2.80 (m, 1H), 3.16 (dt, $J$=16.8, 2.0Hz, 1H),
3.76–3.84 (m, 1H), 3.85 (s, 3H), 5.16 (d, $J$=9.2Hz, 1H),
6.89–6.99 (m, 3H), 7.04 (d, $J$=1.2Hz, 1H), 7.07 (dd, $J$=8.0, 1.2Hz, 1H),

7.10 (dd, $J$=10.0, 8.0Hz, 1H), 7.25 (d, $J$=8.0Hz, 1H),
7.75 (brs, 2H).

[0136]

Examples 7 and 8
Synthesis of (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one and (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one

[Formula 15]

Synthesis of 1-(4-fluorophenyl)hepta-5,6-dienyl-1-amine

2.65 g of the title compound was obtained from (4-fluorobenzyl)-(4-fluorobenzylidene)amine (3 g) and 6-iodohexa-1,2-diene (2.97 g) according to the method described in Journal of the American Chemical Society, 2003, vol.125, p.11956. The property values of the compound are as follows.

\(^1\text{H}-\text{NMR}(\text{CDCl}_3)\delta (\text{ppm}):

1.25-1.37 (m, 1H), 1.39-1.50 (m, 1H), 1.63-1.75 (m, 2H), 1.95-2.04 (m, 2H), 3.88 (t, J=6.8 Hz, 1H), 4.63 (dt, J=6.8, 2.8 Hz, 2H), 5.04 (quintet, J=6.8 Hz, 1H), 6.99 (t, J=8.8 Hz, 2H), 7.26 (dd, J=8.8, 5.6 Hz, 2H).

[0137]

Synthesis of (2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidine

Acetic acid (0.74 mL) was added to a solution
of an allylpalladium chloride dimer (472 mg) and 1,1'-bis(diphenylphosphino)ferrocene (1.43 g) in THF (200 mL), and the reaction solution was stirred at room temperature for 10 minutes. A solution of 1-(4-fluorophenyl)hepta-5,6-dienyl-1-amine (2.65 g) in THF (50 mL) was added to the reaction solution, which was then stirred at 70°C for 1.5 hours. The reaction solution was left to cool to room temperature. Then, diethyl ether and 1 N aqueous hydrochloric acid were added to the reaction solution, and the aqueous layer was separated. The resulting aqueous layer was washed with diethyl ether, and then a 5 N sodium hydroxide solution was added to the aqueous layer until the pH was adjusted to 11 or less. Chloroform was added to the aqueous layer, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain 2.4 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z206[M+H].

\[ ^1H-NMR(CDCl_3) \delta (ppm): \]

1.24-1.60 (m, 3H), 1.67-1.77 (m, 2H), 1.88-1.95 (m, 1H),
3.24-3.30 (m, 1H), 3.67 (dd, J=11.2, 2.8Hz, 1H), 5.01 (brd, J=10.4Hz, 1H), 5.17 (brd, J=16.8Hz, 1H), 5.88 (ddd, J=16.8, 10.4, 6.4Hz, 1H), 6.98 (t, J=8.8Hz, 2H), 7.35 (dd, J=8.8, 5.6Hz, 2H).

[0138]

Synthesis of 1-\{(2R*, 6S*)-2-(4-fluorophenyl)-6-vinylpiperidin-1-yl\}-3-buten-1-one
Diethyl cyanophosphonate (2.1 mL) was added to a solution of (2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidine (934 mg), vinylacetic acid (1.15 mL), and triethylamine (3.82 mL) in DMF (10 mL), and the reaction solution was stirred at room temperature for six hours. Ethyl acetate and 1 N aqueous hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with saturated sodium bicarbonate water, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane -> heptane:ethyl acetate = 1:1) to obtain 744 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm): 1.58-1.65 (m, 2H), 1.75-1.92 (m, 3H), 2.40-2.47 (m, 1H), 3.24 (d, J=6.4 Hz, 2H) 4.81 (d, J=10.4 Hz, 2H), 5.00 (d, J=17.2 Hz, 1H), 5.14 (d, J=15.6 Hz, 1H), 5.18 (d, J=13.2 Hz, 1H), 5.39-5.50 (m, 1H), 5.58-5.78 (m, 1H), 5.97-6.09 (m, 1H), 6.96 (t, J=8.8 Hz, 2H), 7.26 (dd, J=8.8, 5.6 Hz, 2H).

[0139]

Synthesis of (6R*,9aS*)-6-(4-fluorophenyl)-3,6,7,8,9,9a-hexahydroquinolinizin-4-one

A solution of 1-[(2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one (744 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-
ylidene][benzylidene]ruthenium (IV) dichloride (116 mg) in methylene chloride (250 mL) was heated under reflux for two hours. The reaction solution was left to cool to room temperature and then concentrated. The residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate = 4:1 -> ethyl acetate) to obtain 550 mg of the title compound. The property values of the compound are as follows. 

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm): 1.39-1.53 (m, 1H), 1.60-1.75 (m, 2H), 1.84-1.94 (m, 1H), 1.97-2.06 (m, 1H), 2.19-2.30 (m, 1H), 2.92-3.10 (m, 2H), 4.26-4.36 (m, 1H), 5.29 (t, J=3.6 Hz, 1H), 5.67 (brd, J=10.0 Hz, 1H), 5.83-5.88 (m, 1H), 6.96 (t, J=7.2 Hz, 2H), 7.16 (dd, J=7.2, 5.6 Hz, 2H).

[0140]

**Synthesis of (6R*, 9aS*)-6-(4-fluorophenyl)octahydroquinolinizin-4-one**

Platinum oxide (10 mg) was added to a solution of (6R*, 9aS*)-6-(4-fluorophenyl)-3,6,7,8,9,9a-hexahydroquinolinizin-4-one (550 mg) in methanol (5 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for three hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 550 mg of the title compound. The property values of the compound are as follows. 

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.30-1.42 (m, 1H), 1.45-1.53 (m, 3H),
1.67-1.86 (m, 2H), 1.93-2.00 (m, 2H), 2.01-2.08 (m, 1H),
2.14-2.25 (m, 1H), 2.42-2.58 (m, 2H), 3.58-3.66 (m, 1H),
5.37 (t, J=3.2 Hz, 1H), 6.96 (t, J=8.8 Hz, 2H),
7.14 (dd, J=8.8, 5.6 Hz, 2H).
[0141]

Synthesis of (E)-(6S*,9aR*)-6-(4-fluorophenyl)-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 0.6 mL) was added to a solution of (6R*,9aS*)-6-(4-
fluorophenyl)octahydroquinolizin-4-one (133 mg) in THF (7 mL) at -78°C. The reaction solution was stirred at -
78°C for one hour, and then a solution of 3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzaldehyde (116 mg) in THF (3 mL) was added to the reaction solution. The reaction solution was further stirred at -78°C for one hour and 20 minutes, and ethyl acetate and a saturated ammonium chloride solution were added to the reaction solution. The mixture was returned to room temperature, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 249 mg of a crude aldol adduct. Thionyl chloride (0.08 mL) was added to a solution of the crude aldol adduct (249 mg) in methylene chloride (5 mL), and the reaction solution was stirred at room temperature for one hour. The reaction solution was cooled to 0°C, and chloroform and a 2 N sodium hydroxide solution were added to the reaction solution. The reaction solution
was stirred for 10 minutes, and the organic layer was separated. The resulting organic layer was washed with brine, dried over magnesium sulfate, and then concentrated under reduced pressure. Sodium methoxide (5.2 M solution in methanol, 0.16 mL) was added to a solution of the residue in THF (5 mL), and the reaction solution was stirred at room temperature for 30 minutes. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate -> ethyl acetate:methanol = 5:1) to obtain 127 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 446[M+H]. \(^1\)H-NMR(CDCl\(_3\))\(\delta\) (ppm):

- 1.34-1.45 (m, 1H), 1.49-1.78 (m, 4H), 2.00-2.07 (m, 1H),
- 2.17-2.28 (m, 2H), 2.34 (s, 3H), 2.66-2.77 (m, 1H),
- 3.06-3.14 (m, 1H), 3.76-3.84 (m, 1H),
- 3.86 (s, 3H), 5.52 (brs, 1H), 6.94 (brs, 1H),
- 7.00 (t, J=8.8Hz, 2H), 7.03 (d, J=1.6Hz, 1H),
- 7.05 (dd, J=9.6, 1.6Hz, 1H), 7.21 (dd, J=8.8, 5.6Hz, 2H),
- 7.25 (d, J=9.6Hz, 1H), 7.80 (brd, J=2.4Hz, 1H), 7.83 (brs, 1H).

[0142]

Synthesis of (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-
(6S,9αR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

The racemate (E)-(6S*,9αR*)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one obtained above (127 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 13 minutes (49 mg; >99% ee) and the title optically active compound with a retention time of 20 minutes (41 mg; >99% ee).

The property values of the title optically active compound with a retention time of 13 minutes (Example 7) are as follows.

ESI-MS; m/z 446 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.34-1.45 (m, 1H), 1.49-1.78 (m, 4H), 2.00-2.07 (m, 1H),
2.17-2.28 (m, 2H), 2.34 (s, 3H), 2.66-2.77 (m, 1H),
3.06-3.14 (m, 1H), 3.76-3.84 (m, 1H), 3.86 (s, 3H),
5.52 (brs, 1H), 6.94 (brs, 1H), 7.00 (t, J=8.8Hz, 2H),
7.03 (d, J=1.6Hz, 1H), 7.05 (dd, J=9.6, 1.6Hz, 1H),
7.21 (dd, J=8.8, 5.6Hz, 2H), 7.25 (d, J=9.6Hz, 1H),
7.80 (brd, J=2.4Hz, 1H), 7.83 (brs, 1H).

The property values of the title optically active compound with a retention time of 20 minutes (Example 8) are as follows.

ESI-MS; m/z 446 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.34-1.45 (m, 1H), 1.49-1.78 (m, 4H), 2.00-2.07 (m, 1H),
2.17-2.28 (m, 2H), 2.34 (s, 3H), 2.66-2.77 (m, 1H),
3.06-3.14 (m, 1H), 3.76-
3.84 (m, 1H), 3.86 (s, 3H), 5.52 (brs, 1H),
6.94 (brs, 1H), 7.00 (t, J=8.8 Hz, 2H), 7.03 (d, J=1.6 Hz, 1H),
7.05 (dd, J=9.6, 1.6 Hz, 1H), 7.21 (dd, J=8.8, 5.6 Hz, 2H),
7.25 (d, J=9.6 Hz, 1H), 7.80 (brd, J=2.4 Hz, 1H), 7.83 (brs, 1H).

Examples 9 and 10
Synthesis of (E)-(6S,8S,9aR)-6-phenyl-8-hydroxy-3-[3-
 methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one and (E)-
(6R,8R,9aS)-6-phenyl-8-hydroxy-3-[3-methoxy-4-(4-
 methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one

[Formula 16]

15 Synthesis of (6S*,9aR*)-8-hydroxy-6-
phenyloctahydroquinolizin-4-one

A solution of (4S*,9aR*)-4-
phenylhexahydroquinolizine-2,6-dione that is a known
compound described in a document (CAS No. 149526-09-0,
93.4 mg) in methanol (5.0 mL) was cooled to 0°C. Sodium
borohydride (21.8 mg) was added to the reaction
solution, which was then stirred for 30 minutes. Water
and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 95.2 mg of a crude alcohol compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm): 1.75-1.80 (m, 3H), 1.80-2.00 (m, 2H), 2.04-2.18 (m, 2H), 2.45-2.76 (m, 3H), 3.40-3.42 (m, 1/4H), 3.89-3.98 (m, 1H), 4.20-4.24 (m, 3/4H), 6.05-6.06 (m, 3/4H), 6.26-6.28 (m, 1/4H), 7.20-7.32 (m, 3H), 7.32-7.37 (m, 2H).

[0144]

Synthesis of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-phenyloctahydroquinolizin-4-one

A solution of (6S*,9aR*)-8-hydroxy-6-phenyloctahydroquinolizin-4-one (96.4 mg) in DMF (5.0 mL) was cooled to 0°C. Imidazole (80.3 mg), TBSCI (88.9 mg), and DMAP (4.8 mg) were sequentially added to the reaction solution, which was then stirred at room temperature overnight. Saturated sodium bicarbonate water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 77 mg of the
title compound. The property values of the compound are as follows.

\[^1\text{H-NMR (CDCl}_3\text{)} \delta (\text{ppm}):\]

0.00 (s, 3H), 0.06 (s, 3H), 0.77 (s, 9H), 1.67-1.79 (m, 1H),

1.81-1.88 (m, 1H), 1.92-2.08 (m, 2H), 2.12-2.22 (m, 2H),

2.52-2.72 (m, 4H), 4.08-4.15 (m, 1H), 4.26-4.30 (m, 1H),

6.10 (dd, J=6.8, 2.4 Hz, 1H), 7.24-7.28 (m, 1H), 7.32-

7.41 (m, 4H).

[0145]

**Synthesis of (E)-(6S\*, 8S\*, 9aR\*)-8-(tert-butyldimethylsilanyloxy)-6-phenyl-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one**

LDA (1.5 M solution in THF, 185 \(\mu\)L) was added to a solution of (6S\*, 8S\*, 9aR\*)-8-(tert-butyldimethylsilanyloxy)-6-phenyloctahydroquinolizin-4-one (54 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (30.0 mg) in THF (1.0 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for 1.5 hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 60.8
mg of an alcohol compound. A solution of the resulting alcohol compound (60.8 mg) in methylene chloride (3.0 mL) was cooled to 0°C. Triethylamine (44.3 μL) and methanesulfonyl chloride (12.3 μL) were added to the reaction solution, which was then stirred at room temperature for 30 minutes. Triethylamine (162 μL) and methanesulfonyl chloride (61.5 μL) were added to the reaction solution, which was then stirred overnight to complete the reaction. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain a mesyl compound.

Sodium methoxide (11.5 mg) was added to a solution of the resulting mesyl compound in THF (2.0 mL), and the reaction solution was stirred at room temperature for six hours and 40 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatopag NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 36.0 mg of the title compound. The property values of the compound are as follows.
$^1$H-NMR (CDCl$_3$) δ (ppm):
0.00 (s, 3H), 0.06 (s, 3H), 0.77 (s, 9H), 1.72–1.84 (m, 2H),
1.91–1.98 (m, 1H), 2.14–2.28 (m, 2H), 2.42 (s, 3H),
2.53–2.57 (m, 1H), 2.89–3.06 (m, 2H), 3.97 (s, 3H),
4.18–4.25 (m, 1H), 4.28–4.32 (m, 1H),
6.15 (dd, J=7.2, 3.2 Hz, 1H), 7.04 (dd, J=1.2 Hz, 1H),
7.11–7.14 (m, 2H), 7.24–7.28 (m, 1H), 7.35–7.39 (m, 5H),
7.86 (d, J=1.2 Hz, 1H), 7.90 (brs, 1H).
[0146]

Synthesis of (E)-(6$^*$S,8$^*$S,9aR*)-6-phenyl-8-hydroxy-3-
[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one

TBAF (1.0 M solution in THF, 194 µL) was
added to a solution of (E)-(6$^*$S,8$^*$S,9aR*)-8-(tert-
butyldimethylsilyloxy)-6-phenyl-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one (36.0 mg) in
THF (mL), and the reaction solution was stirred at room
temperature overnight. A saturated ammonium chloride
solution and ethyl acetate were added to the reaction
solution, and the organic layer was separated. The
resulting organic layer was washed with brine, dried
over anhydrous magnesium sulfate, and then concentrated
under reduced pressure. The residue was purified by
silica gel column chromatography (carrier: Chromatorex
NH; elution solvent: heptane-ethyl acetate system ->
ethyl acetate-methanol system) to obtain 13.3 mg of the
title compound. The property values of the compound
are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.68-1.92 (m, 3H), 2.08-2.16 (m, 1H), 2.21-2.27 (m, 1H),
2.32 (s, 3H), 2.58-2.65 (m, 1H), 2.80-2.87 (m, 1H),
2.91-2.98 (m, 1H), 3.87 (s, 3H), 4.04-4.12 (m, 1H),
4.24-4.28 (m, 1H), 6.12 (dd, J=6.8, 2.4 Hz, 1H), 6.95 (s, 1H),
7.02-7.05 (m, 2H), 7.23-7.39 (m, 6H), 7.77 (s, 1H), 7.82 (s, 1H)

[0147]

Synthesis of (E)-(6S, 8S, 9aR)-6-phenyl-8-hydroxy-3-[3-

methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R, 8R, 9aS)-6-phenyl-8-hydroxy-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one

The racemate (E)-(6S*, 8S*, 9aR*)-6-phenyl-8-

hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one obtained above

(12.0 mg) was separated by CHIRALPAK™ AD-H manufactured

by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 5.1 minutes

(3.3 mg; >99% ee) and the title optically active compound with a retention time of 12.7 minutes (4.1 mg; >99% ee).

The property values of the title optically active compound with a retention time of 5.1 minutes (Example 9) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.68-1.92 (m, 3H), 2.08-2.16 (m, 1H), 2.21-2.27 (m, 1H),
2.32 (s, 3H), 2.58-2.65 (m, 1H), 2.80-2.87 (m, 1H),
2.91-2.98 (m, 1H), 3.87 (s, 3H), 4.04-4.12 (m, 1H),
4.24-4.28 (m, 1H), 6.12 (dd, J=6.8, 2.4 Hz, 1H), 6.95 (s, 1H),
7.02-7.05 (m, 2H), 7.23-7.39 (m, 6H), 7.77 (s, 1H), 7.82 (s, 1H)

The property values of the title optically active compound with a retention time of 12.7 minutes (Example 10) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.68-1.92 (m, 3H), 2.08-2.16 (m, 1H), 2.21-2.27 (m, 1H),
2.32 (s, 3H), 2.58-2.65 (m, 1H), 2.80-2.87 (m, 1H),
2.91-2.98 (m, 1H), 3.87 (s, 3H), 4.04-4.12 (m, 1H),
4.24-4.28 (m, 1H), 6.12 (dd, J=6.8, 2.4 Hz, 1H), 6.95 (s, 1H),
7.02-7.05 (m, 2H), 7.23-7.39 (m, 6H), 7.77 (s, 1H), 7.82 (s, 1H)

Examples 11 and 12

Synthesis of (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

[Formula 17]
Synthesis of 1-(4-bromobutyryl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one

6.66 g of the title compound was obtained from 4-methoxypyridine (2.0 mL), 4-fluorophenylmagnesium bromide (1.0 M solution in THF, 20.7 mL), and 4-bromobutyryl chloride (2.4 mL) according to the method described in Tetrahedron Letters, 1986, vol.27, p.4549-4552. The property values of the compound are as follows.

$^{1}$H-NMR(CDCl$_3$)$\delta$(ppm):

2.20-2.32 (m, 2H), 2.79-2.86 (m, 3H), 3.10-3.16 (m, 1H),
3.47-3.55 (m, 2H), 5.47 (brd, J=8.0 Hz, 1H), 6.00 (brs, 1H),
6.99-7.03 (m, 2H), 7.18-7.21 (m, 2H), 7.75 (brs, 1H).

[0149]

Synthesis of (4S*,9aR*)-4-(4-fluorophenyl)hexahydroquinolizine-2,6-dione

1.05 g of the title compound was obtained from 1-(4-bromobutyryl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one (2.0 g), tributyltin hydride (1.87 mL), and AIBN (386 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol.58, p.4198-4199. The property values of the compound are as follows.

$^{1}$H-NMR(CDCl$_3$)$\delta$(ppm):

1.58-1.82 (m, 2H), 1.85-2.01 (m, 2H), 2.34-2.39 (m, 1H),
2.45-2.56 (m, 3H), 2.80 (dd, J=15.6, 7.2 Hz, 1H), 2.97-
3.01 (m, 1H), 3.49-3.56 (m, 1H), 6.54 (brd, J=7.2 Hz, 1H), 6.99-
7.03 (m, 2H), 7.21-7.24 (m, 2H).
[0150]

Synthesis of (6S*,9aR*)-6-(4-fluorophenyl)-8-hydroxyoctahydroquinolizin-4-one

A solution of (4S*,9aR*)-4-(4-fluorophenyl)hexahydroquinolizine-2,6-dione (790 mg) in methanol (20 mL) was cooled to 0°C. Sodium borohydride (149 mg) was added to the reaction solution, which was then stirred for two hours and 15 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 760 mg of a crude alcohol compound. The property values of the compound are as follows.

$^{1}H$-NMR($CDCl_3$) $\delta$(ppm):
1.52-2.15 (m, 7H), 2.44-2.69 (m, 3H), 3.30-3.36 (m, 1/3H), 3.86-3.94 (m, 1H), 4.22 (brs, 2/3H), 5.99-6.00 (brd, $J=6.4$Hz, 2/3H), 6.22-6.23 (brd, $J=6.4$Hz, 1/3H), 7.00-7.04 (m, 4/3H), 7.15-7.18 (m, 2/3H), 7.22-7.27 (m, 2H).

[0151]

Synthesis of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(4-fluorophenyl)octahydroquinolizin-4-one and (6S*,8R*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(4-fluorophenyl)octahydroquinolizin-4-one

A solution of (6S*,9aR*)-6-(4-fluorophenyl)-8-hydroxyoctahydroquinolizin-4-one (203 mg) in DMF (5.0 mL) was cooled to 0°C. Imidazole (262 mg), TBSCl (291
mg), and DMAP (9.42 mg) were sequentially added to the reaction solution, which was then stirred at room temperature for two hours. Saturated sodium bicarbonate water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 183 mg of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)octahydroquinolinizin-4-one and 31.8 mg of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)octahydroquinolinizin-4-one.

The property values of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)octahydroquinolinizin-4-one are as follows.

\[ ^1H-NMR\text{(CDCl}_3)\delta\text{(ppm)}: 0.00\text{(s,} 3H), 0.05\text{(s,} 3H), 0.76\text{(s,} 9H), 1.65-1.75\text{(m,} 2H), 1.75-1.85\text{(m,} 1H), 1.85-2.08\text{(m,} 2H), 2.08-2.20\text{(m,} 2H), 2.41-2.52\text{(m,} 1H), 2.52-2.70\text{(m,} 2H), 4.01-4.06\text{(m,} 1H), 4.26-4.27\text{(m,} 1H), 6.04\text{(brd,} J=6.4Hz, 1H), 7.03-7.08\text{(m,} 2H), 7.27-7.31\text{(m,} 2H).\]

The property values of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)octahydroquinolinizin-4-one are as follows.

\[ ^1H-NMR\text{(CDCl}_3)\delta\text{(ppm)}: 0.04\text{(s,} 3H), 0.07\text{(s,} 3H), 0.88\text{(s,} 9H), 1.57-1.63\text{(m,} 1H), \]
1.70-1.82 (m, 4H), 1.86-1.99 (m, 2H), 2.43-2.60 (m, 3H),
3.29-3.35 (m, 1H), 3.80-3.88 (m, 1H), 6.17-6.19 (m, 1H),
7.01-7.06 (m, 2H), 7.13-7.16 (m, 2H).

[0152]

5 Synthesis of (E)-(6S*, 8S*, 9aR*)-8-(tert-
butyldimethylsilylanyloxy)-6-(4-fluorophenyl)-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzyldene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 1.11 mL) was
10 added to a solution of (6S*, 8S*, 9aR*)-8-(tert-
butyldimethylsilylanyloxy)-6-(4-
fluorophenyl)octahydroquinolizin-4-one (298 mg) in THF
(5.0 mL) at 0°C. The reaction solution was stirred at
0°C for one hour, and then a solution of 3-methoxy-4-(4-
15 methyl-1H-imidazol-1-yl)benzaldehyde (179 mg) in THF (3
mL) was added to the reaction solution. The reaction
solution was further stirred at 0°C for 40 minutes.
Water and ethyl acetate were added to the reaction
solution, and the organic layer was separated. The
resulting organic layer was dried over magnesium
sulfate and then concentrated under reduced pressure to
obtain 443 mg of a crude aldol adduct. A solution of
the crude aldol adduct (443 mg) in methylene chloride
(7 mL) was cooled to 0°C. Triethylamine (416 µL) and
methanesulfonyl chloride (115 µL) were added to the
reaction solution, which was then stirred at room
temperature for 5.5 hours. Saturated sodium
bicarbonate water and ethyl acetate were added to the
reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine and then dried over magnesium sulfate and concentrated under reduced pressure to obtain a crude mesyl compound. Sodium methoxide (121 mg) and methanol (1.0 mL) were added to a solution of the crude mesyl compound in THF, and the reaction solution was stirred at room temperature for two hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 330 mg of the title compound. The property values of the compound are as follows.

\textsuperscript{1}H-NMR (CDCl\textsubscript{3}) \delta (ppm):

0.00 (s, 3H), 0.05 (s, 3H), 0.77 (s, 9H), 1.75-1.96 (m, 3H),
2.12 (s, 3H), 2.12-2.24 (m, 2H), 2.44-2.52 (m, 1H),
2.84-3.02 (m, 2H), 3.97 (s, 3H), 4.11-4.20 (m, 1H),
4.26-4.32 (m, 1H), 6.08-6.12 (m, 1H), 7.03-7.18 (m, 7H),
7.22-7.40 (m, 2H), 7.87 (s, 1H).

[0153]

Synthesis of (E)-(6S*,8S*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)octahydroquinolizin-4-one
TBAF (1.0 M solution in THF, 1.15 mL) was added to a solution of (E)-(6S*,8S*,9aR*)-8-(tert-butyldimethylsilylanyloxy)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one (330 mg) in THF (5.0 mL), and the reaction solution was stirred at room temperature overnight. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 232 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl₃) δ (ppm): 1.75-1.96 (m, 3H), 2.07-2.15 (m, 1H), 2.17-2.27 (m, 1H), 2.34 (s, 3H), 2.52-2.56 (m, 1H),
2.78-2.84 (m, 1H), 2.88-2.96 (m, 1H), 3.88 (s, 3H),
4.01-4.08 (m, 1H), 4.26-4.30 (m, 1H), 6.04-6.10 (m, 1H),
6.96 (s, 1H), 7.00-7.06 (m, 4H), 7.16-7.34 (m, 3H), 7.82 (s, 1H),
7.82-7.84 (m, 1H).

[0154]

Synthesis of (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-
4-(4-methyl-1H-imidazol-1-yl)benzylidene)octahydroquinolizin-4-one

The racemate (E)-(6S*,8S*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one obtained above (232 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 5.0 minutes (89 mg; >99% ee) and the title optically active compound with a retention time of 9.7 minutes (89 mg; >99% ee).

The property values of the title optically active compound with a retention time of 5.0 minutes (Example 11) are as follows.

$^1$H-NMR(CDCl$_3$) $\delta$(ppm): $^1$H-NMR(CDCl$_3$) $\delta$(ppm):

1.75-1.96 (m, 3H), 2.07-2.15 (m, 1H), 2.17-
2.27 (m, 1H), 2.34 (s, 3H), 2.52-2.56 (m, 1H), 2.78-2.84 (m, 1H),
2.88-2.96 (m, 1H), 3.88 (s, 3H), 4.01-4.08 (m, 1H),
4.26-4.30 (m, 1H), 6.04-6.10 (m, 1H), 6.96 (s, 1H),
7.00-7.06 (m, 4H), 7.16-7.34 (m, 3H), 7.82 (s, 1H),
7.82-7.84 (m, 1H).

The property values of the title optically active compound with a retention time of 9.7 minutes (Example 12) are as follows.

$^1$H-NMR(CDCl$_3$) $\delta$(ppm):

$^1$H-NMR(CDCl$_3$) $\delta$(ppm): 1.75-1.96 (m, 3H), 2.07-2.15 (m, 1H), 2.17-2.27 (m, 1H), 2.34 (s, 3H), 2.52-
2.56 (m, 1H), 2.78-2.84 (m, 1H), 2.88-
2.96 (m, 1H), 3.88 (s, 3H), 4.01-4.08 (m, 1H), 4.26-
4.30 (m, 1H), 6.04-6.10 (m, 1H), 6.96 (s, 1H), 7.00-
7.06 (m, 4H), 7.16-7.34 (m, 3H), 7.82 (s, 1H), 7.82-7.84 (m, 1H).

[0155]
Examples 13 and 14

Synthesis of (E)-(6S,9aS)-6-(3,4,5-trifluorophenyl)-3-
[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one and (E)-
(6R,9aR)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one

[Formula 18]

\[
\begin{align*}
\text{Synthesis of } & 1-(4\text{-bromobutyryl})-2-(3,4,5-
\text{trifluorophenyl})-2,3\text{-dihydro-1H-pyridin-4-one} \\
1.02 \text{ g of the title compound was obtained} \\
\text{from 4-methoxypyridine (1.52 mL), 3,4,5-} \\
\text{trifluorophenylmagnesium bromide (0.3 M solution in} \\
\text{THF, 50 mL), and 4-bromobutyryl chloride (1.74 mL)} \\
\text{according to the method described in Tetrahedron} \\
\text{Letters, 1986, vol.27, p.4549-4552. The property} \\
\text{values of the compound are as follows.}
\end{align*}
\]
$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

2.24-2.31 (m, 2H), 2.77-2.88 (m, 3H), 3.06-3.18 (m, 1H),
3.51-3.55 (m, 2H), 5.48 (brd, $J$= 8.0 Hz, 1H), 5.98 (brs, 1H),
6.82-6.90 (m, 2H), 7.72 (brs, 1H).

[0156]

Synthesis of (6S*, 9aR*)-4-(3, 4, 5-trifluorophenyl)hexahydroquinolizine-2, 6-dione

331 mg of the title compound was obtained from 1-(4-bromobutyryl)-2-(3, 4, 5-trifluorophenyl)-2, 3-dihydro-1H-pyridin-4-one (1.15 g), tributyltin hydride (973 µL), and AIBN (201 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol. 58, p. 4198-4199. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.61-1.69 (m, 1H), 1.72-1.82 (m, 1H), 1.87-1.97 (m, 1H),
1.99-2.07 (m, 1H), 2.23-2.31 (m, 1H), 2.39
(ddd, $J$= 14.8, 3.2, 1.6 Hz, 1H), 2.47-2.57 (m, 2H),
2.81 (ddd, $J$= 15.2, 7.2, 0.8 Hz, 1H),
2.92 (ddd, $J$= 15.2, 2.4, 1.6 Hz, 1H), 3.52-3.59 (m, 1H), 6.45 (brd, $J$= 7.2 Hz, 1H), 6.88-6.92 (m, 2H).

[0157]

Synthesis of (6S*, 9aR*)-8-hydroxy-6-(3, 4, 5-trifluorophenyl)octahydroquinolizin-4-one

A solution of (6S*, 9aR*)-4-(3, 4, 5-trifluorophenyl)hexahydroquinolizine-2, 6-dione (331 mg) in methanol (10 mL) was cooled to 0°C. Sodium
borohydride (64.1 mg) was added to the reaction solution, which was then stirred for one hour. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 340 mg of a crude alcohol compound. The property values of the compound are as follows.

\[ \text{H-NMR (CDCl}_3\text{)} \delta (\text{ppm}): \]
1.57-1.64 (m, 1H), 1.70-2.00 (m, 3H), 2.00-2.12 (m, 1H),
2.20-2.60 (m, 5H), 3.28-3.35 (m, 1/2H), 3.81-3.89 (m, 1H),
4.23-4.26 (m, 1/2H), 5.91 (brd, J=6.4Hz, 1/2H), 6.15 (brd, J=4.8Hz, 1/2H), 6.80-6.94 (m, 2H).

[0158]

Synthesis of (6S*,9aR*)-6-(3,4,5-trifluorophenyl)octahydroquinolinizin-4-one

A solution of (6S*,9aR*)-8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolinizin-4-one (161 mg) in methylene chloride (5 mL) was cooled to 0°C. Triethylamine (450 μL) and methanesulfonyl chloride (125 μL) were added to the reaction solution, which was then stirred at room temperature for 4.5 hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 203 mg of a crude
mesyl compound. Sodium borohydride (204 mg) was added to a solution of the resulting crude mesyl compound (203 mg) in NMP (5.0 mL), and the reaction solution was heated to 100°C and stirred for 2.5 hours. The reaction solution was returned to room temperature. Then, water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 79 mg of the title compound. The property values of the compound are as follows.

1H-NMR (CDCl$_3$) $\delta$ (ppm):

1.38-2.00 (m, 6H), 2.10-2.22 (m, 1H), 2.25-2.34 (m, 1H),
2.42-2.62 (m, 2H), 2.74-2.80 (m, 1H), 3.19-3.30 (m, 2H),
6.00-6.05 (brs, 1H), 6.79-6.83 (m, 2H).

[0159]

Synthesis of (E)-(6S*,9aS*)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 372 $\mu$L) was added to a solution of (6S*,9aR*)-6-(3,4,5-

25 trifluorophenyl)octahydroquinolizin-4-one (79 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (66.4 mg) in
THF (1 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for 30 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 88 mg of a crude aldol adduct. A solution of the crude aldol adduct (88 mg) in methylene chloride (3.0 mL) was cooled to 0°C. Triethylamine (147 μL) and methanesulfonyl chloride (40.9 μL) were added to the reaction solution, which was then stirred at room temperature for 2.5 hours. Sodium methoxide (28% solution in methanol, 102 mL) and ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for 40 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 72 mg of a mixture of the crude aldol adduct with the title compound. 72 mg of the resulting mixture was re-dissolved in methylene chloride (3.0 mL), and the reaction solution was cooled to 0°C. Triethylamine (147 μL) and methanesulfonyl chloride (61.3 μL) were added to the reaction solution, which
was then stirred at room temperature for four hours and 15 minutes. Sodium methoxide (28% solution in methanol, 102 mL) and ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for two hours and 15 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 54.0 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.51-1.80 (m, 5H), 1.88-2.06 (m, 2H), 2.26-2.34 (m, 1H),
2.33 (s, 3H), 2.69-2.76 (m, 1H), 2.86-2.96 (m, 1H),
3.40-3.46 (m, 1H), 3.88 (s, 3H), 6.12-6.16 (brs, 1H),
6.86-6.91 (m, 2H), 6.96 (brs, 1H), 7.03-7.05 (m, 2H),
7.26-7.30 (m, 1H), 7.78-7.84 (brs, 1H), 7.83 (s, 1H).

[0160]

Synthesis of (E)-(6S,9aS)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,9aR)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

The racemate (E)-(6S*,9aS*)-6-(3,4,5-
trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one obtained above (54 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: hexane:ethanol = 50:50) to obtain the title optically active compound with a retention time of 6.6 minutes (18.6 mg; >99% ee) and the title optically active compound with a retention time of 7.8 minutes (21.0 mg; >95% ee).

The property values of the title optically active compound with a retention time of 6.6 minutes (Example 13) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm): 1.51-1.80 (m, 5H), 1.88-2.06 (m, 2H), 2.26-2.34 (m, 1H), 2.33 (s, 3H), 2.69-2.76 (m, 1H), 2.86-2.96 (m, 1H), 3.40-3.46 (m, 1H), 3.88 (s, 3H), 6.12-6.16 (brs, 1H), 6.86-6.91 (m, 2H), 6.96 (brs, 1H), 7.03-7.05 (m, 1H), 7.26-7.30 (m, 1H), 7.78-7.84 (brs, 1H), 7.83 (s, 1H).

The property values of the title optically active compound with a retention time of 7.8 minutes (Example 14) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.51-1.80 (m, 5H), 1.88-2.06 (m, 2H), 2.26-2.34 (m, 1H), 2.33 (s, 3H), 2.69-2.76 (m, 1H), 2.86-2.96 (m, 1H), 3.40-3.46 (m, 1H), 3.88 (s, 3H), 6.12-6.16 (brs, 1H), 6.86-6.91 (m, 2H), 6.96 (brs, 1H), 7.03-7.05 (m, 2H), 7.26-7.30 (m, 1H), 7.78-7.84 (brs, 1H), 7.83 (s, 1H).

[0161]
Examples 15 and 16

Synthesis of (E)-(6S,8S,9aR)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,8R,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

(Formula 19)

Synthesis of 1-(4-bromobutyryl)-2-(3,4,5-trifluorophenyl)-2,3-dihydro-1H-pyridin-4-one

1.02 g of the title compound was obtained from 4-methoxypyridine (1.52 mL), 3,4,5-trifluorophenylmagnesium bromide (0.3 M solution in THF, 50 mL), and 4-bromobutyryl chloride (1.74 mL) according to the method described in Tetrahedron Letters, 1986, vol.27, p.4549-4552. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$)$\delta$(ppm):

2.24-2.31 (m, 2H), 2.77-2.88 (m, 3H), 3.06-3.18 (m, 1H),

3.51-3.55 (m, 2H), 5.48 (brd, J=8.0Hz, 1H), 5.98 (brs, 1H),

6.82-6.90 (m, 2H), 7.72 (brs, 1H).

[0162]
Synthesis of (6S*,9aR*)-4-(3,4,5-trifluorophenyl)hexahydroquinolizine-2,6-dione

331 mg of the title compound was obtained from 1-(4-bromobutyryl)-2-(3,4,5-trifluorophenyl)-2,3-dihydro-1H-pyridin-4-one (1.15 g), tributyltin hydride (973 µL), and AIBN (201 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol. 58, p. 4198-4199. The property values of the compound are as follows.

\[ ^1H-NMR(\text{CDCl}_3) \delta (\text{ppm}): \]
1.61-1.69 (m, 1H), 1.72-1.82 (m, 1H), 1.87-1.97 (m, 1H),
1.99-2.07 (m, 1H), 2.23-2.31 (m, 1H),
2.39 (ddd, J=14.8, 3.2, 1.6Hz, 1H), 2.47-2.57 (m, 2H),
2.81 (ddd, J=15.2, 7.2, 0.8Hz, 1H),
2.92 (ddd, J=15.2, 2.4, 1.6Hz, 1H),
3.52-3.59 (m, 1H), 6.45 (brd, J=7.2Hz, 1H), 6.88-6.92 (m, 2H).

[0163]

Synthesis of (6S*,9aR*)-8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one

A solution of (6S*,9aR*)-4-(3,4,5-trifluorophenyl)hexahydroquinolizine-2,6-dione (331 mg) in methanol (10 mL) was cooled to 0°C. Sodium borohydride (64.1 mg) was added to the reaction solution, which was then stirred for one hour. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated
under reduced pressure to obtain 340 mg of a crude alcohol compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.57-1.64 (m, 1H), 1.70-2.00 (m, 3H), 2.00-2.12 (m, 1H),
2.20-2.60 (m, 5H), 3.28-3.35 (m, 1/2H), 3.81-3.89 (m, 1H),
4.23-4.26 (m, 1/2H), 5.91 (brd, J=6.4Hz, 1/2H),
6.15 (brd, J=4.8Hz, 1/2H), 6.80-6.94 (m, 2H).

[0164]

Synthesis of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one and (6S*,8R*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one

A solution of (6S*,9aR*)-8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one (171 mg) in DMF (5.0 mL) was cooled to 0°C. Imidazole (233 mg), TBSCl (258 mg), and DMAP (6.98 mg) were sequentially added to the reaction solution, which was then stirred at room temperature for 4.5 hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 103 mg of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-
fluorophenyl)octahydroquinolizin-4-one and 60.5 mg of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one.

The property values of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
0.00 (s, 3H), 0.03 (s, 3H), 0.75 (s, 9H), 1.61-1.74 (m, 2H), 1.74-1.80 (m, 1H), 1.82-2.02 (m, 2H), 2.07-2.14 (m, 2H), 2.35-2.40 (m, 1H), 2.53 (ddd, J=12.4, 8.8, 5.6Hz, 1H), 2.60-2.67 (m, 1H), 3.90-3.96 (m, 1H), 4.23-4.26 (m, 1H), 5.99 (brd, J=7.2Hz, 1H), 6.84-6.93 (m, 2H)

The property values of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
0.00 (s, 3H), 0.03 (s, 3H), 0.84 (s, 9H), 1.38-1.47 (m, 1H), 1.53-1.60 (m, 2H), 1.67-1.80 (m, 2H), 1.82-1.99 (m, 2H), 2.33-2.38 (m, 1H), 2.40-2.48 (m, 1H), 2.48-2.56 (m, 1H), 3.22-3.29 (m, 1H), 3.68-3.76 (m, 1H), 6.06 (brs, 1H), 6.72-6.76 (m, 2H).

[0165]

Synthesis of (E)-(6S*,8S*,9aR*)-8-(tert-butyldimethylsilyloxy)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 332 µL) was added to a solution of (6S*,8S*,9aR*)-8-(tert-
butyldimethylsilanyloxy)-6-(3,4,5-
fluorophenyl)octahydroquinolizin-4-one (59.2 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at
0°C for one hour, and then a solution of 3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzaldehyde (59.2 mg) in THF
(1 mL) was added to the reaction solution. The
reaction solution was further stirred at 0°C for 30
minutes. Water and ethyl acetate were added to the
reaction solution, and the organic layer was separated.
The resulting organic layer was dried over magnesium
sulfate and then concentrated under reduced pressure to
obtain 139 mg of a crude aldol adduct. A solution of
the crude aldol adduct (139 mg) in methylene chloride
(3.0 mL) was cooled to 0°C. Triethylamine (185 μL) and
methanesulfonyl chloride (51.3 μL) were added to the
reaction solution, which was then stirred at room
temperature for two hours and 10 minutes. Sodium
methoxide (28% solution in methanol, 128 mg) and
ethanol (1.0 mL) were added to the reaction solution,
which was then stirred at room temperature for 40
minutes. Water and ethyl acetate were added to the
reaction solution, and the organic layer was separated.
The resulting organic layer was washed with brine,
dried over anhydrous magnesium sulfate, and then
concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (elution
solvent: heptane-ethyl acetate system -> ethyl acetate-
methanol system) to obtain 61 mg of a mixture of the
crude aldol adduct with the title compound. 61 mg of the resulting mixture was re-dissolved in methylene chloride (3.0 mL), and the reaction solution was cooled to 0°C. Triethylamine (147 µL) and methanesulfonyl chloride (51.3 µL) were added to the reaction solution, which was then stirred at room temperature for four hours and 15 minutes. Sodium methoxide (28% solution in methanol, 128 mg) and ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for two hours and 15 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 44.1 mg of the title compound. The property values of the compound are as follows.

\[
\begin{align*}
{^1}H\text{-NMR (CDCl}_3\text{)} \delta (\text{ppm}) : \\
0.00 (s, 3H), 0.03 (s, 3H), 0.75 (s, 9H), 1.68-1.78 (m, 2H), \\
1.78-1.87 (m, 1H), 2.08-2.20 (m, 2H), 2.38 (s, 3H), \\
2.38-2.41 (m, 1H), 2.82-2.88 (m, 1H), 2.93-3.00 (m, 1H), \\
3.92 (s, 3H), 4.02-4.07 (m, 1H), 4.25-4.29 (m, 1H), \\
6.05 (brd, J=7.2Hz, 1H), 6.95-7.00 (m, 3H), 7.04-7.09 (m, 2H), \\
7.30-7.36 (m, 1H), 7.80-7.88 (m, 2H).
\end{align*}
\]

Synthesis of (E)-(6S*,8S*,9αR*)-6-(3,4,5-
trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

TBAF (1.0 M solution in THF, 144 μL) was added to a solution of \((E)-(6S^*,8S^*,9aR^*)-8-(\text{tert-butyl}dимethylsиланоxy)-6-(3,4,5-trifluorophenyl)-3-[3\text{-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene}]\text{octahydroquinolizin-4-one (44.1 mg)}\) in THF (1.0 mL), and the reaction solution was stirred at room temperature overnight. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 25.4 mg of the title compound. The property values of the compound are as follows.

\(^1\text{H-NMR (CDCl}_3\)\(\delta\) (ppm):

1.67-1.84 (m, 2H), 1.84-1.94 (m, 1H), 2.07-2.20 (m, 2H), 2.41 (s, 3H), 2.41-2.48 (m, 1H), 2.76-2.86 (m, 1H), 2.86-2.96 (m, 1H), 3.88 (s, 3H), 3.97-4.05 (m, 1H), 4.29-4.34 (m, 1H), 5.98-6.04 (m, 1H), 6.94-7.06 (m, 5H), 7.26-7.30 (m, 1H), 7.78 (s, 1H), 7.81 (s, 1H).


Synthesis of \((E)-(6S,8S,9aR)-6-(3,4,5\text{-trifluorophenyl})-8\text{-hydroxy-3-[3\text{-methoxy-4-(4-methyl-1H-imidazol-1-yl)}\text{benzylidene}]octahydroquinolizin-4-one}\)
(E)-(6R,8R,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one

The racemate (E)-(6S*,8S*,9aR*)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one obtained above (25.4 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd.

(2 cm x 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 4.4 minutes (13.3 mg; >99% ee) and the title optically active compound with a retention time of 5.2 minutes (12.1 mg; >97% ee).

The property values of the title optically active compound with a retention time of 4.4 minutes (Example 15) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.67-1.84 (m, 2H), 1.84-1.94 (m, 1H), 2.07-
2.20 (m, 2H), 2.41 (s, 3H), 2.41-2.48 (m, 1H), 2.76-2.86 (m, 1H), 2.86-2.96 (m, 1H), 3.88 (s, 3H), 3.97-4.05 (m, 1H), 4.29-4.34 (m, 1H), 5.98-6.04 (m, 1H), 6.94-7.06 (m, 5H), 7.26-7.30 (m, 1H), 7.78 (s, 1H), 7.81 (s, 1H).

The property values of the title optically active compound with a retention time of 5.2 minutes (Example 16) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.67-1.84 (m, 2H), 1.84-1.94 (m, 1H), 2.07-2.20 (m, 2H),
2.41 (s, 3H), 2.41-2.48 (m, 1H), 2.76-2.86 (m, 1H),
2.86-2.96 (m, 1H), 3.88 (s, 3H), 3.97-4.05 (m, 1H),
4.29-4.34 (m, 1H), 5.98-6.04 (m, 1H), 6.94-7.06 (m, 5H),
7.26-7.30 (m, 1H), 7.78 (s, 1H), 7.81 (s, 1H).

Examples 17 and 18
Synthesis of (E)-(6S,8R,9aR)-6-(3,4,5-trifluorophenyl)-
8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one and (E)-
(6R,8S,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one

[Formula 20]

Synthesis of 1-(4-bromobutyryl)-2-(3,4,5-
trifluorophenyl)-2,3-dihydro-1H-pyridin-4-one

1.02 g of the title compound was obtained
from 4-methoxypyridine (1.52 mL), 3,4,5-
trifluorophenylmagnesium bromide (0.3 M solution in
THF, 50 mL), and 4-bromobutyryl chloride (1.74 mL)
according to the method described in Tetrahedron
values of the compound are as follows.
Synthesis of (6S*,9aR*)-4-(3,4,5-
trifluorophenyl)hexahydroquinolizine-2,6-dione

331 mg of the title compound was obtained from 1-(4-bromobutryl)-2-(3,4,5-trifluorophenyl)-2,3-
dihydro-1H-pyridin-4-one (1.15 g), tributyltin hydride (973 μL), and AIBN (201 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol. 58, p. 4198-4199. The property values of the compound are as follows.

1H-NMR (CDCl₃) δ (ppm):
1.61-1.69 (m, 1H), 1.72-1.82 (m, 1H), 1.87-1.97 (m, 1H),
1.99-2.07 (m, 1H), 2.23-2.31 (m, 1H), 2.39 (ddd, J=14.8, 3.2, 1.6Hz, 1H), 2.47-2.57 (m, 2H),
2.81 (ddd, J=15.2, 7.2, 0.8Hz, 1H),
2.92 (ddd, J=15.2, 2.4, 1.6Hz,
1H), 3.52-3.59 (m, 1H), 6.45 (brd, J=7.2Hz, 1H), 6.88-6.92 (m, 2H).

Synthesis of (6S*,9aR*)-8-hydroxy-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one

A solution of (6S*,9aR*)-4-(3,4,5-
trifluorophenyl)hexahydroquinolizine-2,6-dione (331 mg)
in methanol (10 mL) was cooled to 0°C. Sodium
borohydride (64.1 mg) was added to the reaction solution, which was then stirred for one hour. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 340 mg of a crude alcohol compound. The property values of the compound are as follows.

1H-NMR (CDCl₃) δ (ppm):
1.57-1.64 (m, 1H), 1.70-2.00 (m, 3H), 2.00-2.12 (m, 1H),
2.20-2.60 (m, 5H), 3.28-3.35 (m, 1/2H), 3.81-3.89 (m, 1H),
4.23-4.26 (m, 1/2H), 5.91 (brd, J=6.4 Hz, 1/2H),
6.15 (brd, J=4.8 Hz, 1/2H), 6.80-6.94 (m, 2H).

[0171]

Synthesis of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolinizin-4-one and (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolinizin-4-one

A solution of (6S*,9aR*)-8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolinizin-4-one (171 mg) in DMF (5.0 mL) was cooled to 0°C. Imidazole (233 mg), TBSCl (258 mg), and DMAP (6.98 mg) were sequentially added to the reaction solution, which was then stirred at room temperature for 4.5 hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic
layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 103 mg of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolinizin-4-one and 60.5 mg of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolinizin-4-one.

The property values of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolinizin-4-one are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

0.00 (s, 3H), 0.03 (s, 3H), 0.75 (s, 9H), 1.61-1.74 (m, 2H),

1.74-1.80 (m, 1H), 1.82-2.02 (m, 2H), 2.07-2.14 (m, 2H),

2.35-2.40 (m, 1H), 2.53 (ddd, $J$=12.4, 8.8, 5.6 Hz, 1H),

2.60-2.67 (m, 1H), 3.90-3.96 (m, 1H), 4.23-4.26 (m, 1H),

5.99 (br, $J$=7.2 Hz, 1H), 6.84-6.93 (m, 2H)

The property values of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolinizin-4-one are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

0.00 (s, 3H), 0.03 (s, 3H), 0.84 (s, 9H), 1.38-1.47 (m, 1H),

1.53-1.60 (m, 2H), 1.67-1.80 (m, 2H), 1.82-1.99 (m, 2H),

2.33-2.38 (m, 1H), 2.40-2.48 (m, 1H), 2.48-2.56 (m, 1H),

3.22-3.29 (m, 1H), 3.68-3.76 (m, 1H), 6.06 (brs, 1H), 6.72-6.76 (m, 2H).

[0172]
(E)-(6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 153 µL) was added to a solution of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one (47.7 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (24.9 mg) in THF (1 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for 30 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 27.2 mg of a crude aldol adduct. A solution of the crude aldol adduct (27.2 mg) in methylene chloride (1.0 mL) was cooled to 0°C. Triethylamine (48.2 µL) and methanesulfonyl chloride (13.4 µL) were added to the reaction solution, which was then stirred at room temperature for five hours. Sodium methoxide (28% solution in methanol, 50 mg) and ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for 1.5 hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous
magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system → ethyl acetate-methanol system) to obtain 21.0 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

0.06 (s, 3H), 0.09 (s, 3H), 0.89 (s, 9H), 1.54-1.64 (m, 1H),
1.64-1.74 (m, 1H), 1.80-1.92 (m, 2H), 2.00-2.10 (m, 1H),

2.33 (s, 3H), 2.42-2.50 (m, 1H), 2.72-2.80 (m, 1H),
2.88-2.98 (m, 1H), 3.41-3.48 (m, 1H), 3.81-3.90 (m, 1H),
3.88 (s, 3H), 6.20-6.23 (m, 1H), 6.82-6.90 (m, 2H),
6.95 (brs, 1H), 7.02-7.06 (m, 2H), 7.26-7.30 (m, 1H),
7.81 (brs, 1H), 7.84 (s, 1H).

[0173]

**Synthesis of (E)-(6S*,8R*,9aR*),6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one**

TBAF (1.0 M solution in THF, 68.6 µL) was added to a solution of (E)-(6S*,8R*,9aR*)-8-(tert-butyldimethylsilylanyloxy)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one (21.0 mg) in THF (1.0 mL), and the reaction solution was stirred at room temperature overnight. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine,
dried over anhydrous magnesium sulfate, and then
concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (carrier:
Chromatorex NH; elution solvent: heptane-ethyl acetate
system -> ethyl acetate-methanol system) to obtain 11.5
mg of the title compound. The property values of the
compound are as follows.
$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
  1.50-1.61 (m, 1H), 1.68-1.90 (m, 3H), 1.98-2.12 (m, 1H),
  2.34 (s, 3H), 2.56-2.64 (m, 1H), 2.72-2.80 (m, 1H),
  2.88-3.00 (m, 1H), 3.45-3.51 (m, 1H), 3.81-3.96 (m, 1H),
  3.89 (s, 3H), 6.26-6.30 (m, 1H), 6.88-6.92 (m, 2H),
  6.96 (dd, $J=1.2, 1.2$ Hz, 1H), 7.03-7.06 (m, 2H), 7.28-
  7.30 (m, 1H),
  7.83-7.85 (m, 2H).
[0174]

Synthesis of (E)-(6S,8R,9aR)-6-(3,4,5-trifluorophenyl)-
8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one and (E)-

(6R,8S,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one

The racemate (E)-(6S*,8R*,9aR*)-6-(3,4,5-
trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)benzylidene]octahydroquinolizin-4-one
obtained above (11.5 mg) was separated by CHIRALPAK™
AD-H manufactured by Daicel Chemical Industries, Ltd.
(2 cm × 25 cm; mobile phase: ethanol) to obtain the
title optically active compound with a retention time of 4.8 minutes (4.9 mg; >99% ee) and the title optically active compound with a retention time of 6.0 minutes (4.4 mg; >99% ee).

The property values of the title optically active compound with a retention time of 4.8 minutes (Example 17) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.50-1.61 (m, 1H), 1.68-1.90 (m, 3H), 1.98-2.12 (m, 1H),

2.34 (s, 3H), 2.56-2.64 (m, 1H), 2.72-2.80 (m, 1H),

2.88-3.00 (m, 1H), 3.45-3.51 (m, 1H), 3.81-3.96 (m, 1H),

3.89 (s, 3H), 6.26-6.30 (m, 1H), 6.88-6.92 (m, 2H), 6.96 (dd, J=1.2, 1.2 Hz, 1H), 7.03-7.06 (m, 2H), 7.28-7.30 (m, 1H),

7.83-7.85 (m, 2H).

The property values of the title optically active compound with a retention time of 6.0 minutes (Example 18) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.50-1.61 (m, 1H), 1.68-1.90 (m, 3H), 1.98-2.12 (m, 1H),

2.34 (s, 3H), 2.56-2.64 (m, 1H), 2.72-2.80 (m, 1H),

2.88-3.00 (m, 1H), 3.45-3.51 (m, 1H), 3.81-3.96 (m, 1H),

3.89 (s, 3H), 6.26-6.30 (m, 1H), 6.88-6.92 (m, 2H), 6.96 (dd, J=1.2, 1.2 Hz, 1H), 7.03-7.06 (m, 2H), 7.28-7.30 (m, 1H),

7.83-7.85 (m, 2H).

Examples 19 and 20

Synthesis of (E)-(6S,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

[Formula 21]

\[ \text{Synthesis of } 1-(4\text{-bromobutyryl})-2-(4\text{-fluorophenyl})-2,3\text{-dihydro}-1H\text{-pyridin-4-one} \]

6.66 g of the title compound was obtained from 4-methoxypyridine (2.0 mL), 4-fluorophenylmagnesium bromide (1.0 M solution in THF, 20.7 mL), and 4-bromobutyryl chloride (2.4 mL) according to the method described in Tetrahedron Letters, 1986, vol.27, p.4549-4552. The property values of the compound are as follows.

\(^1\text{H-NMR (CDCl}_3\text{)} \delta (\text{ppm}): \]

2.20-2.32 (m, 2H), 2.79-2.86 (m, 3H), 3.10-3.16 (m, 1H), 3.47-3.55 (m, 2H), 5.47 (brd, J=8.0 Hz, 1H), 6.00 (brs, 1H), 6.99-7.03 (m, 2H), 7.18-7.21 (m, 2H), 7.75 (brs, 1H).

[0176]

\[ \text{Synthesis of (4S*,9aR*)-4-} \]

\[ \text{fluorophenyl)hexahydroquinolizine-2,6-dione} \]

1.05 g of the title compound was obtained from 1-(4-bromobutyryl)-2-(4-fluorophenyl)-2,3-dihydro-
1H-pyridin-4-one (2.0 g), tributyltin hydride (1.87 mL), and AIBN (386 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol.58, p.4198-4199. The property values of the compound are as follows.

$^1$H-NMR(CDCl$_3$)δ(ppm):

1.58-1.82(m,2H), 1.85-2.01(m,2H), 2.34-2.39(m,1H),
2.45-2.56(m,3H), 2.80(dd, J=15.6,7.2Hz,1H), 2.97-
3.01(m,1H), 3.49-3.56(m,1H), 6.54(brd, J=7.2Hz,1H),
6.99-7.03(m,2H), 7.21-7.24(m,2H).

[0177]

Synthesis of (6S*,9aR*)-6-(4-fluorophenyl)-8-
hydroxyoctahydroquinolizin-4-one

A solution of (4S*,9aR*)-4-(4-
fluorophenyl)hexahydroquinolizine-2,6-dione (790 mg) in methanol (20 mL) was cooled to 0°C. Sodium borohydride (149 mg) was added to the reaction solution, which was then stirred for two hours and 15 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 760 mg of a crude alcohol compound. The property values of the compound are as follows.

$^1$H-NMR(CDCl$_3$)δ(ppm):

1.52-2.15(m,7H), 2.44-2.69(m,3H), 3.30-3.36(m,1/3H),
3.86-3.94(m,1H), 4.22(brs,2/3H), 5.99-6.00(brd, J=6.4Hz,
2/3H), 6.22-6.23(brd, J=6.4Hz,1/3H), 7.00-7.04(m,4/3H),
7.15-7.18 (m, 2/3H), 7.22-7.27 (m, 2H).

[0178]

Synthesis of (6S*,9aS*)-6-(4-fluorophenyl)octahydroquinolizin-4-one

A solution of (6S*,9aR*)-6-(4-fluorophenyl)-8-hydroxyoctahydroquinolizin-4-one (760 mg) in methylene chloride (10 mL) was cooled to 0°C. Triethylamine (2.42 mL) and methanesulfonyl chloride (671 μL) were added to the reaction solution, which was then stirred at room temperature for two hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.12 g of a crude mesyl compound. Sodium borohydride (547 mg) was added to a solution of the resulting crude mesyl compound (1.12 g) in NMP (10 mL), and the reaction solution was heated to 100°C and stirred for two hours and 20 minutes. The reaction solution was returned to room temperature. Then, water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 500 mg of the title compound. The property values of the
compound are as follows.

$^{1}{H}$-NMR (CDCl$_3$) $\delta$(ppm):
1.40-1.80 (m, 6H), 1.80-2.00 (m, 3H), 2.32-2.41 (m, 1H),
2.41-2.60 (m, 2H), 3.27-3.33 (m, 1H), 6.08-6.10 (m, 1H),
6.98-7.05 (m, 2H), 7.15-7.18 (m, 2H).

[0179]

Synthesis of (E)-(6S*,9aS*)-6-(4-fluorophenyl)-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 1.75 mL) was added to a solution of (6S*,9aS*)-6-(4-
fluorophenyl)octahydroquinolizin-4-one (500 mg) in THF (10 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzaldehyde (437 mg) in THF (1 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for one hour. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 660 mg of a crude aldol adduct. A solution of the crude aldol adduct (660 mg) in methylene chloride (5.0 mL) was cooled to 0°C. Triethylamine (1.19 mL) and methanesulfonyl chloride (330 $\mu$L) were added to the reaction solution, which was then stirred at room temperature for three hours and 20 minutes. Sodium methoxide (28% solution in methanol, 1.64 g) and
ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for one hour and 50 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 445 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm):

1.54-2.07 (m, 7H), 2.31 (s, 3H), 2.40-2.43 (m, 1H),

2.66-2.76 (m, 1H), 2.86-2.94 (m, 1H), 3.42-3.50 (m, 1H),

3.88 (s, 3H), 6.19-6.20 (m, 1H), 6.94 (s, 1H), 7.00-7.08 (m, 4H),

7.21-7.30 (m, 3H), 7.75 (s, 1H), 7.84 (s, 1H).

[0180]

Synthesis of (E)-(6S,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

The racemate (E)-(6S*,9aS*)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one obtained above (445 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm;
mobile phase: hexane:ethanol = 50:50) to obtain the title optically active compound with a retention time of 9.3 minutes (139 mg; >99% ee) and the title optically active compound with a retention time of 11.2 minutes (139 mg; >97% ee).

The property values of the title optically active compound with a retention time of 9.3 minutes (Example 19) are as follows.
\[ ^1H-NMR(CDCl_3) \delta (ppm): \]
10 1.50-1.61 (m, 1H), 1.68-1.90 (m, 3H), 1.98-2.12 (m, 1H),
2.34 (s, 3H), 2.56-2.64 (m, 1H), 2.72-2.80 (m, 1H),
2.88-3.00 (m, 1H), 3.45-3.51 (m, 1H), 3.81-3.96 (m, 1H),
3.89 (s, 3H), 6.26-6.30 (m, 1H), 6.88-6.92 (m, 2H),
6.96 (dd, J=1.2, 1.2Hz, 1H), 7.03-7.06 (m, 2H), 7.28-
15 7.30 (m, 1H), 7.83-7.85 (m, 2H).

The property values of the title optically active compound with a retention time of 11.2 minutes (Example 20) are as follows.
\[ ^1H-NMR(CDCl_3) \delta (ppm): \]
20 1.50-1.61 (m, 1H), 1.68-1.90 (m, 3H), 1.98-2.12 (m, 1H),
2.34 (s, 3H), 2.56-2.64 (m, 1H), 2.72-2.80 (m, 1H),
2.88-3.00 (m, 1H), 3.45-3.51 (m, 1H), 3.81-3.96 (m, 1H),
3.89 (s, 3H), 6.26-6.30 (m, 1H), 6.88-6.92 (m, 2H), 6.96 (dd,
J=1.2, 1.2Hz, 1H), 7.03-7.06 (m, 2H), 7.28-7.30 (m, 1H),
25 7.83-7.85 (m, 2H).

[0181]
Examples 21 and 22

Synthesis of (E)-(5S)-(4-fluorophenyl)-2-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydroindolizin-3-one and (E)-(5R)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-hexahydroindolizin-3-one

[Formula 22]

Synthesis of 1-(3-bromopropionyl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one

To a solution of 4-methoxypyridine (3.0 g) in tetrahydrofuran (50 mL), 4-fluorophenylmagnesium bromide (1 M solution in tetrahydrofuran; 27.5 mL) was added dropwise at -40°C to -20°C over 10 minutes. To this solution, 3-bromopropionyl chloride (2.77 mL) was added dropwise at -40°C to -20°C, and the reaction solution was stirred at -20°C for 30 minutes. The reaction solution was poured into a 10% hydrochloric acid solution, and the mixture was stirred for 20 minutes, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.9 g of the title compound. The property
values of the compound are as follows.

ESI-MS; m/z 327 [M+H]. $^1$H-NMR (CDCl$_3$) δ (ppm):

2.86 (d, J=16.4 Hz, 2H), 3.00-3.30 (m, 2H), 3.67 (t, J=6.8 Hz, 2H),
3.84 (t, J=6.4 Hz, 1H), 5.49 (d, J=8.0 Hz, 1H), 6.90-7.10 (m, 3H),
7.10-7.30 (m, 2H).

[0182]

Synthesis of 5-(4-fluorophenyl)hexahydroindolizine-3,7-dione

A solution of tributyltin hydride (3.88 mL) and 2,2'-azobis(isobutyronitrile) (0.56 g) in benzene (25 mL) was added dropwise to a solution of 1-(3-bromopropionyl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one obtained above (2.9 g) in benzene (60 mL) at 90°C over four hours. The reaction solution was stirred at the same temperature for three hours. The reaction solution was returned to room temperature and poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 600 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 248 [M+H]. $^1$H-NMR (CDCl$_3$) δ (ppm):

1.68-1.80 (m, 1H), 2.24-2.40 (m, 2H), 2.42-2.66 (m, 3H),
2.78-2.86 (m, 1H), 2.95 (td, J=2.0, 14.8 Hz, 1H), 3.70-3.80 (m, 1H), 5.83 (d, J=7.6 Hz, 1H), 6.98-7.05 (m, 2H), 7.22-7.30 (m, 2H).
Synthesis of 5-(4-fluorophenyl)-7-hydroxyhexahydroindolizin-3-one

Sodium borohydride (230 mg) was added to a solution of 5-(4-fluorophenyl)hexahydroindolizine-3,7-dione obtained above (500 mg) in ethanol (75 mL) at room temperature, and the reaction solution was stirred for one hour. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 500 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 250 [M+H]+. 

1H-NMR (CDCl3) δ (ppm): 
1.20-2.60 (m, 9H), 3.60-3.90 (m, 1H), 4.10-4.30 (m, 1H), 5.35-5.55 (m, 1H), 6.90-7.10 (m, 2H), 7.10-7.35 (m, 2H).

Synthesis of 5-(4-fluorophenyl)hexahydroindolizin-3-one

Methanesulfonyl chloride (0.563 mL) was added to a solution of 5-(4-fluorophenyl)-7-hydroxyhexahydroindolizin-3-one obtained above (500 mg) and triethylamine (2.43 mL) in dichloromethane (90 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 800 mg of a mesylate compound. The
mesylate compound (800 mg) was dissolved in 1-methyl-2-
pyrrolidinone (114 mL), and sodium borohydride (3.0 g)
was added thereto. The reaction solution was stirred
at 100°C for 1.5 hours. The reaction solution was
returned to room temperature and poured into water,
followed by extraction with ethyl acetate. The extract
was washed with brine, dried over anhydrous magnesium
sulfate, and then concentrated under reduced pressure.
The residue was purified by silica gel column
chromatography (heptane-ethyl acetate system) to obtain
270 mg of the title compound. The property values of
the compound are as follows.

ESI-MS: m/z 234 [M]+H]. 1H-NMR (CDCl₃) δ (ppm):
1.20-1.32 (m, 1H), 1.48 (tq, J=3.2, 13.6 Hz, 1H), 1.56-
1.90 (m, 4H), 2.20-2.34 (m, 2H), 2.40-2.54 (m, 2H),
3.52-3.64 (m, 1H), 5.41 (d, J=5.2 Hz, 1H), 6.96-
7.06 (m, 2H), 7.12-7.22 (m, 2H).

[0185]

Synthesis of diethyl [5-(4-fluorophenyl)-3-
oxooctahydroindolizin-2-yl]phosphonate

Iodotrimethylsilane (0.228 mL) was added to a
solution of 5-(4-fluorophenyl)hexahydroindolizin-3-one
obtained above (170 mg) and N,N,N′,N′-
tetramethylethlenediamine (0.544 mL) in
dichloromethane (2.5 mL) at 0°C, and the reaction
solution was stirred at 0°C for 30 minutes. Iodine (367
mg) was added to the reaction solution at 0°C, and the
reaction solution was stirred at the same temperature
for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 270 mg of an iodine compound. A solution of the resulting iodine compound (270 mg) in triethyl phosphite (5.56 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 260 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z370[M⁺+H].

[0186]

Synthesis of (E)-(5S)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydroindolizin-3-one and (E)-(5R)-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-hexahydroindolizin-3-one

Lithium hydroxide (26.7 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (80 mg) and diethyl [5-(4-fluorophenyl)-3-oxo(octahydroindolizin-2-yl]phosphonate obtained above (100 mg) in tetrahydrofuran (1 mL) and ethanol (4 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction
solution was added to ice-sodium bicarbonate water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 20 mg of a racemate of the title compound. The resulting racemate (20 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: 50% ethanol-hexane) to obtain the title optically active compound with a retention time of 27 minutes (7.2 mg; >99% ee) and the title optically active compound with a retention time of 33 minutes (7.2 mg; >93% ee).

The property values of the title optically active compound with a retention time of 27 minutes (Example 21) are as follows.

ESI-MS; m/z 432[M+H]. $^1$H-NMR (CDCl$_3$) δ (ppm):

1.33 (dq, J=3.6, 12.4 Hz, 1H), 1.55-1.70 (m, 1H), 1.70-
2.00 (m, 3H), 2.32 (s, 3H), 2.41 (brd, J=12.8 Hz, 1H),
2.80 (td, J=3.2, 18 Hz, 1H), 3.30 (ddd, J=2.8, 8.0, 18 Hz, 1H),
3.60-3.75 (m, 1H), 3.90 (s, 3H), 5.63 (d, J=5.6 Hz, 1H),
6.95 (s, 1H), 7.04 (t, J=8.8 Hz, 2H), 7.14 (s, 1H),
7.17 (d, J=8.0 Hz, 1H), 7.20-7.32 (m, 3H),
7.45 (t, J=2.8 Hz, 1H), 7.77 (s, 1H).

The property values of the title optically active compound with a retention time of 33 minutes (Example 22) are as follows.
ESI-MS; m/z 432 [M+H]. 1H-NMR (CDCl₃) δ (ppm):

1.33 (dq, J=3.6, 12.4 Hz, 1H), 1.55-1.70 (m, 1H), 1.70-2.00 (m, 3H), 2.32 (s, 3H), 2.41 (brd, J=12.8 Hz, 1H),
2.80 (td, J=3.2, 18 Hz, 1H), 3.30 (ddd, J=2.8, 8.0, 18 Hz, 1H),
3.60-3.75 (m, 1H), 3.90 (s, 3H), 5.63 (d, J=5.6 Hz, 1H),
6.95 (s, 1H), 7.04 (t, J=8.8 Hz, 2H), 7.14 (s, 1H),
7.17 (d, J=8.0 Hz, 1H), 7.20-7.32 (m, 3H),
7.45 (t, J=2.8 Hz, 1H), 7.77 (s, 1H).

[0187]

Examples 23, 24, 25, and 26

Synthesis of (E)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydroindolizin-3-one, (E)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-hexahydroindolizin-3-one, (Z)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydroindolizin-3-one, and (Z)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-

hexahydroindolizin-3-one

[Formula 23]

Synthesis of 5-(3,4-difluorophenyl)hexahydroindolizine-3,7-dione
To a solution of 4-methoxypyridine (2.7 g) in tetrahydrofuran (50 mL), 3,4-difluorophenylmagnesium bromide (0.5 M solution in tetrahydrofuran; 50 mL) was added dropwise at -40°C to -20°C over 10 minutes. To this solution, 3-bromopropionyl chloride (2.49 mL) was added dropwise at -40°C to -20°C, and the reaction solution was stirred at -20°C for 30 minutes. The reaction solution was poured into a 10% hydrochloric acid solution, and the mixture was stirred for 20 minutes, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 3.4 g of 1-(3-bromopropionyl)-2-(3,4-difluorophenyl)-2,3-dihydro-1H-pyridin-4-one. A solution of tributyltin hydride (5.75 mL) and 2,2'-azobis(isobutyronitrile) (0.657 g) in benzene (50 mL) was added dropwise to a solution of 1-(3-bromopropionyl)-2-(3,4-difluorophenyl)-2,3-dihydro-1H-pyridin-4-one obtained above (3.4 g) in benzene (50 mL) at 90°C over four hours. The reaction solution was stirred at the same temperature for three hours. The reaction solution was returned to room temperature and poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.4 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 266 [M^+H].

Synthesis of 5-(3,4-difluorophenyl)-7-hydroxyhexahydroindolizin-3-one

Sodium borohydride (644 mg) was added to a solution of 5-(3,4-difluorophenyl)hexahydroindolizine-3,7-dione obtained above (1.4 g) in ethanol (20 mL) at room temperature, and the reaction solution was stirred for one hour. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.5 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 268 [M^+H].

Synthesis of 5-(3,4-difluorophenyl)hexahydroindolizin-3-one

Methanesulfonyl chloride (1.58 mL) was added to a solution of 5-(3,4-difluorophenyl)-7-hydroxyhexahydroindolizin-3-one obtained above (1.4 g) and triethylamine (6.8 mL) in dichloromethane (25.2 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The
extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.9 g of a mesylate compound. The resulting mesylate compound (1.9 g) was dissolved in 1-methyl-2-pyrrolidinone (271 mL), and sodium borohydride (7.13 g) was added thereto. The reaction solution was stirred at 100°C for 1.5 hours. The reaction solution was returned to room temperature and poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 500 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 252 [M]+. 1H-NMR (CDCl3) δ (ppm):
1.20-1.32 (m, 1H), 1.45 (tq, J=3.2, 13.6 Hz, 1H), 1.52-1.90 (m, 4H), 2.20-2.32 (m, 2H), 2.44-2.54 (m, 2H), 3.52-3.62 (m, 1H), 5.39 (d, J=5.2 Hz, 1H), 6.88-6.96 (m, 1H), 6.96-7.06 (m, 1H), 7.06-7.18 (m, 1H).

[0190]

Synthesis of diethyl [5-(3,4-difluorophenyl)-3-oxooctahydroindolizin-2-yl]phosphonate

Iodotrimethylsilane (0.227 mL) was added to a solution of 5-(3,4-difluorophenyl)hexahydroindolizin-3-one obtained above (200 mg) and N,N,N',N'-tetramethylethlenediamine (0.601 mL) in dichloromethane (5 mL) at 0°C, and the reaction solution
was stirred at 0°C for 30 minutes. Iodine (404 mg) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to a mixture of ice with a sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 320 mg of an iodine compound. A solution of the iodine compound obtained above (320 mg) in triethyl phosphite (5 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 328 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 388 [M+H].

[0191]

**Synthesis of (E)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydropindolin-3-one, (E)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-hexahydropindolin-3-one, (Z)-(5S)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aS)-hexahydropindolin-3-one, and (Z)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-(8aR)-**
hexahydroindolizin-3-one

Lithium hydroxide (66.8 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (200 mg) and diethyl [5-(3,4-difluorophenyl)-3-oxooctahydroindolizin-2-yl]phosphonate obtained above (328 mg) in tetrahydrofuran (1 mL) and ethanol (4 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to a mixture of ice with sodium bicarbonate water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 60 mg of a racemate of the title compound E-isomer and 20 mg of a racemate of the title compound Z-isomer. The resulting racemate of E-isomer (20 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: 70% ethanol-hexane) to obtain the title optically active compound with a retention time of 23 minutes (6.3 mg; >99% ee) and the title optically active compound with a retention time of 30 minutes (6.1 mg; >99% ee). The resulting racemate of Z-isomer (20 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: 70% ethanol-hexane) to obtain the title optically active
compound with a retention time of 19 minutes (3.0 mg; >99% ee) and the title optically active compound with a retention time of 25 minutes (3.0 mg; >99% ee). The property values of the compound are as follows.

The property values of the (E) title optically active compound with a retention time of 23 minutes (Example 23) are as follows.

ESI-MS; m/z 450 [M]+H. 1H-NMR (CDCl3) δ (ppm):
1.33 (dq, J=3.6, 12.4 Hz, 1H), 1.55-1.70 (m, 1H), 1.70-
2.05 (m, 3H),
2.32 (s, 3H), 2.36 (brd, J=14.4 Hz, 1H), 2.69 (td, J=3.2, 17.6 Hz, 1H), 3.25-3.38 (m, 1H), 3.60-3.70 (m, 1H), 3.90 (s, 3H),
5.61 (d, J=5.2 Hz, 1H), 6.96 (s, 1H), 6.92-7.02 (m, 1H),
7.02-7.20 (m, 4H), 7.30 (d, J=8.0 Hz, 1H), 7.45 (t, J=2.8 Hz, 1H),
7.77 (s, 1H).

The property values of the (E) title optically active compound with a retention time of 30 minutes (Example 24) are as follows.

ESI-MS; m/z 450 [M]+H. 1H-NMR (CDCl3) δ (ppm):
1.33 (dq, J=3.6, 12.4 Hz, 1H), 1.55-1.70 (m, 1H), 1.70-
2.05 (m, 3H),
2.32 (s, 3H), 2.36 (brd, J=14.4 Hz, 1H), 2.69 (td, J=3.2, 17.6 Hz, 1H), 3.25-3.38 (m, 1H), 3.60-3.70 (m, 1H), 3.90 (s, 3H),
5.61 (d, J=5.2 Hz, 1H), 6.96 (s, 1H), 6.92-7.02 (m, 1H),
7.02-7.20 (m, 4H), 7.30 (d, J=8.0 Hz, 1H), 7.45 (t, J=2.8 Hz, 1H),
7.77 (s, 1H).

The property values of the (Z) title optically active compound with a retention time of 19
minutes (Example 25) are as follows.

ESI-MS; m/z 450 [M^+H]. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}) \delta (ppm):
1.34 (dq, J = 3.2, 12.8 Hz, 1H), 1.52 (tq, J = 3.2, 12.8 Hz, 1H), 1.60-1.96 (m, 3H), 2.31 (s, 3H), 2.26-2.36 (m, 1H), 2.56-2.66 (m, 1H), 3.08-3.22 (m, 1H), 3.58-3.68 (m, 1H), 3.91 (s, 3H), 5.50 (d, J = 5.6 Hz, 1H), 6.76 (t, J = 2.4 Hz, 1H), 6.90-7.30 (m, 6H), 7.79 (s, 1H), 8.25 (s, 1H).

The property values of the (Z) title

optically active compound with a retention time of 25

minutes (Example 26) are as follows.

ESI-MS; m/z 450 [M^+H]. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}) \delta (ppm):
1.34 (dq, J = 3.2, 12.8 Hz, 1H), 1.52 (tq, J = 3.2, 12.8 Hz, 1H), 1.60-1.96 (m, 3H), 2.31 (s, 3H), 2.26-2.36 (m, 1H), 2.56-2.66 (m, 1H), 3.08-3.22 (m, 1H), 3.58-3.68 (m, 1H), 3.91 (s, 3H), 5.50 (d, J = 5.6 Hz, 1H), 6.76 (t, J = 2.4 Hz, 1H), 6.90-7.30 (m, 6H), 7.79 (s, 1H), 8.25 (s, 1H).

[0192]

Examples 27 and 28

Synthesis of (E)-(5R,8aS)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]hexahydroindolizin-3-one and (E)-(5S,8aR)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]hexahydroindolizin-3-one

[Formula 24]
Synthesis of 1-[(2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidin-1-yl]propanone

Acrylic chloride (0.31 mL) was added to a solution of (2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidine (520 mg) and diisopropylamine (0.66 mL) in methylene chloride (10 mL), and the reaction solution was stirred at room temperature for five hours. Chloroform and 1 N aqueous hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with saturated sodium bicarbonate water, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane -> heptane:ethyl acetate = 1:1) to obtain 201 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
1.59-1.70 (m, 1H), 1.78-1.96 (m, 4H), 2.40-2.47 (m, 1H),
4.85 (dt, $J$=10.4, 1.2Hz, 1H), 4.93-5.01 (m, 1H),
5.03 (d, $J$=17.2Hz, 1H), 5.50 (ddd, $J$=17.2, 10.4, 7.6Hz, 1H),
5.67-5.72 (m, 2H), 6.36 (dd, $J$=17.2, 1.6Hz, 1H),
6.60 (dd, $J$=17.2, 10.4Hz, 1H), 6.98 (t, $J$=8.8Hz, 2H),
7.26 (dd, $J$=8.8, 5.6Hz, 2H).

[0193]
(5R*,8aS*)-5-(4-fluorophenyl)-6,7,8,8a-tetrahydro-5H-indolizin-3-one

A solution of 1-[(2R*,6S*)-2-(4-
fluorophenyl)-6-vinylpiperidin-1-yl]propenone (201 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene][benzyldene]ruthenium (IV) dichloride (33 mg) in methylene chloride (100 mL) was heated under reflux for 17 hours. The reaction solution was left to cool to room temperature and then concentrated. The residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate = 4:1 -> ethyl acetate) to obtain 105 mg of the title compound. The property values of the compound are as follows.

\[ \text{H-NMR (CDCl}_3\text{)} \delta (ppm):
1.28-1.40 (m, 1H), 1.60-1.81 (m, 2H), 1.86-1.94 (m, 1H),
2.00-2.09 (m, 1H), 2.11-2.19 (m, 1H), 4.05 (brd,
J=12.8 Hz, 1H), 4.50 (dd, J=9.2, 3.2 Hz, 1H), 6.03 (dd,
J=6.0, 2.0 Hz, 1H), 6.98-7.04 (m, 3H),
7.25 (dd, J=7.2, 5.6 Hz, 2H).

[0194]

**Synthesis of (5R*,8aS*)-5-(4-fluorophenyl)hexahydroindolizin-3-one**

Platinum oxide (10 mg) was added to a solution of (5R*,8aS*)-5-(4-fluorophenyl)-6,7,8,8a-tetrahydro-5H-indolizin-3-one (105 mg) in methanol (5 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for three hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 87 mg of the title compound. The property value
of the compound is as follows.
ESI-MS; m/z 234 [M'+H].

[0195]

Synthesis of (5S*,8aR*)-5-(4-fluorophenyl)-2-
iodohexahydroindolizin-3-one

Iodotrimethylsilane (0.08 mL) was added to a
solution of (5R*,8aS*)-5-(4-
fluorophenyl)hexahydroindolizin-3-one (87 mg) and
N,N,N',N'-tetramethylethylenediamine (0.2 mL) in
methylene chloride (5 mL) at 0°C, and the reaction
solution was stirred at 0°C for 20 minutes. Iodine (142
mg) was added to the reaction solution, which was then
stirred at 0°C for 40 minutes. Ethyl acetate and a
saturated sodium thiosulfate solution were added to the
reaction solution, and the organic layer was separated.
The resulting organic layer was washed with brine,
dried over magnesium sulfate, and then concentrated
under reduced pressure to obtain 120 mg of the title
compound. The property value of the compound is as
follows.
ESI-MS; m/z 360 [M'+H].

[0196]

Synthesis of diethyl [(5S*,8aR*)-5-(4-fluorophenyl)-3-
oxooctahydroindolizin-2-yl]phosphonate

A mixture of (5S*,8aR*)-5-(4-fluorophenyl)-2-
iodohexahydroindolizin-3-one (120 mg) with triethyl
phosphite (2 mL) was stirred at 120°C for 14 hours. The
reaction solution was left to cool to room temperature
and then concentrated under reduced pressure to obtain 123 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 370 [M^+H].

[0197]

Synthesis of (E)-(5R*,8aS*)-5-(4-fluorophenyl)-2-(1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-3-one

Lithium hydroxide monohydrate (42 mg) was added to a mixed solution of diethyl [(5S*,8aR*)-5-(4-fluorophenyl)-3-oxooctahydroindolizin-2-yl]phosphonate (123 mg) and 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (72 mg) in tetrahydrofuran (3 mL) and ethanol (1 mL), and the reaction solution was stirred at room temperature for one hour. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate = 1:1 -> ethyl acetate) to obtain 80 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 432 [M^+H].\(^1\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):

1.34-1.45 (m, 1H), 1.42-1.54 (m, 1H), 1.57-1.80 (m, 2H),
1.91-2.15 (m, 3H) 2.30 (s, 3H), 2.63-2.71 (m, 1H), 3.25 (ddd,
16.8, 6.4, 1.6Hz, 1H), 3.56-3.64 (m, 1H), 3.86 (s, 3H),
Synthesis of (E)-(5R,8aS)-5-(4-fluorophenyl)-2-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyridoxin-3-one} and (E)-(5S,8aR)-5-(4-fluorophenyl)-2-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyridoxin-3-one}

The racemate (E)-(5R*,8aS*)-5-(4-fluorophenyl)-2-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyridoxin-3-one} obtained above (80 mg) was separated by CHIRALPAK™ IA manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 23 minutes (28 mg; >99% ee) and the title optically active compound with a retention time of 26 minutes (26 mg; >99% ee).

The property values of the title optically active compound with a retention time of 23 minutes (Example 27) are as follows.

$^1$H-NMR (CDCl$_3$)$\delta$(ppm):

2.34-1.45 (m, 1H), 1.42-1.54 (m, 1H), 1.57-1.80 (m, 2H), 1.91-2.15 (m, 3H) 2.30 (s, 3H), 2.63-2.71 (m, 1H), 3.25 (ddd, 16.8, 6.4, 1.6Hz, 1H), 3.56-3.64 (m, 1H), 3.86 (s, 3H), 4.36 (dd, J=10.0, 3.2Hz, 1H), 6.92 (brs, 1H), 7.00-7.05 (m, 3H),
7.08 (brd, J=9.2, 1H), 7.20 (brs, 1H), 7.24 (d, J=9.2Hz, 1H),
7.28 (dd, J=8.8, 5.6Hz, 2H), 7.72 (s, 1H).

The property values of the title optically active compound with a retention time of 26 minutes
(Example 28) are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm) 1.34-1.45 (m, 1H), 1.42-1.54 (m, 1H),
1.57-1.80 (m, 2H), 1.91-2.15 (m, 3H) 2.30 (s, 3H), 2.63-
2.71 (m, 1H), 3.25 (ddd, 16.8, 6.4, 1.6Hz, 1H), 3.56-3.64 (m, 1H),
3.86 (s, 3H), 4.36 (dd, J=10.0, 3.2Hz, 1H), 6.92 (brs, 1H),
7.00-7.05 (m, 3H), 7.08 (brd, J=9.2, 1H), 7.20 (brs, 1H),
7.24 (d, J=9.2Hz, 1H), 7.28 (dd, J=8.8, 5.6Hz, 2H), 7.72 (s, 1H).

[0199]

Examples 29 and 30

Synthesis of (E)-(6R,9aS)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(4-
methoxyphenyl)octahydroquinolizin-4-one and (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]-6-(4-methoxyphenyl)octahydroquinolizin-4-one

[Formula 25]

Synthesis of 1-(4-methoxyphenyl)hepta-5,6-dienyl-1-
amine
462 mg of the title compound was obtained from (4-methoxybenzyl)-(4-methoxybenzylidene)amine (600 mg) and 6-iodohexa-1,2-diene (500 mg) according to the method described in Journal of the American Chemical Society, 2003, vol.125, p.11956. The property value of the compound is as follows.

ESI-MS; m/z201[M+−NH₃].

[0200]

Synthesis of (2R*,6S*)-2-(4-methoxyphenyl)-6-vinylpiperidine

Acetic acid (0.12 mL) was added to a solution of an allylpalladium chloride dimer (78 mg) and 1,1'-bis(diphenylphosphino)ferrocene (236 mg) in THF (50 mL), and the reaction solution was stirred at room temperature for 10 minutes. A solution of 1-(4-methoxyphenyl)hepta-5,6-dienyl-1-amine (462 mg) in THF (10 mL) was added to the reaction solution, which was then stirred at 70°C for 15 hours. The reaction solution was left to cool to room temperature. Then, diethyl ether and 1 N aqueous hydrochloric acid were added to the reaction solution, and the aqueous layer was separated. The resulting aqueous layer was washed with diethyl ether, and then a 5 N sodium hydroxide solution was added to the aqueous layer until the pH was adjusted to 11 or less. Chloroform was added to the aqueous layer, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate, and concentrated under reduced pressure to
obtain 320 mg of the title compound. The property value of the compound is as follows.
ESI-MS; m/z 218 [M⁺+H].

[0201]

5 Synthesis of 1-[(2R*, 6S*)-2-(4-methoxyphenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one

Diethyl cyanophosphonate (0.67 mL) was added to a solution of (2R*, 6S*)-2-(4-methoxyphenyl)-6-vinylpiperidine (320 mg), vinylacetic acid (0.37 mL), and triethylamine (1.23 mL) in DMF (5 mL), and the reaction solution was stirred at room temperature for nine hours. Ethyl acetate and 1 N aqueous hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with saturated sodium bicarbonate water, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane → heptane:ethyl acetate = 1:1) to obtain 100 mg of the title compound. The property value of the compound is as follows.
ESI-MS; m/z 286 [M⁺+H].

[0202]

Synthesis of (6R*, 9aS*)-6-(4-methoxyphenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one

A solution of 1-[(2R*, 6S*)-2-(4-methoxyphenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one (100 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-
trimethylphenyl)-4,5-dihydroimidazol-2-ylidene][benzylidene]ruthenium (IV) dichloride (30 mg) in methylene chloride (50 mL) was heated under reflux for 1.5 hours. The reaction solution was left to cool to room temperature and then concentrated. The residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate = 4:1 -> ethyl acetate) to obtain 28 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
1.42-1.53(m,1H), 1.60-1.77(m,2H), 1.82-1.91(m,1H),
2.00-2.07(m,1H), 2.17-2.27(m,1H), 2.92-3.10(m,2H),
3.77(s,3H), 4.25-4.35(m,1H), 5.30(t, J=4.4Hz,1H), 5.66(brd, J=10.0Hz,1H), 5.82-5.88(m,1H), 6.82(d, J=8.8Hz,2H),
7.11(d, J=8.8Hz,2H).

[0203]

**Synthesis of (6R*,9aS*)-6-(4-methoxyphenyl)octahydroquinolizin-4-one**

Platinum oxide (2 mg) was added to a solution of (6R*,9aS*)-6-(4-methoxyphenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one (28 mg) in methanol (5 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for 13 hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 23 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
1.34-1.44 (m, 1H), 1.47-1.86 (m, 5H), 1.90-1.98 (m, 2H), 2.04-2.21 (m, 2H), 2.48-2.53 (m, 2H), 3.57-3.66 (m, 1H), 3.77 (s, 3H), 5.38 (t, J=3.2 Hz, 1H), 6.82 (d, J=8.8 Hz, 2H), 7.10 (d, J=8.8, 2H).

[0204]

Synthesis of (6R*,9aS*)-3-iodo-6-(4-methoxyphenyl)octahydroquinolizin-4-one

Iodotrimethylsilane (0.02 mL) was added to a solution of (6R*,9aS*)-6-(4-methoxyphenyl)octahydroquinolizin-4-one (23 mg) and N,N,N',N'-tetramethylethylenediamine (0.05 mL) in methylene chloride (3 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (34 mg) was added to the reaction solution, which was then stirred at 0°C for one hour. Ethyl acetate and a saturated sodium thiosulfate solution were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain 34 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 38[M+H].

[0205]

Synthesis of diethyl [(6S*,9aR*)-6-(4-methoxyphenyl)-4-oxooctahydroquinolizin-3-yl]phosphonate

A mixture of (6R*,9aS*)-3-iodo-6-(4-methoxyphenyl)octahydroquinolizin-4-one (34 mg) with
triethyl phosphite (1 mL) was stirred at 120°C for five hours. The reaction solution was left to cool to room temperature and then concentrated under reduced pressure to obtain 35 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z396[M^+H].

[0206]

Synthesis of (E)-(6R^*,9aS^*)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(4-methoxyphenyl)octahydroquinolizin-4-one

Lithium hydroxide monohydrate (11 mg) was added to a mixed solution of diethyl [(6S^*,9aR^*)-6-(4-methoxyphenyl)-4-oxooctahydroquinolizin-3-yl]phosphonate (35 mg) and 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (19 mg) in tetrahydrofuran (2 mL) and ethanol (0.5 mL), and the reaction solution was stirred at room temperature for three hours. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate = 1:1 -> ethyl acetate) to obtain 28 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z458[M^+H]. ^1H-NMR(CDCl_3) δ (ppm):

1.39-1.49 (m, 1H), 1.52-1.76 (m, 4H), 1.98-2.05 (m, 1H),
2.18-2.24 (m, 2H) 2.32 (s, 3H), 2.66-2.76 (m, 1H),
3.09 (brd, J=16.0 Hz, 1H), 3.75-3.84 (m, 4H), 3.85 (s, 3H),
5.56 (brt, J=3.2 Hz, 1H), 6.85 (d, J=8.8 Hz, 2H), 6.94 (brs, 1H),
7.03 (brs, 1H), 7.04 (brd, J=8.0 Hz, 1H), 7.16 (d, J=8.8 Hz, 2H),
7.24 (d, J=8.0 Hz, 1H), 7.78 (s, 1H), 7.81 (brd, J=2.4 Hz, 1H).

[0207]

Synthesis of (E)-(6R,9aS)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(4-methoxyphenyl)octahydroquinolinizin-4-one and (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(4-methoxyphenyl)octahydroquinolinizin-4-one

The racemate (E)-(6R*,9aS*)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(4-methoxyphenyl)octahydroquinolinizin-4-one obtained above (28 mg) was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 19 minutes (9.8 mg; >99% ee) and the title optically active compound with a retention time of 32 minutes (8.6 mg; >99% ee).

The property values of the title optically active compound with a retention time of 19 minutes (Example 29) are as follows.

ESI-MS: m/z458 [M+H]+. \( ^{1} \text{H}-\text{NMR (CDCl}_{3}\text{)} \delta \text{ppm):} \\
1.39-1.49 (m, 1H), 1.52-1.76 (m, 4H), 1.98-2.05 (m, 1H),
2.18-2.24 (m, 2H) 2.32 (s, 3H), 2.66-2.76 (m, 1H), 3.09 (brd,
16.0 Hz, 1H), 3.75-3.84 (m, 4H), 3.85 (s, 3H), 5.56 (brt, J=3.2 Hz, 1H), 6.85 (d, J=8.8 Hz, 2H), 6.94 (brs, 1H), 7.03 (brs, 1H), 7.04 (brd, J=8.0 Hz, 1H), 7.16 (d, J=8.8 Hz, 2H), 7.24 (d, J=8.0 Hz, 1H), 7.78 (s, 1H), 7.81 (brd, J=2.4 Hz, 1H).

The property values of the title optically active compound with a retention time of 32 minutes (Example 30) are as follows.

ESI-MS; m/z 458 [M]+H. 1H-NMR (CDCl3) δ (ppm):
1.39-1.49 (m, 1H), 1.52-1.76 (m, 4H), 1.98-2.05 (m, 1H), 2.18-2.24 (m, 2H) 2.32 (s, 3H), 2.66-2.76 (m, 1H), 3.09 (brd, 16.0 Hz, 1H), 3.75-3.84 (m, 4H), 3.85 (s, 3H), 5.56 (brt, J=3.2 Hz, 1H), 6.85 (d, J=8.8 Hz, 2H), 6.94 (brs, 1H), 7.03 (brs, 1H), 7.04 (brd, J=8.0 Hz, 1H), 7.16 (d, J=8.8 Hz, 2H), 7.24 (d, J=8.0 Hz, 1H), 7.78 (s, 1H), 7.81 (brd, J=2.4 Hz, 1H).

Examples 31 and 32

Synthesis of (E)-(4S,10aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrindo[1,2-a]azepin-6-one and

(E)-(4R,10aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrindo[1,2-a]azepin-6-one

[Formula 26]
Synthesis of 1-[(2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidin-1-yl]-4-penten-1-one

To a solution of (2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidine (460 mg) and diisopropylamine (0.59 mL) in methylene chloride (10 mL), 4-pentenoyl chloride (0.37 mL) was added, and the reaction solution was stirred at room temperature for 1.5 hours. Chloroform and 1 N aqueous hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with saturated sodium bicarbonate water, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane -> heptane:ethyl acetate = 1:1) to obtain 307 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 288 [M' + H].

[0209]

Synthesis of (4R*,10aS*)-4-(4-fluorophenyl)-1,3,4,7,8,10a-hexahydro-2H-pyrido[1,2-a]azepin-6-one

A solution of 1-[(2R*,6S*)-2-(4-fluorophenyl)-6-vinylpiperidin-1-yl]-4-penten-1-one (307 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene][benzylidene]ruthenium (IV) dichloride (64 mg) in methylene chloride (150 mL) was heated under reflux for 25 hours. The reaction solution was left to cool
to room temperature and then concentrated. The residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate = 4:1 → ethyl acetate) to obtain 146 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z260 [M+H],$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.46-1.78 (m, 4H), 2.00-2.10 (m, 1H), 2.20-2.30 (m, 1H) 2.45-2.47 (m, 3H), 3.26 (td, J=12.8, 5.2 Hz, 1H), 4.68-4.76 (m, 1H), 5.39-5.45 (m, 1H), 5.71-5.80 (m, 2H), 6.95 (t, J=8.8 Hz, 2H), 7.25 (dd, J=8.8, 5.2 Hz, 2H).

[0210]

Synthesis of (4R*,10aR*)-4-(4-fluorophenyl)octahydropyrido[1,2-a]azepin-6-one

Platinum oxide (10 mg) was added to a solution of (4R*,10aS*)-4-(4-fluorophenyl)-1,3,4,7,8,10a-hexahydro-2H-pyrido[1,2-a]azepin-6-one (146 mg) in methanol (5 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for 25 hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 140 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z262 [M+H],$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.20-1.32 (m, 1H), 1.40-1.74 (m, 6H), 1.80-1.97 (m, 3H), 1.98-2.08 (m, 1H), 2.30-2.41 (m, 1H), 2.59-2.75 (m, 2H), 3.68 (td, J=10.0, 5.6 Hz, 1H), 5.87 (d, J=6.0 Hz, 1H), 6.97 (t, J=8.8 Hz, 2H), 7.32 (dd, J=8.8, 5.6 Hz, 2H).
Synthesis of (4R*,10aS*)-4-(4-fluorophenyl)-7-iodooctahydropyrido[1,2-a]azepin-6-one

Iodotrimethylsilane (0.11 mL) was added to a solution of (4R*,10aR*)-4-(4-fluorophenyl)octahydropyrido[1,2-a]azepin-6-one (140 mg) and N,N,N',N'-tetramethylethlenediamine (0.28 mL) in methylene chloride (15 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (204 mg) was added to the reaction solution, which was then stirred at 0°C for one hour. Ethyl acetate and a saturated sodium thiosulfate solution were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain 208 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 388[M+H].

Synthesis of diethyl [(4R*,10aS*)-4-(4-fluorophenyl)-6-oxodecahydropyrido[1,2-a]azepin-7-yl]phosphonate

A mixture of (4R*,10aS*)-4-(4-fluorophenyl)-7-iodooctahydropyrido[1,2-a]azepin-6-one (208 mg) with triethyl phosphite (2 mL) was stirred at 120°C for 1.5 hours. The reaction solution was left to cool to room temperature and then concentrated under reduced pressure to obtain 213 mg of the title compound. The
property value of the compound is as follows.

ESI-MS; m/z 398 [M^+H].

[0213]

Synthesis of (E)-(4S*,10aS*)-4-(4-fluorophenyl)-7-[(3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene)octahydropyrido[1,2-a]azepin-6-one

Lithium hydroxide monohydrate (68 mg) was
added to a mixed solution of diethyl [(4R*,10aS*)-4-(4-
fluorophenyl)-6-oxodecahydropyrido[1,2-a]azepin-7-
yl]phosphonate (213 mg) and 3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)benzaldehyde (116 mg) in tetrahydrofuran
(6 mL) and ethanol (1.5 mL), and the reaction solution
was stirred at room temperature for 25 hours. Ethyl
acetate and brine were added to the reaction solution,
and the organic layer was separated. The resulting
organic layer was dried over magnesium sulfate and then
concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (carrier:
Chromatorex NH; elution solvent: heptane:ethyl acetate
= 1:1 -> ethyl acetate) to obtain 125 mg of the title
compound. The property values of the compound are as
follows.

ESI-MS; m/z 460 [M^+H]. ^1H-NMR (CDCl_3) δ (ppm):
1.37-1.46 (m, 1H), 1.49-1.75 (m, 4H), 1.84-1.98 (m, 2H), 1.99-
2.10 (m, 1H), 2.24-2.31 (m, 2H), 2.33 (s, 3H), 2.59-2.65 (m, 2H),
3.85 (s, 3H), 3.88-3.97 (m, 1H), 5.84 (dd, J=7.2, 2.4Hz, 1H),
6.93 (brs, 1H), 6.99 (t, J=8.8Hz, 2H), 7.02 (brs, 1H),
7.04 (d, J=1.6Hz, 1H), 7.08 (dd, J=8.4, 1.6Hz, 1H), 7.23 (d,
J=8.4Hz,1H), 7.49(dd,J=8.8,5.6Hz,2H), 7.81(brs,1H).

[0214] Synthesis of (E)-(4S,10aS)-4-((4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrido[1,2-a]azepin-6-one and
(E)-(4R,10aR)-4-((4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrido[1,2-a]azepin-6-one

The racemate (E)-(4S*,10aS*)-4-((4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrido[1,2-a]azepin-6-one obtained above (60 mg) was separated by CHIRALCEL™ OD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: hexane:ethanol = 8:2) to obtain

the title optically active compound with a retention time of 12 minutes (7.9 mg; >99% ee) and the title optically active compound with a retention time of 15 minutes (7.7 mg; >94% ee).

The property values of the title optically active compound with a retention time of 12 minutes

(Example 31) are as follows.

ESI-MS; m/z 460 [M+H].

1H-NMR (CDCl₃) δ (ppm):

1.37-1.46 (m, 1H), 1.49-1.75 (m, 4H), 1.84-1.98 (m, 2H), 1.99-2.10 (m, 1H), 2.24-2.31 (m, 2H), 2.33 (s, 3H), 2.59-2.65 (m, 2H), 25 3.85 (s, 3H), 3.88-3.97 (m, 1H), 5.84 (dd, J=7.2, 2.4Hz, 1H), 6.93 (brs, 1H) 6.99 (t, J=8.8Hz, 2H), 7.02 (brs, 1H), 7.04 (d, J=1.6Hz, 1H), 7.08 (dd, J=8.4, 1.6Hz, 1H), 7.23 (d, J=8.4Hz, 1H), 7.49 (dd, J=8.8, 5.6Hz, 2H), 7.81 (brs, 1H).
The property values of the title optically active compound with a retention time of 15 minutes (Example 32) are as follows.

ESI-MS; m/z460 [M+H]. $^1$H-NMR (CDCl$_3$) δ (ppm):

5 1.37-1.46 (m, 1H), 1.49-1.75 (m, 4H), 1.84-1.98 (m, 2H), 1.99-2.10 (m, 1H), 2.24-2.31 (m, 2H), 2.33 (s, 3H), 2.59-2.65 (m, 2H), 3.85 (s, 3H), 3.88-3.97 (m, 1H), 5.84 (dd, J=7.2, 2.4Hz, 1H),

6 6.93 (brs, 1H), 6.99 (t, J=8.8Hz, 2H), 7.02 (brs, 1H), 7.04 (d, J=1.6Hz, 1H), 7.08 (dd, J=8.4, 1.6Hz, 1H), 7.23 (d, J=8.4Hz, 1H),

10 7.49 (dd, J=8.8, 5.6Hz, 2H), 7.81 (brs, 1H).

[0215]

Example 33

Synthesis of (E)-(5R,7aS)-5-((3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrrolidin-3-one

[Formula 27]

\[
\text{Synthesis of methyl (S)-2-tert-butoxycarbonylamino-5-(3,4-difluorophenyl)-5-oxopentanoate}
\]

To a solution of (S)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester (5.5 g) in tetrahydrofuran (100 mL), 3,4-difluorophenylmagnesium bromide (0.5 M solution in tetrahydrofuran; 50 mL) was added dropwise at -40°C over
10 minutes, and the reaction solution was stirred at -40°C to 0°C for two hours. Water was added to the solution in small portions, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 8.0 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 380 [M+Na]+. H-NMR (CDCl3) δ (ppm): 1.41 (s, 9H), 1.75-2.12 (m, 1H), 2.20-2.50 (m, 1H), 2.92-3.16 (m, 2H), 3.76 (s, 3H), 4.38 (s, 1H), 5.16 (s, 1H), 6.90-7.85 (m, 3H).

Synthesis of (2S,5R)-5-(3,4-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester

A solution of 4 N hydrochloric acid in ethyl acetate (92.3 mL) was added dropwise to a solution of methyl (S)-2-tert-butoxycarbonylamino-5-(3,4-difluorophenyl)-5-oxopentanoate (8.0 g) in ethyl acetate (90 mL) at room temperature, and the solution was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure to obtain 5.4 g of a yellow oil. The crude product was dissolved in ethyl acetate (100 mL). Saturated sodium bicarbonate water (100 mL) was added dropwise thereto, and the reaction solution was stirred
at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 4.8 g of a pale red oil. The resulting pale red oil (1 g) was dissolved in ethyl acetate (30 mL). Palladium-carbon (containing 50% water, 130 mg) was added to the solution, and the reaction solution was stirred in a hydrogen atmosphere for four hours. Palladium-carbon in the reaction solution was removed by filtration through celite, and the filtrate was concentrated under reduced pressure to obtain 1.0 g of a yellow oil. The resulting yellow oil was dissolved in DMF (20 mL). Triethylamine (1.87 mL) and di-tert-butyl dicarbonate (1.96 g) were added to the solution, and the reaction solution was stirred at room temperature for three days. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.83 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 364 [M+Na].\(^1\)H-NMR (CD\(_3\)OD) \(\delta\) (ppm):
1.18 and 1.40 (s, 9H), 1.80-1.90 (m, 1H), 1.90-2.10 (m, 1H), 2.20-2.30 (m, 1H), 2.30-2.45 (m, 1H), 3.80 (s, 3H), 4.20-
4.50 (m, 1H), 4.73-4.95 (m, 1H), 7.10-7.28 (m, 1H), 7.28-7.40 (m, 1H), 7.52-7.70 (m, 1H).

(0217)

Synthesis of tert-butyl (E)-(2R,5S)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylvinyl)pyrrolidine-1-carboxylate

Lithium borohydride (212 mg) was added to a solution of (2S,5R)-5-(3,4-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester (0.83 g) in tetrahydrofuran (10 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.0 g of an alcohol compound. DMSO (0.34 mL) was added dropwise to a solution of oxalyl chloride (0.41 mL) in dichloromethane (15 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (1.0 g) in dichloromethane (10 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (3.11 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over
anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.0 g of an aldehyde compound. Sodium hydride (60% oil, 0.272 g) was added to a solution of trimethyl phosphonoacetate (1.86 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (1.0 g) in DMF (10 mL), and the reaction solution was stirred at room temperature for three hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.95 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 390 [M⁺+Na]. ¹H-NMR (CDCl₃) δ (ppm):
1.10-1.60 (m, 9H), 1.80-1.92 (m, 2H), 2.06-2.20 (m, 1H), 2.24-2.36 (m, 1H), 3.78 (s, 3H), 4.40-5.00 (m, 2H), 6.03 (d, J=14.8 Hz, 1H), 6.90-7.20 (m, 4H).

[0218]

Synthesis of tert-butyl (2R,5S)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylvinyl)pyrrolidine-1-carboxylate

Palladium-carbon (containing 50% water, 124 mg) was added to a solution of tert-butyl (E)-(2R,5S)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylviny1)pyrrolidine-1-carboxylate (0.95 g)
in ethyl acetate (30 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for six hours. Palladium-carbon in the reaction solution was removed by filtration through celite, and the filtrate was concentrated under reduced pressure to obtain 0.90 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z392 [M+Na]+. 1H-NMR (CDCl3) δ (ppm):
1.10-1.50 (m, 9H), 1.60-1.70 (m, 1H), 1.70-1.90 (m, 2H),
1.94-2.06 (m, 1H), 2.16-2.32 (m, 2H), 2.36-2.50 (m, 2H),
3.70 (s, 3H), 3.98 (s, 1H), 4.10-4.90 (m, 1H), 6.90-7.25 (m, 3H).

[0219]

Synthesis of (5R,7aS)-5-(3,4-difluorophenyl)hexahydropyrroloidin-3-one

tert-Butyl (2R,5S)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonyl)ethyl)]pyrroloidine-1-carboxylate (0.95 g) was dissolved in ethyl acetate (10 mL). A solution of 4 N hydrochloric acid in ethyl acetate (10 mL) was added thereto, and the reaction solution was stirred at 50°C for three hours. The reaction solution was concentrated under reduced pressure to obtain 1.2 g of a yellow oil. The resulting yellow oil was dissolved in ethanol (10 mL). A 5 N sodium hydroxide solution (10 mL) was added thereto, and the reaction solution was stirred at 50°C for two hours. The reaction solution was cooled to 0°C and neutralized with 5 N hydrochloric acid. The reaction solution was concentrated under reduced pressure, and the residue
was suspended in dichloromethane (40 mL). Thionyl chloride (2.55 mL) was added thereto, and the reaction solution was stirred at 50°C for one hour. The reaction solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (10 mL), followed by addition of a 5 N sodium hydroxide solution (10 mL). The reaction solution was stirred at room temperature for 30 minutes and then poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 620 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 238 [M'+H].

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.55-1.70 (m, 1H), 1.85-2.05 (m, 3H), 2.30-2.40 (m, 1H), 2.50-2.70 (m, 2H), 2.70-2.85 (m, 1H), 4.03-4.17 (m, 1H), 4.61 (d, J=9.2 Hz, 1H), 6.89-7.02 (m, 2H), 7.07-7.15 (m, 1H).

[0220]

Synthesis of diethyl [(5R,7aS)-5-(3,4-difluorophenyl)-3-oxohexahydropyrrolidin-2-yl]phosphonate

Iodotrimethylsilane (0.17 mL) was added to a solution of (5R,7aS)-5-(3,4-difluorophenyl)hexahydropyrrolidin-3-one (210 mg) and N,N,N',N'-tetramethylethylenediamine (0.451 mL) in dichloromethane (5 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (303 mg) was
added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 320 mg of an iodine compound. A solution of the resulting iodine compound (320 mg) in triethyl phosphate (5 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 328 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 374 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.30-1.40 (m, 6H), 1.60-1.75 (m, 1H), 1.80-2.10 (m, 2H), 2.20-2.40 (m, 1H), 2.50-2.75 (m, 2H), 3.30-3.50 (m, 1H), 4.00-4.30 (m, 5H), 4.64 (d, J=8.8Hz, 1H), 6.90-7.17 (m, 3H).

[0221]

Synthesis of (E)-5R,7aS)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrrolidin-3-one

Lithium hydroxide (66.8 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (200 mg) and diethyl ((5R,7aS)-5-(3,4-difluorophenyl)-3-oxohexahydropyrrolidin-2-
yl)phosphonate (328 mg) in tetrahydrofuran (1 mL) and ethanol (4 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice-sodium bicarbonate water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 300 mg of a crude product of the title compound. The crude product (15 mg) was re-refined by a preparative optical resolution column (CHIRALPAK™ IA manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm), ethanol-hexane system) to obtain 6.0 mg of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 436 [M+H]. $^1$H-NMR (CDCl₃) δ (ppm):
- 1.70-1.84 (m, 1H), 2.11 (dd, J=12.8, 7.2 Hz, 1H),
- 2.18 (quint, J=6.0 Hz, 1H), 2.32 (s, 3H), 2.60-2.76 (m, 1H),
- 2.93 (ddd, J=3.6, 6.8, 16.4 Hz, 1H), 3.40 (ddd, J=2.0, 5.4, 16.4 Hz, 1H), 3.89 (s, 3H), 4.11 (sext, J=6.0 Hz, 1H), 4.79 (d, J=9.2 Hz, 1H), 6.92-7.04 (m, 3H), 7.09 (d, J=1.2 Hz, 1H), 7.08-7.18 (m, 2H), 7.20-7.23 (m, 1H), 7.28 (d, J=8.0 Hz, 1H),
- 7.77 (d, J=1.2 Hz, 1H).

Example 34

Synthesis of (E)-(3R,9aR)-3-(3,4-difluorophenyl)-6-(3-methoxy-4-(4-methyl-1H-imidazol-1-
yl]benzylidene]octahydropyrrolo[1,2-a]azepin-5-one

[Formula 28]

\[
\begin{array}{c}
\text{F} \\
\text{O} \\
\text{N} \\
\text{N} \\
\text{F} \\
\end{array}
\]

**Synthesis of tert-butyl (2R,5R)-2-(3,4-difluorophenyl)-5-[(E)-4-methoxycarbonyl-3-buteryl]pyrrolidine-1-carboxylate**

A solution of tert-butyl (2R,5S)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylethyl)pyrrolidine-1-carboxylate (2.0 g) in tetrahydrofuran (50 mL) was added dropwise to a solution of lithium aluminum hydride (0.268 g) in tetrahydrofuran (75 mL) at 0°C, and the reaction solution was stirred at the same temperature for 30 minutes. Water (0.27 mL), a 15% sodium hydroxide solution (0.27 mL), and water (0.81 mL) were sequentially added to the reaction solution, which was then stirred for 20 minutes. Then, the inorganic salt precipitated in the reaction solution was removed by filtration through celite, and the filtrate was concentrated to obtain 1.8 g of an alcohol compound. DMSO (0.678 mL) was added dropwise to a solution of oxalyl chloride (0.819 mL) in dichloromethane (40 mL) at -70°C, and the reaction solution was stirred at the same temperature for three
minutes. A solution of the alcohol compound obtained above (1.8 g) in dichloromethane (10 mL) was added dropwise to the reaction solution at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (6.21 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.0 g of an aldehyde compound. Sodium hydride (60% oil, 0.278 g) was added to a solution of trimethyl phosphonoacetate (1.27 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. The reaction solution was added to a solution of the resulting aldehyde (1.8 g) in DMF (10 mL), and the mixture was stirred at room temperature for three hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.3 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 418 [M+Na]. 1H-NMR (CDCl3) δ (ppm):
1.00-1.50 (m, 9H), 1.56-1.90 (m, 3H), 1.96-2.16 (m, 2H), 2.20-
2.44 (m, 3H), 3.71 (s, 3H), 3.90-4.00 (m, 1H), 4.74 (s, 1H),
5.92 (d, J=15.6 Hz, 1H), 7.00-7.25 (m, 4H).

[0223]

Synthesis of tert-butyl (2R,5R)-2-(3,4-difluorophenyl)-
5-(4-methoxycarbonylbutyl)pyrrolidine-1-carboxylate

Palladium-carbon (containing 50% water, 0.376 g) was added to a solution of tert-butyl (2R,5R)-2-
(3,4-difluorophenyl)-5-{(E)-4-methoxycarbonyl-3-
butenyl}pyrrolidine-1-carboxylate (1.3 g) in ethyl acetate (50 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for six hours. Palladium-carbon in the reaction solution was removed by filtration through celite, and the filtrate was concentrated under reduced pressure to obtain 1.3 g of the title compound.

ESI-MS: m/z 420 [M+Na].

1H-NMR (CDCl₃) δ (ppm):
1.00-2.10 (m, 18H), 2.26-2.40 (m, 1H), 2.37 (t, J=7.2 Hz, 2H),
3.66 (s, 3H), 3.86-3.90 (m, 1H), 4.66-4.80 (m, 1H), 7.00-
7.26 (m, 3H).

[0224]

Synthesis of (3R,9aR)-3-(3,4-
difluorophenyl)octahydropyrrolo[1,2-a]azepin-5-one

A solution of 4 N hydrochloric acid in ethyl acetate (3.16 mL) was added to a solution of tert-butyl (2R,5R)-2-(3,4-difluorophenyl)-5-(4-
methoxycarbonylbutyl)pyrrolidine-1-carboxylate (0.30 g) in ethyl acetate (10 mL). The reaction solution was stirred at 50°C for three hours and then concentrated
under reduced pressure to obtain 0.24 g of a yellow oil. A 5 N sodium hydroxide solution (2.0 mL) was added to a solution of the resulting yellow oil (0.24 g) in ethanol (3.2 mL), and the reaction solution was stirred at 50°C for two hours. The reaction solution was cooled to 0°C and neutralized with 5 N hydrochloric acid. The reaction solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (13.5 mL). Thionyl chloride (0.86 mL) was added to the solution, and the reaction solution was stirred at 50°C for one hour. The reaction solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (10 mL). A 5 N sodium hydroxide solution (5 mL) was added to the solution. The reaction solution was stirred at room temperature for 30 minutes and then poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.62 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 531[2M+H]+. 1H-NMR (CDCl3) δ (ppm):

1.46–1.74 (m, 4H), 1.86–2.22 (m, 6H), 2.43–2.53 (m, 1H), 2.66 (dd, J=7.2, 14.4Hz, 1H), 3.76–3.88 (m, 1H), 5.25 (d, J=7.6Hz, 1H), 6.93–6.99 (m, 1H), 7.00–7.13 (m, 2H).
Synthesis of diethyl [(3R,9aR)-3-(3,4-difluorophenyl)-5-oxooctahydropyrrolo[1,2-a]azepin-6-yl]phosphonate

Iodotrimethylsilane (0.109 mL) was added to a solution of (3R,9aR)-3-(3,4-difluorophenyl)octahydropyrrolo[1,2-a]azepin-5-one (0.15 g) and N,N,N',N'-tetramethylethylenediamine (0.29 mL) in dichloromethane (3.57 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes.

Iodine (0.194 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.25 g of an iodine compound. A solution of the resulting iodine compound (0.25 g) in triethyl phosphite (7 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.25 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 402 [M+H].

Synthesis of (E)-(3R,9aR)-3-(3,4-difluorophenyl)-6-[3-
methoxy-4-((4-methyl-1H-imidazol-1-yl)benzylidene)octahydropyrrolo[1,2-a]azepin-5-one

Lithium hydroxide (0.0668 g) was added to a mixed solution of 3-methoxy-4-((4-methyl-1H-imidazol-1-yl)benzaldehyde (0.20 g) and diethyl ((3R,9aR)-3-(3,4-difluorophenyl)-5-oxooctahydropyrrolo[1,2-a]azepin-6-yl]phosphonate (0.25 g) in tetrahydrofuran (1 mL) and ethanol (4 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice-sodium bicarbonate water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.20 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 464 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.70-2.40 (m, 9H), 2.31 (s, 3H), 2.90-3.00 (m, 1H),
3.85 (s, 3H), 3.84-3.98 (m, 1H), 5.28-5.34 (m, 1H), 6.94 (s, 1H),
6.98-7.18 (m, 6H), 7.22-7.30 (m, 1H), 7.74 (s, 1H).
[0227]
Example 35
Synthesis of methyl (E)-4-((4S*,9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxooctahydroquinolizin-4-yl]benzoate
Synthesis of 1-(4-carbomethoxyphenyl)hepta-5,6-dienyl-1-amine

595 mg of the title compound was obtained from (4-carbomethoxybenzyl)-(4-carbomethoxybenzylidene)amine (985 mg) and 6-iodohexa-1,2-diene (723 mg) according to the method described in Journal of the American Chemical Society, 2003, vol.125, p.11956. The property value of the compound is as follows.

ESI-MS; m/z 229 [M+ − NH3].

[0228]

Synthesis of (2R*, 6S*)-2-(4-carbomethoxyphenyl)-6-vinylpiperidine

Acetic acid (0.2 mL) was added to a solution of an allylpalladium chloride dimer (116 mg) and 1,1'-bis(diphenylphosphino)ferrocene (350 mg) in THF (50 mL), and the reaction solution was stirred at room temperature for 10 minutes. A solution of 1-(4-carbomethoxyphenyl)hepta-5,6-dienyl-1-amine (595 mg) in THF (10 mL) was added to the reaction solution, which was then stirred at 70°C for 18 hours. The reaction
solution was left to cool to room temperature. Then, diethyl ether and 1 N aqueous hydrochloric acid were added to the reaction solution, and the aqueous layer was separated. The resulting aqueous layer was washed with diethyl ether, and then a 5 N sodium hydroxide solution was added to the aqueous layer until the pH was adjusted to 11 or less. Chloroform was added to the aqueous layer, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate, and concentrated under reduced pressure to obtain 422 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 246[M⁺+H].

15 Synthesis of 1-[(2R*,6S*)-2-(4-carbomethoxyphenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one

Diethyl cyanophosphonate (0.78 mL) was added to a solution of (2R*,6S*)-2-(4-carbomethoxyphenyl)-6-vinylpiperidine (422 mg), vinylacetic acid (0.44 mL), and triethylamine (1.44 mL) in DMF (5 mL), and the reaction solution was stirred at room temperature for one hour. Ethyl acetate and 1 N aqueous hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with saturated sodium bicarbonate water, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution
solvent: heptane -> heptane:ethyl acetate = 1:1) to obtain 281 mg of the title compound. The property value of the compound is as follows.

ESI-MS:m/z314[M^+H].

5

Synthesis of (6R*,9aS*)-6-(4-carbomethoxyphenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one

A solution of 1-[(2R*,6S*)-2-(4-carbomethoxyphenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one (281 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene][benzylidene]ruthenium (IV) dichloride (53 mg) in methylene chloride (150 mL) was heated under reflux for 1.5 hours. The reaction solution was left to cool to room temperature and then concentrated. The residue was purified by silica gel column chromatography (elution solvent: heptane:ethyl acetate = 4:1 -> ethyl acetate) to obtain 145 mg of the title compound. The property value of the compound is as follows.

ESI-MS:m/z286[M^+H].

[0231]

Synthesis of (6R*,9aS*)-6-(4-carbomethoxyphenyl)octahydroquinolizin-4-one

Platinum oxide (10 mg) was added to a solution of (6R*,9aS*)-6-(4-carbomethoxyphenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one (145 mg) in methanol (5 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for three
hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 125 mg of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 288 [M+H]. 1H-NMR (CDCl3) δ (ppm):
1.25-1.37 (m, 1H), 1.46-1.64 (m, 3H), 1.70-1.86 (m, 2H), 1.92-2.01 (m, 2H), 2.04-2.12 (m, 1H), 2.16-2.27 (m, 1H), 2.47-2.53 (m, 2H), 3.59-3.68 (m, 1H), 3.89 (s, 3H), 5.40 (t, J=3.6 Hz, 1H), 7.26 (d, J=8.4 Hz, 2H), 7.96 (d, J=8.4 Hz, 2H).

Synthesis of (6R*,9aS*)-6-(4-carbomethoxyphenyl)-3-iodooctahydroquinolizin-4-one

Iodotrimethylsilane (0.1 mL) was added to a solution of (6R*,9aS*)-6-(4-
carbomethoxyphenyl)octahydroquinolizin-4-one (125 mg) and N,N,N',N'-tetramethylethylenediamine (0.23 mL) in methylene chloride (10 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (166 mg) was added to the reaction solution, which was then stirred at 0°C for one hour. Ethyl acetate and a saturated sodium thiosulfate solution were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain 180 mg of the title compound. The property value of the compound is as follows.

ESI-MS: m/z 414 [M+H].
Synthesis of diethyl [(6S*,9aR*)-6-(4-carbomethoxyphenyl)-4-oxooctahydroquinolinizin-3-yl]phosphonate

A mixture of (6R*,9aS*)-6-(4-carbomethoxyphenyl)-3-iodooctahydroquinolinizin-4-one (180 mg) with triethyl phosphite (2 mL) was stirred at 120°C for two hours. The reaction solution was left to cool to room temperature and then concentrated under reduced pressure to obtain 185 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 424 [M+H]+.

Synthesis of methyl (E)-4-[(4S*,9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]-6-oxooctahydroquinolinizin-4-yl]benzoate

Lithium hydroxide monohydrate (55 mg) was added to a mixed solution of diethyl [(6S*,9aR*)-6-(4-carbomethoxyphenyl)-4-oxooctahydroquinolinizin-3-yl]phosphonate (185 mg) and 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (94 mg) in tetrahydrofuran (4 mL) and ethanol (1 mL), and the reaction solution was stirred at room temperature for two hours. Ethyl acetate and brine were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate = 1:1 -> ethyl acetate) to obtain 191 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 486[M+H]+. 1H-NMR (CDCl₃) δ (ppm):
1.30-1.42 (m, 1H), 1.48-1.80 (m, 4H), 2.02-2.09 (m, 1H), 2.22-2.28 (m, 2H), 2.30 (s, 3H), 2.66-2.78 (m, 1H), 3.12 (brd, J=16.0Hz, 1H), 3.78-3.86 (m, 4H), 3.90 (s, 3H), 5.56 (brt, J=3.6Hz, 1H), 6.93 (brs, 1H), 7.02 (dd, J=1.2Hz, 1H), 7.05 (dd, J=9.2, 1.2Hz, 1H), 7.25 (d, J=9.2Hz, 1H), 7.33 (d, J=8.0Hz, 2H), 7.72 (d, J=0.8Hz, 1H), 7.79 (d, J=2.8Hz, 1H), 7.99 (d, J=8.0Hz, 2H).

[0235]

Example 36

Synthesis of (E)-(6S*,9aR*)-6-(4-hydroxymethylphenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

[Formula 30]

Lithium aluminum hydride (4 mg) was added to a solution of methyl (E)-4-[(4S*,9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-
oxooctahydroquinolizin-4-yl)benzoate (50 mg) in THF (1 mL) at 0°C, and the reaction solution was stirred at 0°C for two hours. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate:methanol = 5:1) to obtain 24 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 458[M+H].$^1$H-NMR(CDCl$_3$)δ (ppm):
1.36-1.46 (m, 1H), 1.53-1.78 (m, 4H), 2.00-2.07 (m, 1H), 2.20-2.27 (m, 2H), 2.31 (s, 3H), 2.66-2.78 (m, 1H), 3.11 (brd, J=15.6 Hz, 1H), 3.76-3.85 (m, 1H), 3.86 (s, 3H), 4.67 (s, 2H), 5.55 (brs, 1H), 6.94 (brs, 1H), 7.04 (d, J=1.2 Hz, 1H), 7.05 (dd, J=8.0, 1.2 Hz, 1H), 7.26 (d, J=8.0 Hz, 3H), 7.33 (d, J=8.0 Hz, 2H), 7.74 (d, J=1.2 Hz, 1H), 7.81 (d, J=2.4 Hz, 1H).

20 [0236]

Example 37

Synthesis of (E)-(6S*,9aR*)-6-(4-cyanophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one
Dess-Martin periodinane (37 mg) was added to a solution of (E)-(6S*,9aR*)-6-(4-hydroxymethylphenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one (20 mg) in methylene chloride (2 mL), and the reaction solution was stirred at room temperature for 30 minutes. Saturated sodium bicarbonate water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain a crude aldehyde compound. Hydroxylamine hydrochloride (9 mg) and sodium acetate (11 mg) were added to a solution of the resulting crude aldehyde compound in ethanol (3 mL), and the reaction solution was stirred at room temperature for 12 hours. Saturated sodium bicarbonate water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain a crude oxime compound. To a solution of the
resulting crude oxime compound in THF (5 mL), 1,1'-carbonyldiimidazole (70 mg) was added, and the reaction solution was heated to reflux for five hours. The reaction solution was left to cool to room temperature. Then, ethyl acetate and water were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane:ethyl acetate = 1:1 -> ethyl acetate) to obtain 6 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 453 [M+H]. 1H-NMR (CDCl₃) δ (ppm):

1.25-1.40 (m, 1H), 1.43-1.56 (m, 1H), 1.62-1.85 (m, 3H), 2.03-2.11 (m, 1H), 2.13-2.32 (m, 2H) 2.33 (s, 3H), 2.67-2.77 (m, 1H), 3.11 (brd, J=16.4 Hz, 1H), 3.76-3.85 (m, 1H), 3.86 (s, 3H), 5.50 (brs, 1H), 6.94 (brs, 1H), 7.02 (d, J=1.2 Hz, 1H), 7.04 (dd, J=8.0, 1.2 Hz, 1H), 7.26 (d, J=8.0 Hz, 1H), 7.36 (d, J=7.6 Hz, 2H), 7.62 (d, J=7.6 Hz, 2H), 7.77 (d, J=2.8 Hz, 1H), 7.81 (s, 1H).

Example 38

Synthesis of (E)-4-[(4S*, 9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-

oxooctahydroquinolizin-4-yl]benzoic acid
A 2 N sodium hydroxide solution (1 mL) was added to a solution of methyl (E)-4-\{(4S*,9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxooctahydroquinolizin-4-yl]benzoate (80 mg) in methanol (2 mL), and the reaction solution was stirred at room temperature for 18 hours. 2 N hydrochloric acid (1 mL) was added to the reaction solution, and the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (elution solvent: chloroform:methanol = 5:1) to obtain 77 mg of the title compound. The property values of the compound are as follows. ESI-MS: m/z472[M+H].$^1$H-NMR(CDCl$_3$) δ (ppm):

1.33-1.44 (m, 1H), 1.52-1.84 (m, 4H), 2.02-2.11 (m, 1H), 2.22-2.32 (m, 2H) 2.40 (s, 3H), 2.67-2.78 (m, 1H), 3.11 (brd, J=16.0 Hz, 1H), 3.79-3.86 (m, 1H), 3.87 (s, 3H), 5.58 (bsr, 1H), 6.97 (bsr, 1H), 7.06 (bsr, 1H), 7.07 (d, J=8.4 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 7.33 (d, J=8.4 Hz, 2H), 7.81 (bsr, 1H), 8.02 (d, J=8.4 Hz, 2H), 8.10 (bsr, 1H).

[0238]

Example 39
Synthesis of \((E)-(6S^*, 9aR^*)-6-(4-aminophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one\)

[Formula 33]

A solution of \((E)-4-\{(4S^*, 9aR^*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxooctahydroquinolinizin-4-yl\}benzoic acid (58 mg), diphenylphosphoryl azide (51 mg), and triethylamine (0.026 mL) in toluene (3 mL) was heated under reflux for one hour. The reaction solution was left to cool to room temperature and concentrated under reduced pressure. 5 N hydrochloric acid (3 mL) was added to the residue, and the reaction solution was heated under reflux for one hour. The reaction solution was left to cool to room temperature and adjusted to pH 11 or less by a 5 N sodium hydroxide solution, followed by extraction with chloroform. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate) to
obtain 9 mg of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 443 (M+H). $^1$H-NMR (CDCl$_3$) δ (ppm):

1.22-1.32 (m, 1H), 1.47-1.78 (m, 4H), 1.82-2.01 (m, 2H),
2.34 (s, 3H), 2.35-2.44 (m, 1H), 2.64-2.72 (m, 1H), 2.84-2.91 (m, 1H), 3.42-3.50 (m, 1H), 3.87 (s, 3H), 6.13 (brd, J=3.2 Hz, 1H), 6.67 (d, J=8.4 Hz, 2H), 6.94 (brs, 1H),
7.01 (brs, 1H), 7.02 (d, J=8.4 Hz, 2H), 7.05 (brd, J=8.4 Hz, 1H),
7.25 (d, J=8.4 Hz, 1H), 7.81 (brs, 2H).

Example 40

Synthesis of (E)-4-((4S*, 9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxoocthydroquinolizin-4-yl)-N,N-dimethylbenzamide

[Formula 34]

IPEA (0.03 mL), HOBT (10 mg), and EDC (14 mg) were sequentially added to a solution of (E)-4-((4S*, 9aR*)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-oxoocthydroquinolizin-4-yl)benzoic acid (22 mg) and dimethylamine (2 M solution in THF, 0.12 mL) in DMF (2 mL), and the reaction solution was stirred at room temperature for two hours. Then, the
reaction solution was further stirred at 100°C for six hours. The reaction solution was left to cool to room temperature. Ethyl acetate and saturated sodium bicarbonate water were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: ethyl acetate:methanol 9:1) to obtain 19 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 499 [M+H]. 1H-NMR (CDCl3) δ (ppm):
1.32-1.43 (m, 1H), 1.47-1.77 (m, 4H), 2.00-2.07 (m, 1H), 2.20-2.30 (m, 2H), 2.32 (s, 3H), 2.66-2.78 (m, 1H), 2.99 (brs, 3H),
3.05-3.16 (m, 4H), 3.76-
3.85 (m, 1H), 3.86 (s, 3H), 5.58 (brs, 1H),
6.94 (brs, 1H), 7.04 (brs, 1H), 7.06 (brd, J=8.8Hz, 1H),
7.26 (d, J=8.8Hz, 1H), 7.29 (d, J=7.6Hz, 2H), 7.38 (d, J=7.6Hz, 2H), 7.75 (brs, 1H), 7.81 (d, J=2.4Hz, 1H).

[0240]
Examples 41 and 42

Synthesis of (E)-(6S,9aR)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one and (E)-(6R,9aS)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one
Synthesis of 1-(3-fluorophenyl)hepta-5,6-dienyl-1-amine

765 mg of the title compound was obtained from (3-fluorobenzyl)-(3-fluorobenzylidene)amine (913 mg) and 6-iodohexa-1,2-diene (904 mg) according to the method described in Journal of the American Chemical Society, 2003, vol.125, p.11956. The property values of the compound are as follows.

\[ \text{H-NMR (CDCl}_3\text{)}\delta(\text{ppm}): \]

10 1.27-1.52 (m, 2H), 1.65-1.80 (m, 2H), 1.95-2.05 (m, 2H), 3.92 (t, J=6.8Hz, 1H), 4.65 (dt, J=6.8, 3.2Hz, 2H), 5.05 (quintet, J=6.8Hz, 1H), 6.91-6.97 (m, 1H), 7.02-7.07 (m, 1H), 7.09 (d, J=8.0Hz, 1H), 7.26-7.30 (m, 1H).

Synthesis of (2R*,6S*)-2-(3-fluorophenyl)-6-vinylpiperidine

Acetic acid (0.22 mL) was added to a solution of an allylpalladium chloride dimer (136 mg) and 1,1'-bis(diphenylphosphino)ferrocene (426 mg) in THF (70 mL) in a nitrogen atmosphere, and the reaction solution was stirred at room temperature for 10 minutes. A solution
of 1-(3-fluorophenyl)hepta-5,6-dienyl-1-amine (765 mg) in THF (40 mL) was added to the reaction solution at room temperature, and the reaction solution was stirred at 70°C for 14 hours. The reaction solution was left to cool to room temperature. Then, diethyl ether and 2 N hydrochloric acid were added to the reaction solution, and the aqueous layer was separated. The resulting aqueous layer was washed with diethyl ether, and then a 5 N sodium hydroxide solution was added to the aqueous layer under ice-cooling until the pH was adjusted to 11 or less. Chloroform was added to the aqueous layer, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate, and concentrated under reduced pressure to obtain 748 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 206 [M+H].

\(^1\)H-NMR (CDCl\(_3\)) \(\delta (ppm)\):

1.30-1.60 (m, 3H), 1.68-1.80 (m, 2H), 1.88-1.96 (m, 1H), 3.30-3.43 (m, 1H), 3.66-3.77 (m, 1H), 5.04 (brd, J=10.0 Hz, 1H), 5.20 (brd, J=17.2 Hz, 1H), 5.91 (ddd, J=17.2, 10.4, 6.8 Hz, 1H), 6.89-6.97 (m, 1H), 7.10-7.20 (m, 2H), 7.23-7.31 (m, 1H).

[0242]

**Synthesis of 1-[(2R*,6S*)-2-(3-fluorophenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one**

Diethyl cyanophosphonate (1.78 mL) was added to a solution of (2R*,6S*)-2-(3-fluorophenyl)-6-vinylpiperidine (748 mg), vinylacetic acid (0.96 mL), and triethylamine (3.1 mL) in DMF (15 mL) at room
temperature, and the reaction solution was stirred at room temperature for 27 hours. Ethyl acetate and 1 N hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was sequentially washed with saturated sodium bicarbonate water and brine, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 587 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 274 [M^+H].^3H-NMR (CDCl_3) δ (ppm):
1.58-1.66 (m, 1H), 1.76-1.92 (m, 2H), 2.37-2.46 (m, 1H), 3.25 (d, J=6.4 Hz, 2H), 4.85 (d, J=10.4 Hz, 2H), 5.03 (d, J=17.2 Hz, 1H), 5.12-
5.24 (m, 2H), 5.50 (ddd, J=17.2, 10.0, 7.2 Hz, 1H), 5.58-
5.82 (m, 1H), 5.98-6.10 (m, 1H), 6.89-6.96 (m, 1H), 7.01 (d, J=10.4 Hz, 1H), 7.04-7.12 (m, 1H), 7.22-7.30 (m, 1H).

[0243]

Synthesis of (6R*, 9aS*)-6-(3-fluorophenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one

A solution of 1-[(2R*, 6S*)-2-(3-fluorophenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one (587 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene][benzylidene]ruthenium (IV) dichloride (92 mg) in methylene chloride (250 mL) was heated under reflux in a nitrogen atmosphere for two hours. The reaction
solution was left to cool to room temperature. Then, triethylamine (0.5 mL) was added thereto, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 460 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 246 [M⁺+H]. $^1$H-NMR (CDCl₃) δ (ppm):

1.39-1.54 (m, 1H), 1.60-1.78 (m, 2H), 1.85-1.95 (m, 1H), 1.98-

2.07 (m, 1H), 2.21-2.32 (m, 1H), 2.94-3.12 (m, 2H), 4.27-

4.37 (m, 1H), 5.34 (t, J=4.0 Hz, 1H), 5.68 (brd, J=10.0 Hz, 1H),

5.84-5.90 (m, 1H), 6.85-6.93 (m, 2H), 6.98-7.02 (m, 1H), 7.22-

7.29 (m, 1H).

[0244]

15 **Synthesis of (6R*,9aS*)-6-(3-fluorophenyl)octahydroquinolizin-4-one**

Platinum oxide (20 mg) was added to a solution of (6R*,9aS*)-6-(3-fluorophenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one (460 mg) in methanol (10 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for three hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 383 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 248 [M⁺+H]. $^1$H-NMR (CDCl₃) δ (ppm):
299
1.29-1.42 (m, 1H), 1.47-1.65 (m, 3H), 1.69-1.87 (m, 2H), 1.92-2.01 (m, 2H), 2.02-2.10 (m, 1H), 2.14-2.26 (m, 1H), 2.45-2.58 (m, 2H), 3.57-3.67 (m, 1H), 5.40 (brt, J=4.0 Hz, 1H), 6.84-6.93 (m, 2H), 6.97-7.02 (m, 1H), 7.23-7.29 (m, 1H).

Synthesis of (6R*, 9aS*)-6-(3-fluorophenyl)-3-iodooctahydroquinolizin-4-one

Iodotrimethylsilane (0.34 mL) was added to a solution of (6R*, 9aS*)-6-(3-fluorophenyl)octahydroquinolizin-4-one (383 mg) and N,N,N',N'-tetramethylethlenediamine (0.82 mL) in methylene chloride (15 mL) under ice-cooling in a nitrogen atmosphere, and the reaction solution was stirred under ice-cooling for 30 minutes. Iodine (590 mg) was added to the reaction solution under ice-cooling, and the reaction solution was stirred under ice-cooling for one hour. Ethyl acetate and a saturated sodium thiosulfate solution were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain 597 mg of the title compound. The property value of the compound is as follows.

ESI-MS: m/z 374 [M+H].

Synthesis of diethyl [(6S*, 9aR*)-6-(3-fluorophenyl)-4-oxooctahydroquinolizin-3-yl]phosphonate

A mixture of (6R*, 9aS*)-6-(3-fluorophenyl)-3-
iodooctahydroquinolinizin-4-one (597 mg) with triethyl phosphite (6 mL) was stirred at 120°C for five hours. The reaction solution was left to cool to room temperature and then concentrated under reduced pressure to obtain 670 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 384 [M+H].

[0247]

Synthesis of (E)-(6S*, 9aR*)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] octahydroquinolinizin-4-one

Lithium hydroxide monohydrate (220 mg) was added to a mixed solution of diethyl [(6S*, 9aR*)-6-(3-fluorophenyl)-4-oxooctahydroquinolinizin-3-yl]phosphonate (670 mg) and 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (378 mg) in tetrahydrofuran (15 mL) and ethanol (5 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. Ethyl acetate was added to the reaction solution, which was then sequentially washed with saturated sodium bicarbonate water and brine. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system) to obtain 583 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 446 [M+H]. $^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
Synthesis of (E)-(6S,9aR)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizn-4-one and (E)-(6R,9aS)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizn-4-one

The racemate (E)-(6S*,9aR*)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizn-4-one obtained above (20 mg) was separated by CHIRALPAK™ IA manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 26 minutes (7.3 mg; >99% ee) and the title optically active compound with a retention time of 34 minutes (6.7 mg; >99% ee).

The property values of the title optically active compound with a retention time of 26 minutes (Example 41) are as follows.

ESI-MS: m/z 446[M+H]+. 1H-NMR (CDCl3) δ (ppm):

1.34-1.47 (m, 1H), 1.52-1.80 (m, 4H), 2.01-2.08 (m, 1H), 2.17-2.28 (m, 2H), 2.37 (s, 3H), 2.67-2.78 (m, 1H), 3.06-3.14 (m, 1H), 3.77-3.87 (m, 1H), 3.87 (s, 3H), 5.54 (brs, 1H), 6.88-6.99 (m, 3H), 7.03-7.11 (m, 3H), 7.23-7.34 (m, 2H),

7.82 (brd, J=2.4 Hz, 1H), 7.91 (brs, 1H).
7.82 (brd, J=2.4 Hz, 1H), 7.91 (brs, 1H).

The property values of the title optically active compound with a retention time of 34 minutes (Example 42) are as follows.

ESI-MS: m/z 446 [M]+H]. 1H-NMR (CDCl3) δ (ppm):

1.34-1.47 (m, 1H), 1.52-1.80 (m, 4H), 2.01-2.08 (m, 1H), 2.17-2.28 (m, 2H), 2.37 (s, 3H), 2.67-2.78 (m, 1H), 3.06-3.14 (m, 1H), 3.77-3.87 (m, 1H), 3.87 (s, 3H), 5.54 (brs, 1H), 6.88-6.99 (m, 3H), 7.03-7.11 (m, 3H), 7.23-7.34 (m, 2H),

7.82 (brd, J=2.4 Hz, 1H), 7.91 (brs, 1H).

Examples 43 and 44

Synthesis of (E)-(6S,9aR)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one and (E)-(6R,9aS)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one

[Formula 36]

Synthesis of 1-(2-fluorophenyl)hepta-5,6-dienyl-1-amine

617 mg of the title compound was obtained from (2-fluorobenzyl)-(2-fluorobenzylidene)amine (890 mg) and 6-iodohexa-1,2-diene (881 mg) according to the method described in Journal of the American Chemical...
Society, 2003, vol.125, p.11956. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.31-1.43 (m, 1H), 1.44-1.57 (m, 1H), 1.68-1.84 (m, 2H), 1.97-
2.06 (m, 2H), 4.21 (t, $J$=6.8 Hz, 1H), 4.64 (dt, $J$=6.8, 3.2 Hz, 2H),
5.06 (quintet, $J$=6.8 Hz, 1H), 6.98-7.06 (m, 1H), 7.10-
7.15 (m, 1H), 7.18-7.26 (m, 1H), 7.35-7.42 (m, 1H).

[0250]

Synthesis of (2R*,6S*)-2-(2-fluorophenyl)-6-
vinylpiperidine

Acetic acid (0.17 mL) was added to a solution of an allylpalladium chloride dimer (110 mg) and 1,1'-bis(diphenylphosphino)ferrocene (344 mg) in THF (60 mL) in a nitrogen atmosphere, and the reaction solution was stirred at room temperature for 10 minutes. A solution of 1-(2-fluorophenyl)hepta-5,6-dienyl-1-amine (617 mg) in THF (30 mL) was added to the reaction solution at room temperature, and the reaction solution was stirred at 70°C for 14 hours. The reaction solution was left to cool to room temperature. Then, diethyl ether and 2 N hydrochloric acid were added to the reaction solution, and the aqueous layer was separated. The resulting aqueous layer was washed with diethyl ether, and then a 5 N sodium hydroxide solution was added to the aqueous layer under ice-cooling until the pH was adjusted to 11 or less. Chloroform was added to the aqueous layer, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate, and
concentrated under reduced pressure to obtain 518 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 206 [M^+H]^+. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}) \delta (ppm):

1.28-1.68 (m, 3H), 1.70-1.79 (m, 1H), 1.79-1.88 (m, 1H),
1.88-1.98 (m, 1H), 3.26-3.38 (m, 1H), 4.09 (d, J=11.2 Hz, 1H),
5.04 (d, J=10.8 Hz, 1H), 5.20 (d, J=17.2 Hz, 1H), 5.85-
5.97 (m, 1H), 6.97-7.05 (m, 1H), 7.08-7.15 (m, 1H), 7.16-
7.26 (m, 1H), 7.54-7.63 (m, 1H).

[0251]

Synthesis of 1-[(2R*, 6S*)-2-[(2-fluorophenyl)-6-
vinylpiperidin-1-yl]-3-buten-1-one

Diethyl cyanophosphonate (1.23 mL) was added to a solution of (2R*, 6S*)-2-[(2-fluorophenyl)-6-
vinylylpyperidine (518 mg), vinylacetic acid (0.66 mL),
and triethylamine (2.1 mL) in DMF (10 mL) at room temperature, and the reaction solution was stirred at room temperature for 21 hours. Ethyl acetate and 1 N hydrochloric acid were added to the reaction solution, and the organic layer was separated. The resulting organic layer was sequentially washed with saturated sodium bicarbonate water and brine, dried over magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 442 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 274 [M^+H]^+. \textsuperscript{1}H-NMR (CDCl\textsubscript{3}) \delta (ppm):
305
1.50-1.64 (m, 1H), 1.74-2.05 (m, 4H), 2.10-2.21 (m, 1H),
3.03 (brdd, J=16.4, 5.6 Hz, 1H), 3.16 (dd, J=16.0, 6.8 Hz, 1H),
5.01-5.16 (m, 4H), 5.20 (d, J=17.2 Hz, 1H), 5.46-5.57 (m, 1H),
5.82-6.02 (m, 2H), 6.97-7.10 (m, 2H), 7.19-7.24 (m, 1H),
7.29-7.36 (m, 1H).
[0252]
Synthesis of (6R*,9aS*)-6-(2-fluorophenyl)-
3,6,7,8,9,9a-hexahydroquinolinizin-4-one

A solution of 1-[(2R*,6S*)-2-(2-
fluorophenyl)-6-vinylpiperidin-1-yl]-3-buten-1-one (442 mg) and tricyclohexylphosphine[1,3-bis(2,4,6-
trimethylphenyl)-4,5-dihydroimidazol-2-
ylidene][benzylidene]ruthenium (IV) dichloride (69 mg)
in methylene chloride (180 mL) was heated under reflux
in a nitrogen atmosphere for two hours. The reaction
solution was left to cool to room temperature. Then,
triethylamine (0.5 mL) was added thereto, and the
reaction solution was concentrated under reduced
pressure. The residue was purified by silica gel

column chromatography (elution solvent: heptane-ethyl
acetate system) to obtain 368 mg of the title compound.
The property values of the compound are as follows.
ESI-MS; m/z 246 [M+H].¹H-NMR (CDCl₃) δ (ppm):
1.40-1.55 (m, 1H), 1.60-1.83 (m, 2H), 1.89-2.00 (m, 1H),
2.07-2.25 (m, 2H), 2.91-3.10 (m, 2H), 4.31-4.41 (m, 1H),
5.47 (brt, J=4.0 Hz, 1H), 5.68 (dd, J=10.0, 0.8 Hz, 1H), 5.80-
5.88 (m, 1H), 6.97-7.08 (m, 2H), 7.12-7.22 (m, 2H).
[0253]
Synthesis of (6R*,9aS*)-6-(2-fluorophenyl)octahydroquinolizin-4-one

Platinum oxide (16 mg) was added to a solution of (6R*,9aS*)-6-(2-fluorophenyl)-3,6,7,8,9,9a-hexahydroquinolizin-4-one (368 mg) in methanol (8 mL), and the reaction solution was stirred in a hydrogen stream at room temperature for two hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 309 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 248 [M⁺+H].

1H-NMR (CDCl₃) δ (ppm):

1H 1.25-1.40 (m, 1H), 1.52-1.70 (m, 2H), 1.72-1.87 (m, 2H), 1.90-2.05 (m, 2H), 2.07-2.18 (m, 2H), 2.37-2.56 (m, 2H), 3.63-3.73 (m, 1H), 5.53 (t, J=4.0 Hz, 1H), 6.96-7.08 (m, 2H), 7.10-7.22 (m, 2H).

20 Synthesis of (6R*,9aS*)-6-(2-fluorophenyl)-3-iodooctahydroquinolizin-4-one

Iodotrimethylsilane (0.28 mL) was added to a solution of (6R*,9aS*)-6-(2-fluorophenyl)octahydroquinolizin-4-one (309 mg) and N,N,N',N'-tetramethylethylenediamine (0.66 mL) in methylene chloride (12 mL) under ice-cooling in a nitrogen atmosphere, and the reaction solution was stirred under ice-cooling for 30 minutes. Iodine
(476 mg) was added to the reaction solution under ice-cooling, and the reaction solution was stirred under ice-cooling for one hour. Ethyl acetate and a saturated sodium thiosulfate solution were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over magnesium sulfate, and then concentrated under reduced pressure to obtain 500 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 374[M⁺+H].

[0255]

Synthesis of diethyl (6S*,9aR*)-6-(2-fluorophenyl)-4-oxooctahydroquinolizin-3-yl]phosphonate

A mixture of (6R*,9aS*)-6-(2-fluorophenyl)-3-iodooctahydroquinolizin-4-one (500 mg) with triethyl phosphite (6 mL) was stirred at 120°C for five hours. The reaction solution was left to cool to room temperature and then concentrated under reduced pressure to obtain 501 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 384[M⁺+H].

[0256]

Synthesis of (E)-(6S*,9aR*)-6-(2-fluorophenyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

Lithium hydroxide monohydrate (169 mg) was added to a mixed solution of diethyl [(6S*,9aR*)-6-(2-
fluorophenyl)-4-oxooctahydroquinolizin-3-yl]phosphonate (501 mg) and 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (290 mg) in tetrahydrofuran (12 mL) and ethanol (4 mL) at room temperature, and the reaction solution was stirred at room temperature for two hours. Ethyl acetate was added to the reaction solution, which was then sequentially washed with saturated sodium bicarbonate water and brine. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system) to obtain 483 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 446 [M+H]. $^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.29-1.43 (m, 1H), 1.61-1.90 (m, 4H), 2.04-2.32 (m, 3H), 2.35 (s, 3H), 2.65-2.75 (m, 1H), 3.05-3.14 (m, 1H), 3.82-3.92 (m, 1H), 3.85 (s, 3H), 5.68 (brs, 1H), 6.94-6.96 (m, 1H), 7.01-7.10 (m, 4H), 7.16-7.23 (m, 2H), 7.24-7.28 (m, 1H), 7.76 (brd, J = 2.8 Hz, 1H), 7.85 (brs, 1H).

[0257]

Synthesis of (E)-(6S,9aR)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,9aS)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

The racemate (E)-(6S*,9aR*)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]octahydroquinolizin-4-one obtained above (20 mg) was separated by CHIRALPAK™ IA manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 23 minutes (7.6 mg; >99% ee) and the title optically active compound with a retention time of 33 minutes (7.8 mg; >99% ee).

The property values of the title optically active compound with a retention time of 23 minutes (Example 43) are as follows.

ESI-MS; m/z446[M⁺+H].¹H-NMR(CDCl₃)δ(ppm):
1.29-1.43(m,1H), 1.61-1.90(m,4H), 2.04-2.32(m,3H),
2.35(s,3H), 2.65-2.75(m,1H), 3.05-3.14(m,1H), 3.82-
3.92(m,1H), 3.85(s,3H), 5.68(brs,1H), 6.94-
6.96(m,1H), 7.01-7.10(m,4H), 7.16-7.23(m,2H), 7.24-
7.28(m,1H), 7.76(brd, J=2.8Hz,1H), 7.85(brs,1H).

The property values of the title optically active compound with a retention time of 33 minutes (Example 44) are as follows.

ESI-MS; m/z446[M⁺+H].¹H-NMR(CDCl₃)δ(ppm):
1.29-1.43(m,1H), 1.61-1.90(m,4H), 2.04-2.32(m,3H),
2.35(s,3H), 2.65-2.75(m,1H), 3.05-3.14(m,1H), 3.82-
3.92(m,1H), 3.85(s,3H), 5.68(brs,1H), 6.94-
6.96(m,1H), 7.01-7.10(m,4H), 7.16-7.23(m,2H), 7.24-
7.28(m,1H), 7.76(brd, J=2.8Hz,1H), 7.85(brs,1H).

Examples 45 and 46
Synthesis of (E)-(6S,8R,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolinizin-4-one and (E)-(6R,8S,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolinizin-4-one

[Formula 37]

Synthesis of 1-(4-bromobutyryl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one

6.66 g of the title compound was obtained from 4-methoxypyridine (2.0 mL), 4-fluorophenylmagnesium bromide (1.0 M solution in THF, 20.7 mL), and 4-bromobutyryl chloride (2.4 mL) according to the method described in Tetrahedron Letters, 1986, vol.27, p.4549-4552. The property values of the compound are as follows.

$^{1}$H-NMR(CDCl$_3$)$\delta$(ppm):
2.20-2.32(m,2H), 2.79-2.86(m,3H), 3.10-3.16(m,1H), 3.47-3.55(m,2H), 5.47(brd,$J$=8.0Hz,1H), 6.00(brs,1H), 6.99-7.03(m,2H), 7.18-7.21(m,2H), 7.75(brs,1H).

[0259]

Synthesis of (4S*,9aR*)-4-(4-
fluorophenyl)hexahydroquinolizine-2,6-dione

1.05 g of the title compound was obtained from 1-(4-bromobutryl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one (2.0 g), tributyltin hydride (1.87 mL), and AIBN (386 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol.58, p.4198-4199. The property values of the compound are as follows.

\(^1\text{H-NMR}(\text{CDCl}_3)\delta\text{(ppm)}:

1.58-1.82(m,2H),1.85-2.01(m,2H),2.34-2.39(m,1H),2.45-2.56(m,3H),2.80(dd, J=15.6, 7.2Hz, 1H),2.97-3.01(m,1H),3.49-3.56(m,1H),6.54(brd, J=7.2Hz, 1H),6.99-7.03(m,2H),7.21-7.24(m,2H).

(0260)

15 Synthesis of (6S*,8R*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-8-methyloctahydroquinolizin-4-one

Methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was added to a solution of (4S*,9aR*)-4-(4-fluorophenyl)hexahydroquinolizine-2,6-dione (1.0 g) in THF (15 mL) under ice-cooling, and the reaction solution was stirred for 50 minutes. Because the starting material did not disappear, methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was further added to the reaction solution, which was then stirred for 30 minutes. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over
anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain a mixture of the starting material with the title compound. Methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was added to a solution of the resulting mixture in THF (15 mL) again under ice-cooling, and the reaction solution was stirred for one hour. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain a mixture of the starting material with the title compound. Methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was added to a solution of the mixture obtained again in THF (15 mL) again under ice-cooling, and the reaction solution was stirred for 1.5 hours. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel
column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 760 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.26 (s, 3H), 1.56 - 1.68 (m, 3H), 1.80 - 2.01 (m, 3H), 2.01 - 2.12 (m, 1H), 2.42 - 2.64 (m, 3H), 3.79 - 3.85 (m, 1H), 6.06 (brd, $J$ = 6.8 Hz, 1H), 6.99 - 7.05 (m, 2H), 7.18 - 7.26 (m, 2H).

Synthesis of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)-8-methyloctahydroquinolizin-4-one

Triethylamine (201 μL) and TBSOTf (286 mg) were added to a solution of (6S*,8R*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-8-methyloctahydroquinolizin-4-one (100 mg) in THF (1.0 mL) under ice-cooling, and the reaction solution was stirred for one hour and 50 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 116 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
0.00 (s, 3H), 0.12 (s, 3H), 0.72 (s, 9H), 1.48 (s, 3H), 1.68-1.89 (m, 3H), 1.98-2.12 (m, 3H), 2.20-2.28 (m, 1H), 2.58-2.68 (m, 2H), 2.70-2.78 (m, 1H), 4.00-4.06 (m, 1H), 6.11 (brd, J=6.8 Hz, 1H), 7.10-7.19 (m, 2H), 7.27-7.30 (m, 2H).

[0262]

Synthesis of (E)-(6S*, 8R*, 9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one

LDA (1.5 M solution in THF, 434 µL) was added to a solution of (6S*, 8R*, 9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(4-fluorophenyl)-8-methyloctahydroquinolizin-4-one (116 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (83.2 mg) in THF (2.0 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for 40 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 105.3 mg of a crude aldol adduct. A solution of the crude aldol adduct (105.3 mg) in methylene chloride (1.0 mL) was cooled to 0°C. Triethylamine (145 µL) and methanesulfonyl chloride (40 µL) were added to the reaction solution, which was then stirred at room temperature for one hour and 10 minutes. Sodium
methoxide (28% solution in methanol, 334 mg) and methanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for one hour and 20 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 102 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$)δ (ppm):

0.00 (s, 3H), 0.10 (s, 3H), 0.71 (s, 9H), 1.48 (s, 3H), 1.78-1.92 (m, 3H), 2.08 (dd, J=7.2, 14.4, 1H), 2.20-2.30 (m, 1H), 2.45 (s, 3H), 2.60-2.65 (m, 1H), 2.94-3.10 (m, 2H), 4.00 (s, 3H), 4.10-4.16 (m, 1H), 6.15 (brd, J=6.4 Hz, 1H), 7.08-7.18 (m, 5H), 7.30-7.33 (m, 2H), 7.38-7.43 (m, 1H), 7.89 (s, 1H), 7.94 (s, 1H).

[0263]

Synthesis of (E)-(6S*, 8R*, 9aR*)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one

TBAF (1.0 M solution in THF, 404 μL) was added to a solution of (E)-(6S*, 8R*, 9aR*)-8-(tert-butyldimethylsilylanyloxy)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-
methyloctahydroquinolizin-4-one (102 mg) in THF (2.0 mL), and the reaction solution was stirred at room temperature overnight. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 66.4 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm): 1.64-1.78 (m, 3H), 2.05 (s, 3H), 2.07-2.16 (m, 2H), 2.32 (s, 3H), 2.45-2.52 (m, 1H), 2.76-2.85 (m, 1H), 2.90-2.99 (m, 1H), 3.87 (s, 3H), 3.94-4.02 (m, 1H), 6.16 (brd, J=6.4 Hz, 1H), 6.95 (t, J=1.2 Hz, 1H), 7.02-7.07 (m, 4H), 7.24-7.30 (m, 3H), 7.75 (d, J=1.2 Hz, 1H), 7.82 (s, 1H).

[0264]

Synthesis of (E)-(6S,8R,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[(3-methoxy-4-[(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyloctahydroquinolizin-4-one and (E)-(6R,8S,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[(3-methoxy-4-[(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyloctahydroquinolizin-4-one

The racemate (E)-(6S*,8R*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-3-[(3-methoxy-4-[(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyloctahydroquinolizin-
4-one obtained above (66.4 mg) was separated by CHIRALPAK™ IA manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: ethanol) to obtain the title optically active compound with a retention time of 5.7 minutes (27.2 mg; >99% ee) and the title optically active compound with a retention time of 6.9 minutes (28.5 mg; >99% ee).

The property values of the title optically active compound with a retention time of 5.7 minutes (Example 45) are as follows.

$^1$H-NMR(CDCl$_3$)δ(ppm):
1.64-1.78 (m,3H), 2.05 (s,3H), 2.07-2.16 (m,2H), 2.32 (s,3H),
2.45-2.52 (m,1H), 2.76-2.85 (m,1H), 2.90-2.99 (m,1H),
3.87 (s,3H), 3.94-4.02 (m,1H), 6.16 (brd, J=6.4Hz,1H),
6.95 (t, J=1.2Hz,1H), 7.02-7.07 (m,4H), 7.24-7.30 (m,3H),
7.75 (d, J=1.2Hz,1H), 7.82 (s,1H).

The property values of the title optically active compound with a retention time of 6.9 minutes (Example 46) are as follows.

$^1$H-NMR(CDCl$_3$)δ(ppm):
1.64-1.78 (m,3H), 2.05 (s,3H), 2.07-2.16 (m,2H), 2.32 (s,3H),
2.45-2.52 (m,1H), 2.76-2.85 (m,1H), 2.90-2.99 (m,1H),
3.87 (s,3H), 3.94-4.02 (m,1H), 6.16 (brd, J=6.4Hz,1H),
6.95 (t, J=1.2Hz,1H), 7.02-7.07 (m,4H), 7.24-7.30 (m,3H),
7.75 (d, J=1.2Hz,1H), 7.82 (s,1H).

Examples 47, 48, 49, 50, 51, and 52

Synthesis of (E)-(6S,8R,9aR)-6-(4-fluorophenyl)-8-
hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one, (E)-(6R,8S,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one, (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one, (E)-(6R,9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one, (E)-(6S,8S,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one, and (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one

[Formula 38]
319

Synthesis of 1-(4-bromobutyryl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one

6.66 g of the title compound was obtained from 4-methoxypyridine (2.0 mL), 4-fluorophenylmagnesium bromide (1.0 M solution in THF, 20.7 mL), and 4-bromobutyryl chloride (2.4 mL) according to the method described in Tetrahedron Letters, 1986, vol.27, p.4549-4552. The property values of the compound are as follows.

1H-NMR(CDCl₃) δ (ppm):
2.20-2.32 (m, 2H), 2.79-2.86 (m, 3H), 3.10-3.16 (m, 1H), 3.47-3.55 (m, 2H), 5.47 (brd, J=8.0 Hz, 1H), 6.00 (brs, 1H), 6.99-7.03 (m, 2H), 7.18-7.21 (m, 2H), 7.75 (brs, 1H).

[0266]

15 Synthesis of (4S*, 9aR*)-4-(4-fluorophenyl)hexahydroquinolizine-2,6-dione

1.05 g of the title compound was obtained from 1-(4-bromobutyryl)-2-(4-fluorophenyl)-2,3-dihydro-1H-pyridin-4-one (2.0 g), tributyltin hydride (1.87 mL), and AIBN (386 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol.58, p.4198-4199. The property values of the compound are as follows.

1H-NMR(CDCl₃) δ (ppm):
1.58-1.82 (m, 2H), 1.85-2.01 (m, 2H), 2.34-2.39 (m, 1H), 2.45-2.56 (m, 3H), 2.80 (dd, J=15.6, 7.2 Hz, 1H), 2.97-3.01 (m, 1H), 3.49-3.56 (m, 1H), 6.54 (brd, J=7.2 Hz, 1H), 6.99-7.03 (m, 2H), 7.21-7.24 (m, 2H).
Synthesis of (6S*,8R*,9aR*)-6-((4-fluorophenyl)-8-hydroxy-8-methyloctahydroquinolizin-4-one

Methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was added to a solution of (4S*,9aR*)-(4-(4-fluorophenyl)hexahydroquinolizine-2,6-dione (1.0 g) in THF (15 mL) under ice-cooling, and the reaction solution was stirred for 50 minutes. Because the starting material did not disappear, methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was further added to the reaction solution, which was then stirred for 30 minutes. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain a mixture of the starting material with the title compound. Methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was added to a solution of the resulting mixture in THF (15 mL) again under ice-cooling, and the reaction solution was stirred for one hour. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous
magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system → ethyl acetate-methanol system) to obtain a mixture of the starting material with the title compound. Methylmagnesium bromide (0.96 M solution in THF, 5.98 mL) was added to a solution of the mixture obtained again in THF (15 mL) again under ice-cooling, and the reaction solution was stirred for 1.5 hours. A saturated ammonium chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system → ethyl acetate-methanol system) to obtain 760 mg of the title compound. The property values of the compound are as follows.

\[ \text{H-NMR (CDCl}_3\text{) } \delta (\text{ppm}): \]
\[ 1.26 (s, 3H), 1.56-1.68 (m, 3H), 1.80-2.01 (m, 3H), 2.01-2.12 (m, 1H), 2.42-2.64 (m, 3H), 3.79-3.85 (m, 1H), 6.06 (brd, J=6.8Hz, 1H), 6.99-7.05 (m, 2H), 7.18-7.26 (m, 2H). \]

[0268]

Synthesis of (E)-(6S,8R,9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one, (E)-(6R,8S,9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-
methyloctahydroquinolizin-4-one, (E)-(6S,9aR)-6-(4-
fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-
hexahydroquinolizin-4-one, (E)-(6R,9aS)-6-(4-
fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-
hexahydroquinolizin-4-one, (E)-(6S,8S,9aR)-6-(4-
fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-
4-one, and (E)-(6R,8R,9aS)-6-(4-fluorophenyl)-8-
hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]-8-methyloctahydroquinolizin-4-one

Triethylamine (302 µL) and methanesulfonyl chloride (84 µL) were added to a solution of
(6S*,8R*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-8-
methyloctahydroquinolizin-4-one (100 mg) in methylene chloride (3.0 mL) under ice-cooling, and the reaction solution was stirred at room temperature overnight.

Saturated sodium bicarbonate water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 72.0 mg of a crude olefin compound mixture.

Platinum oxide (10.0 mg) was added to a solution of the resulting crude olefin compound mixture (72.0 mg) in methanol (5.0 mL), and the reaction solution was
stirred in a hydrogen atmosphere at 0.4 MPa at room temperature for 31 hours. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure to obtain 70.6 mg of a mixture of a crude reduced compound with the starting material olefin compound. LDA (1.5 M solution in THF, 396 µL) was added to a solution of the resulting mixture of the crude reduced compound with the starting material olefin compound (70.6 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (75.9 mg) in THF (2.0 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for one hour and 10 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 39.5 mg of a crude aldol adduct. A solution of the resulting crude aldol adduct (39.5 mg) in methylene chloride (1.0 mL) was cooled to 0°C. Triethylamine (69 µL) and methanesulfonyl chloride (19.2 µL) were added to the reaction solution, which was then stirred at room temperature for two hours. Sodium methoxide (28% solution in methanol, 320 mg) and ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for 50 minutes. Water and ethyl acetate were added to the
reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 23.1 mg of a mixture of three racemates of the title compounds. The resulting racemate mixture was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: ethanol) to obtain an optically active compound of (E)-((6S*,8R*,9aR*)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-8-methyloctahydroquinolizin-4-one with a retention time of 5.9 minutes (2.1 mg; >99% ee) and an optically active compound thereof with a retention time of 8.8 minutes (1.6 mg; >99% ee).

The property values of the title optically active compound with a retention time of 5.9 minutes (Example 47) are as follows.

$^1$H-NMR(CDC1$_3$) δ (ppm):

0.98 (d, J=6.8 Hz, 3H), 1.50-1.65 (m, 4H), 1.77-
1.90 (m, 1H), 1.96-2.04 (m, 1H), 2.33 (s, 3H), 2.36-
2.43 (m, 1H), 2.65-2.74 (m, 1H), 2.84-2.94 (m, 1H), 3.42-
3.48 (m, 1H), 3.87 (s, 3H), 6.21-6.26 (m, 1H), 6.95 (s, 1H), 7.02-
7.07 (m, 4H), 7.19-7.29 (m, 3H), 7.80-7.84 (m, 1H), 7.84 (s, 1H).

The property values of the title optically
active compound with a retention time of 8.8 minutes (Example 48) are as follows.

\(^1\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):
0.98 (d, \(J=6.8\) Hz, 3H), 1.50-1.65 (m, 4H), 1.77-
1.90 (m, 1H), 1.96-2.04 (m, 1H), 2.33 (s, 3H), 2.36-
2.43 (m, 1H), 2.65-2.74 (m, 1H), 2.84-2.94 (m, 1H), 3.42-
3.48 (m, 1H), 3.87 (s, 3H), 6.21-6.26 (m, 1H), 6.95 (s, 1H), 7.02-
7.07 (m, 4H), 7.19-7.29 (m, 3H), 7.80-7.84 (m, 1H), 7.84 (s, 1H).

Further, an optically active compound of (E)-
(6S*,9aR*)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-
1H-imidazol-1-yl)benzylidene]-8-methyl-1,2,3,6,9,9a-
hexahydroquinolizin-4-one with a retention time of 9.8
minutes (3.6 mg; >99% ee) and an optically active
compound with a retention time of 17.1 minutes (3.1 mg;
>99% ee) were obtained.

The property values of the title optically
active compound with a retention time of 9.8 minutes
(Example 49) are as follows.

\(^1\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):
1.71-1.78 (m, 1H), 1.85 (s, 3H), 1.88-1.95 (m, 1H), 1.95-
2.03 (m, 1H), 2.32 (s, 3H), 2.38-2.48 (m, 1H), 2.68-2.80 (m, 2H),
3.60-3.72 (m, 1H), 3.85 (s, 3H), 5.60-5.64 (m, 1H), 6.27-
6.32 (m, 1H), 6.93 (s, 1H), 6.98-7.06 (m, 4H), 7.24-7.28 (m, 1H),
7.45-7.50 (m, 2H), 7.76 (s, 1H), 7.80 (s, 1H).

The property values of the title optically
active compound with a retention time of 17.1 minutes
(Example 50) are as follows.

\(^1\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):
1.71-1.78 (m, 1H), 1.85 (s, 3H), 1.88-1.95 (m, 1H), 1.95-
2.03 (m, 1H), 2.32 (s, 3H), 2.38-2.48 (m, 1H), 2.68-2.80 (m, 2H),
3.60-3.72 (m, 1H), 3.85 (s, 3H), 5.60-5.64 (m, 1H), 6.27-
6.32 (m, 1H), 6.93 (s, 1H), 6.98-7.06 (m, 4H), 7.24-
7.28 (m, 1H), 7.45-7.50 (m, 2H), 7.76 (s, 1H), 7.80 (s, 1H).

(E)-(6S*, 8S*, 9aR*)-6-(4-fluorophenyl)-8-
hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]-8-methyloctahydroquinolinizin-4-one that
failed to be separated in the above operation was

separated by CHIRALPAK™ IA manufactured by Daicel
Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase:
etanol) to obtain an optically active compound with a
retention time of 11.2 minutes (3.1 mg; >99% ee) and an
optically active compound with a retention time of 16.8
minutes (1.1 mg; >99% ee).

The property values of the title optically
active compound with a retention time of 11.2 minutes
(Example 51) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.01 (d, $J=6.4$ Hz, 3H), 1.23-1.36 (m, 3H), 1.65-
1.80 (m, 2H), 1.82-2.18 (m, 3H), 2.31 (s, 3H), 2.76-
2.92 (m, 2H), 3.82-3.91 (m, 1H), 3.85 (s, 3H),
5.55 (dd, $J=10, 7.6$ Hz, 1H), 6.93 (s, 1H), 6.99-7.04 (m, 4H), 7.22-
7.26 (m, 3H), 7.74-7.77 (m, 1H).

The property values of the title optically
active compound with a retention time of 16.8 minutes
(Example 52) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.01 (d, J=6.4 Hz, 3H), 1.23-1.36 (m, 3H), 1.65-
1.80 (m, 2H), 1.82-2.18 (m, 3H), 2.31 (s, 3H), 2.76-
2.92 (m, 2H), 3.82-3.91 (m, 1H), 3.85 (s, 3H),
5.55 (dd, J=10, 7.6 Hz, 1H), 6.93 (s, 1H), 6.99-7.04 (m, 4H), 7.22-
7.26 (m, 3H), 7.74-7.77 (m, 1H).

Example 53

Synthesis of (E)-(4R, 9aR)-7-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)benzyldiene]-4-phenylhexahydropyrido[2,1-
c][1,4]oxazin-6-one

[Formula 39]

Synthesis of (4R, 9aR)-4-phenylhexahydropyrido[2,1-
c][1,4]oxazin-6-one

A solution of (S)-1-[(R)-2-hydroxy-1-
phenylethyl]-6-oxopiperidine-2-carbonitrile (400 mg)
that is a known compound described in a document (see
p.4823-4829) in saturated hydrochloric acid-ethanol (7
mL) was stirred at room temperature for two days. A
saturated sodium bicarbonate solution and chloroform
were added to the reaction solution, and the organic
layer was separated. The resulting organic layer was
washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 452 mg of a crude ester compound. Sodium borohydride (440 mg) was added to a solution of the resulting crude ester compound (452 mg) in methanol (10 mL) under ice-cooling, and the reaction solution was stirred at 0°C for one hour and 50 minutes and then at room temperature for 30 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 166 mg of a diol compound. Triethylamine (145 µL) and p-toluenesulfonyl chloride (99.1 mg) were added to a solution of the resulting diol compound (108 mg) in methylene chloride (4.0 mL) under ice-cooling, and the reaction solution was stirred at room temperature overnight. The reaction solution was added dropwise to a solution of potassium tert-butoxide (97.2 mg) in THF (4.0 mL) under ice-cooling. Then, potassium tert-butoxide (194 mg) was added to the reaction solution, which was then stirred at room temperature for three hours and 40 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed
with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system → ethyl acetate-methanol system) to obtain 23.3 mg of the title compound. The property values of the compound are as follows.

\[ ^1\text{H-NMR (CDCl}_3\text{)}\delta (\text{ppm}):\]

\begin{align*}
1.28-1.38 (m, 1H), & \quad 1.57-1.68 (m, 1H), \quad 1.79-1.87 (m, 2H), \quad 2.36-2.46 (m, 1H), \quad 2.51-2.58 (m, 1H), \quad 3.27 (dd, J=11.2, 11.2\text{Hz}, 1H), \\
3.57-3.64 (m, 1H), & \quad 3.83-3.87 (m, 2H), \quad 4.49 (d, J=11.2\text{Hz}, 1H), \quad 5.80 (d, J=3.2\text{Hz}, 1H), \quad 7.24-7.36 (m, 3H), \quad 7.51-7.53 (m, 2H).
\end{align*}

[0271]

Synthesis of (E)-(4R,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-phenylhexahydropyrido[2,1-c][1,4]oxazin-6-one

LDA (1.5 M solution in THF, 118 µL) was added to a solution of (4R,9aR)-4-phenylhexahydropyrido[2,1-c][1,4]oxazin-6-one (27.3 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for 30 minutes, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (38.3 mg) in THF (1.0 mL) was added to the reaction solution. The reaction solution was stirred at 0°C for 35 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 37.1 mg of an alcohol compound. A solution of the resulting alcohol compound (37.1 mg) in methylene chloride (2.0 mL) was cooled to 0°C. Triethylamine (69.3 μL) and methanesulfonyl chloride (19.2 μL) were added to the reaction solution, which was then stirred at room temperature for 45 minutes. Sodium methoxide (28% solution in methanol, 160 mg) and methanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for 30 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 14.5 mg of the title compound. The property values of the compound are as follows.

$^{1}$H-NMR (CDCl$_3$) $\delta$(ppm):

1.39-1.49 (m, 1H), 1.88-1.94 (m, 1H), 2.31 (s, 3H), 2.42-

2.50 (m, 1H), 2.97-3.03 (m, 1H), 3.31 (t, J=11.2Hz, 1H), 3.74-

3.82 (m, 1H), 3.85 (s, 3H), 3.86-3.95 (m, 2H), 4.54 (d, J=11.2Hz, 1H), 5.92 (brd, J=3.2Hz, 1H), 6.91-

7.01 (m, 3H), 7.21-7.39 (m, 4H), 7.58-7.61 (m, 2H), 7.71-
7.74 (m, 1H), 7.83 (m, 1H).

Example 54

Synthesis of (E)-(5S,7aR)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrroloidin-3-one

[Formula 40]

Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(3,4-difluorophenyl)-5-oxopentanoate

To a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (6.0 g) in tetrahydrofuran (100 mL), 3,4-difluorophenylmagnesium bromide (0.5 M solution in tetrahydrofuran; 50 mL) was added dropwise at -40°C over 10 minutes, and the reaction solution was stirred at -40°C to 0°C for two hours. Water was added to the solution in small portions, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 8.3 g of the title compound. The property values of the compound are as
follows.

ESI-MS; m/z 394 [M+Na].

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.28 (t, $J=7.6$ Hz, 3H), 1.42 (s, 9H), 2.00-2.13 (m, 1H), 2.25-2.40 (m, 1H), 2.95-3.15 (m, 2H), 4.21 (q, $J=7.6$ Hz, 2H), 4.30-4.45 (m, 1H), 5.10-5.20 (m, 1H), 7.20-7.30 (m, 1H), 7.70-7.83 (m, 2H).

[0273]

Synthesis of (2R,5S)-5-(3,4-difluorophenyl)pyrrolidin-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester

A solution of 4 N hydrochloric acid in ethyl acetate (95.8 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(3,4-difluorophenyl)-5-oxopentanoate (8.3 g) in ethyl acetate (93.4 mL) at room temperature, and the solution was stirred at room temperature for four hours. The reaction solution was concentrated under reduced pressure to obtain 7.5 g of a yellow oil. The crude product was dissolved in ethyl acetate (100 mL).

Saturated sodium bicarbonate water (100 mL) was added dropwise thereto, and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 5.1 g of a pale red oil. Palladium-carbon (containing 50% water, 900 mg) was added to a solution of the resulting pale red oil
in ethyl acetate (70 mL), and the reaction solution was stirred in a hydrogen atmosphere for four hours. Palladium-carbon in the reaction solution was removed by filtration through celite, and the filtrate was concentrated under reduced pressure to obtain 5.1 g of a yellow oil. Triethylamine (7.48 mL) and di-tert-butyl dicarbonate (7.84 g) were added to a solution of the resulting yellow oil in DMF (80 mL), and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 5.9 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 378 [M]+Na.

1H-NMR (CDCl3) δ (ppm):

1.19 and 1.41 (s, 9H), 1.30–1.49 (m, 3H), 1.80–1.95 (m, 1H), 1.95–2.10 (m, 1H), 2.15–2.40 (m, 2H), 4.27 (q, J = 7.6 Hz, 2H), 4.34 and 4.71 (t, J = 7.6 Hz, 1H), 4.40–4.50 and 4.85–4.97 (m, 1H), 7.05–7.15 (m, 1H), 7.20–7.30 (m, 1H), 7.46–7.55 (m, 1H).

[0274]

Synthesis of tert-butyl (E)-(2S,5R)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylvinyl)pyrrolidine-1-carboxylate

Lithium borohydride (1.45 g) was added to a
solution of (2R,5S)-5-(3,4-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (5.9 g) in tetrahydrofuran (50 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.9 g of an alcohol compound. DMSO (1.32 mL) was added dropwise to a solution of oxalyl chloride (1.6 mL) in dichloromethane (50 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (3.9 g) in dichloromethane (20 mL) was added dropwise to the solution at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (13 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.9 g of an aldehyde compound. Sodium hydride (60% oil, 0.754 g) was added to a solution of trimethyl phosphonoacetate (3.43 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. The reaction solution was added to a
solution of the above aldehyde (3.9 g) in DMF (10 mL), and the reaction solution was stirred at room temperature for two hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.5 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 390 [M⁺+Na].

¹H-NMR (CDCl₃) δ (ppm):

1.10–1.50 (m, 9H), 1.77–1.93 (m, 2H), 2.08–2.20 (m, 1H), 2.22–2.36 (m, 1H), 3.78 (s, 3H), 4.40–4.66 (m, 1H), 4.66–4.94 (m, 1H), 6.03 (d, J=14.4 Hz, 1H), 6.90–7.16 (m, 4H).

[0275]

Synthesis of tert-butyl (2S,5R)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylethyl)pyrrolidine-1-carboxylate

Palladium-carbon (containing 50% water, 900 mg) was added to a solution of tert-butyl (E)-(2S,5R)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylvinyl)pyrrolidine-1-carboxylate (4.5 g) in ethyl acetate (100 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for 2.5 hours. Palladium-carbon in the reaction solution was removed by filtration through celite, and the filtrate was concentrated under reduced pressure to obtain 4.1 g of the title compound. The
property values of the compound are as follows.

ESI-MS; m/z 392 [M⁺+Na].

¹H-NMR (CDCl₃) δ (ppm):
1.10-1.50 (m, 9H), 1.60-1.70 (m, 1H), 1.70-1.90 (m, 2H), 1.94-
2.06 (m, 1H), 2.16-2.32 (m, 2H), 2.36-2.50 (m, 2H), 3.70 (s, 3H),
3.98 (s, 1H), 4.60-4.90 (m, 1H), 6.90-7.14 (m, 3H).

[0276]

Synthesis of (5S,7aR)-5-(3,4-
difluorophenyl)hexahydropyrrolidin-3-one

A solution of 4 N hydrochloric acid in ethyl acetate (10 mL) was added to a solution of tert-butyl (2S,5R)-2-(3,4-difluorophenyl)-5-(2-
methoxycarbonyylethyl)pyrrolidine-1-carboxylate (1.5 g) in ethyl acetate (10 mL), and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain 1.5 g of a yellow oil. The crude product was dissolved in ethanol (10 mL). A 5 N sodium hydroxide solution (10 mL) was added thereto, and the reaction solution was stirred at 50°C for one hour. The reaction solution was cooled to 0°C and neutralized with 5 N hydrochloric acid. The solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (20 mL). Thionyl chloride (2.5 mL) was added thereto, and the reaction solution was stirred at 50°C for one hour. The reaction solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (10 mL), followed by
addition of a 5 N sodium hydroxide solution (15 mL). The reaction solution was stirred at room temperature for 30 minutes and then poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 770 mg of the title compound.

The property values of the compound are as follows.

ESI-MS; m/z238 [M+H].

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.55-1.70 (m, 1H), 1.85-2.10 (m, 3H), 2.30-2.40 (m, 1H), 2.50-2.70 (m, 1H), 2.57 (dd, J=8.8, 16.8 Hz, 1H), 2.70-2.85 (m, 1H), 4.03-4.18 (m, 1H), 4.61 (d, J=9.2 Hz, 1H), 6.89-7.02 (m, 2H), 7.07-7.15 (m, 1H).

[0277]

Synthesis of diethyl [(5S,7aR)-5-(3,4-difluorophenyl)-3-oxohexahydropyrrolidin-2-yl]phosphonate

Iodotrimethylsilane (0.162 mL) was added to a solution of (5S,7aR)-5-(3,4-difluorophenyl)hexahydropyrrolidin-3-one (200 mg) and N,N,N',N'-tetramethylethylene diamine (0.430 mL) in dichloromethane (5 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (289 mg) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40
minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 320 mg of an iodine compound. A solution of the resulting iodine compound (320 mg) in triethyl phosphite (5 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 400 mg of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 374 [M+H].

[0278]

**Synthesis of (E)-(5S,7aR)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydropyrrolidin-3-one**

Lithium hydroxide (56.8 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (170 mg) and diethyl [(5S,7aR)-5-(3,4-difluorophenyl)-3-oxohexahydropyrrolidin-2-yl]phosphonate obtained above (400 mg) in tetrahydrofuran (1 mL)-ethanol (4 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice-sodium bicarbonate water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated
under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 250 mg of a crude product of the title compound. The resulting crude product (20 mg) was re-refined by a preparative optical resolution column (CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm), ethanol-hexane system) to obtain 8.4 mg of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 436[M+H].

$^1$H-NMR (CDCl$_3$) δ (ppm):
1.70-1.84 (m, 1H), 2.11 (dd, J=7.2, 12.8 Hz, 1H), 2.18 (quint, J=6.0 Hz, 1H), 2.32 (s, 3H), 2.60-2.76 (m, 1H), 2.93 (ddd, J=3.6, 6.8, 16.4 Hz, 1H), 3.40 (ddd, J=2.0, 5.6, 16.4 Hz, 1H), 3.89 (s, 3H), 4.06-4.16 (m, 1H), 4.79 (d, J=9.2 Hz, 1H), 6.92-7.04 (m, 3H), 7.09 (d, J=1.2 Hz, 1H), 7.10-7.18 (m, 2H), 7.20-7.24 (m, 1H), 7.28 (d, J=8.0 Hz, 1H), 7.76 (d, J=1.2 Hz, 1H).

Example 55

Synthesis of (E)-(3S,9aS)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydropyrrolo[1,2-a]azepin-5-one
Synthesis of tert-butyl (2S,5S)-2-(3,4-difluorophenyl)-5-[(E)-4-methoxycarbonyl-3-butenyl]pyrrolidine-1-carboxylate

A solution of tert-butyl (2S,5R)-2-(3,4-difluorophenyl)-5-(2-methoxycarbonylthethyl)pyrrolidine-1-carboxylate (2.2 g) in tetrahydrofuran (20 mL) was added dropwise to a solution of lithium aluminum hydride (0.295 g) in tetrahydrofuran (20 mL) at 0°C, and the reaction solution was stirred at the same temperature for 30 minutes. Water (0.3 mL), a 15% sodium hydroxide solution (0.3 mL), and water (0.9 mL) were sequentially added to the reaction solution, which was then stirred for 20 minutes. Then, the inorganic salt was removed by filtration, and the filtrate was concentrated to obtain 2.0 g of an alcohol compound. DMSO (0.753 mL) was added dropwise to a solution of oxalyl chloride (0.91 mL) in dichloromethane (30 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the resulting alcohol compound (2.0 g) in dichloromethane (10 mL) was added dropwise to the reaction solution at
-60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (6.9 mL) was added dropwise to the reaction solution, which was then stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.0 g of an aldehyde compound. Sodium hydride (60% oil, 0.306 g) was added to a solution of trimethyl phosphonoacetate (1.39 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. The reaction solution was added to a solution of the resulting aldehyde compound (2.0 g) in DMF (10 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.7 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 418 [M+Na].

[0280]

Synthesis of tert-butyl (2S,5S)-2-(3,4-difluorophenyl)5-(4-methoxycarbonylbutyl)pyrrolidine-1-carboxylate
Palladium-carbon (containing 50% water, 0.492 g) was added to a solution of tert-butyl (2S,5S)-2-(3,4-difluorophenyl)-5-[(E)-4-methoxycarbonyl-3-butenyl]pyrrolidine-1-carboxylate (1.7 g) in ethyl acetate (60 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for two hours. Palladium-carbon in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 1.7 g of the title compound. The property values of the compound are as follows.

ESI-MS; m/z 420 [M⁺+Na].

¹H-NMR (CDCl₃) δ (ppm):
1.00-1.88 (m, 16H), 1.90-2.10 (m, 2H), 2.20-2.30 (m, 1H), 2.36 (t, J=7.2Hz, 2H), 3.67 (s, 3H), 3.80-4.00 (m, 1H), 4.50-4.90 (m, 1H), 6.89-6.96 (m, 1H), 6.97-7.13 (m, 3H).

[0281]

Synthesis of (3S,9aS)-3-(3,4-difluorophenyl)octahydropyrrolo[1,2-a]azepin-5-one tert-Butyl (2S,5S)-2-(3,4-difluorophenyl)-5-(4-methoxycarbonylbutyl)pyrrolidine-1-carboxylate (1.7 g) was dissolved in ethyl acetate (10 mL). A solution of 4 N hydrochloric acid in ethyl acetate (17 mL) was added thereto, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain 1.5 g of a yellow oil. The property value of the compound is as follows.

ESI-MS; m/z 298 [M⁺+H].
The crude product (1.5 g) was dissolved in ethanol (10 mL). A 5 N sodium hydroxide solution (20 mL) was added thereto, and the reaction solution was stirred at 50°C for one hour. The reaction solution was cooled to 0°C and neutralized with 5 N hydrochloric acid. The solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (20 mL). Thionyl chloride (4.0 mL) was added thereto, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure, and the residue was suspended in dichloromethane (10 mL), followed by addition of a 5 N sodium hydroxide solution (15 mL). The reaction solution was stirred at room temperature for 30 minutes and then poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.75 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 266 [M+H].

1H-NMR (CDCl3) δ (ppm):

1.46-1.74 (m, 4H), 1.86-2.22 (m, 6H), 2.43-2.53 (m, 1H),
2.66 (dd, J=7.2, 14.4 Hz, 1H), 3.76-3.88 (m, 1H),
5.25 (d, J=7.6 Hz, 1H), 6.93-6.99 (m, 1H), 7.00-7.13 (m, 2H).
Synthesis of diethyl [(3S,9aS)-3-(3,4-difluorophenyl)-5-oxooctahydropyrrolo[1,2-a]azepin-6-yl]phosphonate

Iodotrimethylsilane (0.164 mL) was added to a solution of (3S,9aS)-3-(3,4-difluorophenyl)octahydropyrrolo[1,2-a]azepin-5-one (0.225 g) and N,N,N',N'-tetramethylethylenediamine (0.435 mL) in dichloromethane (5.36 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.291 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.33 g of an iodine compound. A solution of the resulting iodine compound (0.33 g) in triethyl phosphite (7 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 0.52 g of the title compound. The property value of the compound is as follows.

ESI-MS: m/z 402 [M+H].

Synthesis of (E)-(3S,9aS)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydropyrrolo[1,2-a]azepin-5-one

Lithium hydroxide (0.0668 g) was added to a
mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.20 g) and diethyl [(3S,9aS)-3-(3,4-difluorophenyl)-5-oxooctahydropyrrolo[1,2-a]azepin-6-yl]phosphonate obtained above (0.52 g) in tetrahydrofuran (1 mL)-ethanol (4 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice-sodium bicarbonate water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.223 g of the title compound. The property values of the compound are as follows.

ESI-MS: m/z 464 [M+H]+. \(^1\)H-NMR(CDCl\(_3\)) δ (ppm):

1.70-2.40 (m, 9H), 2.31 (s, 3H), 2.90-3.00 (m, 1H), 3.85 (s, 3H), 3.84-3.98 (m, 1H), 5.28-5.34 (m, 1H), 6.92-6.96 (m, 1H), 6.98-7.18 (m, 6H), 7.25 (d, J=7.6Hz, 1H), 7.71 (d, J=1.6Hz, 1H).

[0284]

Example 56

Synthesis of (E)-(3S,8aS)-3-(4-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]hexahydroindolizin-5-one

[Formula 42]
Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(4-chlorophenyl)-5-oxopentanoate

To a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (CAS No. 128811-48-3; 4.0 g) in tetrahydrofuran (100 mL), 4-chlorophenylmagnesium bromide (1.0 M solution in diethyl ether; 17.1 mL) was added dropwise at -40°C over 20 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 5.6 g of the title compound as a colorless oil. The property values of the compound are as follows.

ESI-MS; m/z 392 [M]+Na. [H-NMR (CDCl3) δ (ppm):
1.28 (t, J = 7.2 Hz, 3H), 1.42 (s, 9H), 2.00–2.50 (m, 2H), 2.95–3.20 (m, 2H), 4.10–4.50 (m, 2H), 4.10–5.20 (m, 2H), 7.41–7.47 (m, 2H), 7.86–7.92 (m, 2H).

[0285]

Synthesis of ethyl (R)-5-(4-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (30 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(4-chlorophenyl)-5-oxopentanoate (5.6 g) in ethyl acetate
(30 mL) at room temperature, and the reaction solution was stirred at room temperature for two hours. The reaction solution was concentrated under reduced pressure to obtain 5.0 g of a yellow oil. Saturated sodium bicarbonate water (100 mL) was added dropwise to a solution of the crude product in ethyl acetate (100 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.5 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 525 [2M^++Na].^1H-NMR (CDCl₃). ∆ (ppm):
1.32 (t, J=7.2 Hz, 3H), 2.18-2.43 (m, 2H), 2.90-3.03 (m, 1H), 3.05-3.20 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.85-4.95 (m, 1H), 7.36-7.41 (m, 2H), 7.79-7.85 (m, 2H).

[0286]

Synthesis of (2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester

Sodium borohydride (1.05 g) was added to a solution of ethyl (R)-5-(4-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (3.5 g) in methanol (80 mL)-acetic acid (20 mL) at -45°C over five minutes. The reaction solution was stirred at -45°C to 0°C for three hours. A disodium hydrogen phosphate solution was added to the reaction solution. The reaction solution
was stirred at room temperature for 20 minutes, and the
organic solvent was evaporated under reduced pressure.
The residue was subjected to extraction with ethyl
acetate. The organic layer was washed with sodium
bicarbonate water, dried over anhydrous magnesium
sulfate, and then concentrated under reduced pressure
to obtain 3.6 g of a yellow oil. Triethylamine (7.49
mL) and di-tert-butyl dicarbonate (3.76 g) were added
to a solution of the resulting oil in dichloromethane
(50 mL), and the reaction solution was stirred at room
temperature for one hour. The reaction solution was
poured into ice water, followed by extraction with
ethyl acetate. The extract was washed with brine,
dried over anhydrous magnesium sulfate, and then
concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (heptane-
ethyl acetate system) to obtain 3.3 g of the title
compound as a yellow oil. The property values of the
compound are as follows.

ESI-MS; m/z 376 [M+Na]^+. 1H-NMR (CDCl3) δ (ppm):
1.17 and 1.41 (s, 9H), 1.26-1.38 (m, 3H), 1.84-2.10 (m, 2H), 2.16-
2.36 (m, 2H), 4.20-4.30 (m, 2H), 4.30-5.00 (m, 2H), 7.25-
7.35 (m, 2H), 7.45-7.60 (m, 2H).
[0287]

**Synthesis of tert-butyl (2S,5R)-2-(4-chlorophenyl)-5-
((E)-2-methoxycarbonylvinyl)pyrrolidine-1-carboxylate**

Lithium borohydride (813 mg) was added to a
solution of (2R,5S)-5-(4-chlorophenyl)pyrrolidine-1,2-
dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (3.3 g) in tetrahydrofuran (50 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.0 g of an alcohol compound as a yellow oil. DMSO (1.09 mL) was added dropwise to a solution of oxalyl chloride (1.24 mL) in dichloromethane (40 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (3.0 g) in dichloromethane (20 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (10.7 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.0 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.579 g) was added to a solution of trimethyl phosphonoacetate (2.63 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (3.0 g) in DMF (10 mL) at room
temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.8 g of the title compound as a yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 388 [M+Na]. $^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.00–1.50 (m, 9H), 1.75–1.95 (m, 2H), 2.05–2.20 (m, 1H), 2.20–2.35 (m, 1H), 3.77 (s, 3H), 4.30–5.00 (m, 2H), 5.95–6.10 (m, 1H), 6.95–7.05 (m, 1H), 7.18 (d, $J$=8.4 Hz, 2H), 7.30 (d, $J$=8.4 Hz, 2H).

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(4-chlorophenyl)pyrrolidin-2-yl]acrylate

A solution of 4 N hydrochloric acid in ethyl acetate (19.4 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(4-chlorophenyl)-5-((E)-2-methoxycarbonylviny1)pyrrolidine-1-carboxylate (2.8 g) in ethyl acetate (5 mL) at room temperature, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain 2.5 g of a yellow solid. Diethyl cyanophosphonate (1.97 mL) was added dropwise to a solution of the resulting yellow solid (2.5 g), vinylacetic acid (1.1 mL), and triethylamine (3.63 mL)
in DMF (40 mL) at 0°C, and the reaction solution was stirred at the same temperature for two hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.2 g of the title compound as a yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 334 [M+H]. \(^1\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):

1.30-3.20 (m, 6H), 3.76 and 3.79 (s, 3H), 4.60-5.20 (m, 4H), 5.70-6.20 (m, 2H), 6.90-7.40 (m, 5H).

[0289]

**Synthesis of (3S,8aR)-3-(4-chlorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one**

Grubbs catalyst 2nd generation (559 mg) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(4-chlorophenyl)pyrrolidin-2-yl]acrylate (2.2 g) in dichloromethane (100 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (4 mL) was added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by
silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.3 g of the title compound as a brown oil. The property values of the compound are as follows.

ESI-MS; m/z 248 [M⁺+H]. ¹H-NMR (CDCl₃) δ (ppm):

1.70-1.90 (m, 2H), 2.05-2.15 (m, 1H), 2.25-2.45 (m, 1H), 2.90-3.05 (m, 2H), 4.20-4.35 (m, 1H), 5.10 (d, J=8.8 Hz, 1H), 5.98-6.04 (m, 1H), 6.06-6.12 (m, 1H), 7.00-7.08 (m, 2H), 7.20-7.28 (m, 2H).

Synthesis of (3S,8aS)-3-(4-chlorophenyl)hexahydroindolizin-5-one

Platinum oxide (151 mg) was added to a solution of (3S,8aR)-3-(4-chlorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (1.3 g) in methanol (50 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for five hours. Platinum oxide was removed from the reaction solution by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.0 g of the title compound as a pale brown solid. The property values of the compound are as follows.

ESI-MS; m/z 250 [M⁺+H]. ¹H-NMR (CDCl₃) δ (ppm):

1.50-1.90 (m, 4H), 1.90-2.10 (m, 2H), 2.15-2.50 (m, 4H), 3.52-3.65 (m, 1H), 5.08 (d, J=8.8 Hz, 1H), 7.06 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H).
[0291]

Synthesis of diethyl [(3S,8aR)-3-(4-chlorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.763 mL) was added dropwise to a solution of (3S,8aS)-3-(4-chlorophenyl)hexahydroindolizin-5-one (1.0 g) and N,N,N',N'-tetramethylethylenediamine (2.05 mL) in dichloromethane (40 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (1.36 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain an iodine compound.

A solution of the resulting iodine compound in triethyl phosphate (20 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 2.5 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 386 [M+H].

[0292]

Synthesis of (E)-(3S,8aS)-3-(4-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one
Lithium hydroxide (355 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (875 mg) and diethyl [(3S,8aR)-3-(4-chlorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate (2.5 g) in tetrahydrofuran (8 mL)-ethanol (30 mL), and the reaction solution was stirred under shading at room temperature for five hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.43 g of the title compound as a colorless solid. The property values of the compound are as follows.

ESI-MS; m/z 448 [M]+H]. 'H-NMR (CDCl$_3$) $\delta$(ppm):

1.66-1.88 (m, 3H), 2.02-2.12 (m, 1H), 2.26-2.40 (m, 2H), 2.30 (s, 3H), 2.68-2.82 (m, 1H), 3.10-3.20 (m, 1H), 3.76-3.90 (m, 1H), 3.85 (s, 3H), 5.20 (d, J=8.8Hz, 1H), 6.94 (s, 1H), 7.02-7.16 (m, 2H), 7.12 (d, J=8.4Hz, 2H), 7.20-7.34 (m, 1H), 7.28 (d, J=8.4Hz, 2H), 7.72 (d, J=1.6Hz, 1H), 7.76 (d, J=2.0Hz, 1H).

Example 57

Synthesis of (E)-(3S,8aS)-3-(2,4,5-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one
Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,4,5-trifluorophenyl)-5-oxopentanoate

To a suspension of magnesium (0.452 g) in tetrahydrofuran (20 mL), 1-bromo-2,4,5-trifluorobenzene (2.2 mL) was added dropwise at 55°C over 15 minutes, and the reaction solution was stirred at room temperature for 30 minutes. This solution was added dropwise to a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (4.0 g) in tetrahydrofuran (25 mL) at -40°C over 10 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.5 g of the title compound as a colorless oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):
1.29(t, J=7.2Hz, 3H), 1.42(s, 9H), 1.90-2.10(m, 1H), 2.20-2.40(m, 1H), 2.90-3.20(m, 2H), 4.21(q, J=7.2Hz, 2H), 4.20-4.50(m, 1H), 5.00-5.20(m, 1H), 6.95-7.05(m, 1H), 7.70-7.80(m, 1H).

[0294]

Synthesis of ethyl (R)-5-(2,4,5-trifluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (20 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,4,5-trifluorophenyl)-5-oxopentanoate (4.5 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred for one hour at room temperature. The reaction solution was concentrated under reduced pressure to obtain 4.0 g of a yellow oil. Saturated sodium bicarbonate water (30 mL) was added dropwise to a solution of the crude product in ethyl acetate (20 mL). The reaction solution was stirred at room temperature for 20 minutes, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.8 g of the title compound as a pale yellow oil. The property value of the compound is as follows.

[0295]

Synthesis of (2R,5S)-5-(2,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-
tern-butyl ester 2-ethyl ester

10% palladium-carbon (containing 50% water, 0.95 g) was added to a solution of ethyl (R)-5-(2,4,5-trifluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (2.8 g) in ethyl acetate (50 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for six hours. Palladium-carbon in the reaction solution was removed by filtration, and then the filtrate was concentrated under reduced pressure to obtain 2.8 g of a reduced compound. Triethylamine (2.13 mL) and di-tern-butyl dicarbonate (2.67 g) were added to a solution of the resulting reduced compound in DMF (30 mL), and the reaction solution was stirred at room temperature for six hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.2 g of the title compound as a yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm):

1.23 and 1.43 (s, 9H), 1.20-1.50 (m, 3H), 1.82-2.08 (m, 2H), 2.18-2.44 (m, 2H), 4.15-4.40 (m, 2H), 4.15-5.30 (m, 2H), 6.80-6.95 (m, 1H), 7.85-8.05 (m, 1H).

[0296]

Synthesis of tert-butyl (2S,5R)-2-(2,4,5-
trifluorophenyl)-5-((E)-2-
methoxycarbonylvinyl)pyrrolidine-1-carboxylate

Lithium borohydride (0.863 g) was added to a
solution of (2R,5S)-5-(2,4,5-
trifluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-
tert-butyl ester 2-ethyl ester (4.2 g) in
tetrahydrofuran (40 mL) at 0°C, and the reaction
solution was stirred at room temperature for 12 hours.
The reaction solution was added to ice water, followed
by extraction with ethyl acetate. The extract was
washed with brine, dried over anhydrous magnesium
sulfate, and then concentrated under reduced pressure
to obtain 3.3 g of an alcohol compound as a yellow oil.
DMSO (1.35 mL) was added dropwise to a solution of
oxalyl chloride (1.63 mL) in dichloromethane (40 mL) at
-70°C, and the reaction solution was stirred at the same
temperature for three minutes. A solution of the above
alcohol compound (3.3 g) in dichloromethane (10 mL) was
added dropwise thereto at -60°C, and the reaction
solution was stirred at the same temperature for 15
minutes. Triethylamine (11.2 mL) was added dropwise to
the solution, and the reaction solution was stirred at
-60°C to 0°C for 30 minutes. The reaction solution was
poured into water, followed by extraction with ethyl
acetate. The extract was washed with brine, dried over
anhydrous magnesium sulfate, and then concentrated
under reduced pressure to obtain 3.3 g of an aldehyde
compound as a pale yellow oil. Sodium hydride (60%
oil, 0.460 g) was added to a solution of trimethyl phosphonoacetate (2.19 g) in DMF (30 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (3.3 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 3.3 g of the title compound as a yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.00-1.50 (m, 9H), 1.80-1.90 (m, 2H), 2.10-2.20 (m, 1H), 2.30-2.45 (m, 1H), 3.78 (s, 3H), 4.30-5.20 (m, 2H), 5.95-6.15 (m, 1H), 6.85-7.15 (m, 3H).

[0297]

**Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(2,4,5-trifluorophenyl)pyrrolidin-2-yl]acrylate**

A solution of 4 N hydrochloric acid in ethyl acetate (17.8 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(2,4,5-trifluorophenyl)-5-((E)-2-methoxycarbonylviny1)pyrrolidine-1-carboxylate (3.3 g) in ethyl acetate (20 mL) at the same temperature, and the reaction solution was stirred at 50°C for 30
minutes. The reaction solution was concentrated under reduced pressure to obtain 2.7 g of a yellow solid. Diethyl cyanophosphonate (2.22 mL) was added dropwise to a solution of the resulting yellow solid (2.7 g), vinylacetic acid (1.23 mL), and triethylamine (4.07 mL) in DMF (30 mL) at 0°C, and the reaction solution was stirred at the same temperature for two hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.2 g of the title compound as a yellow oil. The property value of the compound is as follows.

ESI-MS; m/z 354 [M+H].

[0298]

Synthesis of (3S,8aR)-3-(2,4,5-trifluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.424 g) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(2,4,5-trifluorophenyl)pyrrolidin-2-yl]acrylate (2.2 g) in dichloromethane (40 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (8 mL) was
added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.0 g of the title compound as a brown oil. The property values of the compound are as follows.

ESI-MS; m/z 268 [M+H].

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.68-1.82 (m, 1H), 1.86 (dd, J=6.0, 12.8 Hz, 1H), 2.10-2.20 (m, 1H), 2.30-2.43 (m, 1H), 2.90-3.08 (m, 2H), 4.20-4.35 (m, 1H), 5.31 (d, J=9.2 Hz, 1H), 6.00-6.15 (m, 2H), 6.65-6.75 (m, 1H), 6.85-6.95 (m, 1H).

[0299]

Synthesis of (3S,8aS)-3-(2,4,5-
trifluorophenyl)hexahydroindolizin-5-one

Platinum oxide (84.9 mg) was added to a solution of (3S,8aR)-3-(2,4,5-trifluorophenyl)
2,3,6,8a-tetrahydro-1H-indolizin-3-one (1.0 g) in methanol (30 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for four hours. Platinum oxide in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.75 g of the title compound as a pale brown solid. The property value of the compound is as follows.

ESI-MS; m/z 270 [M+H].
[0300]

Synthesis of diethyl [(3S,8aR)-3-(2,4,5-trifluorophenyl)-5-oxooctahydroindolinizin-6-yl]phosphonate

Iodotrimethylsilane (0.476 mL) was added dropwise to a solution of (3S,8aS)-3-(2,4,5-trifluorophenyl)hexahydroindolinizin-5-one (0.75 g) and N,N,N',N'-tetramethylethylenediamine (1.39 mL) in dichloromethane (20 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.85 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.1 g of an iodine compound.

A solution of the iodine compound (1.1 g) in triethyl phosphite (6 mL) was stirred at 130°C for one hour. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 2.0 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 406[M+H].

[0301]

Synthesis of [(E)-(3S,8aS)-3-(2,4,5-trifluorophenyl)-6-
Lithium hydroxide (0.265 g) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.60 g) and diethyl [(3S,8aR)-3-(2,4,5-trifluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate (2.0 g) in tetrahydrofuran (4 mL)–ethanol (16 mL), and the reaction solution was stirred under shading at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.97 g of the title compound as a colorless solid. The property values of the compound are as follows.

ESI-MS; m/z 468[M+H]. 1H-NMR (CDCl3) δ (ppm):
1.60-1.83 (m, 2H), 1.83-1.94 (m, 1H), 2.00-2.18 (m, 1H), 2.25-2.40 (m, 2H), 2.31 (s, 3H), 2.68-2.84 (m, 1H), 3.12-3.23 (m, 1H), 3.74-3.90 (m, 1H), 3.86 (s, 3H), 5.39 (d, J=8.8 Hz, 1H), 6.74-6.88 (m, 1H), 6.88-7.00 (m, 2H), 7.06 (s, 1H), 7.09 (d, J=8.0 Hz, 1H), 7.24-7.34 (m, 1H), 7.73 (s, 1H), 7.70 (s, 1H).

[0302]

Example 58

Synthesis of (E)-(3S,8aS)-3-(2,3,4-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one
Synthesis of ethyl (R)-2-tert-butoxycarbonylaminoo-5-(2,3,4-trifluorophenyl)-5-oxopentanoate

To a suspension of magnesium (0.452 g) in tetrahydrofuran (20 mL), 1-bromo-2,3,4-trifluorobenzene (2.21 mL) was added dropwise at 55°C over 15 minutes, and the reaction solution was stirred at room temperature for 30 minutes. This solution was added dropwise to a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (4.0 g) in tetrahydrofuran (25 mL) at -40°C over 10 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.2 g of the title compound as a colorless oil. The property values of the compound are as follows.

$^1$H-NMR($CDCl_3$)$\delta$(ppm):
1.29(t,J=7.2Hz,3H), 1.42(s,9H), 1.95-2.20(m,1H), 2.20-2.40(m,1H), 2.95-3.20(m,2H), 4.22(q,J=7.2Hz,2H), 4.20-4.50(m,1H), 5.05-5.25(m,1H), 7.00-7.15(m,1H), 7.60-7.75(m,1H).

[0303]

Synthesis of ethyl (R)-5-(2,3,4-trifluorophenyl)-3,4-
dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (20 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,3,4-trifluorophenyl)-5-oxopentanoate (4.2 g) in ethyl acetate (15 mL) at room temperature, and the reaction solution was stirred for one hour at room temperature. The reaction solution was concentrated under reduced pressure to obtain 4.5 g of a yellow oil. Saturated sodium bicarbonate water (30 mL) was added dropwise to a solution of the crude product in ethyl acetate (20 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.7 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 272[M'+H].

$^1$H-NMR(CDC13) δ (ppm):

1.32(t,J=7.2Hz,3H), 2.18-2.30(m,1H), 2.32-
2.44 (m, 1H), 2.98-3.10 (m, 1H), 3.12-3.24 (m, 1H),
4.25 (q, J=7.2Hz, 2H), 4.85-4.90 (m, 1H), 6.95-
7.05 (m, 1H), 7.25-7.85 (m, 1H).

[0304]

Synthesis of (2R,5S)-5-(2,3,4-
trifluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-
tert-butyl ester 2-ethyl ester

Palladium-carbon (containing 50% water, 0.44
g) was added to a solution of ethyl (R)-5-(2,3,4-
10 trifluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate
(2.2 g) in ethyl acetate (132 mL), and the reaction
solution was stirred in a hydrogen atmosphere at room
temperature for 12 hours. Palladium-carbon in the
reaction solution was removed by filtration, and then
the filtrate was concentrated under reduced pressure to
obtain 2.20 g of a reduced compound. Triethylamine
(5.23 mL) and di-tert-butyl dicarbonate (2.80 g) were
added to a solution of the resulting reduced compound
in DMF (30.3 mL), and the reaction solution was stirred
at room temperature for six hours. The reaction
solution was poured into ice water, followed by
extraction with ethyl acetate. The extract was washed
with brine, dried over anhydrous magnesium sulfate, and
then concentrated under reduced pressure. The residue
was purified by silica gel column chromatography
(heptane-ethyl acetate system) to obtain 4.2 g of the
title compound as a yellow oil. The property values of
the compound are as follows.
$^{1}$H-NMR (CDCl$_3$) $\delta$(ppm):
1.22 and 1.53 (s, 9H), 1.18-1.48 (m, 3H), 1.85-2.08 (m, 2H), 2.20-2.44 (m, 2H), 4.26 (q, J=7.2 Hz, 2H), 4.25-5.25 (m, 2H), 6.90-7.05 (m, 1H), 7.70-7.90 (m, 1H).

5 [0305]

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(2,3,4-trifluorophenyl)pyrrolidin-2-yl]acrylate

Lithium borohydride (0.863 g) was added to a solution of (2R,5S)-5-(2,3,4-
10 trifluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-
tert-butyl ester 2-ethyl ester (4.2 g) in tetrahydrofuran (40 mL) at 0°C, and the reaction solution was stirred at room temperature for 4 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.3 g of an alcohol compound as a yellow oil.

DMSO (1.12 mL) was added dropwise to a solution of oxaly chloride (1.26 mL) in dichloromethane (40 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (3.3 g) in dichloromethane (10 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (8.78 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was
poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.3 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.460 g) was added to a solution of trimethyl phosphonoacetate (2.19 g) in DMF (30 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (3.3 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.8 g of tert-butyl (2S,5R)-2-(2,3,4-trifluorophenyl)-5-[(E)-(2-methoxycarbonylviny1)]pyrrolidine-1-carboxylate as a yellow oil.

A solution of 4 N hydrochloric acid in ethyl acetate (9.73 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(2,3,4-trifluorophenyl)-5-[(E)-(2-methoxycarbonylviny1)]pyrrolidine-1-carboxylate (1.8 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced
pressure to obtain 1.8 g of a yellow solid. Diethyl cyanophosphonate (1.21 mL) was added dropwise to a solution of the resulting yellow solid (1.8 g), vinylacetic acid (0.671 mL), and triethylamine (2.22 mL) in DMF (30 mL) at 0°C, and the reaction solution was stirred at room temperature for two hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.2 g of the title compound as a yellow oil. The property value of the compound is as follows.

ESI-MS; m/z 354 [M' + H].

[0306]

Synthesis of (3S, 8aR)-3-(2,3,4-trifluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.231 g) was added to a solution of methyl (E)-3-[(2R, 5S)-1-(3-butenoyl)-5-(2,3,4-trifluorophenyl)pyrrolidin-2-yl]acrylate (1.2 g) in dichloromethane (20 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (4 mL) was added to the reaction solution, which was then stirred
for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.61 g of the title compound as a brown oil. The property values of the compound are as follows.

ESI-MS; m/z 268 [M+H]. \(^1^H\)-NMR (CDCl₃) δ (ppm):
1.68–1.82 (m, 1H), 1.87 (dd, J=6.0, 12.8Hz, 1H), 2.10–2.18 (m, 1H), 2.32–2.45 (m, 1H), 2.90–3.10 (m, 2H), 4.24–4.34 (m, 1H), 5.33 (d, J=8.8Hz, 1H), 5.96–6.06 (m, 1H), 6.06–6.14 (m, 1H), 6.56–6.65 (m, 1H), 6.78–6.90 (m, 1H).

Synthesis of (3S,8aS)-3-(2,3,4-trifluorophenyl)hexahydroindolizin-5-one

Platinum oxide (0.0596 g) was added to a solution of (3S,8aR)-3-(2,3,4-trifluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (0.61 g) in methanol (30.5 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for five hours. Platinum oxide in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.46 g of the title compound as a pale brown solid. The property values of the compound are as follows.

ESI-MS; m/z 270 [M+H]. \(^1^H\)-NMR (CDCl₃) δ (ppm):
1.50–1.70 (m, 2H), 1.74–1.90 (m, 2H), 1.95–2.10 (m, 2H), 2.16–
2.50 (m, 4H), 3.55-3.70 (m, 1H), 5.28 (d, J=9.2 Hz, 1H), 6.60-6.70 (m, 1H), 6.70-6.95 (m, 1H).

[0308]

Synthesis of diethyl [(3S,8aR)-3-(2,3,4-trifluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.316 mL) was added dropwise to a solution of (3S,8aS)-3-(2,3,4-trifluorophenyl)hexahydroindolizin-5-one (0.46 g) and N,N,N',N'-tetramethylethlenediamine (0.877 mL) in dichloromethane (11.5 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.563 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.71 g of an iodine compound.

A solution of the resulting iodine compound (0.71 g) in triethyl phosphite (4 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 2.0 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 406 [M+H].
Synthesis of (E)-(3S,8αS)-3-(2,3,4-trifluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]hexahydroindolizin-5-one

Lithium hydroxide (0.177 g) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.40 g) and diethyl ((3S,8αR)-3-(2,3,4-trifluorophenyl)-5-oxooctahydroindolizin-6-yl)phosphonate (2.0 g) in tetrahydrofuran (4 mL)-ethanol (16 mL), and the reaction solution was stirred under shading at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.506 g of the title compound as a colorless solid. The property values of the compound are as follows.

ESI-MS: m/z 468 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.64-1.82 (m, 2H), 1.86-1.94 (m, 1H), 2.08-2.16 (m, 1H), 2.26-2.44 (m, 2H), 2.30 (s, 3H), 2.70-2.83 (m, 1H), 3.12-3.20 (m, 1H), 3.76-3.88 (m, 1H), 3.85 (s, 3H), 5.41 (d, J=8.8 Hz, 1H), 6.70-6.80 (m, 1H), 6.84-6.96 (m, 2H), 7.02-7.12 (m, 2H), 7.20-7.30 (m, 1H), 7.72 (s, 1H), 7.76 (d, J=2.4 Hz, 1H).

Example 59

Synthesis of (E)-(3S,8αS)-3-(2,5-difluorophenyl)-6-[3-
methoxy-4-[(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one

[Formula 45]

Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,5-difluorophenyl)-5-oxopentanoate

To a suspension of magnesium (0.569 g) in tetrahydrofuran (20 mL), 1-bromo-2,5-difluorobenzene (2.64 mL) was added dropwise at 55°C over 15 minutes, and the reaction solution was stirred at room temperature for one hour. This solution was added dropwise to a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (5.0 g) in tetrahydrofuran (25 mL) at -40°C over 20 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 5.7 g of the title compound as a colorless oil. The property values of the compound are
as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.20-1.46 (m, 12H), 1.96-2.40 (m, 2H), 2.95-3.20 (m, 2H), 4.10-5.40 (m, 4H), 6.80-7.60 (m, 3H).

Synthesis of ethyl (R)-5-(2,5-difluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (25.9 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,5-difluorophenyl)-5-oxopentanoate (5.7 g) in ethyl acetate (20.7 mL) at room temperature, and the reaction solution was stirred for one hour at room temperature. The reaction solution was concentrated under reduced pressure to obtain 6.0 g of a yellow oil. Saturated sodium bicarbonate water (30 mL) was added dropwise to a solution of the crude product in ethyl acetate (20 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 4.2 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS: m/z 254 [M$^+$+H]. $^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.32 (t, $J$= 7.2 Hz, 3H), 2.16-2.30 (m, 1H), 2.30-2.44 (m, 1H), 2.98-3.12 (m, 1H), 3.14-
3.26 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.85-4.95 (m, 1H), 7.00-
7.15 (m, 2H), 7.70-7.80 (m, 1H).

[0312]

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-
(2,5-difluorophenyl)pyrrolidin-2-yl]acrylate

Sodium borohydride (0.99 g) was added to a
solution of ethyl (R)-5-(2,5-difluorophenyl)-3,4-
dihydro-2H-pyrrole-2-carboxylate (3.3 g) in methanol
(40 mL)-acetic acid (10 mL) at -60°C over 15 minutes.
The reaction solution was stirred at -60°C to 0°C for
one hour. A sodium bicarbonate solution was added to
the reaction solution. The mixture was stirred at room
temperature for 20 minutes, and the organic solvent was
evaporated under reduced pressure. The residue was
subjected to extraction with ethyl acetate, washed with
sodium bicarbonate water, and then dried over anhydrous
magnesium sulfate. The residue was concentrated under
reduced pressure to obtain 3.3 g of a yellow oil.
Triethylamine (7.06 mL) and di-tert-butyl dicarbonate
(3.55 g) were added to a solution of the resulting oil
in dichloromethane (50 mL), and the reaction solution
was stirred at room temperature for 12 hours. The
reaction solution was poured into ice water, followed
by extraction with ethyl acetate. The extract was
washed with brine, dried over anhydrous magnesium
sulfate, and then concentrated under reduced pressure.
The residue was purified by silica gel column
chromatography (heptane-ethyl acetate system) to obtain
4.2 g of (2R,5S)-5-(2,5-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester as a yellow oil.

Lithium borohydride (1.03 g) was added to a solution of (2R,5S)-5-(2,5-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (4.2 g) in tetrahydrofuran (40 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.3 g of an alcohol compound as a yellow oil. DMSO (1.24 mL) was added dropwise to a solution of oxalyl chloride (1.4 mL) in dichloromethane (50 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (3.3 g) in dichloromethane (10 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (9.12 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.4 g of an aldehyde compound as a pale
yellow oil. Sodium hydride (60% oil, 0.524 g) was added to a solution of trimethyl phosphonoacetate (2.58 g) in DMF (30 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (3.4 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 3.7 g of tert-butyl (2S,5R)-2-(2,5-difluorophenyl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate as a yellow oil.

A solution of 4 N hydrochloric acid in ethyl acetate (20 mL) was added dropwise to a solution of the resulting ester (3.7 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain 3.8 g of a yellow solid. Diethyl cyanophosphonate (2.48 mL) was added dropwise to a solution of the resulting yellow solid (3.8 g), vinylacetic acid (1.38 mL), and triethylamine (4.56 mL) in DMF (37 mL) at 0°C, and the reaction solution was stirred at room temperature for two hours. The reaction solution was poured into ice
water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.6 g of the title compound as a yellow oil. The property value of the compound is as follows.

ESI-MS; m/z 336[M^+H].

[0313]

Synthesis of (3S,8aR)-3-(2,5-difluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.594 g) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(2,5-difluorophenyl)pyrrolidin-2-yl]acrylate (4.6 g) in dichloromethane (60 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (8 mL) was added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.3 g of the title compound as a brown oil. The property values of the compound are as follows.

ESI-MS; m/z 250[M^+H]. ^1H-NMR (CDCl₃) δ (ppm):
1.68–1.83 (m, 1H), 1.88 (dd, J=6.0, 12.8 Hz, 1H), 2.06–
2.20 (m, 1H), 2.10–2.44 (m, 1H), 2.90–3.10 (m, 2H), 4.20–
4.35 (m, 1H), 5.36 (d, J=8.8 Hz, 1H), 6.00–6.20 (m, 2H), 6.53–
6.65 (m, 1H), 7.80–6.90 (m, 1H), 6.90–7.05 (m, 1H).

[0314]

Synthesis of (3S,8αS)-3-(2,5-
difluorophenyl)hexahydroindolizin-5-one

Platinum oxide (0.127 g) was added to a
solution of (3S,8αR)-3-(2,5-difluorophenyl)-2,3,6,8α-
tetrahydro-1H-indolizin-3-one (1.3 g) in methanol (65
mL), and the reaction solution was stirred in a
hydrogen atmosphere at room temperature for five hours.
Platinum oxide in the reaction solution was removed by
filtration, and the filtrate was concentrated under
reduced pressure. The residue was purified by silica
gel column chromatography (heptane-ethyl acetate
system) to obtain 1.2 g of the title compound as a pale
brown solid. The property values of the compound are
as follows.

[0315]

ESI-MS; m/z252[M⁺+H].¹H-NMR(CDCl₃) δ (ppm):
1.54–1.70 (m, 2H), 1.74–1.90 (m, 2H), 1.96–2.12 (m, 2H), 2.12–
2.50 (m, 4H), 3.50–3.70 (m, 1H), 5.31 (d, J=9.6 Hz, 1H), 6.55–
6.70 (m, 1H), 6.80–6.90 (m, 1H), 6.90–7.05 (m, 1H).

[0315]

Synthesis of diethyl [(3S,8αR)-3-(2,5-difluorophenyl)-
5-oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.884 mL) was added
dropwise to a solution of (3S,8αS)-3-(2,5-
difluorophenyl)hexahydroindolizin-5-one (1.2 g) and N,N,N',N'-tetramethylethylenediamine (2.46 mL) in dichloromethane (30 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (1.58 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.8 g of an iodine compound.

A solution of the resulting iodine compound (1.8 g) in triethyl phosphite (9.0 mL) was stirred at 130°C for one hour. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 4.1 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 388 [M+H].

[0316]

Synthesis of (E)−(3S,8aS)-3-(2,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one

Lithium hydroxide (0.443 g) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (1.0 g) and diethyl [(3S,8aR)-3-(2,5-difluorophenyl)-5-oxooctahydroindolizin-6-
yl)phosphonate (4.1 g) in tetrahydrofuran (4 mL)-ethanol (16 mL), and the reaction solution was stirred under shading at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.85 g of the title compound as a colorless oil. The property values of the compound are as follows.

ESI-MS; m/z 450 [M+H]. 1H-NMR (CDCl3) δ (ppm):
1.64-1.94 (m, 3H), 2.02-2.14 (m, 1H), 2.28-2.42 (m, 2H),
2.31 (s, 3H), 2.70-2.84 (m, 1H), 3.12-3.24 (m, 1H), 3.76-
3.90 (m, 1H), 3.87 (s, 3H), 5.44 (d, J=8.8Hz, 1H), 6.66-
6.74 (m, 1H), 6.84-6.94 (m, 1H), 6.95 (s, 1H), 6.97-7.08 (m, 1H),
7.07 (s, 1H), 7.08 (d, J=8.0Hz, 1H), 7.27 (d, J=8.0Hz, 1H),
7.73 (s, 1H), 7.78 (s, 1H).

[0317]

Example 60

Synthesis of (E)-(3S,8aS)-3-(3-fluorophenyl)-6-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]hexahydroindolizin-5-one

[Formula 46]
Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(3-fluorophenyl)-5-oxopentanoate

To a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (4.0 g) in tetrahydrofuran (100 mL), 3-fluorophenylmagnesium bromide (1.0 M solution in tetrahydrofuran; 17.1 mL) was added dropwise at -40°C over 10 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction from the reaction solution with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 5.5 g of the title compound as a colorless oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm): 1.24-1.36(m,3H), 1.38-1.46(s,9H), 2.00-2.50(m,2H), 2.95-3.20(m,2H), 4.15-5.20(m,4H), 6.90-7.80(m,4H).

[0318]

Synthesis of ethyl (R)-5-(3-fluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (25 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(3-fluorophenyl)-5-oxopentanoate (5.5 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution
was stirred at room temperature for one hour. The reaction solution was concentrated under reduced pressure to obtain 5.0 g of a yellow oil. Saturated sodium bicarbonate water (30 mL) was added dropwise to a solution of the crude product in ethyl acetate (20 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.5 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 236 [M+H]. ¹H-NMR (CDCl₃) δ (ppm):

1.32 (t, J=7.2 Hz, 3H), 2.18-2.43 (m, 2H), 2.90-3.03 (m, 1H), 3.08-3.20 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.85-4.95 (m, 1H), 7.10-7.20 (m, 1H), 7.38 (d, J=8.0, 14.0 Hz, 1H), 7.55-7.70 (m, 2H).

[0319]

**Synthesis of (2R,5S)-5-(3-fluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester**

Palladium-carbon (containing 50% water, 0.50 g) was added to a solution of ethyl (R)-5-(3-fluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (3.5 g) in ethyl acetate (50 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for four hours. Palladium-carbon in the reaction solution was removed by filtration, and then
the filtrate was concentrated under reduced pressure to obtain 3.5 g of a reduced compound. Triethylamine (7.51 mL) and di-tert-butyl dicarbonate (4.47 g) were added to a solution of the resulting reduced compound in DMF (50 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.2 g of the title compound as a yellow oil. The property values of the compound are as follows.

\[ \text{H-NMR (CDCl}_3\text{)} \delta \text{ (ppm):} \]
1.17 and 1.42 (s, 9H), 1.20-1.48 (m, 3H), 1.86-2.21 (m, 2H), 2.16-2.38 (m, 2H), 4.10-4.40 (m, 2H), 4.25-5.05 (m, 2H), 6.80-7.00 (m, 1H), 7.20-7.40 (m, 3H).

[0320]

**Synthesis of tert-butyl (2S,5R)-2-(3-fluorophenyl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate**

Lithium borohydride (1.03 g) was added to a solution of (2R,5S)-5-(3-fluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (4.2 g) in tetrahydrofuran (40 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was
washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.7 g of an alcohol compound as a yellow oil. DMSO (1.42 mL) was added dropwise to a solution of oxalyl chloride (1.61 mL) in dichloromethane (80 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (3.7 g) in dichloromethane (10 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (10.5 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 3.8 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.524 g) was added to a solution of trimethyl phosphonoacetate (2.82 g) in DMF (25 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (3.8 g) in DMF (25 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.0 g of the title compound as a yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

1.00-1.50 (m, 9H), 1.80-1.94 (m, 2H), 2.08-2.20 (m, 1H), 2.26-2.36 (m, 1H), 3.78 (s, 3H), 4.20-5.00 (m, 2H), 5.95-6.15 (m, 1H), 6.80-7.35 (m, 5H).

[0321]

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(3-fluorophenyl)pyrrolidin-2-yl]acrylate

A solution of 4 N hydrochloric acid in ethyl acetate (32.1 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(3-fluorophenyl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate (4.0 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain 3.8 g of a yellow solid. Diethyl cyanophosphonate (2.81 mL) was added dropwise to a solution of the resulting yellow solid (3.8 g), vinylacetic acid (1.56 mL), and triethylamine (5.17 mL) in DMF (40 mL) at 0°C, and the reaction solution was stirred at the same temperature for two hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid
solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.7 g of the title compound as a yellow oil. The property value of the compound is as follows.

ESI-MS; m/z 318 [M+H].

Synthesis of (3S,8aR)-3-(3-fluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.304 g) was added to a solution of methyl (E)-3-[[2R,5S]-1-(3-butenoyle)-5-(3-fluorophenyl)pyrrolidin-2-yl]acrylate (1.2 g) in dichloromethane (40 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (4 mL) was added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.60 g of the title compound as a brown oil. The property values of the compound are as follows.

ESI-MS; m/z 232 [M+H]. \( ^1\)H-NMR (CDCl\textsubscript{3}; δ (ppm)): 1.78-1.92 (m, 2H), 2.04-2.14 (m, 1H), 2.30-2.43 (m, 1H), 2.94-3.02 (m, 2H), 4.25-4.35 (m, 1H), 5.12 (d, J=8.8Hz, 1H), 5.95-
6.08 (m, 1H), 6.06-6.15 (m, 1H), 6.75-6.85 (m, 1H), 6.85-6.95 (m, 2H), 7.20-7.30 (m, 1H).

[0323]

**Synthesis of (3S,8aS)-3-(3-fluorophenyl)hexahydroindolizin-5-one**

Platinum oxide (0.0786 g) was added to a solution of (3S,8aR)-3-(3-fluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (0.60 g) in methanol (30 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for five hours. Platinum oxide in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.560 g of the title compound as a pale brown solid. The property values of the compound are as follows.

ESI-MS; m/z 234 [M+H]+.  
^1^H-NMR (CDCl3) δ (ppm):
1.54-1.88 (m, 4H), 1.94-2.10 (m, 2H), 2.14-2.50 (m, 4H), 3.54-3.66 (m, 1H), 5.00 (d, J=9.2 Hz, 1H), 6.76-6.84 (m, 1H), 6.84-6.96 (m, 2H), 7.20-7.30 (m, 1H).

[0324]

**Synthesis of diethyl [(3S,8aR)-3-(3-fluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate**

Iodotrimethylsilane (0.444 mL) was added dropwise to a solution of (3S,8aS)-3-(3-fluorophenyl)hexahydroindolizin-5-one (0.539 g) and N,N,N',N'-tetramethylethylenediamine (1.20 mL) in
dichloromethane (27 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.792 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.85 g of an iodine compound.

A solution of the resulting iodine compound (0.85 g) in triethyl phosphite (10 mL) was stirred at 130°C for one hour. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 1.9 g of the title compound. The property value of the compound is as follows. ESI-MS; m/z 370[M⁺H]. [0325]

\[ \text{Synthesis of } (E)-(3S,8aS)-3-(3-fluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]hexahydroindolizin-5-one \]

Lithium hydroxide (0.217 g) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.49 g) and diethyl [(3S,8aR)-3-(3-fluorophenyl)-5-oxo-octahydroindolizin-6-yl]phosphonate (1.9 g) in tetrahydrofuran (4 mL)-ethanol (16 mL), and the reaction solution was stirred under shading at room
temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.76 g of the title compound as a colorless solid. The property values of the compound are as follows.

ESI-MS; m/z432[M+H]. 1H-NMR (CDCl3) δ (ppm):
1.70-1.90 (m, 3H), 2.02-2.12 (m, 1H), 2.26-2.40 (m, 2H),
2.30 (s, 3H), 2.70-2.82 (m, 1H), 3.12-3.22 (m, 1H), 3.76-3.90 (m, 1H), 3.85 (s, 3H), 5.22 (d, J=8.8Hz, 1H), 6.84-7.00 (m, 2H), 6.94 (s, 1H), 6.99 (d, J=8.0Hz, 1H), 7.05 (s, 1H), 7.08 (d, J=8.0Hz, 1H), 7.24-7.36 (m, 2H), 7.72 (d, J=1.6Hz, 1H), 7.77 (d, J=2.4Hz, 1H).

Example 61

Synthesis of (E)-(3S,8aS)-3-(2,6-difluoropyridin-3-yl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one

[Formula 47]
Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,6-difluoropyridin-3-yl)-5-oxopentanoate

To a solution of diisopropylamine (0.653 mL) in tetrahydrofuran (30 mL), n-butyl lithium (1.57 M solution in hexane, 2.97 mL) was added at -78°C over five minutes, and the reaction solution was stirred at the same temperature for 20 minutes. 2,6-Difluoropyridine (0.388 mL) was added dropwise to the solution at -78°C, and the reaction solution was stirred at -78°C for three hours. A solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (1.0 g) in tetrahydrofuran (5.0 mL) was added dropwise to this solution at -78°C, and the reaction solution was stirred at 0°C for one hour.

Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.2 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.30 (t, $J=7.2$Hz, 3H), 1.41 (s, 9H), 1.94-2.08 (m, 1H), 2.28-2.40 (m, 1H), 2.98-3.22 (m, 2H), 4.22 (q, $J=7.2$Hz, 2H), 4.30-4.45 (m, 1H), 5.05-5.20 (m, 1H), 6.95 (dd, $J=2.4, 8.0$Hz, 1H), 8.50 (q, $J=8.0$Hz, 1H).
Synthesis of ethyl (R)-5-(2,6-difluoropyridin-3-yl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (6.0 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,6-difluoropyridin-3-yl)-5-oxopentanoate (1.2 g) in ethyl acetate (50 mL) at room temperature, and the reaction solution was stirred for one hour at room temperature. The reaction solution was concentrated under reduced pressure to obtain 1.0 g of a yellow oil. Saturated sodium bicarbonate water (30 mL) was added dropwise to a solution of the crude product in ethyl acetate (20 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.0 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS: m/z 255 [M+H].

1H-NMR (CDCl₃) δ (ppm):

1.32 (t, J=7.2 Hz, 3H), 2.19-2.31 (m, 1H), 2.33-2.45 (m, 1H), 3.00-3.12 (m, 1H), 3.14-3.28 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.85 (t, J=8.0 Hz, 1H), 6.90 (dd, J=2.8, 8.0 Hz, 1H), 8.67 (q, J=8.0 Hz, 1H).

Synthesis of (2R,5S)-5-(2,6-difluoropyridin-3-
yl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
2-ethyl ester

10% palladium-carbon (containing 50% water, 0.10 g) was added to a solution of ethyl (R)-5-(2,6-
difluoropyridin-3-yl)-3,4-dihydro-2H-pyrrole-2-
carboxylate (0.90 g) in ethyl acetate (50 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for six hours. Palladium-carbon in the reaction solution was removed by filtration, and then the filtrate was concentrated under reduced pressure to obtain 0.90 g of a reduced compound.

Triethylamine (1.93 mL) and di-tert-butyl dicarbonate (1.15 g) were added to a solution of the resulting reduced compound in DMF (50 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.68 g of the title compound as a yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm):

1.22 and 1.42 (s, 9H), 1.28-1.40 (m, 3H), 1.84-2.18 (m, 2H), 2.22-2.48 (m, 2H), 4.26 (q, J=7.2 Hz, 2H), 4.20-5.40 (m, 2H), 6.75-6.90 (m, 1H), 8.50-8.75 (m, 1H).

[0329]
Synthesis of tert-butyl (2S,5R)-2-(2,6-difluoropyridin-3-yl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate

Lithium aluminum hydride (43.6 mg) was added to a solution of (2R,5S)-5-(2,6-difluoropyridin-3-yl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (0.68 g) in tetrahydrofuran (30 mL) at -40°C, and the reaction solution was stirred at -40°C to 0°C for 30 minutes. The reaction solution was cooled to -40°C again. Lithium aluminum hydride (66 mg) was added to the reaction solution, which was then stirred at -40°C to 0°C for 30 minutes. Water (0.13 mL), a 15% sodium hydroxide solution (0.15 mL), and water (0.39 mL) were sequentially added to the reaction solution at 0°C, and the mixture was stirred at room temperature for 20 minutes. The insoluble matter in the mixture was removed by filtration, and then the filtrate was concentrated under reduced pressure to obtain 0.63 g of an alcohol compound as a yellow oil.

DMSO (0.399 mL) was added dropwise to a solution of oxalyl chloride (0.455 mL) in dichloromethane (20 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the alcohol compound (0.75 g) in dichloromethane (5 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (3.93 mL) was added dropwise to the solution, and the reaction
solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.80 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.113 g) was added to a solution of trimethyl phosphonoacetate (0.609 g) in DMF (5 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (0.80 g) in DMF (5 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.85 g of the title compound as a yellow oil. The property values of the compound are as follows.

\[ ^{1}H\text{-NMR}(CDCl_{3})\delta (ppm): \]

\[ 1.00-1.50 (m, 9H), 1.75-2.00 (m, 2H), 2.10-2.25 (m, 1H), 2.30-2.50 (m, 1H), 3.78 (s, 3H), 4.40-4.75 (m, 1H), 4.85-5.20 (m, 1H), \]

\[ 6.04 (d, J=15.2Hz, 1H), 6.84 (d, J=7.2Hz, 1H), 6.85-7.10 (m, 1H), 7.65-7.90 (m, 1H). \]

[0330]

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-
(2,6-difluoropyridin-3-yl)pyrrolidin-2-yl)acrylate

A solution of 4 N hydrochloric acid in ethyl acetate (6.07 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(2,6-difluoropyridin-3-yl)-5-[(E)-
5 (2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate
(0.85 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at 50°C for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain 0.85 g of a yellow solid.

Diethyl cyanophosphonate (0.598 mL) was added dropwise to a solution of the resulting yellow solid (0.85 g), vinylacetic acid (0.334 mL), and triethylamine (1.1 mL) in DMF (20 mL) at 0°C, and the reaction solution was stirred at room temperature for two hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.58 g of the title compound as a yellow oil. The property value of the compound is as follows.

ESI-MS; m/z 337 [M^+H].

[0331]

Synthesis of (3S,8aR)-3-(2,6-difluoropyridin-3-yl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.147 g) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-
butenoyl)-5-(2,6-difluoropyridin-3-yl)pyrrolidin-2-yl)acrylate (0.58 g) in dichloromethane (20 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (4 mL) was added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.314 g of the title compound as a brown solid. The property values of the compound are as follows:

ESI-MS: m/z 251 [M⁺+H]. ¹H-NMR (CDCl₃) δ (ppm):
1.62-1.78 (m, 1H), 1.86-1.94 (m, 1H), 2.13-2.22 (m, 1H), 2.34-2.47 (m, 1H), 2.96-3.04 (m, 2H), 4.25-4.35 (m, 1H), 5.27 (d, J=8.8 Hz, 1H), 6.00-6.15 (m, 2H), 6.71 (dd, J=2.8, 8.0 Hz, 1H), 7.39 (dd, J=8.0, 17.6 Hz, 1H).

[0332]

Synthesis of (3S,8aS)-3-(2,6-difluoropyridin-3-yl)hexahydropyridin-5-one

Platinum oxide (35.1 mg) was added to a solution of (3S,8aR)-3-(2,6-difluoropyridin-3-yl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (0.314 g) in methanol (20 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for five hours. Platinum oxide was removed from the reaction solution by filtration, and the filtrate was concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.30 g of the title compound as a pale brown solid. The property values of the compound are as follows.

ESI-MS; m/z 253[M+H]. $^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.48-1.68 (m, 4H), 1.75-1.90 (m, 1H), 2.00-2.12 (m, 1H), 2.16-2.52 (m, 4H), 3.53-3.70 (m, 1H), 5.21 (d, J=9.2 Hz, 1H), 6.74 (dd, J=3.2, 8.0 Hz, 1H), 7.47 (dd, J=8.0, 17.6 Hz, 1H).

Synthesis of diethyl [(3S,8aR)-3-(2,6-difluoropyridin-3-yl)-5-oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.23 mL) was added dropwise to a solution of (3S,8aS)-3-(2,6-difluoropyridin-3-yl)hexahydroindolizin-5-one (0.30 g) and N,N,N',N'-tetramethylethylenediamine (0.617 mL) in dichloromethane (15 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.409 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.45 g of an iodine compound.

A solution of the resulting iodine compound (0.45 g) in triethyl phosphite (10 mL) was stirred at
130°C for one hour. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 1.0 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z389 [M^+H].

[0334]

Synthesis of (E)-(3S,8aS)-3-(2,6-difluoropyridin-3-yl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one

Lithium hydroxide (0.106 g) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.24 g) and diethyl [(3S,8aR)-3-(2,6-difluoropyridin-3-yl)-5-oxooctahydroindolizin-6-yl]phosphonate (1.0 g) in tetrahydrofuran (4 mL)-ethanol (16 mL), and the reaction solution was stirred under shading at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.42 g of the title compound as a colorless solid. The property values of the compound are as follows.

ESI-MS; m/z451 [M^+H]. ^1H-NMR (CDCl₃) δ (ppm):

1.56-1.82 (m, 2H), 1.82-2.00 (m, 1H), 2.10-2.20 (m, 1H), 2.24-2.48 (m, 2H), 2.30 (s, 3H), 2.70-2.84 (m, 1H), 3.12-3.22 (m, 1H), 3.76-3.90 (m, 1H), 3.86 (s, 3H), 5.34 (d, J=9.2Hz, 1H),
6.77 (d, J=8.0 Hz, 1H), 6.94 (s, 1H), 7.06 (s, 1H),
7.10 (d, J=8.0 Hz, 1H), 7.20-7.35 (m, 1H),
7.54 (dd, J=8.0 Hz, 1H), 7.73 (s, 1H), 7.75 (s, 1H).

[0335]

5 Example 62

Synthesis of (E)-(3S,8aS)-3-(2,4-difluorophenyl)-6-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzylidene]hexahydropyridolinizin-5-one

[Formula 48]

10 Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-
(2,4-difluorophenyl)-5-oxopentanoate

To a suspension of magnesium (736 mg) in
tetrahydrofuran (20 mL), 1-bromo-2,4-difluorobenzene
(3.42 mL) was added dropwise at 45°C over five minutes,
and the reaction solution was stirred at room
temperature for one hour. This solution was added
dropwise to a solution of (R)-5-oxopyrrolidine-1,2-
dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (6.0
g) in tetrahydrofuran (50 mL) at -40°C over 20 minutes,
and the reaction solution was stirred at -40°C to 0°C
for one hour. Water was added to the solution in small
portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 7.5 g of the title compound as a colorless oil.

$^1$H-NMR (CDCl$_3$) δ (ppm):

1.29 (t, J=7.2 Hz, 3H), 1.42 (s, 9H), 1.95-2.10 (m, 1H), 2.20-2.35 (m, 1H), 2.95-3.20 (m, 2H), 4.21 (q, J=7.2 Hz, 2H), 4.30-4.45 (m, 1H), 5.05-5.20 (m, 1H), 6.82-6.92 (m, 1H), 6.92-7.02 (m, 1H), 7.90-8.00 (m, 1H).

[0336]

**Synthesis of ethyl (R)-5-(2,4-difluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate**

A solution of 4 N hydrochloric acid in ethyl acetate (42.9 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(2,4-difluorophenyl)-5-oxopentanoate (8.1 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure to obtain 7.0 g of a yellow oil. Saturated sodium bicarbonate water (100 mL) was added dropwise to a solution of the crude product in ethyl acetate (100 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The
extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 5.1 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 254 [M+H]. $^1$H-NMR (CDCl$_3$) δ (ppm):
1.32 (t, J=7.2 Hz, 3H), 2.15-2.29 (m, 1H), 2.30-2.40 (m, 1H), 2.95-3.10 (m, 1H), 3.10-3.25 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.80-4.90 (m, 1H), 6.80-6.89 (m, 1H), 6.89-6.98 (m, 1H), 8.04-8.12 (m, 1H).

[0337]

Synthesis of (2R,5S)-5-(2,4-difluorophenyl)pyrroolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester

10% palladium-carbon (containing 50% water, 800 mg) was added to a solution of ethyl (R)-5-(2,4-difluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (5.1 g) in ethyl acetate (100 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for eight hours. Palladium-carbon in the reaction solution was removed by filtration, and then the filtrate was concentrated under reduced pressure to obtain 5.0 g of a reduced compound.

Triethylamine (10.7 mL) and di-tert-butyl dicarbonate (6.42 g) were added to a solution of the resulting reduced compound in DMF (50 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate.
The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 7.4 g of the title compound as a yellow oil.

The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm):
1.20 and 1.42 (s, 9H), 1.20-1.40 (m, 3H), 1.84-2.10 (m, 2H), 2.16-2.42 (m, 2H), 4.26 (q, J=7.2 Hz, 2H), 4.20-5.30 (m, 2H), 6.70-6.80 (m, 1H), 6.80-6.95 (m, 1H), 7.90-8.10 (m, 1H).

[0338]

Synthesis of tert-butyl (2S,5R)-2-(2,4-difluorophenyl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate

Lithium borohydride (1.82 g) was added to a solution of (2R,5S)-5-(2,4-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (7.4 g) in tetrahydrofuran (100 mL) at 0°C, and the reaction solution was stirred at room temperature for five hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 6.5 g of an alcohol compound as a yellow oil. DMSO (2.36 mL) was added dropwise to a solution of oxalyl chloride (2.69 mL) in dichloromethane (100 mL) at -70°C, and the reaction solution was stirred at the same temperature for three
minutes. A solution of the above alcohol compound (6.5 g) in dichloromethane (20 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (23.2 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 6.5 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.92 g) was added to a solution of trimethyl phosphonoacetate (4.95 g) in DMF (50 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (6.5 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 4.74 g of the title compound as a yellow oil. The property values of the compound are as follows.

\[ ^1H-NMR(CDCl_3) \delta (ppm): \]

1.10-1.50 (m, 9H), 1.78-1.92 (m, 2H), 2.06-2.22 (m, 1H), 2.28-
2.40 (m, 1H), 3.78 (s, 3H), 4.40-4.70 (m, 1H), 4.90-5.30 (m, 1H),
5.95-6.15 (m, 1H), 6.78 (t, J=9.6 Hz, 1H), 6.87 (t, J=8.4 Hz, 1H),
6.95-7.10 (m, 1H), 7.15-7.30 (m, 1H).

[0339]

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-
(2,4-difluorophenyl)pyrrolidin-2-yl]acrylate

A solution of 4 N hydrochloric acid in ethyl acetate (20 mL) was added dropwise to a solution of
tert-butyl (2S,5R)-2-(2,4-difluorophenyl)-5-[(E)-(2-
10 methoxycarbonylvinyl)]pyrrolidine-1-carboxylate (2.8 g)
in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at 50°C for 30 minutes.
The reaction solution was concentrated under reduced pressure to obtain 2.5 g of a yellow solid. Diethyl
15 cyanophosphonate (1.97 mL) was added dropwise to a solution of the resulting yellow solid (2.5 g),
vinylacetic acid (1.1 mL), and triethylamine (3.63 mL)
in DMF (40 mL) at 0°C, and the reaction solution was stirred at the same temperature for two hours. The
reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate
20 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography
(heptane-ethyl acetate system) to obtain 1.9 g of the title compound as a yellow oil. The property values of
the compound are as follows.

ESI-MS; m/z 336 [M^+ + H]^+.

^1H-NMR (CDCl₃) δ (ppm):

1.66-3.20 (m, 6H), 3.76 and 3.80 (s, 3H), 4.20-5.40 (m, 4H), 5.80-6.00 (m, 1H), 6.09 (d, J=15.6 Hz, 1H), 6.70-7.30 (m, 4H).

[0340]

Synthesis of (3S,8aR)-3-(2,4-difluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (481 mg) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(2,4-difluorophenyl)pyrrolidin-2-yl]acrylate (1.9 g) in dichloromethane (50 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for five hours. The reaction solution was returned to room temperature. Triethylamine (4 mL) was added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.85 g of the title compound as a brown oil. The property values of the compound are as follows.

ESI-MS; m/z 250 [M^+ + H]^+.

^1H-NMR (CDCl₃) δ (ppm):

1.68-1.84 (m, 1H), 1.86 (dd, J=6.4, 12.8 Hz, 1H), 2.06-2.18 (m, 1H), 2.30-2.42 (m, 1H), 2.90-3.08 (m, 2H), 4.20-4.34 (m, 1H), 5.34 (d, J=8.8 Hz, 1H), 5.98-6.14 (m, 2H), 6.70-6.90 (m, 3H).

[0341]
Synthesis of (3S,8aS)-3-(2,4-difluorophenyl)hexahydroindolizin-5-one

Platinum oxide (95 mg) was added to a solution of (3S,8aR)-3-(2,4-difluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (0.85 g) in methanol (40 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for five hours. Platinum oxide in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.72 g of the title compound as a pale brown solid. The property values of the compound are as follows.

ESI-MS; m/z252[M+H]+. ¹H-NMR(CDCl₃)δ(ppm):
1.52-1.68 (m, 2H), 1.74-1.90 (m, 2H), 1.96-2.10 (m, 2H), 2.14-2.52 (m, 4H), 3.50-3.65 (m, 1H), 5.30 (d, J=9.2Hz, 1H), 6.70-6.90 (m, 2H), 6.91 (dd, J=8.8, 14.4Hz, 1H).

[0342]

Synthesis of diethyl [(3S,8aR)-3-(2,4-difluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.551 mL) was added dropwise to a solution of (3S,8aS)-3-(2,4-difluorophenyl)hexahydroindolizin-5-one (0.72 g) and N,N,N′,N′-tetramethylethylenediamine (1.48 mL) in dichloromethane (30 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.982 g) was added to the reaction solution at 0°C, and
the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.3 g of an iodine compound.

A solution of the resulting iodine compound (1.3 g) in triethyl phosphate (23.2 mL) was stirred at 130°C for one hour. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 1.8 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 388[M+H].

Synthesis of (E)-(3S,8aS)-3-(2,4-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one

Lithium hydroxide (406 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (550 mg) and diethyl [(3S,8aR)-3-(2,4-difluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate (1.8 g) in tetrahydrofuran (5 mL)-ethanol (20 mL), and the reaction solution was stirred under shading at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was
washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.76 g of the title compound as a colorless solid. The property values of the compound are as follows.

ESI-MS; m/z 450 [M+H]. 1H-NMR (CDCl₃) δ (ppm):
1.60-1.83 (m, 2H), 1.84-1.93 (m, 1H), 2.04-2.13 (m, 1H), 2.28-2.40 (m, 2H), 2.30 (s, 3H), 2.70-2.83 (m, 1H), 3.12-3.20 (m, 1H),
3.76-3.88 (m, 1H), 3.86 (s, 3H), 5.42 (d, J=8.8 Hz, 1H), 6.74-6.88 (m, 2H), 6.94 (s, 1H), 6.90-7.04 (m, 1H), 7.06 (s, 1H),
7.09 (d, J=8.0 Hz, 1H), 7.26 (d, J=8.0 Hz, 1H), 7.72 (s, 1H),
7.77 (d, J=2.4 Hz, 1H).

Example 63

Synthesis of (E)-(3S,8aS)-3-(3-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one

[Formula 49]

20 Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(3-chlorophenyl)-5-oxopentanoate

To a solution of (R)-5-oxopyrrolidine-1,2-
dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (2.0 g) in tetrahydrofuran (100 mL), 3-chlorophenylmagnesium bromide (0.5 M solution in tetrahydrofuran; 17.1 mL) was added dropwise at -40°C over 20 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.5 g of the title compound as a colorless oil. The property values of the compound are as follows.

$^1$H-NMR(CDCl$_3$) $\delta$(ppm):
1.28(t, J=7.2 Hz, 3H), 1.42(s, 9H), 2.00-2.20(m, 1H), 2.20-2.40(m, 1H), 2.95-3.20(m, 2H), 4.21(d, J=7.2 Hz, 2H), 4.30-4.45(m, 1H), 5.20-5.30(m, 1H), 7.41(t, J=8.0 Hz, 1H), 7.54(d, J=8.0 Hz, 1H), 7.82(d, J=8.0 Hz, 1H), 7.92(t, J=2.0 Hz, 1H).

Synthesis of ethyl (R)-5-(4-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (20 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(3-chlorophenyl)-5-oxopentanoate (2.5 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at room temperature for 12 hours. The
reaction solution was concentrated under reduced pressure to obtain 2.0 g of a yellow oil. Saturated sodium bicarbonate water (100 mL) was added dropwise to a solution of the crude product in ethyl acetate (100 mL), and the reaction solution was stirred at room temperature for 20 minutes. The reaction solution was subjected to extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.5 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 252 [M+H].\(^1\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):

1.32 (t, J=7.2 Hz, 3H), 2.15-2.45 (m, 2H), 2.90-3.05 (m, 1H), 3.05-3.20 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.85-4.95 (m, 1H), 7.35 (t, J=8.0 Hz, 1H), 7.40-7.45 (m, 1H), 7.74 (td, J=1.6, 8.0 Hz, 1H), 7.90 (t, J=1.6 Hz, 1H).

[0346]

Synthesis of (2R,5S)-5-(3-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester

Sodium borohydride (0.451 g) was added to a solution of ethyl (R)-5-(3-chlorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (1.5 g) in methanol (40 mL) acetic acid (10 mL) at -45°C over five minutes. The reaction solution was stirred at -45°C to 0°C for three hours. A disodium hydrogen phosphate solution was added to the reaction solution. The mixture was
stirred at room temperature for 20 minutes, and the organic solvent was evaporated under reduced pressure. The residue was subjected to extraction with dichloromethane, and the extract was dried over anhydrous magnesium sulfate. The extract was concentrated to obtain 1.4 g of a reduced compound. Triethylamine (3.21 mL) and di-tert-butyl dicarbonate (1.61 g) were added to a solution of the reduced compound (1.4 g) in dichloromethane (20 mL), and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.7 g of the title compound as a yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm):

1.17 and 1.42 (s, 9H), 1.20-1.44 (m, 3H), 1.80-2.14 (m, 2H), 2.14-2.38 (m, 2H), 4.10-5.20 (m, 4H), 7.12-7.28 (m, 2H), 7.38-7.50 (m, 1H), 7.54-7.61 (m, 1H).

[0347]

Synthesis of tert-butyl (2S,5R)-2-(3-chlorophenyl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrrolidine-1-carboxylate

Lithium borohydride (394 mg) was added to a solution of (2R,5S)-5-(3-chlorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (1.6
g) in tetrahydrofuran (30 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was added to ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.6 g of an alcohol compound as a yellow oil. DMSO (0.619 mL) was added dropwise to a solution of oxalyl chloride (0.66 mL) in dichloromethane (40 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (1.6 g) in dichloromethane (20 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (5.72 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 1.6 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.309 g) was added to a solution of trimethyl phosphonoacetate (1.4 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was added to a solution of the above aldehyde (1.6 g) in DMF (10 mL) at room temperature, and the reaction solution was stirred at
room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 1.34 g of the title compound as a yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 388 [M+Na]+. 1H-NMR (CDCl₃) δ (ppm):
1.00-1.50 (m, 9H), 1.60-1.95 (m, 2H), 2.05-2.45 (m, 2H),
3.73 and 3.78 (s, 3H), 4.30-5.10 (m, 2H), 5.95-6.15 (m, 1H), 6.90-
7.10 (m, 1H), 7.13 (d, J=7.6 Hz, 1H), 7.15-7.30 (m, 3H).

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(3-chlorophenyl)pyrroolidin-2-yl]acrylate

A solution of 4 N hydrochloric acid in ethyl acetate (10 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(3-chlorophenyl)-5-[(E)-(2-methoxycarbonylvinyl)]pyrroolidine-1-carboxylate (1.34 g) in ethyl acetate (5 mL) at room temperature, and the reaction solution was stirred at 50°C for one hour. The reaction solution was concentrated under reduced pressure to obtain 1.0 g of a yellow solid. Diethyl cyanophosphonate (2.29 mL) was added dropwise to a solution of the resulting yellow solid (1.0 g), vinylacetic acid (1.27 mL), and triethylamine (4.22 mL) in DMF (30 mL) at 0°C, and the reaction solution was
stirred at room temperature for two hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.72 g of the title compound as a yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 334 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.20-3.20 (m, 6H), 3.76 and 3.80 (s, 3H), 4.22-4.36 (m, 1H), 4.54-5.22 (m, 3H), 5.78-6.00 (m, 1H), 6.00-6.16 (m, 1H), 6.90-7.40 (m, 5H).

[0349]

Synthesis of (3S,8aR)-3-(3-chlorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.45 g) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(3-chlorophenyl)pyrrolidin-2-yl]acrylate (0.72 g) in dichloromethane (40 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for three hours. The reaction solution was returned to room temperature. Triethylamine (1 mL) was added to the reaction solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by
silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.36 g of the title compound as a brown oil. The property values of the compound are as follows.

5 ESI-MS; m/z 248 [M+H]. $^1$H-NMR (CDCl$_3$) $\delta$(ppm):
1.76-1.92 (m, 2H), 2.02-2.14 (m, 1H), 2.29-2.42 (m, 1H), 2.94-3.02(m, 2H), 4.24-4.34 (m, 1H), 5.09 (d, J=8.8Hz, 1H), 5.96-6.06 (m, 1H), 6.06-6.14 (m, 1H), 6.98 (d, J=7.2Hz, 1H), 7.08 (s, 1H), 7.17 (d, J=7.2Hz, 1H), 7.21 (d, J=7.2Hz, 1H).

[0350]

**Synthesis of (3S,8aS)-3-(3-chlorophenyl)hexahydroindolizin-5-one**

Platinum oxide (42.4 mg) was added to a solution of (3S,8aR)-3-(3-chlorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (0.36 g) in methanol (30 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for five hours. Platinum oxide in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.32 g of the title compound as a pale yellow solid. The property values of the compound are as follows.

25 ESI-MS; m/z 250 [M+H]. $^1$H-NMR (CDCl$_3$) $\delta$(ppm):
1.55-1.90 (m, 4H), 1.95-2.10 (m, 2H), 2.15-2.50 (m, 4H), 3.55-3.68 (m, 1H), 5.08 (d, J=8.8Hz, 1H), 6.99-7.04 (m, 1H), 7.08-7.11 (m, 1H), 7.15-7.19 (m, 1H), 7.22 (t, J=8.0Hz, 1H).
[0351]

Synthesis of diethyl [(3S,8aR)-3-(3-chlorophenyl)-5-
oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.244 mL) was added dropwise to a solution of (3S,8aS)-3-(3-
chlorophenyl)hexahydroindolizin-5-one (0.32 g) and N,N,N',N'-tetramethylethylenediamine (0.657 mL) in dichloromethane (20 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.435 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with 1 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.50 g of an iodine compound.

A solution of the resulting iodine compound (0.50 g) in triethyl phosphite (6.0 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 0.52 g of the title compound. The property value of the compound is as follows.

ESI-MS; m/z 386 [M+H].

[0352]

Synthesis of (E)-(3S,8aS)-3-(3-chlorophenyl)-6-(3-
methoxy-4-(4-methyl-1H-imidazol-1-
Lithium hydroxide (0.142 g) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.28 g) and diethyl [(3S,8aR)-3-(3-chlorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate (0.52 g) in tetrahydrofuran (1 mL)-ethanol (4 mL), and the reaction solution was stirred under shading at room temperature for three hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.438 g of the title compound as a colorless oil. The property values of the compound are as follows.

ESI-MS; m/z 448 [M^+H]. ^1H-NMR (CDCl₃) δ (ppm):

1.70-1.90 (m, 3H), 2.02-2.14 (m, 1H), 2.25-2.40 (m, 2H), 2.30 (s, 3H), 2.70-2.83 (m, 1H), 3.10-3.20 (m, 1H), 3.75-3.90 (m, 1H), 3.85 (s, 3H), 5.19 (d, J=8.8 Hz, 1H), 6.92-6.96 (m, 1H), 7.02-7.12 (m, 3H), 7.13-7.29 (m, 4H), 7.72 (d, J=1.6 Hz, 1H), 7.76 (d, J=2.0 Hz, 1H).

[0353]

Example 64

Synthesis of (E)-(3S,8aS)-3-(3,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one
Synthesis of ethyl (R)-2-tert-butoxycarbonylamino-5-(3,5-difluorophenyl)-5-oxopentanoate

To a solution of (R)-5-oxopyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (3.0 g) in tetrahydrofuran (70 mL), 3,5-difluorophenylmagnesium bromide (0.5 M solution in tetrahydrofuran; 25.7 mL) was added dropwise at -40°C over 10 minutes, and the reaction solution was stirred at -40°C to 0°C for one hour. Water was added to the solution in small portions at 0°C, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 3.0 g of the title compound as a pale yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.20-1.42 (m, 3H), 1.42 (s, 9H), 1.95-2.50 (m, 2H), 2.90-3.20 (m, 2H), 4.22 (q, J=7.2Hz, 2H), 4.10-5.30 (m, 2H), 6.90-7.06 (m, 1H), 7.40-7.50 (m, 2H).
Synthesis of ethyl (R)-5-(3,5-difluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate

A solution of 4 N hydrochloric acid in ethyl acetate (20 mL) was added dropwise to a solution of ethyl (R)-2-tert-butoxycarbonylamino-5-(3,5-difluorophenyl)-5-oxopentanoate (3.0 g) in ethyl acetate (20 mL) at room temperature, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure to obtain 2.0 g of a yellow oil. Saturated sodium bicarbonate water (50 mL) was added dropwise to a solution of the crude product in ethyl acetate (20 mL), and the reaction solution was stirred at room temperature for 20 minutes, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.0 g of the title compound as a pale red oil. The property values of the compound are as follows.

ESI-MS; m/z 254 [M+H]+. 1H-NMR (CDCl₃) δ (ppm):
1.32 (t, J=7.2 Hz, 3H), 2.22-2.44 (m, 2H), 2.88-3.00 (m, 1H), 3.05-3.16 (m, 1H), 4.25 (q, J=7.2 Hz, 2H), 4.86-4.98 (m, 1H), 6.85-6.95 (m, 1H), 7.35-7.45 (m, 2H).

Synthesis of (2R,5S)-5-(3,5-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester

10% palladium-carbon (containing 50% water,
0.441 g) was added to a solution of ethyl (R)-5-(3,5-
difluorophenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate
(2.0 g) in ethyl acetate (50 mL), and the reaction
solution was stirred in a hydrogen atmosphere at room
temperature for four hours. Palladium-carbon in the
reaction solution was removed by filtration, and then
the filtrate was concentrated under reduced pressure to
obtain 2.0 g of a reduced compound as a yellow oil.

Triethylamine (2.93 mL) and di-tert-butyl
dicarbonate (3.07 g) were added to a solution of the
resulting reduced compound in DMF (20 mL), and the
reaction solution was stirred at room temperature for
one hour. The reaction solution was poured into ice
water, followed by extraction with ethyl acetate. The
extract was washed with brine, dried over anhydrous
magnesium sulfate, and then concentrated under reduced
pressure. The residue was purified by silica gel
column chromatography (heptane-ethyl acetate system) to
obtain 2.7 g of the title compound as a yellow oil.
The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.20 and 1.42 (s, 9H), 1.16-1.50 (m, 3H), 1.84-2.12 (m, 2H), 2.16-
2.40 (m, 2H), 4.28 (q, J=7.2Hz, 2H), 4.20-5.00 (m, 2H), 6.60-
6.72 (m, 1H), 7.06-7.24 (m, 2H).

[0356]

Synthesis of tert-butyl (2S,5R)-2-(3,5-difluorophenyl)-
5-((E)-2-methoxycarbonylviny1)pyrrolidine-1-carboxylate

Lithium borohydride (0.687 g) was added to a
solution of (2R,5S)-5-(3,5-difluorophenyl)pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester (2.7 g) in tetrahydrofuran (30 mL) at 0°C, and the reaction solution was stirred at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.7 g of an alcohol compound as a yellow oil. DMSO (1.14 mL) was added dropwise to a solution of oxalyl chloride (1.39 mL) in dichloromethane (40 mL) at -70°C, and the reaction solution was stirred at the same temperature for three minutes. A solution of the above alcohol compound (2.7 g) in dichloromethane (20 mL) was added dropwise thereto at -60°C, and the reaction solution was stirred at the same temperature for 15 minutes. Triethylamine (11.3 mL) was added dropwise to the solution, and the reaction solution was stirred at -60°C to 0°C for 30 minutes. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 2.7 g of an aldehyde compound as a pale yellow oil. Sodium hydride (60% oil, 0.521 g) was added to a solution of trimethyl phosphonoacetate (2.37 g) in DMF (20 mL) at room temperature, and the reaction solution was stirred for 20 minutes. This solution was
added to a solution of the above aldehyde (2.7 g) in DMF (10 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. The reaction solution was poured into water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 2.4 g of the title compound as a yellow oil. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):
1.10-1.60 (m, 9H), 1.75-1.95 (m, 2H), 2.05-2.20 (m, 1H), 2.25-2.40 (m, 1H), 3.78 (s, 3H), 4.40-5.10 (m, 2H), 5.96-6.14 (m, 1H), 6.62-6.72 (m, 1H), 6.72-6.82 (m, 2H), 6.90-7.06 (m, 1H).

[0357]

Synthesis of methyl (E)-3-[(2R,5S)-1-(3-butenoyl)-5-(3,5-difluorophenyl)pyrrolidin-2-yl]acrylate

A solution of 4 N hydrochloric acid in ethyl acetate (30 mL) was added dropwise to a solution of tert-butyl (2S,5R)-2-(3,5-difluorophenyl)-5-((E)-2-methoxycarbonylviny1)pyrrolidine-1-carboxylate (1.2 g) in ethyl acetate (5 mL) at room temperature, and the reaction solution was stirred at 50°C for one hour. The reaction solution was concentrated under reduced pressure to obtain 1.0 g of a yellow solid. Diethyl cyanophosphonate (2.05 mL) was added dropwise to a solution of the resulting yellow solid (1.0 g),
vinylacetic acid (1.14 mL), and triethylamine (3.78 mL) in DMF (30 mL) at 0°C, and the reaction solution was stirred at the same temperature for one hour. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was sequentially washed with a 1 N hydrochloric acid solution, saturated sodium bicarbonate water, and brine, and then dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.78 g of the title compound as a yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 336[M\(^{+}\)+H]. \(^{1}\)H-NMR (CDCl\(_3\)) \(\delta\) (ppm):

1.20-3.16 (m, 6H), 3.76 and 3.80 (s, 3H), 4.56-5.24 (m, 4H), 5.78-6.00 (m, 1H), 6.00-6.14 (m, 1H), 6.60-6.86 (m, 3H), 6.90-7.10 (m, 1H).

[0358]

Synthesis of (3S,8aR)-3-(3,5-difluorophenyl)-2,3,6,8a-
tetrahydro-1H-indolizin-3-one

Grubbs catalyst 2nd generation (0.487 g) was added to a solution of methyl (E)-3-[(2R,5S)-1-(3-
butenoyl)-5-(3,5-difluorophenyl)pyrrolidin-2-
yl]acrylate (0.78 g) in dichloromethane (70 mL), and the reaction solution was heated under reflux in a nitrogen atmosphere for three hours. The reaction solution was returned to room temperature. Triethylamine (1.0 mL) was added to the reaction
solution, which was then stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.44 g of the title compound as a brown oil.

The property values of the compound are as follows.

ESI-MS; m/z 250 [M’+H].^1H-NMR (CDCl3) δ (ppm):
1.76-1.90 (m, 2H), 2.03-2.16 (m, 1H), 2.28-2.44 (m, 1H), 2.90-3.06 (m, 2H), 4.24-4.34 (m, 1H), 5.08 (d, J=9.2 Hz, 1H), 5.98-6.06 (m, 1H), 6.06-6.14 (m, 1H), 6.58-6.68 (m, 3H).

[0359]

Synthesis of (3S,8aS)-3-(3,5-difluorophenyl)hexahydroindolizin-5-one

Platinum oxide (20 mg) was added to a solution of (3S,8aR)-3-(3,5-difluorophenyl)-2,3,6,8a-tetrahydro-1H-indolizin-3-one (0.17 g) in methanol (25 mL), and the reaction solution was stirred in a hydrogen atmosphere at room temperature for 2.5 hours. Platinum oxide in the reaction solution was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.167 g of the title compound as a yellow oil. The property values of the compound are as follows.

ESI-MS; m/z 252 [M’+H].^1H-NMR (CDCl3) δ (ppm):
1.52-1.90 (m, 4H), 1.96-2.12 (m, 2H), 2.14-2.50 (m, 4H), 3.53-3.65 (m, 1H), 5.05 (d, J=9.2 Hz, 1H), 6.55-6.70 (m, 3H).
Synthesis of diethyl [(3S,8aR)-3-(3,5-difluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate

Iodotrimethylsilane (0.128 mL) was added dropwise to a solution of (3S,8aS)-3-(3,5-difluorophenyl)hexahydroindolizin-5-one (0.167 g) and N,N,N',N'-tetramethylethylenediamine (0.341 mL) in dichloromethane (20 mL) at 0°C, and the reaction solution was stirred at 0°C for 30 minutes. Iodine (0.228 g) was added to the reaction solution at 0°C, and the reaction solution was stirred at the same temperature for 40 minutes. The reaction solution was added to ice-sodium thiosulfate solution, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 0.25 g of an iodine compound.

A solution of the resulting iodine compound (0.25 g) in triethyl phosphite (6.25 mL) was stirred at 130°C for two hours. The reaction solution was returned to room temperature and concentrated under reduced pressure to obtain 0.40 g of the title compound. The property value of the compound is as follows.

ESI-MSm/z388[M+H].

Synthesis of (E)-(3S,8aS)-3-(3,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one
Lithium hydroxide (56.8 mg) was added to a mixed solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (0.12 g) and diethyl [(3S,8aR)-3-(3,5-difluorophenyl)-5-oxooctahydroindolizin-6-yl]phosphonate (0.25 g) in tetrahydrofuran (1.0 mL)-ethanol (4.0 mL), and the reaction solution was stirred under shading at room temperature for 12 hours. The reaction solution was poured into ice water, followed by extraction with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane-ethyl acetate system) to obtain 0.22 g of the title compound as a colorless oil. The property values of the compound are as follows.

ESI-MS: m/z 450 [M+H]+. 1H-NMR (CDCl3) δ (ppm):
1.70-1.90 (m, 3H), 2.04-2.14 (m, 1H), 2.26-2.40 (m, 2H),
2.30 (s, 3H), 2.68-2.82 (m, 1H), 3.12-3.22 (m, 1H), 3.76-
3.90 (m, 1H), 3.86 (s, 3H), 5.17 (d, J=9.2 Hz, 1H), 6.62-
6.76 (m, 3H), 6.94 (s, 1H), 7.06 (s, 1H), 7.08 (d, J=8.0 Hz, 1H),
7.26 (d, J=8.0 Hz, 1H), 7.72 (d, J=1.2 Hz, 1H),
7.76 (d, J=2.0 Hz, 1H).

[0362]
Examples 65 and 66

Synthesis of (E)-(6S,9aS)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one and (E)-(6R,9aR)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
Synthesis of 1-(4-bromobutyryl)-2-(3,4-difluorophenyl)-2,3-dihydro-1H-pyridin-4-one

To a suspension of magnesium (1.38 g) and a small amount of an iodine piece in anhydrous diethyl ether (70 mL), 1-bromo-3,4-difluorobenzene (10 g) was added dropwise in a nitrogen atmosphere while heating under reflux. When the reaction started, the reaction vessel was removed from the oil bath. The remaining 1-bromo-3,4-difluorobenzene was added dropwise such that the reaction mixture was mildly refluxed, followed by stirring at room temperature for three hours. A solution of 4-methoxypyridine (6.8 mL) in THF (50 mL) was added to the reaction mixture. To the reaction mixture, 4-bromobutyryl chloride (6 mL) was added dropwise at -25°C over 15 minutes, and the reaction mixture was further stirred for one hour. 5 N aqueous hydrochloric acid (30 mL) was added to the reaction mixture, and the reaction mixture was stirred at room temperature for 10 minutes, followed by extraction with ethyl acetate. The organic layer was washed with
brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain 11.1 g of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

2.22-2.32 (m, 2H), 2.68-2.88 (m, 3H), 3.08-3.18 (m, 1H), 3.51-3.55 (m, 2H), 5.48 (d, J=8.4 Hz, 1H), 6.00 (brs, 1H), 6.90-

7.15 (m, 2H), 7.70 (brs, 1H).

[0363]

Synthesis of (6S*, 9aS*)-4-(3,4-difluorophenyl)hexahydroquinolizine-2,6-dione

5.46 g of the title compound was obtained from 1-(4-bromobutyryl)-2-(3,4-difluorophenyl)-2,3-dihydro-1H-pyridin-4-one (11.1 g) in the same manner as in Examples 13 and 14. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.58-1.67 (m, 1H), 1.70-1.80 (m, 1H), 1.86-1.94 (m, 1H), 1.94-2.04 (m, 1H), 2.35-2.41 (m, 1H), 2.45-2.57 (m, 3H), 2.80 (dd, J=15.2 Hz, 7.2 Hz, 1H), 2.93-2.99 (m, 1H), 3.50-3.57 (m, 1H),

6.50 (d, J=7.2 Hz, 1H), 6.96-7.00 (m, 1H), 7.07-7.13 (m, 1H).

[0364]

Synthesis of (6S*, 9aS*)-6-(3,4-difluorophenyl)octahydroquinolizin-4-one

2.11 g of the title compound was obtained from (6S*, 9aS*)-4-(3,4-
difluorophenyl)hexahydroquinolizine-2,6-dione (3 g) in the same manner as in Examples 13 and 14. The property values of the compound are as follows.

\[^1\text{H}-\text{NMR}(\text{CDCl}_3)\delta(\text{ppm}):\]

5 1.38-2.00 (m, 8H), 2.28-2.35 (m, 1H), 2.42-2.60 (m, 2H), 3.24-3.32 (m, 1H), 6.06 (brd, J=4.4Hz, 1H), 6.89-6.94 (m, 1H) 6.97-7.03 (m, 1H), 7.08-7.16 (m, 1H).

[0365]

Synthesis of (E)-(6S,9aS)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one and (E)-(6R,9aR)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one

2.59 g of a racemate mixture of the title compound was obtained from (6S\(^*\),9aS\(^*\))-6-(3,4-difluorophenyl)octahydroquinolinizin-4-one (2.11 g) in the same manner as in Examples 21 and 22. The racemate was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: hexane:ethanol = 55:45; flow rate: 10 mL/min) to obtain the title optically active compound with a retention time of 24 minutes (835 mg) and the title optically active compound with a retention time of 29 minutes (823 mg).

The property values of the title optically active compound with a retention time of 24 minutes (Example 65) are as follows.
$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.54-1.79 (m, 4H), 1.90-2.05 (m, 3H), 2.31 (s, 3H), 2.33-2.40 (m, 1H), 2.68-2.76 (m, 1H), 2.87-2.95 (m, 1H), 3.41-3.48 (m, 1H), 3.88 (s, 3H), 6.17 (brd, $J$=4.4Hz, 1H), 6.94 (s, 1H), 6.98-7.28 (m, 6H), 7.30 (d, $J$=1.2Hz, 1H), 7.84 (s, 1H).

The property values of the title optically active compound with a retention time of 29 minutes (Example 66) are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.54-1.79 (m, 4H), 1.90-2.05 (m, 3H), 2.31 (s, 3H), 2.33-2.40 (m, 1H), 2.68-2.76 (m, 1H), 2.87-2.95 (m, 1H), 3.41-3.48 (m, 1H), 3.88 (s, 3H), 6.17 (brd, $J$=4.4Hz, 1H), 6.94 (s, 1H), 6.98-7.28 (m, 6H), 7.30 (d, $J$=1.2Hz, 1H), 7.84 (s, 1H).

[0366]

Examples 67 and 68

Synthesis of (E)-[6S,9aS]-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one and (E)-[6R,9aR]-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one

[Formula 52]

Synthesis of (6S*,9aS*)-6-(4-
chlorophenyl)octahydroquinolinizin-4-one

(6S*,9aS*)-4-(4-chlorophenyl)hexahydroquinolinizin-2,6-dione (15.8 g) was obtained from 4-methoxypyridine (14.2 mL) in the same manner as in Examples 13 and 14. 2.26 g of the title compound was obtained from 3 g of the resulting compound in the same manner as in Examples 13 and 14. The property values of the compound are as follows.

^1H-NMR(CDCl₃)δ(ppm):

1.22-1.98 (m, 9H), 2.32-2.60 (m, 3H), 3.34-3.31 (m, 1H),
6.09 (brd, J=4.4Hz, 1H), 7.12-7.16 (m, 2H), 7.29-7.32 (m, 2H).

[0367]

Synthesis of (E)-(6S,9aS)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolinizin-4-one

3.1 g of a racemate mixture of the title compound was obtained from (6S*,9aS*)-6-(4-chlorophenyl)octahydroquinolinizin-4-one (2.26 g) in the same manner as in Examples 21 and 22. The racemate was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm × 25 cm; mobile phase: hexane:ethanol = 50:50; flow rate: 10 mL/min) to obtain the title optically active compound with a retention time of 25 minutes (1.02 g) and the title optically active compound with a retention time of 32 minutes (1.13 g).
The property values of the title optically active compound with a retention time of 25 minutes (Example 67) are as follows.

\[ ^1H-NMR (CDCl_3) \delta (ppm): \]
5 1.54-1.79 (m, 4H), 1.84-2.04 (m, 3H), 2.31 (s, 3H), 2.37-2.44 (m, 1H), 2.67-2.76 (m, 1H), 2.86-2.94 (m, 1H), 3.40-3.46 (m, 1H), 3.87 (s, 3H), 6.19 (brd, J=4 Hz, 1H), 6.94 (s, 1H), 7.01-7.04 (m, 2H), 7.19-7.34 (m, 4H), 7.72 (d, J=1.6 Hz, 1H), 7.83 (s, 1H).

The property values of the title optically active compound with a retention time of 32 minutes (Example 68) are as follows.

\[ ^1H-NMR (CDCl_3) \delta (ppm): \]
5 1.54-1.79 (m, 4H), 1.84-2.04 (m, 3H), 2.31 (s, 3H), 2.37-2.44 (m, 1H), 2.67-2.76 (m, 1H), 2.86-2.94 (m, 1H), 3.40-3.46 (m, 1H), 3.87 (s, 3H), 6.19 (brd, J=4 Hz, 1H), 6.94 (s, 1H), 7.01-7.04 (m, 2H), 7.19-7.34 (m, 4H), 7.72 (d, J=1.6 Hz, 1H), 7.83 (s, 1H).

[0368]

Examples 69 and 70

Synthesis of (E)-(S)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-hexahydroquinolizin-4-one and (E)-(R)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-hexahydroquinolizin-4-one
Synthesis of $(S^*)$-6-(3,4,5-trifluorophenyl)-
1,2,3,8,9,9a-hexahydroquinolizin-4-one

A solution of $(6S^*,9aS^*)$-8-hydroxy-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one obtained in
Examples 13 and 14 (3.57 g) in THF (30 mL) was cooled
to 0°C. Triethylamine (3.2 mL) and methanesulfonyl
chloride (1.3 mL) were added to the reaction solution,
which was then stirred at room temperature for 30
minutes. Potassium tert-butoxide (3.9 g) and THF (60
mL) were added to the reaction mixture, and the
reaction mixture was heated under reflux for 80 minutes
and left to cool. Then, water and ethyl acetate were
added to the reaction solution, and the organic layer
was separated. The resulting organic layer was washed
with brine, dried over anhydrous magnesium sulfate, and
then concentrated under reduced pressure. The residue
was purified by silica gel column chromatography
(elution solvent: heptane-ethyl acetate system) to
obtain 1.65 g of the title compound. The property
values of the compound are as follows.

$^1$H-NMR(CDC$_3$)$\delta$(ppm):
1.60-1.68 (m, 1H), 1.76-2.00 (m, 4H), 2.22-2.38 (m, 4H), 2.47-2.55 (m, 1H), 3.62-3.69 (m, 1H), 5.15 (t, J=4Hz, 1H), 6.80-6.84 (m, 2H).

[0369]

Synthesis of (E)-(S)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-hexahydroquinolinizine-4-one and (E)-(R)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-hexahydroquinolinizine-4-one

1.1 g of a racemate mixture of the title compound was obtained from (S*)-6-(3,4,5-trifluorophenyl)-1,2,3,8,9,9a-hexahydroquinolinizine-4-one (1.02 g) in the same manner as in Examples 21 and 22.

The racemate was separated by CHIRALPAK™ AD-H manufactured by Daicel Chemical Industries, Ltd. (2 cm x 25 cm; mobile phase: hexane:ethanol = 50:50; flow rate: 10 mL/min) to obtain the title optically active compound with a retention time of 18 minutes (202 mg) and the title optically active compound with a retention time of 25 minutes (216 mg).

The property values of the title optically active compound with a retention time of 18 minutes (Example 69) are as follows.

^H-NMR (CDCl3) δ (ppm):

1.55-1.65 (m, 1H), 1.71-1.82 (m, 2H), 2.06-2.13 (m, 1H), 2.30 (s, 3H), 2.32-2.42 (m, 2H), 2.63-2.73 (m, 1H), 3.03-3.10 (m, 1H), 3.74-3.82 (m, 1H), 3.86 (s, 3H),
5.54 (t, J=3.6 Hz, 1H), 6.84–7.03 (m, 5H), 7.26 (d, J=8 Hz, 1H),
7.62 (s, 1H), 7.72 (s, J=1.2 Hz, 1H).

The property values of the title optically active compound with a retention time of 25 minutes
(Example 70) are as follows.

$^1$H-NMR (CDCl$_3$) δ (ppm):
1.55–1.65 (m, 1H), 1.71–1.82 (m, 2H), 2.06–2.13 (m, 1H),
2.30 (s, 3H), 2.32–2.42 (m, 2H), 2.63–2.73 (m, 1H), 3.03–
3.10 (m, 1H), 3.74–3.82 (m, 1H), 3.86 (s, 3H),
5.54 (t, J=3.6 Hz, 1H), 6.84–7.03 (m, 5H), 7.26 (d, J=8 Hz, 1H),
7.62 (s, 1H), 7.72 (s, J=1.2 Hz, 1H).

Example 71

Synthesis of (E)-(6S,8S,9aR)-8-fluoro-3-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-
trifluorophenyl)octahydroquinolizin-4-one

[Formula 54]

```
O
N=N
N
```

Synthesis of 1-(4-bromobutyryl)-2-(3,4,5-
trifluorophenyl)-2,3-dihydro-1H-pyridin-4-one

1.02 g of the title compound was obtained
from 4-methoxypyridine (1.52 mL), 3,4,5-
trifluorophenylmagnesium bromide (0.3 M solution in
THF, 50 mL), and 4-bromobutyryl chloride (1.74 mL) according to the method described in Tetrahedron Letters, 1986, vol.27, p.4549-4552. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

2.24-2.31 (m, 2H), 2.77-2.88 (m, 3H), 3.06-3.18 (m, 1H), 3.51-3.55 (m, 2H), 5.48 (brd, $J$=8.0 Hz, 1H), 5.98 (brs, 1H), 6.82-6.90 (m, 2H), 7.72 (brs, 1H).

[0371]

10 **Synthesis of (6S*, 9aR*)-4-(3,4,5-trifluorophenyl)hexahydroquinolizine-2,6-dione**

331 mg of the title compound was obtained from 1-(4-bromobutyryl)-2-(3,4,5-trifluorophenyl)-2,3-dihydro-1H-pyridin-4-one (1.15 g), tributyltin hydride (973 $\mu$L), and AIBN (201 mg) according to the method described in The Journal of Organic Chemistry, 1993, vol.58, p.4198-4199. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$ (ppm):

1.61-1.69 (m, 1H), 1.72-1.82 (m, 1H), 1.87-1.97 (m, 1H), 1.99-2.07 (m, 1H), 2.23-2.31 (m, 1H), 2.39 (ddd, $J$=14.8, 3.2, 1.6 Hz, 1H), 2.47-2.57 (m, 2H), 2.81 (ddd, $J$=15.2, 7.2, 0.8 Hz, 1H), 2.92 (ddd, $J$=15.2, 2.4, 1.6 Hz, 1H), 3.52-3.59 (m, 1H), 6.45 (brd, $J$=7.2 Hz, 1H), 6.88-6.92 (m, 2H).

[0372]

**Synthesis of (6S*, 9aR*)-8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one**

A solution of (6S*, 9aR*)-4-(3,4,5-
trifluorophenyl)hexahydroquinolizine-2,6-dione (331 mg) in methanol (10 mL) was cooled to 0°C. Sodium borohydride (64.1 mg) was added to the reaction solution, which was then stirred for one hour. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure to obtain 340 mg of a crude alcohol compound. The property values of the compound are as follows.

\(^1H\)-NMR (CDCl\(_3\), δ (ppm):
1.57-1.64 (m, 1H), 1.70-2.00 (m, 3H), 2.00-2.12 (m, 1H), 2.20-2.60 (m, 5H), 3.28-3.35 (m, 1/2H), 3.81-3.89 (m, 1H), 4.23-4.26 (m, 1/2H), 5.91 (brd, J=6.4Hz, 1/2H), 6.15 (brd, J=4.8Hz, 1/2H), 6.80-6.94 (m, 2H).

[0373]

Synthesis of (6S\(^*\),8S\(^*\),9αR\(^*\))-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-
fluorophenyl)octahydroquinolizin-4-one and
(6S\(^*\),8R\(^*\),9αR\(^*\))-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one

A solution of (6S\(^*\),9αR\(^*\))-8-hydroxy-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one (171 mg) in DMF (5.0 mL) was cooled to 0°C. Imidazole (233 mg), TBSCl (258 mg), and DMAP (6.98 mg) were sequentially added to the reaction solution, which was then stirred at room temperature for 4.5 hours. Water and ethyl
acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system) to obtain (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one (103 mg) and (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one (60.5 mg).

The property values of (6S*,8S*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one are as follows.

1H-NMR (CDCl₃) δ (ppm):
0.00 (s, 3H), 0.03 (s, 3H), 0.75 (s, 9H), 1.61-1.74 (m, 2H), 1.74-1.80 (m, 1H), 1.82-2.02 (m, 2H), 2.07-2.14 (m, 2H), 2.35-2.40 (m, 1H), 2.53 (ddd, J = 12.4, 8.8, 5.6 Hz, 1H), 2.60-2.67 (m, 1H), 3.90-3.96 (m, 1H), 4.23-4.26 (m, 1H), 5.99 (brd, J = 7.2 Hz, 1H), 6.84-6.93 (m, 2H)

The property values of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one are as follows.

1H-NMR (CDCl₃) δ (ppm):
0.00 (s, 3H), 0.03 (s, 3H), 0.84 (s, 9H), 1.38-1.47 (m, 1H), 1.53-1.60 (m, 2H), 1.67-1.80 (m, 2H), 1.82-1.99 (m, 2H), 2.33-2.38 (m, 1H), 2.40-2.48 (m, 1H), 2.48-2.56 (m, 1H), 3.22-3.29 (m, 1H), 3.68-3.76 (m, 1H), 6.06 (brs, 1H), 6.72-
6.76 (m, 2H).

[0374]

Synthesis of (E)-[(6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one

LDA (1.5 M solution in THF, 153 µL) was added to a solution of (6S*,8R*,9aR*)-8-(tert-butyldimethylsilanyloxy)-6-(3,4,5-fluorophenyl)octahydroquinolizin-4-one (47.7 mg) in THF (2.0 mL) at 0°C. The reaction solution was stirred at 0°C for one hour, and then a solution of 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde (24.9 mg) in THF (1 mL) was added to the reaction solution. The reaction solution was further stirred at 0°C for 30 minutes. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to obtain 27.2 mg of a crude aldol adduct.

A solution of the crude aldol adduct (27.2 mg) in methylene chloride (1.0 mL) was cooled to 0°C. Triethylamine (48.2 µL) and methanesulfonyl chloride (13.4 µL) were added to the reaction solution, which was then stirred at room temperature for five hours. Sodium methoxide (28% solution in methanol, 50 mg) and ethanol (1.0 mL) were added to the reaction solution, which was then stirred at room temperature for 1.5
hours. Water and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 21.0 mg of the title compound. The property values of the compound are as follows.

$^1$H-NMR (CDCl$_3$) $\delta$(ppm):

0.06(s, 3H), 0.09(s, 3H), 0.89(s, 9H), 1.54-1.64(m, 1H), 1.64-1.74(m, 1H), 1.80-1.92(m, 2H), 2.00-2.10(m, 1H), 2.33(s, 3H), 2.42-2.50(m, 1H), 2.72-2.80(m, 1H), 2.88-2.98(m, 1H), 3.41-3.48(m, 1H), 3.81-3.90(m, 1H), 3.88(s, 3H), 6.20-6.23(m, 1H), 6.82-6.90(m, 2H), 6.95(brs, 1H), 7.02-7.06(m, 2H), 7.26-7.30(m, 1H), 7.81(brs, 1H), 7.84(s, 1H).

[0375]

Synthesis of (E)-(6S*, 8R*, 9aR*)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one

TBAF (1.0 M solution in THF, 68.6 µL) was added to a solution of (E)-(6S*, 8R*, 9aR*)-8-(tert-butyldimethylylsilanyloxy)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]octahydroquinolizin-4-one (21.0 mg) in THF (1.0 mL), and the reaction solution was stirred at room temperature overnight. A saturated ammonium
chloride solution and ethyl acetate were added to the reaction solution, and the organic layer was separated. The resulting organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system -> ethyl acetate-methanol system) to obtain 11.5 mg of the title compound. The property values of the compound are as follows.

\[ ^{1}H-NMR\text{(CDCl}_{3}\text{)}\delta\text{(ppm):} \]

1.50-1.61(m,1H), 1.68-1.90(m,3H), 1.98-2.12(m,1H),
2.34(s,3H), 2.56-2.64(m,1H), 2.72-2.80(m,1H), 2.88-
3.00(m,1H), 3.45-3.51(m,1H), 3.81-3.96(m,1H), 3.89(s,3H),
6.26-6.30(m,1H), 6.88-6.92(m,2H),
6.96(dd,J=1.2,1.2Hz,1H), 7.03-7.06(m,2H), 7.28-
7.30(m,1H), 7.83-7.85(m,2H).

[0376]

Synthesis of (E)-(6S,8R,9aR)-6-(3,4,5-trifluorophenyl)-
8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzyldiene]octahydroquinolizin-4-one and (E)-(6R,8S,9aS)-6-(3,4,5-trifluorophenyl)-8-hydroxy-3-[3-
methoxy-4-(4-methyl-1H-imidazol-1-
yl)benzyldiene]octahydroquinolizin-4-one

The racemate (E)-(6S*,8R*,9aR*)-6-(3,4,5-
trifluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one obtained above (11.5 mg) was separated by CHIRALPAK™
DEMANDE OU BREVET VOLUMINEUX

LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D’UN TOME.

CECI EST LE TOME 1 DE 2
CONTENANT LES PAGES 1 À 442

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets

JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE VOLUME

THIS IS VOLUME 1 OF 2
CONTAINING PAGES 1 TO 442

NOTE: For additional volumes, please contact the Canadian Patent Office

NOM DU FICHIER / FILE NAME :

NOTE POUR LE TOME / VOLUME NOTE:
1. A compound represented by the formula (I):

![Chemical Structure]

or a pharmaceutically acceptable salt thereof,

wherein --- represents a single bond or a double bond;

Ar₁ represents a phenyl group that may be substituted
with 1 to 3 substituents selected from Substituent
Group A1 or a pyridinyl group that may be substituted
with 1 to 3 substituents selected from Substituent
Group A1; R¹ and R² are the same or different and each
represent a group selected from the following
Substituent Group A1; Z₁ represents a methylene group or
vinylene group, which may be substituted with 1 or 2
substituents selected from Substituent Group A1, an
oxygen atom, or an imino group that may be substituted
a substituent selected from Substituent Group A1; and
p, q, and r are the same or different and represent an
integer of 0 to 2:

Substituent Group A1: (1) a halogen atom, (2) a
hydroxyl group, (3) a cyano group, (4) a C3-8
cycloalkyl group, (5) a C3-8 cycloalkoxy group, (6) a
C1-6 alkyl group, wherein the C1-6 alkyl group may be
substituted with 1 to 3 substituents selected from the
group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, C1-6 alkoxy group, and C3-8 cycloalkoxy group, (7) a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, and C3-8 cycloalkoxy group, (8) an amino group that may be substituted with one or two C1-6 alkyl groups, wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (9) a carbamoyl group that may be substituted with one or two C1-6 alkyl groups, wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (10) a carboxyl group, (11) a C1-6 alkoxy carbonyl group, wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, and C3-8 cycloalkoxy group, (12) a C1-6 alkyl group, and (13) a C1-6 alkylsulfonyl group.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is represented by the formula (II):
wherein Ar₁ represents a phenyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A₁ or a pyridinyl group that may be substituted with 1 to 3 substituents selected from Substituent Group A₁; R¹ and R² are the same or different and each represent a group selected from the following Substituent Group A₁; Z₁ represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A₁, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A₁; and p, q, and r are the same or different and represent an integer of 0 to 2; Substituent Group A₁: (1) a halogen atom, (2) a hydroxyl group, (3) a cyano group, (4) a C₃-8 cycloalkyl group, (5) a C₃-8 cycloalkoxy group, (6) a C₁-6 alkyl group, wherein the C₁-6 alkyl group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C₃-8 cycloalkyl group, C₁-6 alkoxy group, and C₃-8 cycloalkoxy group, (7) a C₁-6 alkoxy group, wherein the C₁-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C₃-8 cycloalkyl group, and C₃-8 cycloalkoxy group, (8) an amino group that may be substituted with one or two C₁-6 alkyl groups, wherein the C₁-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (9) a carboxamidyl
group that may be substituted with one or two C1-6 alkyl groups, wherein the C1-6 alkyl groups may be substituted with 1 to 3 halogen atoms, (10) a carboxyl group, (11) a C1-6 alkoxy carbonyl group, wherein the C1-6 alkoxy group may be substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, hydroxyl group, cyano group, C3-8 cycloalkyl group, and C3-8 cycloalkoxy group, (12) a C1-6 alkyl group and (13) a C1-6 alkylsulfonyl.

3. The compound or pharmacologically acceptable salt thereof according to claim 3, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, hydroxyl group, and halogen atom.

4. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z₁ represents a methylene group that may be substituted with 1 or 2 halogen atoms.

5. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, hydroxyl group, and halogen atom; and p, q, and r each represent 1.

6. The compound or pharmacologically acceptable salt thereof according to claim 5, wherein Z₁ represents
a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a Cl-6 alkyl group and hydroxyl group; and p, q, and r each represent 1.

7. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z$_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a Cl-6 alkyl group, hydroxyl group, and halogen atom; p and q each represent 1; and r represents 0.

8. The compound or pharmacologically acceptable salt thereof according to claim 7, wherein Z$_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a Cl-6 alkyl group and hydroxyl group; p and q each represent 1; and r represents 0.

9. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z$_1$ represents an oxygen atom; and p, q, and r each represent 1.

10. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z$_1$ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a Cl-6 alkyl group, halogen atom, and hydroxyl group; p represents 1; and q and r each represent 0.
11. The compound or pharmacologically acceptable salt thereof according to claim 10, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group and hydroxyl group; p represents 1; and q and r each represent 0.

12. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group, halogen atom, and hydroxyl group; p and r each represent 1; and q represents 0.

13. The compound or pharmacologically acceptable salt thereof according to claim 12, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group and hydroxyl group; p and r each represent 1; and q represents 0.

14. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein Z₁ represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C₁-6 alkyl group, halogen atom, and hydroxyl group; p represents 1; q represents 2; and r represents 0.
15. The compound or pharmacologically acceptable salt thereof according to claim 14, wherein \( Z_1 \) represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group and hydroxyl group; \( p \) represents 1; \( q \) represents 2; and \( r \) represents 0.

16. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein \( Z_1 \) represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group, halogen atom, and hydroxyl group; \( p \) and \( r \) each represent 1; and \( q \) represents 2.

17. The compound or pharmacologically acceptable salt thereof according to claim 16, wherein \( Z_1 \) represents a methylene group, wherein the methylene group may be substituted with 1 or 2 substituents selected from the group consisting of a C1-6 alkyl group and hydroxyl group; \( p \) and \( r \) each represent 1; and \( q \) represents 2.

18. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein \( Z_1 \) represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups or halogen atoms; \( p \) represents 0; and \( q \) and \( r \) each represent 1.

19. The compound or pharmacologically acceptable
salt thereof according to claim 18, wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups; $p$ represents 0; and $q$ and $r$ each represent 1.

20. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups or halogen atoms; $p$ and $q$ each represent 1; and $r$ represents 0.

21. The compound or pharmaceutically acceptable salt thereof according to claim 20, wherein $Z_1$ represents a vinylene group, wherein the vinylene group may be substituted with one or two C1-6 alkyl groups; $p$ and $q$ each represent 1; and $r$ represents 0.

22. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein $Ar_1$ represents a phenyl group substituted with 1 to 3 halogen atoms.

23. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein $Ar_1$ represents a phenyl group substituted with 1 to 3 fluorine atoms or chlorine atoms.

24. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein $Ar_1$ represents a phenyl group substituted with 2 or 3 halogen atoms.

25. The compound or pharmaceutically acceptable
salt thereof according to any one of claims 2, 22, 23, and 24, wherein \(\text{Ar}_1\) represents a phenyl group substituted with a fluorine atom.

26. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein \(R^1\) and \(R^2\) are the same or different and each represent a substituent selected from the group consisting of a Cl-6 alkyl group, halogen atom, and hydroxyl group.

27. The compound or pharmacologically acceptable salt thereof according to claim 1 or 2, wherein the compound is selected from the following group:

1) \((E)-(3S)-(3,4,5\text{-trifluorophenyl})-6-[3\text{-methoxy}-4\text{-}(4\text{-methyl}-1\text{H-\text{imidazol-1-yl\text{benzylidene}}})-(9R)-\text{hexahydroindolizin-5-one,}\)

2) \((E)-(3R)-(3,4,5\text{-trifluorophenyl})-6-[3\text{-methoxy}-4\text{-}(4\text{-methyl}-1\text{H-\text{imidazol-1-yl\text{benzylidene}}})-(9R)-\text{hexahydroindolizin-5-one,}\)

3) \((E)-(3S)-(3,4,5\text{-trifluorophenyl})-6-[3\text{-methoxy}-4\text{-}(4\text{-methyl}-1\text{H-\text{imidazol-1-yl\text{benzylidene}}})-(9S)-\text{hexahydroindolizin-5-one,}\)

4) \((E)-(3R)-(3,4,5\text{-trifluorophenyl})-6-[3\text{-methoxy}-4\text{-}(4\text{-methyl}-1\text{H-\text{imidazol-1-yl\text{benzylidene}}})-(9S)-\text{hexahydroindolizin-5-one,}\)

5) \((E)-(3R)-(3,4\text{-difluorophenyl})-6-[3\text{-methoxy}-4\text{-}(4\text{-methyl}-1\text{H-\text{imidazol-1-yl\text{benzylidene}}})-(9R)-\text{hexahydroindolizin-5-one,}\)

6) \((E)-(3S)-(3,4\text{-difluorophenyl})-6-[3\text{-methoxy}-4\text{-}(4\text{-methyl}-1\text{H-\text{imidazol-1-yl\text{benzylidene}}})-(9S)-\)
hexahydroindolizin-5-one,
7) \((E)-(6R,9aS)-6-(4\text{-}fluorophenyl)-3-[3\text{-}methoxy-4-(4-
\text{methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
8) \((E)-(6S,9aR)-6-(4\text{-}fluorophenyl)-3-[3\text{-}methoxy-4-(4-
\text{methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
9) \((E)-(6S,8S,9aR)-6\text{-}phenyl-8\text{-}hydroxy-3-[3\text{-}methoxy-4-(4-
\text{methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
10) \((E)-(6R,8R,9aS)-6\text{-}phenyl-8\text{-}hydroxy-3-[3\text{-}methoxy-4-(4-
\text{methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
11) \((E)-(6S,8S,9aR)-6-(4\text{-}fluorophenyl)-8\text{-}hydroxy-3-[3\text{-}
\text{methoxy-4-(4\text{-}methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
12) \((E)-(6R,8R,9aS)-6-(4\text{-}fluorophenyl)-8\text{-}hydroxy-3-[3\text{-}
\text{methoxy-4-(4\text{-}methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
13) \((E)-(6S,9aS)-6-(3,4,5\text{-}trifluorophenyl)-3-[3\text{-}
\text{methoxy-4-(4\text{-}methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
14) \((E)-(6R,9aR)-6-(3,4,5\text{-}trifluorophenyl)-3-[3\text{-}
\text{methoxy-4-(4\text{-}methyl}-1\text{H}-\text{imidazol}-1\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
15) \((E)-(6S,8S,9aR)-6-(3,4,5\text{-}trifluorophenyl)-8-
\text{hydroxy-3-[3\text{-}methoxy-4-(4\text{-}methyl}-1\text{H}-\text{imidazol}-1-
\text{-}yl)\text{benzylidene}]\)
octahydroquinoliniz-4-one,
16) \((E)-(6R, 8R, 9aS)-6-(3, 4, 5\text{-trifluorophenyl})-8\text{-hydroxy}-3\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]}\text{octahydroquinolizín-4-one},\)

17) \((E)-(6S, 8R, 9aR)-6-(3, 4, 5\text{-trifluorophenyl})-8\text{-hydroxy}-3\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]}\text{octahydroquinolizín-4-one},\)

18) \((E)-(6R, 8S, 9aS)-6-(3, 4, 5\text{-trifluorophenyl})-8\text{-hydroxy}-3\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]}\text{octahydroquinolizín-4-one},\)

19) \((E)-(6S, 9aS)-6-(4\text{-fluorophenyl})-3\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]}\text{octahydroquinolizín-4-one},\)

20) \((E)-(6R, 9aR)-6-(4\text{-fluorophenyl})-3\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]}\text{octahydroquinolizín-4-one},\)

21) \((E)-(5S)-(4\text{-fluorophenyl})-2\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]}-(8aS)-\text{hexahydroindolizín-3-one},\)

22) \((E)-(5R)-(4\text{-fluorophenyl})-2\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]}-(8aR)-\text{hexahydroindolizín-3-one},\)

23) \((E)-(5S)-(3, 4\text{-difluorophenyl})-2\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]}-(8aS)-\text{hexahydroindolizín-3-one},\)

24) \((E)-(5R)-(3, 4\text{-difluorophenyl})-2\text{-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldene]}-(8aR)-\text{hexahydroindolizín-3-one},\)

25) \((Z)-(5S)-(3, 4\text{-difluorophenyl})-2\text{-[3-methoxy-4-(4-}
methyl-1H-imidazol-1-yl)benzylidene]-{(8aS)-hexahydroindolizin-3-one,
26) (Z)-(5R)-(3,4-difluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]-{(8aR)-hexahydroindolizin-3-one,
27) (E)-(5R,8aS)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-3-one,
28) (E)-(5S,8aR)-5-(4-fluorophenyl)-2-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-3-one,
29) (E)-(6R,9aS)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-6-(4-methoxyphenyl)
octahydroquinolinizig-4-one,
30) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-
1-yl)benzylidene]-6-(4-methoxyphenyl)
octahydroquinolinizig-4-one,
31) (E)-(4S,10aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
octahydropyridero[1,2-a]azepin-6-one,
32) (E)-(4R,10aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]
octahydropyridero[1,2-a]azepin-6-one,
33) (E)-(5R,7aS)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydropyrrolidin-3-one,
34) (E)-(3R,9aR)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydropyrrolo[1,2-a]azepin-5-one,
35) methyl (E)-4-{(4S*, 9aR*)}-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-oxooctahydroquinolizin-4-yl}benzoate,
36) (E)-(6S*, 9aR*)-6-(4-hydroxymethylphenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]
octahydroquinolizin-4-one,
37) (E)-(6S*, 9aR*)-6-(4-cyanophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]
octahydroquinolizin-4-one,
38) (E)-4-{(4S*, 9aR*)}-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-oxooctahydroquinolizin-4-yl}benzoic acid,
39) (E)-(6S*, 9aR*)-6-(4-aminophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]
octahydroquinolizin-4-one,
40) (E)-4-{(4S*, 9aR*)}-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-oxooctahydroquinolizin-4-yl)-N,N-dimethylbenzamide,
41) (E)-(6S, 9aR)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]
octahydroquinolizin-4-one,
42) (E)-(6R, 9aS)-6-(3-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]
octahydroquinolizin-4-one,
43) (E)-(6S, 9aR)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]
octahydroquinolizin-4-one,
615

44) (E)-(6R, 9aS)-6-(2-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]octahydroquinolizin-4-one,

45) (E)-(6S, 8R, 9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-octahydroquinolizin-4-one,

46) (E)-(6R, 8S, 9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-octahydroquinolizin-4-one,

47) (E)-(6S, 8R, 9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-octahydroquinolizin-4-one,

48) (E)-(6R, 8S, 9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-octahydroquinolizin-4-one,

49) (E)-(6S, 9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one,

50) (E)-(6R, 9aS)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-1,2,3,6,9,9a-hexahydroquinolizin-4-one,

51) (E)-(6S, 8S, 9aR)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-octahydroquinolizin-4-one,

52) (E)-(6R, 8R, 9aS)-6-(4-fluorophenyl)-8-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-8-methyl-octahydroquinolizin-4-one,

53) (E)-(4R, 9aS)-7-[3-methoxy-4-(4-methylimidazol-1-...
616

y1)benzylidene]-4-phenylhexahydropyrrolo[2,1-c][1,4]oxazin-6-one,
54) (E)-(5S,7aR)-5-(3,4-difluorophenyl)-2-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydropyrrolidin-3-one,
55) (E)-(3S,9aS)-3-(3,4-difluorophenyl)-6-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
octahydropyrrolo[1,2-a]azepin-5-one,
56) (E)-(3S,8aS)-3-(4-chlorophenyl)-6-[3-methoxy-4-(4-
methy1-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-
5-one,
57) (E)-(3S,8aS)-3-(2,4,5-trifluorophenyl)-6-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydroindolizin-5-one,
58) (E)-(3S,8aS)-3-(2,3,4-trifluorophenyl)-6-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydroindolizin-5-one,
59) (E)-(3S,8aS)-3-(2,5-difluorophenyl)-6-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydroindolizin-5-one,
60) (E)-(3S,8aS)-3-(3-fluorophenyl)-6-[3-methoxy-4-(4-
methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-
5-one,
61) (E)-(3S,8aS)-3-(2,6-difluoropyridin-3-yl)-6-[3-
methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydroindolizin-5-one,
62) (E)-(3S,8aS)-3-(2,4-difluorophenyl)-6-[3-methoxy-4-
(4-methyl-1H-imidazol-1-yl)benzylidene]
hexahydroindolizin-5-one,
63) (E)-(3S,8aS)-3-(3-chlorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one,
64) (E)-(3S,8aS)-3-(3,5-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one,
65) (E)-(6S,9aS)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
66) (E)-(6R,9aR)-6-(3,4-difluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
67) (E)-(6S,9aS)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
68) (E)-(6R,9aR)-6-(4-chlorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]octahydroquinolizin-4-one,
69) (E)-(S)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-hexahydroquinolizin-4-one,
70) (E)-(R)-6-(3,4,5-trifluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-1,2,3,8,9,9a-hexahydroquinolizin-4-one,
71) (E)-(6S,8S,9aR)-8-fluoro-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
72) (E)-(6S,8R,9aR)-8-methoxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
73) (E)-(R)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-3,4,8,9-tetrahydro-7H-pyrido[2,1-c][1,4]oxazin-6-one,
74) (E)-(S)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-3,4,8,9-tetrahydro-7H-pyrido[2,1-c][1,4]oxazin-6-one,
75) (E)-(4R,9aR)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydropyrido[2,1-c][1,4]oxazin-6-one,
76) (E)-(4S,9aS)-4-(4-fluorophenyl)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene] hexahydropyrido[2,1-c][1,4]oxazin-6-one,
77) (E)-(6S,8R,9aR)-8-fluoro-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
78) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
79) (E)-(6S,9aR)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-6-(3,4,5-trifluorophenyl)-1,2,3,6,7,9a-hexahydroquinolizin-4-one,
80) (E)-(4R,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
81) (E)-(4S,9aS)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
82) (E)-(4S,9aR)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
83) (E)-(4R,9aS)-7-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
84) (E)-(6R,7S,9aR)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
85) (E)-(6S,7R,9aS)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
86) (E)-(6R,7R,9aR)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
87) (E)-(6S,7S,9aS)-7-hydroxy-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-6-(3,4,5-trifluorophenyl)octahydroquinolizin-4-one,
88) (E)-(6S,9aR)-6-(4-fluorophenyl)-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]-1,2,3,6,9,9a-hexahydroquinolizin-4-one,
89) (3S,8aS)-6-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzyldiene]}-2,3,6,9a-hexahydroquinolizin-4-one,
620

1-yl)phenyl)-(E)-methylidene)-3-(2,4,6-trifluorophenyl)hexahydroindolizin-5-one,
90) (6S,9aR)-6-(3,4-difluorophenyl)-3-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene)octahydroquinolizin-4-one,
91) (6S,9aR)-6-(3,4,5-trifluorophenyl)-3-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene)octahydroquinolizin-4-one,
92) (6S,9aR)-6-(4-chlorophenyl)-3-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene)octahydroquinolizin-4-one,
93) (E)-(3S,8aS)-3-(2,3-difluorophenyl)-6-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]hexahydroindolizin-5-one,
94) (4R,9aS)-4-(4-fluorophenyl)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
95) (4R,9aS)-4-(3,4-difluorophenyl)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
96) (4R,9aS)-4-(4-chlorophenyl)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene)hexahydropyrido[2,1-c][1,4]oxazin-6-one,
97) methyl (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,
98) methyl (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-
imidazol-1-yl)phenyl]-E-methylidene]-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,

99) methyl (4R,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,

100) methyl (4S,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-6-oxo-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylate,

101) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

102) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

103) (4S,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

104) (4R,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

105) (4S,9aR)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,

106) (4R,9aS)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-E-methylidene]-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
107) (4R,9aR)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
108) (4S,9aS)-2-ethyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
109) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-methyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
110) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-methyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
111) (4S,9aR)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-propyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
112) (4R,9aS)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-2-propyl-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
113) (4R*,9aS*)-2-acetyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one,
114) (4R*,9aS*)-2-methanesulfonyl-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-4-(3,4,5-trifluorophenyl)octahydropyrido[1,2-a]pyrazin-6-one, and
115) (4R*,9aS*)-7-{1-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-(E)-methylidene}-6-oxo-4-(3,4,5-
trifluorophenyl)octahydropyrido[1,2-a]pyrazine-2-carboxylic acid dimethylamide.

28. A pharmaceutical agent comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 27 as an active ingredient.

29. The pharmaceutical agent according to claim 28, which is a prophylactic or therapeutic agent for a disease caused by amyloid-β.

30. The pharmaceutical agent according to claim 29, wherein the disease caused by amyloid-β is Alzheimer's disease, senile dementia, Down's syndrome, or amyloidosis.

Smart & Bigge
Ottawa, Canada
Patent Agents